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A B S T R A C T
Background
Ophthalmia neonatorum is an infection of the eyes in newborns that can lead to blindness, particularly if the infection is caused by Neisseria
gonorrhoeae. Antiseptic or antibiotic medication is dispensed into the eyes of newborns, or dispensed systemically, soon aEer delivery to
prevent neonatal conjunctivitis and potential vision impairment.
Objectives
1. To determine if any type of systemic or topical eye medication is better than placebo or no prophylaxis in preventing ophthalmia
neonatorum.
2. To determine if any one systemic or topical eye medication is better than any other medication in preventing ophthalmia neonatorum.
Search methods
We searched CENTRAL, MEDLINE, Embase, LILACS, and three trials registers, date of last search 4 October 2019. We also searched references
of included studies and contacted pharmaceutical companies.
Selection criteria
We included randomised and quasi-randomised controlled trials of any topical, systemic, or combination medical interventions used to
prevent ophthalmia neonatorum in newborns compared with placebo, no prophylaxis, or with each other.
Data collection and analysis
We used standard methods expected by Cochrane. Outcomes were: blindness or any adverse visual outcome at 12 months, conjunctivitis
at 1 month (gonococcal (GC), chlamydial (CC), bacterial (BC), any aetiology (ACAE), or unknown aetiology (CUE)), and adverse eIects.
Main results
We included 30 trials with a total of 79,198 neonates. Eighteen studies were conducted in high-income settings (the USA, Europe, Israel,
Canada), and 12 were conducted in low- and middle-income settings (Africa, Iran, China, Indonesia, Mexico). FiEeen of the 30 studies were
quasi-randomised. We judged every study to be at high risk of bias in at least one domain. Ten studies included a comparison arm with no
prophylaxis. There were 14 diIerent prophylactic regimens and 12 diIerent medications in the 30 included studies.
Any prophylaxis compared to no prophylaxis
Unless otherwise indicated, the following evidence comes from studies assessing one or more of the following interventions: tetracycline
1%, erythromycin 0.5%, povidone-iodine 2.5%, silver nitrate 1%. None of the studies reported data on the primary outcomes: blindness
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or any adverse visual outcome at any time point. There was only very low-certainty evidence on the risk of GC with prophylaxis (4/5340
newborns) compared to no prophylaxis (5/2889) at one month (risk ratio (RR) 0.79, 95% confidence interval (CI) 0.24 to 2.65, 3 studies). Low-
certainty evidence suggested there may be little or no diIerence in eIect on CC (RR 0.96, 95% CI 0.57 to 1.61, 4874 newborns, 2 studies) and
BC (RR 0.84, 95% CI 0.37 to 1.93, 3685 newborns, 2 studies). Moderate-certainty evidence suggested a probable reduction in risk of ACAE at
one month (RR 0.65, 95% 0.54 to 0.78, 9666 newborns, 8 studies assessing tetracycline 1%, erythromycin 0.5%, povidone-iodine 2.5%, silver
nitrate 1%, colostrum, bacitracin-phenacaine ointment). There was only very low-certainty evidence on CUE   (RR 1.75, 95% CI 0.37 to
8.28, 330 newborns, 1 study). Very low-certainty evidence on adverse eIects suggested no increased nasolacrimal duct obstruction (RR
0.93, 95% CI 0.68 to 1.28, 404 newborns, 1 study of erythromycin 0.5% and silver nitrate 1%) and no increased keratitis (single study of 40
newborns assessing silver nitrate 1% with no events).  
Any prophylaxis compared to another prophylaxis
Overall, evidence comparing diIerent interventions  did not suggest any consistently superior intervention.  However, most of this
evidence was of low-certainty and was extremely limited.
Authors' conclusions
There are no data on whether prophylaxis for ophthalmia neonatorum prevents serious outcomes such as blindness or any adverse
visual outcome. Moderate-certainty evidence suggests that  the use of prophylaxis  may  lead to  a reduction in the incidence of ACAE
in newborns but the evidence for eIect on GC, CC or BC was less certain. Comparison of individual interventions did not suggest any
consistently superior intervention, but data were limited. A trial comparing tetracycline, povidone-iodine (single administration), and
chloramphenicol for GC and CC could potentially provide the community with an eIective, universally applicable prophylaxis against
ophthalmia neonatorum.
P L A I N   L A N G U A G E   S U M M A R Y
Medication to prevent infection of the eye in newborns
What was the aim of the review?
The aim of this Cochrane Review was to determine if any medication is better than placebo or no preventive action in preventing
ophthalmia neonatorum. Cochrane Review authors collected and analysed all relevant studies to answer this question and found 30
studies.
Key messages
There are no data on whether prophylaxis for ophthalmia neonatorum prevents serious outcomes such as blindness or visual impairment.
Moderate-certainty evidence suggests that the use of prophylaxis may lead to a reduction in the incidence of any conjunctivitis of any
cause in newborns but the evidence for eIect on gonococcal or chlamydial conjunctivitis was of low to very-low certainty. Comparison of
individual interventions did not suggest any consistently superior intervention, but data were limited.
What was studied in the review?
Ophthalmia neonatorum, also known as neonatal conjunctivitis, is an infection of the eye surface that aIects newborn babies within the
first month of life. It is usually caused by infection (bacterial or viral) picked up during birth. If leE untreated, it can lead to blindness. The
World Health Organization (WHO) recommends the following treatments to prevent ophthalmia neonatorum:
• tetracycline hydrochloride 1% eye ointment;
• erythromycin 0.5% eye ointment;
• povidone-iodine 2.5% solution (water-based);
• silver nitrate 1% solution;
• chloramphenicol 1% eye ointment.
Cochrane Review authors considered these treatments and others to prevent the development of conjunctivitis in newborns.  They
assessed the two main types of conjunctivitis separately - gonococcal conjunctivitis (caused by  Neisseria gonorrhoeae) and
chlamydial conjunctivitis (caused by Chlamydia trachomatis) - as well as conjunctivitis due to any bacteria (including Neisseria
gonorrhoeae and Chlamydia trachomatis), conjunctivitis due to any cause or conjunctivitis of unknown cause.
What are the main results of the review?
Cochrane Review authors identified 30 studies with a total of 79,198 newborns. Eighteen studies took place in high-income settings (the
USA, Europe, Israel, Canada), and 12 were conducted in low- and middle-income settings (Africa, Iran, China, Indonesia, Mexico). The main
preventive medications evaluated in the included studies were: tetracycline 1%, erythromycin 0.5%, povidone-iodine 2.5%, and silver
nitrate 1%.
Newborns given preventive medication are likely to have a lower chance of conjunctivitis within one month of birth compared with
newborns not given preventive medication (moderate-certainty evidence). The evidence for specific causes of conjunctivitis (gonococcal,
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chlamydial) was less certain as these occurred less frequently in the included studies. None of the studies collected data on blindness or
adverse vision outcomes.
How up-to-date is the review?
Cochrane Review authors searched for studies published up to 4 October 2019.
Interventions for preventing ophthalmia neonatorum (Review)













































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children
Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children
Setting: any maternity setting
Intervention: any prophylaxis, including povidone-iodine, erythromycin, tetracycline, silver nitrate, bacitracin-phenacaine, colostrum
Comparison: no prophylaxis (none of the studies used a placebo or sham treatment)
Anticipated absolute effects* (95% CI)Outcomes
Risk with no prophy-
laxis













Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.  
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.  
Low risk




assessed with: Neisseria gonorrhoeae-positive
culture
follow-up: 1 month























5 per 1000 5 per 1000
(3 to 8)
Chlamydial conjunctivitis
assessed with: Chlamydia trachomatis culture,

















































































































































100 per 1000 96 per 1000
(57 to 161)
Low risk




assessed with: any bacteria-positive culture,
smear, or Gram stain
follow-up: 1 month









3 per 1000 2 per 1000
(2 to 2)
High risk
Any conjunctivitis of any aetiology assessed with:
clinical assessment
follow-up: 1 month









Study populationConjunctivitis of unknown aetiology assessed
with: culture negative









Adverse effects In a single study (Bell 1993), any prophylaxis (erythromycin 0.5% or silver nitrate 1%) did not
appear to be associated with an increased risk of nasolacrimal duct obstruction compared
with no prophylaxis (RR 0.93, 95% CI 0.68 to 1.28).
A single study of 40 newborns comparing silver nitrate 1% with control reported that no events




*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (Appendix 8).
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.







































































































































Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1Downgraded (-1) for risk of bias: studies were at high or unclear risk of bias.
2Downgraded (-2) for imprecision: sparse data.
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B A C K G R O U N D
Description of the condition
Ophthalmia neonatorum, also called neonatal conjunctivitis, is
an inflammatory disorder of the eye surface in newborns in the
first month of life (WHO 1986). In Europe in the late 1800s, a
significant percentage of blind people were blind due to gonococcal
ophthalmia neonatorum. Specifically, it was reported that the
percentage of blindness from ophthalmia neonatorum was 8% in
Copenhagen, 20% in Berlin, 30% in Vienna, and 45% in Paris (Buller
1900; Haussman 1895; Milot 2008). It has been estimated that
during the same period 20% to 80% of children in blind institutions
in Germany were blind due to ophthalmia neonatorum caused
by Neisseria gonorrhoeae (Konigstein 1882). In the USA, amongst
new admissions into schools for the blind between 1906 and 1911,
approximately 24% were due to ophthalmia neonatorum caused by
N gonorrhoeae, with a range of 8% to 45% (Barsam 1966). In 1918, St
Margaret's Hospital in London (UK) was opened specifically for the
treatment of neonates with ophthalmia neonatorum (Anonymous
1918; Anonymous 1919).
To this day, ophthalmia neonatorum remains a significant
cause of childhood corneal blindness in low- and middle-
income countries, mainly from N gonorrhoeae (Whitcher 2001).
There are major epidemiological challenges in determining
the prevalence and incidence of blindness from ophthalmia
neonatorum. Notwithstanding these limitations, cross-sectional
surveys have estimated the percentage of blindness or severe visual
impairment due to ophthalmia neonatorum to be 3% in Ethiopia
(Kello 2003), 0.7% in Bangladesh (Muhit 2007), 0.4% in Malaysia
(Koay 2015), 5% in East Africa (Foster 1991), 0.8% in India (Rahi
1995), and 2% in Tanzania (Foster 1987).
Gonococcal ophthalmia neonatorum is associated with the most
severe consequences. Gonococcal ophthalmia neonatorum is
mainly contracted from the mother's infected birth canal during
delivery, but can also be contracted in utero by ascending
infections. Neonates born to gonorrhoea-infected mothers have
a 30% to 50% risk of developing gonococcal conjunctivitis
(Laga 1989). Untreated or inappropriately treated gonococcal
conjunctivitis can result in corneal perforation and vision loss in
24 hours (Donham 2008; Duke-Elder 1965). In one case series, the
mean duration of corneal perforation from untreated gonococcal
conjunctivitis was 11 days (Kawashima 2009). In areas with low
incidence of gonococcal ophthalmia neonatorum or limited access
to appropriate health care, appropriate clinical diagnosis and
appropriate therapy may be delayed, which can lead to loss of
vision (Bastion 2006; McElnea 2015; Schwab 1985; Wan 1986). AEer
historical declines in rates of gonorrhoea, it made a resurgence
in some high-income countries  In 2012, amongst adults aged
15 to 49 years, it is estimated there were 27 million cases
of gonorrhoea globally (Newman 2015). Furthermore, there is
increasing incidence of drug-resistant strains of N gonorrhoeae
globally (Martin 2015; Van de Laar 2012; WHO 2012). The pooled
mean prevalence of N gonorrhoeae was estimated at 3.7% (95%
confidence interval (CI) 2.8% to 4.6%) in pregnant women in Eastern
and Southern Africa, and 2.7% (95% CI 1.7% to 3.7%) in pregnant
women in West and Central Africa (Chico 2012).
Chlamydial ophthalmia neonatorum is also associated with a
high risk of corneal and conjunctival scarring, haemorrhagic
conjunctivitis, and rarely, loss of vision if leE untreated (Chang
2006; Darville 2015; Whitcher 2001). It is caused by transmission
of Chlamydia trachomatis from the mother to the newborn
during delivery. The risk of chlamydial transmission from an
infected mother to newborns is 15% on average (range = 8% to
44%; Rosenman 2003). Furthermore, an increased prevalence of
chlamydial infection in some high-income countries is associated
with a commensurate rise in risk of chlamydial conjunctivitis
(Quirke 2008). Chlamydial ophthalmia neonatorum is much more
prevalent than gonococcal ophthalmia neonatorum, and has
historically been underdiagnosed due to lack of accurate diagnostic
techniques (Darville 2015; Yip 2008). Pooled mean prevalence of C
trachomatis was higher at 6.9% (95% CI 5.1% to 8.6%) in pregnant
women in Eastern and Southern Africa, and 6.1% (95% CI 4.0% to
8.3%) in pregnant women in West and Central Africa (Chico 2012).
Ophthalmia neonatorum may be caused by bacteria other than
Neisseria and Chlamydia. The relative frequencies of bacterial
causes of ophthalmia neonatorum reported in the literature
vary by study and geographic location (Amini 2008; Chhabra
2008; Di Bartolomeo 2001; Di Bartolomeo 2005; Hammerschlag
1993; Mohile 2002; Sandström 1984). Even though certain
bacteria are frequently cultured from neonates with conjunctivitis
(e.g. Staphylococcus aureus), their role as the causative agent
of conjunctivitis is uncertain because these bacteria may be
frequently cultured from the eyes of asymptomatic neonates
(Amini 2008; Fransen 1987; Krohn 1993).
Finally, some viruses such as herpes simplex and adenovirus can
cause ophthalmia neonatorum (Albert 1994). OEen, no causative
pathogen can be found in newborns with ophthalmia neonatorum
due to methods for obtaining and culturing for bacteria, or due
to causes other than bacteria such as chemical conjunctivitis or
nasolacrimal duct obstruction (Sandström 1987).
While most micro-organisms that cause ophthalmia neonatorum
are acquired during passage through the birth canal, others
are acquired aEer birth from caregivers or the nasopharyngeal
passages of the newborn (Krohn 1993). The relative importance of
intrapartum versus postpartum sources of infection varies based
on extraneous factors such as socioeconomic status of mothers
(Isenberg 1995; Vedantham 2004; Verma 1994).
Description of the intervention
There are four strategies to achieve the public health goal
of eliminating ophthalmia neonatorum and its adverse vision
consequences:
1. preventing spread of sexually transmitted infections;
2. screening women who are pregnant for genital infection;
3. administering prophylaxis to newborns soon aEer birth;
4. diagnosing and treating eye infections in newborns at an early
stage (Foster 1995; Laga 1989).
German-born obstetrician and gynaecologist Carl Siegmund Franz
Credé introduced the third strategy, ophthalmia neonatorum
prophylaxis (Crede 1884; Dunn 2000; Oriel 1991). In a seminal study,
albeit a case series, Credé showed that silver nitrate administered
to newborns reduced the incidence of ophthalmia neonatorum
from 13.6% to 0.05% (Crede 1881). The relevance of prophylaxis for
ophthalmia neonatorum and debate about the optimal medication
has since evolved in response to the discovery of new antibiotics;
concerns about side eIects with silver nitrate such as chemical
Interventions for preventing ophthalmia neonatorum (Review)
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conjunctivitis and impact on maternal-infant bonding; and the
declining prevalence of N gonorrhoeae in some countries and
increased reporting rates of chlamydial ophthalmia neonatorum in
others (Napchan 2005; Wahlberg 1982).
Initially, studies looking for alternatives to silver nitrate mainly
examined penicillin as ophthalmia neonatorum prophylaxis. Later,
erythromycin and tetracycline were studied in comparison to
silver nitrate, and more recently, povidone-iodine. There have
been studies of other prophylactic agents, but the majority of
jurisdictions in the world today appear to use either erythromycin
or povidone-iodine as ophthalmia neonatorum prophylaxis.
However, there remains a high degree of variability in the
agents used for ophthalmia neonatorum prophylaxis, with some
jurisdictions using prophylactic medications that are uncommon or
not well-studied (Guala 2005; Zloto 2016).
Erythromycin and tetracycline gained acceptance as prophylactic
agents in the 1980s because of their allegedly superior activity
against C trachomatis and because they lacked some of the side
eIects of silver nitrate, such as chemical conjunctivitis (Isenberg
1994a). However, it remains unresolved whether these antibiotic
agents are, in fact, any more eIective than silver nitrate in
preventing chlamydial conjunctivitis. Furthermore, the emergence
of beta-lactamase-producing N gonorrhoeae has reduced the
prophylactic eIectiveness of erythromycin and tetracycline (Ison
1998; Martin 2015; Van de Laar 2012; WHO 2012). Povidone-iodine,
introduced in studies in the 1960s as a surgical antiseptic and
disinfectant agent, has been used relatively more recently as a
candidate for ophthalmia neonatorum prophylaxis. It allegedly
has many advantages over silver nitrate, erythromycin, and
tetracycline, including economic feasibility, broader antibacterial
spectrum, lack of generation of bacterial resistance, and no
reports of anaphylaxis (Grzybowski 2018; Isenberg 1994b). Other
prophylactic measures that have been used beyond antimicrobial
or antiseptic agents include cleansing the eyelids with sterile
swabs; cleansing the eyes with distilled water and wiping dry; and
physiological saline.
Credé’s original procedure for ophthalmic prophylaxis called
for administration “directly aEer birth” (Crede 1881). Timing
of prophylaxis of ophthalmia neonatorum aEer birth has been
addressed by one small study (Muhe 1986). This study suggested
that increasing delay in administration of prophylaxis aEer birth
can lead to a trend to increasing failure of the intervention (Muhe
1986). This study also suggested that a delay in prophylaxis
greater than four hours can lead to a four- to five-fold risk
of gonococcal ophthalmia neonatorum (Laga 1989; Muhe 1986).
Three guidelines have suggested optimal timing of prophylaxis,
but cited no evidence: In 2002, the Canadian Pediatric Society
Guideline suggested prophylaxis administration within one  hour
aEer birth (CPS 2002); in 2011, the United States Preventive Services
Task Force recommendation suggested timing of prophylaxis
administration no later than 24 hours aEer birth (USPSTF 2011); and
in 2017, the World Health Organization (WHO) suggested timing of
prophylaxis to be “immediately aEer birth” (WHO 2017).
How the intervention might work
Ophthalmia neonatorum prophylaxis agents used around the
world are antimicrobial or antiseptic agents, which, when
administered topically, or rarely systemically, destroy or inhibit
micro-organisms in the eye to prevent conjunctivitis and keratitis
(Kramer 2002). The micro-organisms may be acquired from the
mother’s infected birth canal, in utero by ascending infections, or
from the hospital or home environment.
Why it is important to do this review
Launched in 1999, Vision 2020 is a global initiative of the WHO
and the International Agency for the Prevention of Blindness
with the goal to eliminate avoidable blindness by 2020 (WHO
1999). Vision 2020 was updated by the WHO in 2013 to develop a
Global Action Plan from 2014 to 2019 “to reduce the prevalence
of avoidable visual impairment by 25% by 2019” (WHO 2013).
Controlling childhood blindness is a high priority of this plan,
as it has been estimated that 4% of all global blindness is due
to childhood blindness, and that 45% of all childhood blindness
is avoidable. Corneal scarring is one of five childhood blindness
conditions prioritised for control. While vitamin A and measles
are responsible for the majority of corneal scarring, ophthalmia
neonatorum is a significant cause of corneal blindness, mainly in
low- and middle-income countries such as those in sub-Saharan
Africa (Gilbert 2012; Robaei 2014; Whitcher 2001; WHO 2013).
In sub-Saharan Africa, the two major agents responsible for corneal
blindness and scarring, N gonorrhoeae and C trachomatis, have
high prevalence in pregnant women.
The WHO, in conjunction with the United Nations Children’s
Fund and the United Nations Population Fund, has developed
guidelines through its Integrated Management of Pregnancy and
Childbirth (IMPAC) strategy to reduce child and maternal mortality
and morbidity. The IMPAC approach includes preventative and
curative elements, targeting health systems, health workers,
families, and communities. The Pregnancy, Childbirth, Postpartum
and Newborn Care guide’s evidence-based recommendations
include eye prophylaxis for prevention of ophthalmia neonatorum.
Evidence on this intervention and the relative eIectiveness of
diIerent prophylactic regimens is therefore essential to this
intervention (WHO 2015).
There is considerable global variability in recommendations on
whether to use ophthalmia neonatorum prophylaxis, and the
prophylactic agent used. Certain jurisdictions still carry out
ophthalmia neonatorum prophylaxis, including Brazil (Caligaris
2010), the USA (USPSTF 2011), Italy (Guala 2005), Spain (Luna 2009),
Canada (Moore 2015), Slovenia (Jug Došler 2015), France (Dageville
2015), Turkey (Eser 2009), certain areas of Central America, some
countries in Africa, parts of the Far East, areas of the Middle
East, and sections of Central Asia (Zloto 2016). Norway, Great
Britain, Sweden, the Netherlands (Rours 2008; Volksgezondheid
1980), Australia (Shaw 1977), Belgium (Tribolet 2016), and Denmark
(Pande 2006), discontinued ophthalmia neonatorum prophylaxis
several years ago (Kramer 2002). As recently as 2010, England and
Wales removed ophthalmia neonatorum from the list of notifiable
diseases, even though there is some evidence of significant under-
reporting of the incidence of ophthalmia neonatorum (Department
of Health, UK 2010; Dharmasena 2015). In Canada, there have
been recent recommendations that ophthalmia neonatorum be
discontinued, although no legislative changes have been made
in the country as yet (Moore 2015). Some groups in Canada
oppose this recommendation (Mulholland 2015), and others
question whether the alternative strategy of prenatal screening
is an optimal sole substitute for prophylaxis (Poliquin 2015). The
Canadian recommendation to discontinue prophylaxis has been
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made in spite of the fact that the rate of chlamydia in Canada
has increased 57.6% (Totten 2015a), and the rate of gonorrhoea
has increased 38.9% from 2003 to 2012, mainly in women
(Totten 2015b). In France, ophthalmia neonatorum prophylaxis is
no longer universally recommended. Ocular prophylaxis is only
recommended for neonates where there is a risk of sexually
transmitted infections in the mother, and where the mother has
had poor prenatal care (AFSSAPS 2010). Still, other jurisdictions are
looking to implement ophthalmia neonatorum prophylaxis (Pastor
2015).
The global variability in practices regarding prophylaxis for
ophthalmia neonatorum may be explained by the following:
1. there is uncertainty about the evidence of eIectiveness and
risk-benefit ratio of the various prophylactic agents, particularly
against C trachomatis and N gonorrhoeae;
2. the prevalence and distribution of N gonorrhoeae and C
trachomatis  is variable, and has evolved over time, raising the
possibility that universal prophylaxis may no longer be justified;
3. the relative eIectiveness of diIerent medications for
prophylaxis of ophthalmia neonatorum remains to be
determined.
In this systematic review, we aimed to synthesise the available
evidence to inform care and policy regarding prophylaxis for
ophthalmia in the newborn.
O B J E C T I V E S
1. To determine if any type of systemic or topical eye medication
is better than placebo or no prophylaxis in preventing ophthalmia
neonatorum.
2. To determine if any one systemic or topical eye medication
is better than any other medication in preventing ophthalmia
neonatorum.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised and quasi-randomised controlled
trials.
Types of participants
Trials that enrolled newborn infants were eligible for inclusion in
the review.
Types of interventions
We included trials comparing any topical, systemic, or combination
medical interventions with placebo, no prophylaxis, or with each
other.
Types of outcome measures
We considered the following outcomes:
Primary outcomes
1. Proportion of infants developing blindness, defined as a visual
acuity of 20/200 or worse measured, e.g., using a Teller visual
acuity card at 12 months.
2. Proportion of infants developing any adverse visual outcome
measured, e.g., with a Teller visual acuity card at 12 months.
3. Proportion of neonates developing gonococcal conjunctivitis
(GC) within 28 days of birth, where diagnosis was made with
a laboratory-based method to identify the infecting organism.
We anticipated  that most studies would not have studied
blindness as an outcome. Because severe GC is associated with
a substantial risk for loss of vision, we considered this outcome
as a substitute for the more important measure of blindness.
Secondary outcomes
1. Proportion of neonates developing chlamydial conjunctivitis
(CC) within 28 days of birth.
2. Proportion of neonates developing bacterial conjunctivitis (BC)
within 28 days of birth: this includes cases of conjunctivitis
confirmed to be of bacterial origin by culture or Gram stain,
or both. In addition to conjunctivitis cases of other bacterial
aetiology, this category includes GC and CC.
3. Proportion of neonates developing any clinical conjunctivitis
within 28 days of birth, referred to as any conjunctivitis cases
of any aetiology (ACAE): this includes all cases of conjunctivitis
clinically diagnosed, irrespective of aetiology. This would
include infectious and non-infectious conjunctivitis. Infectious
conjunctivitis includes BC, mycoplasma conjunctivitis,
chlamydial or viral conjunctivitis. Non-infectious conjunctivitis
includes chemical, toxic, or mechanical conjunctivitis. In cases
where there was selective outcome reporting, and all cases of
clinical conjunctivitis were not reported, this outcome was not
included in comparisons.
4. Proportion of neonates developing conjunctivitis of unknown
aetiology (CUE) within 28 days of birth: this includes cases of
conjunctivitis that are culture-negative, where the aetiology is
unknown. These may be infectious, but showing no growth
of pathogenic agents on culture media, or on other methods
to identify microbiologic aetiology. This may include non-
infectious conjunctivitis, such as chemical conjunctivitis. Finally,
it may be a mix of the aforementioned causes of conjunctivitis.
In many cases, it is calculated by subtracting the total
conjunctivitis cases of any aetiology from the conjunctivitis
cases proven to be of bacterial origin.
5. Proportion of neonates developing the following adverse eIects
of ophthalmia neonatorum prophylaxis:
a. keratitis within 28 days of birth;
b. nasolacrimal duct obstruction within 60 days of birth.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised
controlled trials and controlled clinical trials. There were no
restrictions to language or year of publication. The databases were
last searched on 4 October 2019.
• Cochrane Central Register of Controlled Trials (CENTRAL; 2019,
Issue 10) (which contains the Cochrane Eyes and Vision Trials
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Register) in the Cochrane Library (searched 4 October 2019)
(Appendix 1).
• MEDLINE Ovid (1946 to 4 October 2019) (Appendix 2).
• Embase Ovid (1980 to 4 October 2019) (Appendix 3).
• LILACS (Latin American and Caribbean Health Science
Information database (1982 to 4 October 2019) (Appendix 4).
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 4 October 2019) (Appendix 5).
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov/; searched 4 October
2019) (Appendix 6).
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/en/; searched 4
October 2019) (Appendix 7).
Searching other resources
We checked the reference lists of identified trial reports and existing
review articles and contacted pharmaceutical companies to locate
additional trials.
Data collection and analysis
Selection of studies
Two review authors independently screened titles and abstracts of
records retrieved from the searches, categorising each record as
either include, exclude, or unclear. We retrieved full-text articles of
records that any of the review authors marked as include or unclear.
Two review authors independently assessed the full-text articles
and marked them as include or exclude. We reported reasons
for full-text articles excluded in this process. The review authors
resolved disagreements through discussion and consensus. In
cases where additional information was needed before a decision
could be made on the eligibility of full-text articles, we attempted
to obtain this information from the study investigator.
Data extraction and management
For each eligible study (using all reports from the study), two
review authors independently extracted information on methods,
participants, interventions, outcomes, and funding sources using
data forms developed for this review. We contacted the study
authors for information missing from available reports.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias in each
included study according to methods described in Chapter 8 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2017). We assessed risk of bias for generation and concealment of
the allocation sequence; masking of participants, caregivers/study
personnel, and outcome assessors; completeness of follow-up;
reporting biases (selective outcome reporting); and other sources
of potential bias such as funding.
The review authors judged the risk of bias for each item as high,
low, or unclear. We contacted study authors if the information in the
available reports was insuIicient to make an assessment. We used
the available information if study authors did not respond within
six weeks.
Measures of treatment e<ect
We computed the risk ratio for dichotomous outcomes.
Unit of analysis issues
We considered the individual as the unit of analysis. The assigned
intervention was typically administered to both eyes, and we
considered infants to be infected if at least one eye was aIected.
We excluded studies in which each eye within an infant was
randomised to a diIerent intervention, even if data were reported
separately for each eye. No cluster-randomised or cross-over
randomised controlled trials were identified and indeed they are
not anticipated in this topic area.
Dealing with missing data
We contacted authors of included trials where we identified missing
data on risk of bias or outcomes. If authors provided information
on risk of bias that was not described in the trial reports, then this
information was marked as such in the review. If missing data on an
outcome were not available from study authors, then we assessed
whether a meta-analysis was possible using an intention-to-treat or
available-case approach.
Assessment of heterogeneity
We assessed heterogeneity in eIect estimates from the included
trials through a visual examination of the forest plot and based
on the I2 statistic. We considered I2 values of 60% or greater to
indicate substantial heterogeneity. We did not perform a meta-
analysis when we found substantial heterogeneity, and instead
provided a narrative summary of the findings. We also considered
the nature of interventions and the patient population to evaluate
clinical heterogeneity in the included trials.
Assessment of reporting biases
For meta-analyses in which we included more than 10 trials,
we planned to construct funnel plots to assess the potential for
publication bias. We planned that if a trial protocol was available,
we would assess whether all outcomes relevant to this review that
were specified in the protocol were also described in the published
reports.
Data synthesis
We performed a meta-analysis for comparisons where we found
minimal or no clinical heterogeneity and without substantial
statistical heterogeneity. We used a random-eIects model, except
for comparisons with two eligible studies, when we used a fixed-
eIect model. For trials with more than one comparison group,
we included the trial in relevant non-overlapping comparisons.
In addition, we collapsed data across intervention groups to
include such trials in the comparison of any prophylaxis versus no
prophylaxis. We used the number allocated in the denominator
for our calculations in all cases except when these data were not
available in the trial reports. We did not explicitly consider risk of
bias as a factor when determining whether to include eligible trials
in meta-analyses. We considered sensitivity analyses based on risk
of bias as discussed below.
For outcomes where at least one trial explicitly reported that no
events were observed in either the treatment or control arm, we
performed a meta-analysis using the Mantel-Haenszel method and
a continuity correction proportional to the inverse of the opposite
arm (Sweeting 2004). Specifically, the continuity correction we used
was 1/(r + 1) in the treatment arm and r/(r + 1) in the control
group, where r is the ratio of sample sizes in the two arms. We
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used R (version 3.3.2) to conduct meta-analyses that included the
continuity correction (R Core Team 2013).
Subgroup analysis and investigation of heterogeneity
We planned to consider subgroups by cause of infection, however
the available data were insuIicient to permit such analyses.
We also planned to separately analyse studies conducted in
high-income versus low-income countries using the classification
specified by the United Nations (WESP2016). However, this was not
possible given the diversity in settings in which the included trials
were conducted.
Sensitivity analysis
Where data were available, we excluded studies with high risk of
selection bias in sensitivity analyses.
Summary of findings and assessment of the certainty of the
evidence
We prepared 'Summary of findings' tables using the GRADE
approach for the following eight outcomes (Langendam 2013).
1. Blindness
2. Any adverse visual outcome
3. Gonococcal conjunctivitis (GC)
4. Chlamydial conjunctivitis (CC)
5. Bacterial conjunctivitis (BC)
6. Any conjunctivitis of any aetiology (ACAE)
7. Conjunctivitis of unknown aetiology (CUE)
8. Adverse eIects
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 498 records (Figure
1). AEer removal of 32 duplicates, we screened the remaining
466 records. We obtained the full-text reports of 105 records
for further assessment. Of these, we included 34 reports of 30
studies (see Characteristics of included studies for details). We
excluded 70 reports of 63 studies (see Characteristics of excluded
studies for details). One study (Matinzadeh 2007)is currently
awaiting classification (see Characteristics of studies awaiting
classification); if we receive further information on this study we
will assess it for inclusion in future updates of this review.
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Specific details on each included study are shown in the
Characteristics of included studies table.
Design
Half of the included studies were quasi-randomised (15/30; 50%),
and half were randomised (15/30; 50%); see Figure 2.
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Figure 2.   Table of Trial Settings
 
Sample sizes
The total number of neonates included in the review across all
30 studies was 79,198. The sample size in individual trials ranged
from 40 to 32,058 neonates. The average number of neonates in the
included studies was 2988, with a median of 654.5.
Setting
Of the 30 trials, 18 studies (60%) were conducted in high-income
economies (9 in the USA, 7 in Europe, 1 each in Canada and
Israel), and 12 (40%) were conducted in low- and middle-income
economies (3 in Kenya, 4 in Iran, 1 each in Zaire, Mexico, Indonesia,
China, and Angola). Two studies explicitly reported recruiting
participants at high risk, for example inner-city populations (Figure
2) (Hammerschlag 1980; Hammerschlag 1989).
Time period of trials
A significant number of trials were conducted more than 50 years
ago. Of the 30 included trials, seven (23%) trials were conducted
between 1940 and 1960, with most of these trials (six) taking place
between 1950 and 1960. Four trials (13%) were conducted between
1960 and 1980; eight trials (27%) between 1980 and 2000; seven
trials (23%) between 2000 and 2010; and four trials (13%) from 2010
to the present.
Interventions
Fourteen diIerent prophylactic regimens and 12 diIerent
prophylactic interventions were studied across the 30 included
trials (Figure 3). Silver nitrate was used in the majority of trials (18
out of 30); mainly in older trials up to the early 1990s. Erythromycin
was used in 10 trials; tetracycline in 9 trials; and povidone-iodine
in 9 trials. Povidone-iodine was used mainly in more recent trials
from the 1990s to the present. The route of delivery for medications
was topical ocular administration, with the exception of two trials
that used intramuscular penicillin. No prophylaxis was used as one
arm of the study in 10 of the 30 trials. Of all trials that included no
prophylaxis in one arm of the study, placebo was used in only one
trial: Wahlberg 1982 used physiological normal saline in one arm of
the trial.
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Figure 3.   Table of Trials, Interventions, Method of Allocation, Settings
 
The full list of interventions used in the included studies is as
follows.
1. Silver nitrate solution (18 studies: all 1%)
2. Erythromycin ointment (10 studies: all 0.5%, except for one
study in which concentration was not specified)
3. Tetracycline (9 studies: all 1%; 2 studies used solution instead of
ointment)
4. Povidone-iodine:
a. solution (9 studies: all 2.5%);
b. double application (1 study).
5. Hexarginum (1 study: 10% solution contains 1 g AgNO3 + 36 g
CH3NH2 dissolved in 63 g sterile water)
6. Penicillin:
a. ointment (2 studies: 1 study: penicillin G 1% ointment; 1
study: penicillin ointment 100,000 units/g);
b. intramuscular injection (IM) (2 studies: 1 study: penicillin
10,000 units per IM injection; 1 study: penicillin G 25,000 to
50,000 units per IM injection depending on birthweight)
7. Cetyl-pyridinium chloride solution (2 studies: 1 study: 0.1%; 1
study: 0.05%)
8. Bacitracin-phenacaine ointment (1 study: bacitracin 500 units/
g; 2% phenacaine hydrochloride)
9. Sulphacetimide ointment (1 study: 10% ointment)
10.Chloramphenicol solution (2 studies)
11.Carbethopendecinium bromide solution (1 study)
12.Colostrum (1 study: 2 drops of mother's colostrum in each eye)
Follow-up time
The included trials varied widely in duration of follow-up and the
time at which outcomes were analysed and reported. Eleven out of
30 (37%) studies followed up neonates for one month. Four trials
(13%) followed up neonates for more than one month. In 12 trials
(40%), follow-up was less than one month. In three trials (10%), no
follow-up period was specified. Of the four trials that followed up
neonates for more than one month, two trials followed up neonates
for three to five months, and two trials for 60 days. Of the two trials
that followed up neonates for 60 days, we were able to extract 30-
day data from one trial, and in the other trial, follow-up was only for
the outcome of nasolacrimal duct obstruction. Of the 12 trials that
followed up neonates for less than a month, nine trials followed
neonates for 10 days or less, and three trials followed neonates for
two weeks.
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Outcomes
Eighteen of the 30 included trials (60%) reported the outcome
of gonococcal conjunctivitis (GC). Thirteen of these 18 trials
(43%) reported no actual cases of GC in any arm of the study.
Consequently, only five studies out of the 30 included trials (17%)
reported any cases of neonates with GC.
Thirteen of the 30 included studies (43%) reported the outcome
of chlamydial conjunctivitis (CC). One of these 13 studies found
no cases of CC in either arm of the study. Seven of the 30 trials
(23%) were conducted between 1940 to 1960, when methods to
detect C trachomatis were not readily available. Ten out of 30 trials
(33%) reported rates of bacterial conjunctivitis (BC). Twenty-four
out of 30 trials (80%) reported the outcome of total number of
clinical conjunctivitis cases. In 10 of 30 trials (33%), we were able to
determine rates of conjunctivitis that were culture-negative.
We were unable to extract outcome data from four studies. In
Richter 2006, the outcomes of conjunctivitis were not well defined,
such that they could not be extracted. In Wahlberg 1982, the
outcomes of total conjunctivitis, culture-negative conjunctivitis,
BC, GC, and CC  were not presented by allocation group; the
denominators did not correspond to allocation groups; and the
data were presented as percentages. In Bramantyo 2016, there
were no conjunctivitis cases; follow-up time was only 24 hours;
and conjunctivitis was not specified in the methods as an outcome.
Finally, in Pastor 2015, there was a high loss to follow-up, and
repeated communications with the study authors failed to clarify
confusion over the remaining data, so that we felt the data could
not be extracted.
Excluded studies
We excluded 63 studies (see Figure 1, Characteristics of excluded
studies)
Risk of bias in included studies
The risk of bias is summarised in Figure 4 and Figure 5.
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Figure 4.   (Continued)
Davidson 1951 - - ? ? - ? ? ? ? ? ? - - ?
Fischer 1988 - - ? ? - - ? ? ? ? ? ? ? ?
Ghaemi 2014 + ? ? ? - ? ? ? - ? - ? - ?
Ghahramani 2007 ? ? ? ? - ? ? ? ? ? + ? - ?
Ghotbi 2012 ? ? ? ? - ? ? ? ? ? ? ? ? ?
Graf 1994 ? ? ? ? ? ? ? ? ? ? + ? + ?
Hammerschlag 1980 ? ? ? ? ? - ? ? ? ? ? - - ?
Hammerschlag 1989 - - ? ? ? - ? ? ? ? ? - - ?
Harris 1957 - - ? ? - ? ? ? ? ? ? ? - ?
Hick 1985 + + ? ? ? ? ? ? ? ? ? ? ? ?
Isenberg 1995 - - ? ? - - - - ? + ? ? + ?
Isenberg 2003 - - ? ? ? ? ? ? ? ? ? ? + +
Kaivonen 1965a - - ? ? ? ? ? ? ? ? ? ? - -
Kaivonen 1965b - - ? ? ? ? ? ? ? ? ? ? - ?
Laga 1988 - - ? ? - - ? ? ? ? - - ? ?
Pastor 2015 + ? ? ? - ? ? ? ? ? - ? - ?
Posner 1959 - - ? ? ? ? ? ? ? ? ? ? - ?
Ramirez-Ortiz 2007 + + ? ? ? - ? ? ? ? ? - - +
Richter 2006 ? ? ? ? ? ? ? ? ? ? ? ? - ?
Siegel 1982 - - ? ? ? - ? ? ? ? ? ? ? ?
Wahlberg 1982 ? ? ? ? ? ? ? ? ? ? - ? - ?
Zbojan 2004 ? ? ? ? - ? ? ? ? ? ? ? ? ?
 
 
Figure 5.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of study participants (mothers of infants): Clinical conjunctivitis (subjective)
Blinding of study participants (mothers of infants): Bacterial, gonococcal and chlamydial conjunctivitis (objective)
Blinding of caregiver who administered medication: Clinical conjunctivitis (subjective)
Blinding of caregiver who administered medication: Bacterial, gonococcal and chlamydial conjunctivitis (objective)
Blinding of persons involved in postnatal care: Clinical conjunctivitis (subjective)
Blinding of persons involved in postnatal care: Bacterial, gonococcal and chlamydial conjunctivitis (objective)
Blinding of outcome assessment (detection bias): Clinical conjunctivitis (subjective)
Blinding of outcome assessment (detection bias): Bacterial, gonococcal and chlamydial conjunctivitis (objective)
Incomplete outcome data (attrition bias): Clinical conjunctivitis (subjective)
Incomplete outcome data (attrition bias): Bacterial, gonococcal and chlamydial conjunctivitis (objective)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Allocation
Of the 15 quasi-randomised trials, three trials alternated by day,
six trials alternated by week, two trials alternated by month,
and three trials applied prophylaxis to alternate neonates. In the
remaining quasi-randomised trial, the prophylaxis for each day
was selected from a previously prepared random sequence of
assignments. Amongst the 15 randomised trials, only four trials
reported the method of randomisation; the remaining 11 trials
described allocation using the word “random” or “randomised”
but did not provide any further information on how the random
sequence was generated.
We assessed 15 out of the 30 included trials (50%) as having a
high risk of selection bias based on random sequence generation.
These 15 trials were generally quasi-randomised studies using
alternation by neonate or by day, week, or month. Eleven of the 30
included trials (37%) used the word “random” or “randomised” in
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the methods, but provided no further information on the random
sequence generation process. We found only four trials (13%)
to have a low risk of selection bias based on random sequence
generation.
Similarly, amongst the 30 included trials, we assessed 15 trials
(50%) as having a high risk of selection bias based on inadequate
concealment of allocations prior to assignment. Again, these
15 trials were generally quasi-randomised studies as mentioned
above. Twelve of the 30 included trials (40%) used the word
“random” or “randomised” in the methods, but provided no further
information on the allocation concealment. We found only five
trials (17%) to have a low risk of selection bias based on the fact that
participants or investigators could not foresee the assignment.
Blinding
We assessed masking (blinding) of participants, personnel, and
outcome assessors for studies in this review. We further categorised
“personnel” into three subcategories: 1. mothers of infants; 2.
people administering prophylaxis; and 3. people involved in
postnatal care.
In none of the trials was there any explicit mention of any
attempt to make the interventions look the same, or dispense
them from containers that made them indistinguishable from the
other interventions. In only one trial, Wahlberg 1982, it may have
been the case that the interventions looked the same, and were
dispensed from containers that looked the same, but this was not
explicit. The ophthalmic medications used in each of the included
studies did not look the same, except possibly in Wahlberg 1982.
For instance, silver nitrate is a clear solution; erythromycin is
an ointment; and povidone-iodine is an orange-red solution. The
physical characteristics of the interventions studied in the included
trials are described in Table 1.
In all but five of the 30 included trials, the medications would have
looked strikingly diIerent, either because of colour or consistency.
The diIerence in appearance of the medication would prevent
masking for the person administering the medication and could
lead to bias, which could influence the outcome. In fact, one study,
Fischer 1988, demonstrated lack of adherence to application of
medication secondary to lack of masking, which influenced rates of
conjunctivitis in one arm of the study.
Masking is further aIected by the fact that the majority of the
medications leave a stain on the eyes aEer dispensing. Silver
nitrate leaves lid stains that may last 30 to 48 hours. Povidone-
iodine may stain periocular skin for minutes to hours. Antibiotic
ointments such as erythromycin, tetracycline, and penicillin can
leave a residue that may last for hours. In four of the five above-
mentioned trials in which the medications may have looked the
same, one of the interventions was silver nitrate, which would have
aIected masking of mothers and people involved in postnatal care
due to silver nitrate’s propensity to cause lid stains. In the remaining
trial in which the medications may have looked the same, there
were three intervention arms, with two arms using erythromycin
and tetracycline ointment, and the last arm having no prophylaxis.
In this trial the ointment allocation groups could therefore be
distinguished from the no-prophylaxis group. In fact, in only one of
the 10 trials where no prophylaxis was one of the arms of the study
was any placebo used; hence, there was lack of masking for the
person administering the medication in the remaining nine trials
with a no-prophylaxis arm.
To summarise, in no studies was it possible to mask the person
administering the prophylaxis for ophthalmia neonatorum. There
are also risks of compromising masking in mothers of neonates
and people involved in postnatal care due to the presence of
prophylaxis staining and residue. Finally, for outcome assessments
conducted soon aEer prophylaxis administration, particularly
for the interventions of silver nitrate, antibiotic ointments, and
povidone-iodine, masking could be compromised.
In spite of the performance bias and detection bias introduced
by the appearance and residual staining of the prophylaxis
medications, trials were scored on these categories, by subjective
and objective outcome. We classified clinical conjunctivitis as
a subjective outcome, and BC, CC and GC as an objective
outcome. We considered CUE, which was essentially culture-
negative conjunctivitis, as objective, given that it was derived from
subtracting BC cases from total clinical conjunctivitis cases. Our
'risk of bias' assessment for masking essentially found that there
was much similarity in the classifications between the subjective
and objective outcomes of conjunctivitis. In summary, the vast
majority of studies had a high or unclear risk of performance bias,
and unclear risk of detection bias, across most outcomes.
There is an additional aspect of silver nitrate that introduces a
form of detection bias. Sixteen of the 30 included trials (53%)
used silver nitrate. In 13 of these  trials, there was an outcome
derived from eye culture results. In any trial with silver nitrate,
there could be biased outcome assessment. Silver nitrate causes
a chemical conjunctivitis in the first 72 hours. As a result, more
neonates in the silver nitrate allocation group could be referred for
culture in the first 72 hours. Finding bacteria in the culture does
not necessarily prove that the bacteria caused the conjunctivitis.
The conjunctivitis could be chemical, but growing normal flora of
the eye. Alternatively, the conjunctivitis could be chemical with
a chlamydial carrier. Finally, the conjunctivitis could very well
be caused by the bacteria or chlamydia. Considerations about
incubation periods, and assessing for carriers and normal flora
with asymptomatic cases, could have assisted with diIerential
diagnosis, but no trial made an attempt to distinguish these
possible outcomes.
Incomplete outcome data
We assessed eight of the 24 studies that reported the outcome of
total clinical conjunctivitis cases as at high risk of bias due to the
high proportion of missing outcome data in proportion to event
rates. We judged 13 of these 24 studies to be at unclear risk of bias
due to poor reporting in the study. We graded only three studies as
at low risk of attrition bias. Of the 20 studies that reported BC, CC or
GC we assessed 10 as at high risk and 10 as at unclear risk of attrition
bias. The two studies reporting nasolacrimal duct obstruction as an
outcome had a high risk of attrition bias. We graded the single study
that reported the outcome of keratitis as at low risk of attrition bias.
Selective reporting
We did not have access to the protocols for any of the included
studies, therefore we compared the outcomes listed in the methods
section of the trial with those reported in the results. We judged
19 of the 30 included trials to be at high risk of bias for selective
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outcome reporting. We assessed seven studies as at unclear risk
and only four studies as at low risk of reporting bias.
Other potential sources of bias
More than half of the included studies (18/30; 60%) did not
specify a source of funding. Of the remaining 12 studies
(40%),  nine studies were funded by a non-governmental
organisation, charitable foundation, government agency, hospital,
or medical school;  funding sources that would seem unlikely
to have biased the methodology or results. Three studies were
funded by pharmaceutical companies, which supplied one of
the interventions in the trial (Davidson 1951; Hammerschlag
1980; Posner 1959). In all three studies, outcomes favoured the
intervention supplied and funded by the pharmaceutical company.
We were unable to determine if any aspect of the methodology may
have been aIected to the point of risk of bias by any pharmaceutical
funding.
Only five of the 30 included trials (17%) made a declaration of
interest, specifying there was no conflict of interest. The remaining
25 trials (83%) made no reference to any declaration of interest.
Only three of the 30 included trials (10%)  provided suIiciently
detailed information in the study report to enable ruling out other
potential sources of bias.
We contacted the study authors if the information in the available
reports was insuIicient to permit assessment. Some authors were
not contacted due to the age of the studies. We contacted the study
authors of 14 of the 30 included trials, of which authors of nine
studies provided a response.
E<ects of interventions
See: Summary of findings 1 Any prophylaxis compared to no
prophylaxis for the prevention of ophthalmia neonatorum in
newborn children
None of the trials reported any data on two of the primary
outcomes specified for this review: incidence of blindness and
visual impairment. Data on the remaining outcomes are discussed
below (Table 2). In this review, we did not attempt to rank the
relative eIectiveness of the various interventions; this has to
be addressed in a subsequent network meta-analysis. Instead,
we discuss our findings for important pairwise comparisons of
interventions along with an overall comparison of any prophylaxis
versus no prophylaxis. The individual pairwise comparisons
are organised as follows: interventions compared with silver
nitrate; interventions compared with erythromycin; interventions
compared with tetracycline; and other comparisons.
Any prophylaxis versus no prophylaxis
See Summary of findings 1.
Any prophylaxis was associated with a statistically significant
reduction in risk for any conjunctivitis of any aetiology (ACAE) but
not for GC, BC, CC, or conjunctivitis of unknown aetiology (CUE).
The certainty of evidence was moderate for ACAE but low for all
other outcomes. For the sake of clarity in the narrative, within each
outcome under the overall comparison of any prophylaxis versus
no prophylaxis, we will describe eIects for individual medications
versus no prophylaxis (see Table 3; Table 4; Table 5; Table 6; Table
7; Table 8).
Gonococcal conjunctivitis 
There was only very low-certainty evidence on the risk of GC
with prophylaxis (4/5340 newborns) compared to no prophylaxis
(5/2889) at one month (risk ratio (RR) 0.79, 95% confidence interval
(CI) 0.24 to 2.65, 3 studies, I2 = 0%; Figure 6).
 
Figure 6.   Forest plot of comparison: 1 Any prophylaxis versus no prophylaxis, outcome: 1.1 Gonococcal
conjunctivitis
 
Data on GC were available for the following medications
individually compared with no prophylaxis: silver nitrate,
erythromycin, tetracycline, povidone-iodine, and bacitracin. For all
these medications, a single trial provided data on comparison with
no prophylaxis except erythromycin for which data were provided
by two trials. No events of GC were observed when silver nitrate
(Chen 1992), erythromycin (Ali 2007; Chen 1992), tetracycline (Chen
1992), or povidone-iodine (Ali 2007), were compared with no
prophylaxis. It was thus not possible to estimate the eIect of
prophylaxis with these medications against GC. Bacitracin was
associated with a RR of 0.76 for GC but with very wide CIs (RR 0.76,
95% CI 0.20 to 2.83) (Posner 1959).
Chlamydial conjunctivitis 
In a meta-analysis of two trials, any prophylaxis did not appear
to reduce the incidence of CC (RR 0.96, 95% CI 0.57 to 1.61, 4874
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participants, 2 studies; I2 = 0%; Analysis 1.1). GRADE certainty of the
evidence was low.
Data on CC were available for the following medications
individually compared with no prophylaxis: silver nitrate,
erythromycin, tetracycline, and povidone-iodine. For all these
medications, a single trial provided data on comparison with no
prophylaxis except erythromycin for which data were provided by
two trials. There was little or no diIerence with the risk of CC for
silver nitrate (RR 1.06, 95% CI 0.55 to 2.02; Chen 1992) . Povidone-
iodine was associated with an increased risk of CC (RR 2.00, 95%
CI 0.18 to 22.74; Ali 2007), but this association was not statistically
significant. There was little or no diIerence in CC with erythromycin
(RR 0.93, 95% CI 0.49 to 1.77, 2526 participants, 2 studies; I2 =
0%; Analysis 3.2) and tetracycline (RR 0.82, 95% CI 0.42 to 1.63)
  compared with no prophylaxis (Chen 1992).
Bacterial conjunctivitis 
In a meta-analysis of two trials, any prophylaxis did not appear
to reduce the incidence of BC (RR 0.84, 95% CI 0.37 to 1.93, 3685
participants, 2 studies; I2 = 0%; Analysis 1.2). GRADE certainty of the
evidence was low.
Data on BC were available for the following medications
individually compared with no prophylaxis: erythromycin and
povidone-iodine. A single trial provided data on BC for both these
medications (Ali 2007). There was no evidence that erythromycin
was associated with a reduced risk of BC compared with no
prophylaxis (RR 0.80, 95% CI 0.22 to 2.90) (Ali 2007). Povidone-
iodine did not appear to reduce the incidence of BC compared with
no prophylaxis (RR 1.00, 95% CI 0.30 to 3.36) (Ali 2007).
Any conjunctivitis of any aetiology 
In a meta-analysis of eight trials, any prophylaxis was associated
with a 35% (95% CI 22% to 46%) reduction in risk of ACAE compared
with no prophylaxis (RR 0.65, 95% CI 0.54 to 0.78, 9666 participants,
8 studies; I2 = 11%; Analysis 1.3). GRADE certainty of the evidence
was moderate.
Data on ACAE were available for the following medications
individually compared with no prophylaxis: silver nitrate,
erythromycin, tetracycline, povidone-iodine, and colostrum. In a
meta-analysis of three trials, silver nitrate was associated with
a reduced risk of ACAE compared with no prophylaxis (RR 0.67,
95% CI 0.52 to 0.87, 2713 participants, 3 studies; I2 = 0%; Analysis
2.3). In a meta-analysis of six trials, erythromycin was associated
with a reduced risk of ACAE compared with no prophylaxis (RR
0.68, 95% CI 0.51 to 0.89, 3509 participants, 6 studies; I2 = 38%;
Analysis 3.4). Similarly, in a meta-analysis of two trials, tetracycline
was associated with a reduced risk of ACAE compared with no
prophylaxis (RR 0.72, 95% CI 0.55 to 0.94, 2519 participants, 2
studies; I2 = 0%; Analysis 4.3). Data from a single trial suggest
that povidone-iodine reduces the risk of ACAE compared with no
prophylaxis (RR 0.38, 95% CI 0.18 to 0.77) (Ali 2007). Finally, a
single trial indicates colostrum is associated with a reduction in risk
of ACAE compared with no prophylaxis that was not statistically
significant (RR 0.72, 95% CI 0.45 to 1.14) (Ghaemi 2014).
Conjunctivitis of unknown aetiology 
In a single trial (Ali 2007), any prophylaxis was associated with an
increased risk of CUE compared with no prophylaxis, but the CIs
were very wide (RR 1.75, 95% CI 0.37 to 8.28). GRADE certainty of
the evidence was very low.
Adverse events
In a single trial (Bell 1993), any prophylaxis (erythromycin 0.5%
or silver nitrate 1%) did not appear to be associated with an
increased risk of nasolacrimal duct obstruction compared with
no prophylaxis (RR 0.93, 95% CI 0.68 to 1.28). GRADE certainty
of the evidence was very low. A single trial of silver nitrate 1%
in 40 newborn children reported that no events of keratitis were
observed in the prophylaxis and no-prophylaxis groups (Graf 1994).
Erythromycin versus silver nitrate
See summary of findings in Table 9.
Gonococcal conjunctivitis 
In a meta-analysis of four trials, two of which reported no incidence
of GC, erythromycin was associated with a 2.28-fold increase in risk
of GC compared with silver nitrate (RR 2.28, 95% CI 0.88 to 5.90,
14,855 participants, 4 studies; I2 = 0%; Figure 7). GRADE certainty of
the evidence was very low. The wide CIs indicate that the estimate
is compatible with a 12% reduction in risk and a 5.9-fold increase
in risk.
 
Figure 7.   Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.1 Gonococcal conjunctivitis.
 
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
Chlamydial conjunctivitis
In a meta-analysis of four trials, erythromycin was associated with
a 25% reduction (95% CI 49% reduction to 9% increase) in risk of
CC compared with silver nitrate (RR 0.75, 95% CI 0.51 to 1.09, 13,472
participants, 4 studies; I2 = 30%;   Analysis 8.1; Figure 8). GRADE
certainty of the evidence was low.
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Bacterial conjunctivitis 
In a meta-analysis of two trials, erythromycin was associated with
a lower incidence of BC compared with silver nitrate (RR 0.83, 95%
CI 0.69 to 1.01, 6333 participants; 2 studies; I2 = 55%;  Analysis
8.2). GRADE certainty of the evidence was low. The two trials
had considerable diIerences in study design, which explains the
observed I2 of 55%. The trials were conducted about 35 years apart.
While both trials allocated infants by alternation and were thus at
high risk of selection bias, Christian 1960 alternated infants and
reported inadequate alternation for the first two months of the trial.
Any conjunctivitis of any aetiology 
There was considerable statistical heterogeneity (I2 = 90%) amongst
the four trials that compared erythromycin versus silver nitrate
and reported data for this outcome (Analysis 8.3), thus we did
not conduct a meta-analysis of the four trials. The protective
eIect of erythromycin in Christian 1960 was about three orders
of magnitude higher than that seen in the remaining three trials,
which may be explained by its high risk of selection bias. GRADE
certainty of the evidence was very low. In a sensitivity analysis
excluding Christian 1960, which was at a high risk of selection bias,
there was no evidence that erythromycin reduced the risk of ACAE
any more than silver nitrate (RR 1.02, 95% CI 0.80 to 1.30). GRADE
certainty of the evidence was low.
Conjunctivitis of unknown aetiology 
In a single trial (Isenberg 1995), there was little evidence of any
diIerence between erythromycin and silver nitrate for risk of CUE
(RR 0.96, 95% CI 0.77 to 1.19). GRADE certainty of the evidence was
low (Analysis 8.4).
Adverse events
In one trial, erythromycin was associated with a reduced risk of
nasolacrimal duct obstruction compared with silver nitrate. This
association was not statistically significant (RR 0.81, 95% CI 0.55 to
1.20; Analysis 8.5) (Bell 1993). GRADE certainty of the evidence was
low.
Overall, we rated the certainty of the evidence for erythromycin
versus silver nitrate to be moderate for GC, CC, and BC (see Table
9). We considered the certainty of the evidence for ACAE to be very
low, owing to heterogeneous estimates in the included studies.
Tetracycline versus silver nitrate
See summary of findings in Table 10.
Gonococcal conjunctivitis 
In a meta-analysis of five trials, tetracycline was associated with
a 34% reduction in risk of GC when compared with silver nitrate,
but this eIect was consistent with both a 79% reduction in risk and
a 2.05-fold increase in risk (RR 0.66, 95% CI 0.21 to 2.05,  14,501
participants, 5 studies; I2 = 0%; Figure 9). GRADE certainty of the
evidence was very low. While the statistical heterogeneity was not
high, all five trials were at high or unclear risk of bias for all 'Risk
of bias' domains assessed. Furthermore, three of the five trials
reported no events of GC. We thus considered the overall certainty
of evidence for this analysis to be low.
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Figure 9.   Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.1 Gonococcal conjunctivitis.
 
Chlamydial conjunctivitis 
In a meta-analysis of four trials, tetracycline was associated with
a reduced risk of CC, but the eIect was not statistically significant
(RR 0.64, 95% CI 0.40 to 1.02, 14,142 participants, 4 studies; I2 =
0%; Analysis 9.1; Figure 10). GRADE certainty of the evidence was
low.
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Bacterial conjunctivitis 
No data were available for BC comparing tetracycline versus silver
nitrate.
Any conjunctivitis of any aetiology
In a meta-analysis of four trials, tetracycline was associated with
a lower risk of ACAE compared with silver nitrate (RR 0.80, 95% CI
0.66 to 0.98, 6229 participants, 4 studies; I2 = 0%; Figure 11). One of
the four trials included in this meta-analysis reported no events in
infants treated with silver nitrate. GRADE certainty of the evidence
was moderate.
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Figure 11.   Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.3 Any conjunctivitis of any
aetiology
 
Conjunctivitis of unknown aetiology
No data were available for CUE comparing tetracycline versus silver
nitrate.
Adverse events
In one trial, tetracycline appeared to be associated with a higher
risk of nasolacrimal duct obstruction, but the variance in the
estimate was high (RR 1.57, 95% CI 0.63 to 3.91, 145 participants, 1
study) (Analysis 9.2). GRADE certainty of the evidence was low.
Sulfacetamide versus silver nitrate
See summary of findings in Table 11.
Gonococcal conjunctivitis 
No events of GC were reported in one trial comparing sulfacetamide
versus silver nitrate (Cousineau 1952). GRADE certainty of the
evidence was very low.
Chlamydial conjunctivitis 
No data on CC were available in one trial comparing sulfacetamide
versus silver nitrate (Cousineau 1952).
Bacterial conjunctivitis 
In one trial (Cousineau 1952), sulfacetamide was associated with
little or no diIerence in risk of BC compared with silver nitrate
(RR 0.88, 95% CI 0.45 to 1.74). This association was not statistically
significant. GRADE certainty of the evidence was low.
Any conjunctivitis of any aetiology
In one trial (Cousineau 1952), sulfacetamide was associated with a
lower risk of ACAE than silver nitrate (RR 0.54, 95% CI 0.32 to 0.89).
GRADE certainty of the evidence was moderate.
Conjunctivitis of unknown aetiology
In one trial (Cousineau 1952), sulfacetamide was associated with a
lower risk of CUE than silver nitrate (RR 0.27, 95% CI 0.11 to 0.66).
GRADE certainty of the evidence was moderate.
Adverse events
No adverse events data were available comparing sulfacetamide
versus silver nitrate.
Cetyl-pyridinium chloride versus silver nitrate
See summary of findings in Table 12.
Gonococcal conjunctivitis
No data were available on GC comparing cetyl-pyridinium chloride
versus silver nitrate.
Chlamydial conjunctivitis
No data were available on CC comparing cetyl-pyridinium chloride
versus silver nitrate.
Bacterial conjunctivitis
In a meta-analysis of two trials, cetyl-pyridinium chloride was
associated with a higher risk of BC compared with silver nitrate; this
association was not statistically significant (RR 1.79, 95% CI 0.59 to
5.41, 599 participants, 2 studies; I2 = 15%). GRADE certainty of the
evidence was low.
Any conjunctivitis of any aetiology
In a meta-analysis of two trials, cetyl-pyridinium chloride was
associated with a higher risk of ACAE compared with silver nitrate;
this association was not statistically significant (RR 1.08, 95% CI 0.40
to 2.90, 599 participants, 2 studies; I2 = 60%). GRADE certainty of the
evidence was very low.
Conjunctivitis of unknown aetiology
In a meta-analysis of two trials, cetyl-pyridinium chloride was
associated with a lower risk of CUE compared with silver nitrate;
this association was not statistically significant (RR 0.14, 95% CI
0.01 to 2.71, 599 participants, 2 studies; I2 = 60%) (Kaivonen 1965a;
Kaivonen 1965b). GRADE certainty of the evidence was low.
Adverse events
No adverse events data were available comparing cetyl-pyridinium
chloride versus silver nitrate.
Penicillin versus silver nitrate
See summary of findings in Table 13 and Table 14.
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Gonococcal conjunctivitis
One trial reported no events of GC comparing topical and
intramuscular (IM) penicillin versus silver nitrate (Davidson 1951).
GRADE certainty of the evidence was very low.
Chlamydial conjunctivitis
No data were available on CC comparing topical and IM penicillin
versus silver nitrate.
Bacterial conjunctivitis
In one trial, topical penicillin was associated with a reduced risk
of BC compared with silver nitrate (RR 0.34, 95% CI 0.18 to 0.65)
(Davidson 1951). GRADE certainty of the evidence was moderate.
In one trial, IM penicillin was associated with a reduced risk of BC
compared with silver nitrate; this association was not statistically
significant (RR 0.75, 95% CI 0.46 to 1.24) (Davidson 1951). GRADE
certainty of the evidence was very low.
Any conjunctivitis of any aetiology
Two trials compared topical penicillin versus silver nitrate for
ACAE. While both trials reported that penicillin was associated
with a lower risk of ACAE compared with silver nitrate, their
estimates were statistically heterogeneous (I2 = 93%; Analysis 12.3),
precluding a meta-analysis. The RR for ACAE was 0.15 (95% CI
0.12 to 0.20) in Davidson 1951 and 0.78 (95% CI 0.35 to 1.70)
in Harris 1957. GRADE certainty of the evidence was very low.
Both trials were reported in the 1950s, and were at high risk of
selection bias and unclear risk of performance, detection, and
attrition biases. Multiple factors may explain the heterogeneity
observed in this analysis, including lack of a specific definition
of conjunctivitis in Davidson 1951, requiring interpretation by the
review authors; and use of wax ampoules that the study authors
reported were sometimes defective, leading to evaporation and
potentially increased concentration of silver nitrate, and eventually
frequency of chemical conjunctivitis.
In one trial, IM penicillin was associated with a reduced risk of ACAE
compared with silver nitrate (RR 0.26, 95% CI 0.21 to 0.32) (Davidson
1951). GRADE certainty of the evidence was moderate.
Conjunctivitis of unknown aetiology
In one trial, topical penicillin was associated with a reduced risk
of CUE compared with silver nitrate (RR 0.13, 95% CI 0.10 to 0.18)
(Davidson 1951). GRADE certainty of the evidence was low.
In one trial, IM penicillin was associated with a reduced risk of CUE
compared with silver nitrate (RR 0.21, 95% CI 0.17 to 0.27) (Davidson
1951). GRADE certainty of the evidence was moderate.
Adverse events
No adverse events data were available comparing penicillin versus
silver nitrate.
Povidone-iodine versus silver nitrate
See summary of findings in Table 15.
Gonococcal conjunctivitis
In a single trial (Isenberg 1995), povidone-iodine was associated
with a higher risk of GC than silver nitrate, which was not
statistically significant (RR 1.94, 95% CI 0.60 to 6.29). GRADE
assessment of the evidence was low.
Chlamydial conjunctivitis
In a single trial (Isenberg 1995), povidone-iodine was associated
with a lower risk of CC than silver nitrate (RR 0.52, 95% CI 0.38 to
0.71). GRADE certainty of the evidence was moderate.
Bacterial conjunctivitis
In a single trial (Isenberg 1995), povidone-iodine was associated
with a lower risk of BC than silver nitrate (RR 0.75, 95% CI 0.61 to
0.92). GRADE certainty of the evidence was moderate.
Any conjunctivitis of any aetiology
In a single trial (Isenberg 1995), povidone-iodine was associated
with a lower risk of ACAE than silver nitrate (RR 0.72, 95% CI 0.63 to
0.84). GRADE certainty of the evidence was moderate.
Conjunctivitis of unknown aetiology
In a single trial (Isenberg 1995), povidone-iodine was associated
with a lower risk of CUE than silver nitrate (RR 0.70, 95% CI 0.55 to
0.89). GRADE certainty of the evidence was moderate.
Adverse events
No adverse events data were available comparing povidone-iodine
versus silver nitrate.
Tetracycline versus erythromycin
See summary of findings in Table 16.
Gonococcal conjunctivitis
In a meta-analysis of two trials, there was no evidence that
tetracycline was associated with a statistically significant reduction
in risk of GC compared with erythromycin (RR 0.73, 95% CI 0.18 to
2.95, 10,946 participants, 2 studies; I2 = 0%). GRADE certainty of the
evidence was low.
Chlamydial conjunctivitis
In a meta-analysis of two trials, tetracycline was associated with a
lower risk of CC than erythromycin, but the reduction in risk was
not statistically significant (RR 0.72, 95% CI 0.42 to 1.25, 10,946
participants, 2 studies; I2 = 0%). GRADE certainty of the evidence
was low.
Bacterial conjunctivitis
No data were available on BC comparing tetracycline versus
erythromycin.
Any conjunctivitis of any aetiology
There was significant heterogeneity (I2 = 69%) in estimates
for risk of ACAE from two trials comparing tetracycline and
erythromycin, which precluded a meta-analysis (Analysis 15.2).
A 25% risk reduction (95% CI 46% reduction to 2% increase)
was observed in Chen 1992 (RR 0.75, 95% CI 0.54 to 1.02),
whilst a 38% increase in risk (95% CI 24% reduction to 2.47-
fold increase) was observed in Ghotbi 2012 (RR 1.38, 95% CI
0.76 to 2.47). GRADE certainty of the evidence was very low. The
heterogeneity observed between the two trials may be explained
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by methodological and clinical factors. Ghotbi 2012 reported
randomly allocating neonates to interventions, whilst Chen 1992
alternated the interventions monthly. Furthermore, Ghotbi 2012
was described as “single-blind”, whilst Chen 1992 did not involve
any masking. Clinically, the causative agents of conjunctivitis
in neonates could diIer between the two trials. However, only
Chen 1992 reported culture results, and we are unable to
definitively ascertain diversity in aetiology of conjunctivitis as
a source of heterogeneity. Separately, the ointments used in
the two studies were of identical concentrations, but they were
manufactured by diIerent companies. This diIerence may explain
heterogeneous outcomes to the extent that the manufacturing
protocols contributed to diIerential eIicacy of the antibiotics.
Conjunctivitis of unknown aetiology
No data were available on CUE comparing tetracycline versus
erythromycin.
Adverse events
No adverse events data were available comparing tetracycline
versus erythromycin.
Colostrum versus erythromycin
See summary of findings in Table 17.
Gonococcal conjunctivitis
No data were available on GC comparing colostrum versus
erythromycin.
Chlamydial conjunctivitis
No data were available on CC comparing colostrum versus
erythromycin.
Bacterial conjunctivitis
No data were available on BC comparing colostrum versus
erythromycin.
Any conjunctivitis of any aetiology
In a single trial (Ghaemi 2014), colostrum was associated with a
higher risk of ACAE compared with erythromycin, but the eIect was
not statistically significant (RR 1.49, 95% CI 0.80 to 2.78). The trial
was at low risk of selection bias but at high risk of attrition bias.
GRADE certainty of the evidence was low.
Conjunctivitis of unknown aetiology
No data were available on CUE comparing colostrum versus
erythromycin.
Adverse events
No adverse events data were available comparing colostrum versus
erythromycin.
Povidone-iodine versus erythromycin
See summary of findings in Table 18.
Gonococcal conjunctivitis
Two trials compared povidone-iodine with erythromycin and
reported data on GC; one of the trials reported no events in both
groups (Ali 2007). The second trial (Isenberg 1995) was larger by
about 10 times; only a few events of GC were observed, resulting
in high variance in the estimate. Povidone-iodine was associated
with a lower risk of GC compared with erythromycin, but the eIect
was not statistically significant (RR 0.85, 95% CI 0.36 to 2.01, 2408
participants, 2 studies; I2 = 0%; Figure 12). GRADE certainty of the
evidence was low.
 




In a meta-analysis of two trials, povidone-iodine was associated
with a lower risk of CC compared with erythromycin, but the eIect
was not statistically significant (RR 0.74, 95% CI 0.54 to 1.02, 2408
participants, 2 studies; I2 = 0%; Analysis 17.1). GRADE certainty of
the evidence was low.
Bacterial conjunctivitis
Povidone-iodine was associated with a lower risk of BC compared
with erythromycin, but the eIect was not statistically significant
(RR 0.87, 95% CI 0.71 to 1.07; Analysis 17.2). GRADE certainty of the
evidence was low.
Any conjunctivitis of any aetiology
In a meta-analysis of two trials, povidone-iodine was associated
with a lower risk of ACAE compared with erythromycin; there was
some statistical heterogeneity (RR 0.78, 95% CI 0.68 to 0.90; I2 =
45%; Analysis 17.3). GRADE certainty of the evidence was moderate.
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Conjunctivitis of unknown aetiology
In a meta-analysis of two trials, povidone-iodine was associated
with a lower risk of CUE compared with erythromycin (RR 0.74, 95%
CI 0.58 to 0.93; Analysis 17.4). GRADE certainty of the evidence was
low.
Adverse events
No adverse events data were available comparing povidone-iodine
versus erythromycin.
Penicillin IM versus tetracycline
See summary of findings in Table 19.
Gonococcal conjunctivitis
None of the 32,058 participants in a single trial comparing IM
penicillin versus tetracycline developed GC (Siegel 1982). GRADE
certainty of the evidence was moderate.
Chlamydial conjunctivitis
In a single trial (Siegel 1982), IM penicillin was associated with a
lower risk of CC compared with tetracycline, but the eIect was
not statistically significant (RR 0.75, 95% CI 0.48 to 1.17). GRADE
certainty of the evidence was moderate.
Bacterial conjunctivitis
No data were available on BC comparing IM penicillin versus
tetracycline.
Any conjunctivitis of any aetiology
No data were available on ACAE comparing IM penicillin versus
tetracycline.
Conjunctivitis of unknown aetiology
No data were available on CUE comparing IM penicillin versus
tetracycline.
Adverse events
No adverse events data were available comparing IM penicillin
versus tetracycline.
Povidone-iodine versus tetracycline
See summary of findings in Table 20.
Gonococcal conjunctivitis
No incidence of GC was reported in a single trial of 410 infants
(David 2011). GRADE certainty of the evidence was low.
Chlamydial conjunctivitis
No incidence of CC was reported in a single trial of 410 infants (David
2011). GRADE certainty of the evidence was low.
Bacterial conjunctivitis
In a single trial (David 2011), povidone-iodine was associated with
a higher risk of BC compared with tetracycline; the association was
not statistically significant (RR 2.04, 95% CI 0.99 to 4.22). GRADE
certainty of the evidence was low.
Any conjunctivitis of any aetiology
In a single trial (David 2011), povidone-iodine was associated with
a higher risk of ACAE compared with tetracycline; the association
was not statistically significant (RR 3.01, 95% CI 1.52 to 5.98). GRADE
certainty of the evidence was low.
Conjunctivitis of unknown aetiology
In a single trial comparing povidone-iodine versus tetracycline
(David 2011), 10 events of CUE were reported with povidone-iodine
but no events of CUE were reported with tetracycline, thus the
eIect was not estimable. GRADE certainty of the evidence was low.
Adverse events
No adverse events data were available comparing povidone-iodine
versus tetracycline.
Povidone-iodine versus chloramphenicol
See summary of findings in Table 21.
Gonococcal conjunctivitis
None of the 2004 infants in a single trial comparing povidone-
iodine versus chloramphenicol developed GC (Ramirez-Ortiz 2007).
GRADE certainty of the evidence was low.
Chlamydial conjunctivitis
In a single trial (Ramirez-Ortiz 2007), povidone-iodine was
associated with a higher risk of CC compared with chloramphenicol,
but the association was not statistically significant (RR 1.77, 95% CI
0.97 to 3.22). GRADE certainty of the evidence was low.
Bacterial conjunctivitis
No data were available on BC for povidone-iodine versus
chloramphenicol.
Any conjunctivitis of any aetiology
No data were available on ACAE for povidone-iodine versus
chloramphenicol.
Conjunctivitis of unknown aetiology
No data were available on CUE for povidone-iodine versus
chloramphenicol.
Adverse events
No adverse events data were available for povidone-iodine versus
chloramphenicol.
Povidone-iodine versus carbethopendecinium bromide
See summary of findings in Table 22.
Gonococcal conjunctivitis
No data were available on GC for povidone-iodine versus
carbethopendecinium bromide.
Chlamydial conjunctivitis
No data were available on CC for povidone-iodine versus
carbethopendecinium bromide.
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Bacterial conjunctivitis
No data were available on BC for povidone-iodine versus
carbethopendecinium bromide.
Any conjunctivitis of any aetiology
In a single trial (Zbojan 2004), povidone-iodine was associated with
a lower risk of ACAE, but the eIect was not statistically significant
(RR 0.44, 95% CI 0.15 to 1.35). GRADE certainty of the evidence was
low.
Conjunctivitis of unknown aetiology
No data were available on CUE for povidone-iodine versus
carbethopendecinium bromide.
Adverse events
No adverse events data were available for povidone-iodine versus
carbethopendecinium bromide.
Povidone-iodine twice versus povidone-iodine once
See summary of findings in Table 23.
Gonococcal conjunctivitis
No incidence of GC was reported amongst 719 infants in a single
trial comparing povidone-iodine administered twice versus once
(Isenberg 2003). GRADE certainty of the evidence was very low.
Chlamydial conjunctivitis
In a single trial (Isenberg 2003), povidone-iodine administered
twice was associated with a higher risk of CC compared with a single
dose of povidone-iodine, but the variance in the estimate was large
(RR 1.27, 95% CI 0.26 to 6.24). GRADE certainty of the evidence was
very low.
Bacterial conjunctivitis
In a single trial (Isenberg 2003), povidone-iodine administered
twice was associated with a higher risk of BC compared with a
single dose of povidone-iodine, but the eIect was not statistically
significant (RR 1.69, 95% CI 0.59 to 4.82). GRADE certainty of the
evidence was very low.
Any conjunctivitis of any aetiology
In a single trial (Isenberg 2003), povidone-iodine administered
twice was associated with a higher risk of ACAE compared with a
single dose of povidone-iodine, but the eIect was not statistically
significant (RR 1.32, 95% CI 0.99 to 1.75). GRADE certainty of the
evidence was low.
Conjunctivitis of unknown aetiology
In a single trial (Isenberg 2003), povidone-iodine administered
twice was associated with a higher risk of CUE compared with a
single dose of povidone-iodine, but the eIect was not statistically
significant (RR 1.29, 95% CI 0.95 to 1.74). GRADE certainty of the
evidence was low.
Adverse events
No adverse events data were available for povidone-iodine
administered twice versus once.
Penicillin IM versus topical penicillin
See summary of findings in Table 24.
Gonococcal conjunctivitis
No incidence of GC was reported amongst 2795 infants in a single
trial comparing IM versus topical penicillin (Davidson 1951). GRADE
certainty of the evidence was very low.
Chlamydial conjunctivitis
No incidence of CC was reported amongst 2795 infants in a single
trial comparing IM versus topical penicillin (Davidson 1951).
Bacterial conjunctivitis
In a single trial (Davidson 1951), IM penicillin was associated with a
higher risk of BC compared with topical penicillin (RR 2.19, 95% CI
1.14 to 4.24). GRADE certainty of the evidence was low.
Any conjunctivitis of any aetiology
In a single trial (Davidson 1951), IM penicillin was associated with a
higher risk of ACAE compared with topical penicillin (RR 1.71, 95%
CI 1.26 to 2.32). GRADE certainty of the evidence was low.
Conjunctivitis of unknown aetiology
In a single trial (Davidson 1951), IM penicillin was associated with a
higher risk of CUE compared with topical penicillin (RR 1.58, 95% CI
1.12 to 2.25). GRADE certainty of the evidence was low.
Adverse events
No adverse events data were available for penicillin IM versus
topical penicillin.
D I S C U S S I O N
Summary of main results
No data were available from the included trials for the primary
vision outcomes of blindness and any adverse visual outcome.
Gonococcal conjunctivitis (GC)  may be considered a surrogate
for vision outcomes because it is associated with a high risk of
blindness.
For prophylaxis of GC, the protective eIect of none of the
interventions we examined was statistically significant, but in
general studies were underpowered for this rare outcome and we
judged the evidence to be low-certainty. Based on eIect estimates,
silver nitrate appeared to be more eIective for prophylaxis of
GC than erythromycin or povidone-iodine (Figure 13). A similar
protective eIect with silver nitrate was not observed against
tetracycline, however.
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Figure 13.   Prophylaxis of GC
 
For prophylaxis of  chlamydial conjunctivitis (CC), the protective
eIect of povidone-iodine relative to silver nitrate was statistically
significant, and a consistent eIect was seen relative to
erythromycin (Figure 14). There were limited data against
tetracycline. However, povidone-iodine was associated with a
higher risk of CC compared with chloramphenicol, which was not
statistically significant.
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Figure 14.   Prophylaxis of CC
 
For prophylaxis of bacterial conjunctivitis (BC), povidone-iodine
appeared to be more eIective than silver nitrate and erythromycin
but less eIective than tetracycline (Figure 15). Furthermore,
erythromycin, sulfacetamide, and penicillin were associated with a
protective eIect against BC compared with silver nitrate; only the
eIect of topical penicillin relative to silver nitrate was statistically
significant. Our findings also indicate that administering povidone-
iodine twice was associated with a higher risk of CC, BC, and
any conjunctivitis of any aetiology (ACAE) compared with single
administration of povidone-iodine.
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Figure 15.   Prophylaxis of BC
 
For prophylaxis of ACAE, any prophylaxis was associated with a
lower incidence (Figure 16). Povidone-iodine, erythromycin, silver
nitrate, and tetracycline had a statistically significant protective
eIect against ACAE compared with no prophylaxis. However,
colostrum did not show a statistically significant protective
eIect against ACAE. Furthermore, povidone-iodine, erythromycin,
tetracycline, penicillin, and sulfacetamide seemed to be more
protective against ACAE compared with silver nitrate and povidone-
iodine appeared to be less protective against ACAE compared with
tetracycline.
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Figure 16.   Prophylaxis of ACAE
 
Finally, our findings demonstrate that silver nitrate is associated
with a statistically significant increased risk of chemical
conjunctivitis when compared with povidone-iodine, cetyl-
pyridinium chloride, sulfacetamide, and penicillin (Figure 17).
Povidone-iodine was associated with a reduced risk of chemical
conjunctivitis when compared with erythromycin. There was high
variance in the estimates showing an apparent increased risk of
chemical conjunctivitis observed with povidone-iodine relative to
no prophylaxis and to tetracycline.
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Figure 17.   Prophylaxis of CUE
 
Overall completeness and applicability of evidence
No trials included the primary outcome of blindness or any
adverse visual outcome. There could be ethical and logistical
barriers to conducting such a trial. The very low incidence of
blindness following ophthalmia neonatorum means trials must be
very large to have adequate power to detect clinically meaningful
diIerences in treatment eIects. The low event rate makes it
diIicult to determine if prophylaxis is eIective for GC, and
diIicult to determine the relative eIect of the various prophylactic
medications for the critical outcome of GC.
This review included studies conducted all over the world, in
low-, middle- and high-income countries, and various settings
within countries, with high and low baseline prevalence of
sexually transmitted and other infections that may be causal
agents of ophthalmia neonatorum. Twelve (40%) of the 30 studies
were conducted in low- and middle-income economies, with the
majority in Iran and Kenya. Three studies took place in Kenya, four
studies in Iran and one each in Zaire, Mexico, Indonesia, China, and
Angola). Eighteen studies (60%) were conducted in high-income
countries, with the majority in the USA and Europe. Nine studies
were conducted in the USA, seven in European countries, one in
Canada, and one in Israel.
More than 50% of the trials were conducted more than 20 years
ago, and about a third of them were conducted more than 40 years
ago. Healthcare systems, the epidemiology of infectious diseases,
and drug resistance have changed during this time in many settings,
which makes generalisability diIicult.
The majority of trials studied silver nitrate (61%), erythromycin
(38%), tetracycline (35%), povidone-iodine (27%), and no
prophylaxis (31%). Silver nitrate does not appear to be
manufactured anymore, and, a limited global survey of agents used
for ophthalmia neonatorum prophylaxis found that silver nitrate
is no longer used in the world (Zloto 2016). However, a variation
containing organically bound silver, and alleged to have a similar
eIect to silver nitrate, called Targesin (1% silver protein acetyl
tannate eye drops) is still used in Slovenia (Jug Došler 2015). The
majority of the world seems to use erythromycin or povidone-
iodine for ophthalmia neonatorum prophylaxis.
The practice of ophthalmia neonatorum prophylaxis varies
globally, with many countries no longer considering it to be
an important public health intervention, and some countries
continuing with prophylaxis. This review provides some moderate-
certainty evidence on the use of prophylaxis to prevent all-cause
cases of ophthalmia neonatorum, but not specifically gonococcal
ophthalmia neonatorum, which has a high risk of blindness, and
was the original purpose of prophylaxis. The results provide data
on the relative eIectiveness of the predominant medications used
in the world for ophthalmia neonatorum prophylaxis, but no
conclusions on which prophylaxis is most eIective for the critical
outcome of GC, which leads to an adverse visual outcome.
Quality of the evidence
The certainty of evidence available to address objectives specified
for this review was at best moderate, and was low or very
low for most of the comparisons studied. Major factors that
aIected our assessment of the certainty of the evidence included
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high potential for selection bias (inadequate randomisation),
performance/detection bias due to masking that was either
insuIicient or impossible, and attrition bias. Our assessment of the
certainty of the evidence was aIected by heterogeneity across trials
in only a few instances.
Potential biases in the review process
We conducted an extensive search of the literature; our search may
not have identified studies presented at conferences in paediatrics
and neonatal medicine. We specified a broad inclusion criteria to
encompass quasi-randomised and randomised studies, therefore
we rated several of the included studies to be at high risk of bias
and the certainty of the evidence as low. Furthermore, several
trials included in this review were published over a period of
about six decades. Trial reporting has significantly varied over
time. Consequently, there was insuIicient information to assess
the risk of bias for many of the included trials, which we judged
as unclear and moderated our evaluation of the certainty of the
evidence. The duration of follow-up and time at which outcomes
were assessed were highly varied in the included trials. Whilst our
approach to combine data across trials, which assessed outcomes
at diIerent times in the 28-day period aEer birth, may have added
uncertainty to our estimates, it is unlikely that our approach would
have led to biased estimates. We used an intention-to-treat analysis
for all but three trials. This approach is likely to have led to an
underestimation of eIect in some instances of our meta-analyses.
We chose this approach because an available-case analysis would
have limited the data only to the subgroup of trial participants who
were followed up.
Agreements and disagreements with other studies or
reviews
Another detailed systematic review on the subject of ophthalmia
neonatorum has been published (Darling 2010). This review was
conducted with methods similar to Cochrane methodology, and
the inclusion criteria were similar to those specified for our review.
However, Darling 2010 included trials only reporting data on
gonococcal and chlamydial ophthalmia neonatorum. In contrast,
our systematic review included these outcomes, but also included
the outcomes of BC, culture-negative conjunctivitis, and all clinical
conjunctivitis cases irrespective of aetiology. The data reported
by Darling 2010 for the outcomes of CC and GC were similar
to those identified in our review. Darling 2010 concluded that
the evidence supports the use of ophthalmia prophylaxis where
there is high prevalence of maternal gonorrhoeal and chlamydial
infection at birth. However, the review questioned the current
evidence for North American laws mandating universal neonatal
eye prophylaxis and suggested a "reexamination of this policy". The
Darling 2010 review served as a major catalyst reference for the
revised 6 March 2015 (and reaIirmed in 28 February 2018) Canadian
Pediatric Society Position Statement on Preventing Ophthalmia
Neonatorum, which states: "Paediatricians and other physicians
caring for newborns should advocate to rescind ocular prophylaxis
regulations in jurisdictions in which this is still legally mandated".
The findings of our review are consistent with the evidence review
supporting the recommendations provided by the World Health
Organization (WHO 2017). This evidence review only examined the
outcomes of CC and GC. This review also included randomised
and non-randomised studies. For all neonates, the May 2017
World Health Organization Recommendations on Newborn Health,
and the 2016 World Health Organization Sexually Transmitted
Infection guidelines "recommend topical ocular prophylaxis
for the prevention of gonococcal and chlamydial ophthalmia
neonatorum". The WHO based this recommendation on low-
certainty evidence, although categorised the recommendation as
strong.
The findings of our review are less consistent with the
evidence review supporting the January 2019 updated
recommendation published by the US Preventive Services Task
Force (USPSTF) (Guirguis-Blake 2019; USPSTF 2019). The USPSTF
recommendations were based upon a systematic review that
only reported data on the outcome of gonococcal ophthalmia
neonatorum. In this review, the USPSTF concluded "with high
certainty that the net benefit of topical ocular prophylaxis of
all newborns to prevent gonococcal ophthalmia neonatorum is
substantial". Our review did not find high-certainty evidence for
prevention of gonococcal ophthalmia neonatorum but moderate-
certainty evidence of an eIect on clinical conjunctivitis more
generally.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Overall, evidence comparing diIerent interventions did not suggest
any consistently superior intervention as most of the available
evidence was of low-certainty and was limited. 
Our findings lead to the following implications for practice.
1. Prophylaxis for ophthalmia neonatorum reduces risk of
neonatal clinical conjunctivitis (any conjunctivitis of any
aetiology (ACAE), based on moderate-certainty evidence.
2. Our analyses did not identify any medication as eIective
against gonococcal conjunctivitis (GC), but in general studies
were underpowered for this rare outcome and we judged the
evidence to be low-certainty. Thus practice should be based on
knowledge about known sensitivity of Neisseria gonorrhoeae to
antibiotics. This is especially relevant in the context of world-
wide concern regarding anti-microbial resistance.
3. Silver nitrate and tetracycline may be considered for prophylaxis
of GC, although it seems that silver nitrate is no longer
manufactured. Low-certainty evidence including data from
all available comparisons (i.e., povidone-iodine versus any
prophylaxis, silver nitrate, and erythromycin), suggests that
povidone-iodine appears to be eIective for prophylaxis against
chlamydial conjunctivitis (CC). Although some have suggested
that povidone-iodine may be associated with an elevated risk of
chemical conjunctivitis (Moore 2015), our findings indicate that
it is in fact associated with a lower risk of chemical conjunctivitis.
4. While chloramphenicol appeared to be more eIective than
povidone-iodine for prophylaxis against CC based on low-
certainty evidence, data on its eIectiveness for preventing GC
were limited. Similarly, tetracycline may be an alternative for
povidone-iodine against CC based on low-certainty evidence,
but the data were insuIicient in this regard.
5. Finally, there are no data on whether prophylaxis for ophthalmia
neonatorum prevents serious outcomes such as blindness or
any adverse visual outcome.
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Although moderate-certainty statistically significant evidence in
this review suggests that prophylaxis with antibiotics is more
eIective than silver nitrate for neonatal clinical conjunctivitis
(ACAE), instituting antibiotic prophylaxis may be erroneous.
Studies demonstrate an increasing prevalence of antibiotic
resistance across the globe, specifically for N gonorrhoeae (Lewis
2014). Furthermore, this resistance appeared to be specific against
antibiotics found to be more eIective than silver nitrate for ACAE
in our review, including erythromycin, tetracycline, sulfacetamide,
and penicillin (Unemo 2016). Policy regarding prophylaxis should
thus also be informed by the prevalence of Neisseria and
Chlamydia, their resistance profile against specific antibiotics,
as well as access to prenatal screening and care. In areas of
high prevalence of N gonorrhoeae infection in pregnant women,
low access to antenatal maternal screening, and low access to
high-quality care, ophthalmia neonatorum prophylaxis may be
considered an eIective strategy to prevent blindness. A recent
systematic review has found that N gonorrhoeae prevalence in
pregnancy can be as high as 4.6% (95% CI 4.0% to 5.2%)
in low-income countries (Davey 2016). UNICEF statistics further
indicate that only 42% of pregnant women in least-developed
countries attended at least four antenatal care visits, and only
77% attended at least one visit, suggesting that 23% women
did not receive any antenatal care  (UNICEF  ). Considering that
neonates born to untreated N gonorrhoeae-infected mothers have
a 30% to 50% risk of developing gonococcal ophthalmia, the risk
of blindness in endemic areas is therefore high (Laga 1989). In
areas where rates of N gonorrhoeae are low in pregnancy, rates
of antenatal screening are high, and there is good access to high-
quality care, resource utilisation concerns may render ophthalmia
neonatorum prophylaxis a relatively less attractive strategy to
prevent blindness.
Implications for research
Our findings lead to the following implications for research.
1. A trial comparing tetracycline, povidone-iodine (single
administration), and chloramphenicol for GC and CC is likely
to provide the community with an eIective, universally
applicable prophylaxis against ophthalmia neonatorum. Our
findings suggest that silver nitrate is more eIective than
erythromycin and povidone-iodine for GC with limited evidence
against tetracycline and chloramphenicol (Figure 13). In
addition, povidone-iodine appeared to be more eIective
than silver nitrate and erythromycin but less eIective than
chloramphenicol for CC (Figure 14). Well-designed trials to
determine whether povidone-iodine is more eIective than
tetracycline and whether chloramphenicol is more eIective
than povidone-iodine for GC and CC will thus yield a universally
applicable prophylaxis for ophthalmia neonatorum.
2. Although the eventual goal for prophylaxis for ophthalmia
neonatorum is to prevent vision loss and blindness, it is unlikely
that trials may be designed to address these outcomes. This is
because the outcomes are rare, necessitating large sample sizes
to detect meaningful eIects. It is also imperative that infections
such as gonorrhoea and chlamydia be eIectively treated when
prenatally diagnosed in the mother. A realistic approach to
determine the eIect of prophylaxis for preventing GC, and
the relative eIectiveness of medications to do so, is thus to
conduct well-designed randomised controlled trials in targeted
settings, for example in populations with high risk or prevalence
of infections such as gonorrhoea and chlamydia. The design
of such trials should emphasise procedures to minimise losses
to follow-up and prompt treatment of positive gonococcal or
chlamydial cultures with the goal of avoiding severe adverse
visual outcomes.
3. A control group with no intervention or placebo is not acceptable
in future trials on prophylaxis for ophthalmia neonatorum.
4. Any future trials on the eIectiveness of colostrum for
prophylaxis of ophthalmia neonatorum must adequately justify
the rationale for why colostrum may potentially prevent
ophthalmia neonatorum, particularly GC and CC.
5. Gonococcal and chlamydial infections in the newborn may
aIect and manifest within organs other than the eye. It
is possible that prophylaxis for ophthalmia neonatorum
may inadvertently mask such infection in non-ocular sites,
but subsequently manifest with non-ocular symptoms and
complications. This hypothesis may be addressed in future
trials on prophylaxis for ophthalmia neonatorum by following
up neonates for non-ocular manifestations of gonococcal
and chlamydial infections despite successful prevention of
ophthalmia neonatorum.
6. Finally, in this review, we did not address the relative
eIectiveness of available medications as prophylaxis for
ophthalmia neonatorum. Whilst we included some pairwise
comparisons, a network meta-analysis is needed to address the
relative eIects of diIerent interventions using both direct and
indirect evidence. Our findings suggest that the data available
from the trials identified in this systematic review may be
suIicient for a network meta-analysis for some outcomes such
as ACAE, but not for others such as GC.
Finally, some have suggested that strategies other than prophylaxis
at birth may be eIective to prevent ophthalmia neonatorum, for
example screening and treating pregnant women for gonococcal
or chlamydial infections (Moore 2015). However, randomised
controlled trials may not be the optimal study design to obtain
evidence on the relative eIects of diIerent strategies for preventing
ophthalmia neonatorum due to ethical reasons, for example
withholding treatment from women infected with chlamydia or
gonorrhoea. Other study designs such as interrupted time series
may be optimal to determine the relative eIect of diIerent
strategies to prevent ophthalmia neonatorum in diIerent settings,
for example defined by levels of prenatal screening, baseline risk
of maternal gonorrhoeal and chlamydial infections, or access to
prenatal care and treatment.
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Study characteristics
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1. unclear how many neonates did not self-report back to the clinic with conjunctivitis;
2. unclear how many neonates in each group were examined on a weekly basis;
3. in the erythromycin group, 7/19 with conjunctivitis (37%) reported to the lab for cultures;
4. in the control group, 7/24 with conjunctivitis (29%) attended the laboratory for cultures.
Exclusions after allocation: 10 newborns in povidone-iodine (Betadine) group; 7 neonates in ery-
thromycin group; and 3 neonates in placebo group for “various reasons including infection, lack of co-
operation or failure to return for follow-up”. Total of 20 were excluded.
No discussion on how missing data were handled in the papers.
No reported power calculation.
Participants Setting: Vali-e-Asr Hospital in Tehran, Iran.
Number allocated: 330.
Age: neonates.
Sex: M:F 171 (55%):139 (45%).
Inclusion criteria:
1. all babies born from January 2004 to August 2005 at the Vali-e-Asr Hospital;
2. neonates without congenital eye abnormalities;
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3. neonates of mothers who had not used any form of antibiotics within the last 48 hours;
4. absence of rupture of membranes for more than 18 h;
5. absence of meconium aspiration.
Exclusion criteria: none specified.
No comment on equivalence of baseline criteria.
Interventions Number of interventions: 3.
• Intervention 1: 2.5% sterile povidone-iodine (Betadine) ophthalmic drops (number of drops not spec-
ified) (n = 110).
• Intervention 2: 0.5% erythromycin ophthalmic ointment (amount not specified) (n = 110).
• Intervention 3: no intervention; no placebo used (n = 110).
Time to intervention: “During the first few hours after birth”.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with clinical conjunctivitis confirmed by paediatrician.
2. Infants with positive culture results of eye swabs.
3. Infants with chlamydial conjunctivitis diagnosed by PCR.
4. Infants with gonococcal conjunctivitis (none found in study).
Follow-up: within a month of birth.
Intervals at which outcomes assessed:
1. examined weekly;
2. parents advised to report to clinic if clinical signs of conjunctivitis within 24 h of birth to 1 month after
birth.
Methods indicate follow-up was 1 month, but results seem to suggest follow-up of 2 weeks. A sentence
in the results states: "Nine subjects from group A (18.4%), 19 from group B and 24 (22.4%) from group C
visited the clinic due to conjunctival redness and tearing or [serious] or purulent discharge during the
first 24 h through 2 weeks of birth...".
Notes on definition of conjunctivitis:
Redness and hyperaemia or purulent ocular discharge.
Amongst neonates returning for assessment, unclear how many actually had red eyes and hyperaemia
and how many had purulent ocular discharge.
No adverse events reported.
Notes Date study conducted: June 2004 to August 2005.
Source of funding not specified.
No declaration of interest found in paper.
No reported subgroup analysis.
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Ali 2007  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk Paper states randomised by “simple randomization technique”. No further de-
tails on methods of randomisation. Concerns about randomisation, as exactly
110 in each of the 3 groups after allocation.
Insufficient information about the sequence generation process to permit
judgement of ‘Yes’ or ‘No’
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement of risk of bias
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk The 2 interventions differ in colour and consistency. Povidone-iodine is a red
solution that leads to transient residual staining of the eye that the mother
would notice. Erythromycin is a translucent ointment that the mother would
initially notice in the infant. There was no placebo in the allocation group that
received no prophylaxis. The mothers of neonates with noticeable medication
may handle the eyes of the infant more than mothers of neonates with no pro-
phylaxis. This could lead to differential introduction of pathogenic bacteria in-
to the eyes of these neonates. Masking of the mother was not addressed in this
paper.
Blinding of study partici-




Unclear risk The study does not comment on whether the mothers were masked as to the
intervention dispensed in the neonate’s eyes. As mentioned, the mother can
identify what was dispensed in the infant’s eyes, as povidone-iodine causes lid
staining and erythromycin is an ointment that is noticeable. The mothers of
neonates with noticeable medication may handle the eyes of the infant more
than mothers of neonates with no prophylaxis. This could lead to differential
introduction of pathogenic bacteria into the eyes of these neonates. Lack of
masking of medication appearance may therefore lead to bias in bacterial con-
junctivitis cases, but unlikely in chlamydia cases.




High risk The 2 interventions differ in colour and consistency. Povidone-iodine is a red
solution that leads to transient residual staining of the eye. Erythromycin is a
translucent ointment that the mother would initially notice in the infant. No
placebo was used in the allocation group that received no prophylaxis. There
appears to have been no attempt to mask the appearance of the medication.
The study makes no comment as to whether the person administering the
medication was masked.





High risk No placebo was used in the no-prophylaxis group, therefore the neonates
in the povidone-iodine group and erythromycin group had handling of the
eyes by the person who administers medication, but not in the no-prophylaxis
group. Handling of the eyes by the person who administers medication could
introduce pathogenic medication into the eyes of the neonates and affect bac-
terial conjunctivitis cases. It is uncertain if this could affect chlamydial con-
junctivitis cases, as it was unclear if the person who administered the medica-
tion could also have been involved in the birth process, and if there were mea-
sures to protect hand hygiene.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk Since povidone-iodine causes staining of the eye, and erythromycin ointment
may leave temporary residual medication, those involved in postnatal care
were likely not initially masked to the medication used as prophylaxis. Further-
more, there is no indication in the paper that an attempt was made to mask
those involved in postnatal care. Masking not addressed in the paper.
Blinding of persons in-




Unclear risk The 2 interventions differ in colour and consistency. Povidone-iodine is a red
solution that leads to transient residual staining of the eye. Erythromycin is a
translucent ointment that the mother would initially notice in the infant. No
placebo was used in the allocation group that received no prophylaxis. There
appears to have been no attempt to mask the appearance of the medication.
Ali 2007  (Continued)
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The study makes no comment as to whether the person administering the
medication was masked.




Unclear risk COMMENT: The study does not mention masking of outcome assessors. In the
first hours of clinical assessment for conjunctivitis, there may be lack of mask-
ing as erythromycin is an ointment that leaves residue, and povidone-iodine is
orange-red and leads to eye staining. It is unclear how many cases of conjunc-
tivitis were diagnosed during this time period. In
ambiguous cases of clinical conjunctivitis, whether identified by personnel,
mother, or outcome assessor, there may be differential group behaviour to in-
clude or exclude cases of clinical conjunctivitis. In this paper, conjunctivitis
was defined as redness and hyperaemia OR the presence of purulent ocular
discharge, which leaves open further subjectivity in the diagnosis of conjunc-
tivitis.





Unclear risk COMMENT: The study does not mention masking of outcome assessors. Any
bias in the clinical diagnosis of conjunctivitis will impact the rates of bacterial
and chlamydial conjunctivitis if one knows which prophylaxis has been given
to a neonate.
In ambiguous cases of clinical conjunctivitis, whether identified by personnel,
mother, or outcome assessor, there may be differential assessor behaviour
to include or exclude cases of clinical conjunctivitis, thereby increasing or de-
creasing likelihood of swabbing the neonate’s eye for bacterial or chlamydial
conjunctivitis. Presence of bacteria or chlamydia on a swab does not necessar-
ily prove that the bacteria caused the conjunctivitis, as the bacteria could be
part of the normal flora of the eye, or the chlamydia could be a carrier.
The effect of lack of masking on the outcome of bacterial conjunctivitis, and, in
particular, chlamydial conjunctivitis, is less as compared to the effect on clini-
cal conjunctivitis. PCR was used to diagnosis of chlamydia, which is objective,
but can also be sensitive enough to detect a possible carrier.
However, event rates for chlamydial conjunctivitis were very low in the paper,





High risk QUOTE: "Ten newborns from group A, seven from group B, and three from
group C, were excluded from the study for various reasons including infection,
lack of cooperation, and failure to return for follow-up.”
COMMENT: Differential exclusion, reasons not all clearly outlined. High rates of






High risk QUOTE: “Only 23 (44%) of the neonates of with conjunctivitis who were re-
ferred to the laboratory actually did so. However, all 9 subjects in group A, at-
tended the laboratory. …In group B, among the 19 cases with clinical con-
junctivitis, only seven (37%) attended the laboratory,…In group C, only sev-
en(29%) newborns with conjunctivitis attended the laboratory,…”




High risk QUOTE: “The neonates were then examined on a weekly basis and the parents
were advised to bring the child to the hospital clinic in case such findings were
observed within 24h to one month after birth.”
“Nine subjects from group A, 19 from group B (18.4%) , and 24 (22.4%) from
group C visited the clinic due to conjunctival redness and tearing and or seri-
ous purulent discharge during the first 24h through 2 weeks of birth…”
Ali 2007  (Continued)
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COMMENT: The methods indicate that follow-up was 1 month, but the results
indicate that follow-up was 2 weeks. We also have no data on the distribution
of neonates with purulent discharge.
COMMENT: 1 or more outcomes of interest in the review are reported incom-
pletely so that they cannot be entered in a meta-analysis.






Randomised by computer algorithm using a permuted block design with block size of 18; envelopes of
consecutively ordered random assignments selected by ward clerk and assigned by primary care nurse.
Unit of randomisation: neonate.
Exclusions after allocation: none specified.
Losses to follow-up: 39 women not available for personal observation during the study.
No reported power calculation.
Participants Setting: Washington, USA.
Recruited women from University of Washington Medical Center-associated obstetric clinics.
Number allocated: 669:





Inclusion criteria: women attending the University of Washington Medical Center-associated obstetric
clinics.
Exclusion criteria: women with the following characteristics:
1. younger than 16 years old;
2. with gonorrhoea in the current pregnancy;
3. who lived more than 50 km from the medical centre or had plans to move within 2 months of delivery;
4. with significant social problems;
5. who planned to be in hospital less than 48 h after delivery;
6. who understood English poorly;
7. who lacked telephone access;
8. with positive Neisseria gonorrhoeae culture within 48 h of delivery;
9. with antimicrobials within 48 h of delivery.
Equivalence of baseline characteristics: yes.
Ethnic minorities included but specific ethnicity not reported. Data provided by ethnic group:
• silver nitrate group: 25% ethnic minorities;
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• erythromycin group: 15% ethnic minorities;
• no-prophylaxis group: 19% ethnic minorities.
Interventions Number of interventions: 3.
• Intervention 1: erythromycin 0.5% ointment applied to eyes 1 time allocated to 222 neonates (amount
not specified).
• Intervention 2: silver nitrate 1% solution applied to eyes 1 time allocated to 221 neonates (number of
drops not specified).
• Intervention 3: no prophylaxis (no placebo or sham was used) allocated to 226 neonates.
Time to intervention: not specified.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with conjunctivitis.
2. Infants with nasolacrimal duct impatency.
3. Infants with epiphora.
Follow-up: up to 60 days.
Enrolled women were telephoned by study staI at day 4 or 5, day 8 or 9, day 30, and day 60.
Examined at age 30 to 48 h, and day 13 to 15 and any time parent requested exam for conjunctivitis.
Definition of conjunctivitis: determined by telephone interview and clinical examination. Parents were
asked to telephone if they noticed discharge from the infant's eyes that was more than normal.
Clinical score from 0 to 3 given for each of the following 4 signs (but not reported):




Tear fluid samples, conjunctival smears, and specimens for bacterial isolation were obtained.
Conjunctivitis was defined as:
• the presence of at least 3 leukocytes on a Gram-stained smear;
• staining for Chlamydia trachomatis on a smear for direct fluorescent antibody staining; or
• the presence of leukocyte esterase in a specimen of tears.
Adverse events of epiphora and nasolacrimal duct patency reported.
Notes on definition of conjunctivitis: The clinical definition of conjunctivitis was not specified. Further-
more, it was not specified if all the neonates were examined, smeared, and tear sampled, or only those
with epiphora and/or conjunctivitis. Finally, if only those neonates with a specific eye sign score were
smeared or only those neonates with epiphora were tear sampled, this was not specified.
Notes Dates of recruitment not specified.
Funding: National Eye Institute Grant EY-05239
No declaration of interest specified.
Trial investigators were contacted and reply received.
Subgroup analysis: Cox survival analysis by follow-up times:
1. 0 to 60 days;
Bell 1993  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
2. 0 to 14 days;
3. 15 to 60 days.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk QUOTE: “ At delivery, neonates were randomised with equal frequency to sil-
ver nitrate, erythromycin, or no ocular prophylaxis."
QUOTE: “The random allocations were assigned by computer algorithm using
a permuted block design with a block size of 18.”
Allocation concealment
(selection bias)
Low risk QUOTE: “When a woman was admitted to the labor and delivery suite, the ran-
dom assignment was determined by a ward clerk who took an envelope from
a box of consecutively ordered random assignments. The assignment was car-
ried out by the primary care nurse.”
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention. No placebo was used in the allocation group that received no
prophylaxis. The other 2 interventions differ in colour and consistency. Silver
nitrate is a clear solution, and erythromycin is a translucent ointment. Fur-
thermore, silver nitrate sometimes causes eyelid stain that can last for 30 to 48
hours and a chemical conjunctivitis that can last up to 72 hours. Erythromycin
is a translucent ointment that the mother would initially notice in the infant,
therefore it would be apparent which medication was being dispensed in a
particular infant’s eyes in the first 3 days for silver nitrate. The mothers of
neonates with noticeable medication may handle the eyes of the infant more
than mothers of neonates with no prophylaxis. This could lead to a differential
introduction of pathogenic bacteria into the eyes of these neonates.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




High risk QUOTE: “The assignment was carried out by the primary care nurse.”
COMMENT: No placebo was used in the allocation group that received no pro-
phylaxis. The other 2 interventions differ in colour and consistency. Silver ni-
trate is a clear solution, and erythromycin is a translucent ointment. Further-
more, silver nitrate sometimes causes eyelid stain that can last for 30 to 48
hours and a chemical conjunctivitis that can last up to 72 hours.
The person administering the medication would handle the eyes of neonates
with erythromycin and silver nitrate, but not those of neonates with no pro-
phylaxis as there was no placebo. This could lead to differential introduction of
pathogenic bacteria into the eyes of these neonates.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Low risk COMMENT: Silver nitrate is a clear solution, and erythromycin is a translu-
cent ointment. Furthermore, silver nitrate sometimes causes eyelid stain that
can last for 30 to 48 hours and a chemical conjunctivitis that can last up to 72
hours.
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QUOTE: “Prophylaxis notation in the medical record was covered to keep
study and other clinical personnel masked as to the assignment.”
QUOTE: “I can assure you that all persons providing care were unaware of the
assigned treatment” (letter from author)
QUOTE: “When asked to guess the type of prophylaxis used, the clinicians ex-
ceeded chance guessing by 21% for silver nitrate, 2% for erythromycin, and 9%
for no prophylaxis.”
COMMENT: This guessing was conducted 30 h and 48 h after birth. The per-
centage of prophylaxis correctly guessed by examiner was 54%, 31%, and 42%
for silver nitrate, erythromycin, and no prophylaxis, respectively. This was a
statistically significant difference at < 0.001.
COMMENT: Silver nitrate is a clear solution, and erythromycin is a translu-
cent ointment. Furthermore, silver nitrate sometimes causes eyelid stain that
can last for 30 to 48 hours and a chemical conjunctivitis that can last up to 72
hours.
COMMENT: Even though masking could be compromised for up to 48 hours,
efforts were made to keep study and clinical personnel masked to the assign-
ment.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Low risk QUOTE: “The clinical study personnel were not told of the assignment of indi-
vidual subjects and were not informed of the study’s findings until after the ob-
servation of subjects had ended.”
COMMENT: Some outcome assessments for conjunctivitis would have likely
been conducted at the 30 h and 48 h of birth, considering that the median age
of infants at diagnosis were 9 to 14 days. It was established that at 30 h and 48
h of birth, it was possible to identify the type of prophylaxis an infant received
(see above). However, these likely represent a small proportion of cases in re-
lation to event rate.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis






High risk QUOTE: “Among 669 randomised women, 39 were not available for personal
observation during the study period. These 39 were almost equally distributed
among the three prophylaxis groups: 16(7%) among 221 randomised to silver
nitrate, 12 (5%) among 222 randomised to erythromycin, and 11 (5%) among
226 randomised to no prophylaxis.”
COMMENT: Despite incomplete outcome data being approximately equally
distributed across intervention groups, the reasons for why these infants were
not available for outcome assessment were not provided by the study authors.
Furthermore, these are high losses in follow-up in relation to event rates.
QUOTE: “Among the 521 infants who did not develop conjunctivitis, 10 re-
ceived care from another physician for signs of conjunctivitis without the par-
ents’ first notifying study personnel. These infants are included with those
without conjunctivitis because study personnel could not verify the case by us-
ing study criteria or obtain laboratory specimens from the infant.”
QUOTE: “Inclusion of the 10 suspected cases on conjunctivitis who were
known to study personnel only by parental report did not change the hazard
ratios for silver nitrate and erythromycin prophylaxis (data not shown).”
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COMMENT: This is imputation, which can lead to serious bias in a study. We are







Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




High risk QUOTE: “An examination for suspected conjunctivitis began by observing the
severity of lid edema, erythema, conjunctival hyperemia, purulent discharge,
and bleeding when the mucosa was swabbed. Each sign was graded 0 to 3 ac-
cording to predetermined criteria; the scores were summed for each eye, with
a maximum of 12 possible.”
COMMENT: The clinical scores for suspected conjunctivitis were not reported
in the paper. What clinical score defined conjunctivitis is also not reported.
QUOTE: “Silver nitrate eye prophylaxis caused no sustained deleterious ef-
fects and even some benefit to infants born to women without Neisseria gon-
orrhoeae. However, the effect was modest and against microorganisms of low
virulence.”
QUOTE: “…the microorganisms found in association with the conjunctivitis
were for the most part common flora of the upper respiratory tract and un-
common vaginal flora.” (unpublished observation)
COMMENT: The authors apparently collected data on the micro-organisms
that infected the infants’ eyes, but did not mention this in the methods, or re-
port any of the results of these data.
QUOTE: “The primary outcome measured was conjunctivitis. This was deter-
mined by examination of the infant and cytologic or biochemical confirmation.
Conjunctivitis was defined as the presence of at least three leukocytes on a
Gram-stained smear or on a smear made for direct fluorescent antibody stain-
ing for C trachomatis or by detection of any amount of leukocyte esterase in a
specimen of tears…”
COMMENT: The authors did not report the number of infants, if any, that were
positive for direct fluorescent antibody staining for C trachomatis.
Other bias Unclear risk QUOTE: “Among the 758 women enrolled, 89 were not randomised.”
COMMENT: It is unclear why the 89 women who were enrolled after the 28th
week of pregnancy were then subsequently not randomised.
QUOTE: “The 29 infants who were treated with antimicrobials for medical con-
ditions other than conjunctivitis before age 60 days were not censored from
the study.“
COMMENT: There is postrandomisation administration of an intervention that
could enhance the effect of the prophylactic regimen. The distribution of these
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Method of allocation: "randomly"; no other information provided.
Unit of randomisation: neonate.
Exclusions after allocation: none specified.
Losses to follow-up: none specified.
Number randomised: 60.
No reported power calculation.
Unusual study design: main outcome was bacterial colonies.
Participants Country: Jakarta, Indonesia.
Setting: Cipto Mangunkusumo Hospital, Jakarta.
Ethnic group: not specified.
Total number of participants: 60.
Sex: M:F 29 (48%):31 (52%).
Average age range: not specified.
Inclusion criteria:
1. normal babies born by vaginal delivery at full-term birth.
Exclusion criteria:
1. babies with congenital eye malformation;
2. babies whose parents refused to take part in the study;
3. equivalence of baseline characteristics: yes.
Interventions Number of interventions: 2.
• Intervention: povidone-iodine 2.5% ophthalmic solution applied to eye conjunctiva (n = 30).
• Comparator: chloramphenicol 1% eye ointment applied to eye conjunctiva (n = 30).
Time to intervention: 1 hour after birth.
Pre-intervention manoeuvres: conjunctival swabs were taken from the inferior fornix of the right eyes
before application of prophylaxis.
Postintervention manoeuvres: conjunctival swabs were retaken 2 hours after the prophylactic agent
had been applied.
Outcomes 1. Reduction in bacterial colony-forming units before and after prophylaxis.
2. Comparison of reduction of bacterial colony-forming units between 2 prophylactic agents.
In the results section, but not in the methods, the following outcomes were specified:
1. "...no newborns experienced toxic conjunctivitis or corneal opacities caused by the toxic effects of the
2.5% povidone-iodine ophthalmic solution or the 1% chloramphenicol eye ointment."
2. "...no clinical evidence of conjunctivitis was found."
Adverse events reported: yes; "...no newborns experienced toxic conjunctivitis or corneal opacities
caused by the toxic effects of the 2.5% povidone-iodine ophthalmic solution or the 1% chlorampheni-
col eye ointment."
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Follow-up time: not specified. At least up to 24 h: "In our study, there was no toxic conjunctivitis reac-
tion or corneal opacities found 24 h after the administration of the prophylactic 1% chloramphenicol
eye ointment or the 2.5% povidone-iodine ophthalmic solution."
Notes Date conducted: October to December 2012.
Sources of funding: not specified.
Declaration of interest: "The authors have no funding or conflicts of interest to declare."
No reported subgroup analysis.
Trial investigators were contacted but no response was received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk QUOTE: “A total of 60 samples were divided randomly into 2 groups.”
Allocation concealment
(selection bias)
Unclear risk COMMENT: Not described
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study is described as “double-blind”, but masking of mothers
of the intervention was not specifically addressed. Furthermore, the 2 inter-
ventions differ in colour and consistency. Povidone-iodine is an orange-red so-
lution that can lead to periocular stains that last minutes to hours. Chloram-
phenicol is an ointment that can leave a residue in the eyes that could be no-
ticed for hours.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




High risk COMMENT: The study is described as “double-blind”, but masking of the per-
son administering the medication was not addressed. The 2 interventions dif-
fer in colour and consistency. Povidone-iodine is an orange-red solution that
can lead to periocular stains that last minutes to hours. Chloramphenicol is an
ointment that may leave a residue in the eyes that can be noticed for hours.
The 2 interventions are therefore readily identifiable. Any bias on the part of
the person administering the medication could affect adherence or compli-
ance with the application method of the medication, which, in turn, could af-
fect the medication’s prophylactic effect.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study is described as “double-blind”, but masking of people in-
volved in postnatal care was not addressed. The 2 interventions differ in colour
and consistency. Povidone-iodine is an orange-red solution that can lead to
periocular stains that last minutes to hours. Chloramphenicol is an ointment
that may leave a residue in the eyes that can be noticed for hours.
Bramantyo 2016  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
It is uncertain in this study if there were cases of conjunctivitis identified in the
time period when masking would be affected. However, the follow-up time
could be as short as 24 hours. It is uncertain if people involved in postnatal
care were also involved in identification of cases of conjunctivitis. If they were,
and were unmasked, this could influence decisions to identify clinical conjunc-
tivitis cases.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk COMMENT: The study is described as “double-mask”, but masking of the per-
son who was involved in outcome assessment of conjunctivitis was not specif-
ically addressed in this paper. The 2 interventions differ in colour and consis-
tency. Povidone-iodine is an orange-red solution that can lead to periocular
stains that last minutes to hours. Chloramphenicol is an ointment that may
leave a residue in the eyes that can be noticed for hours.
Conjunctivitis cases appear to be diagnosed in the first 24 h, therefore masking
could have been affected and influenced the outcome.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis






Low risk COMMENT: The issue of loss to follow-up is not discussed in the study. Fol-







Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




High risk COMMENT: A primary outcome of conjunctivitis was not prespecified, and is
reported incompletely.





Methods Parallel-group, single-centre trial.
All infants born in a particular day were randomised to the same prophylaxis using a serially numbered
envelope (daily randomisation as opposed to infant randomisation).
Unit of randomisation: neonate.
Exclusions after randomisation: no comment.
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Losses to follow-up:
1. tetracycline group: 55%;
2. silver nitrate: 54%.
No comment on how missing data were handled.
No reported power calculation.
Unusual study design: none.
Participants Setting: Saint-Germain-en-Laye, France
Number allocated: 900 neonates:
• oxytetracycline: 475;
• silver nitrate: 425.
Age: neonates.
Sex: M:F 488 (54%): 412 (46%).
Inclusion criteria:
• infants born at the maternity ward of Saint-Germain Hospital from February to September 1989.
Exclusion criteria:
• newborns with "disease" or "pathology" were excluded from the study; unclear if this was specified
a priori or after allocation.
No comment on equivalence of baseline criteria.
Interventions Number of interventions: 2.
• Intervention 1: 1% aqueous oxytetracycline hydrochlorate ophthalmic drops (number of drops not
specified) (n = 475).
• Intervention 2: 1% silver nitrate ophthalmic drops (number of drops not specified) (n = 425).
Time to intervention: not specified, according to translation.
Pre-intervention manoeuvres: not specified, according to translation.
Postintervention manoeuvres: not specified, according to translation.
Outcomes Sum of the number of neonates with pathological signs at day 7 with the number of neonates with
pathological signs on day 30.
Sum of the number of neonates with bacteria on Gram stain or culture from ocular specimens at day 7
with the number of neonates with bacteria on Gram stain or culture from ocular specimens on day 30.
1 case of chlamydia on bacterial culture.
2 forms were completed:
1 form was completed during the infant's stay at the maternity hospital in the first week. It is unclear if
the infant was examined daily, by referral by a healthcare provider or parent, or at random during the
first week.
The eye was graded as:
1. normal;
2. minimal signs - palpebral oedema or tearing;
3. pathological signs.
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Conjunctival irritation and any amount of purulent discharge
Any abnormality noted by a paediatrician, either minimal or pathological, was referred to an ophthal-
mologist.
Only infants with pathological signs had their eyes cultured.
Another form was completed apparently by the mother of the infant at any time upon date of discharge
until day 30. It is unclear who completed the form.
An attempt was made to examine the infant once at the end of the first month of age by a general prac-
titioner or paediatrician.
It is unclear when these cultures were done in relation to the development of the pathological signs.
Follow-up: 2 examinations were performed on each child: Exam 1 any time from day 1 to day 7 while in
hospital by paediatrician. Exam 2 any time from day 7 to day 30 by paediatrician or general practition-
er.
Definition of conjunctivitis or ophthalmia neonatorum: not explicitly defined in paper, according to
translation.
No adverse events reported.
Notes Source of funding not provided.
Date of study: February to September 1989
No declaration of interest specified.
No reported subgroup analysis.
Trial investigators were contacted and reply received.
Article translated from French to English.
High loss to follow-up on day 30.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: (translated from French) “the topical medication… was randomized
every day at 13:00 to be given during 24 hours to all newborns”
COMMENT: Sequence generated by some rule based on day.
Allocation concealment
(selection bias)
High risk QUOTE: “A serially numbered envelope sealed was taken to determine the
treatment of the day which changed every day at 1 pm” (letter from author)
QUOTE: (translated from French) “The nurses, who knew which drop was giv-
en, wrote down on a notebook what medication was given on that day, and
the name… of the child who received them…”
COMMENT: It is unclear what role the nurses had in enrolling participants. Ran-
domisation was by day, therefore whilst there may be allocation concealment
by day, there was no allocation concealment by the next intervention for the
next neonate that same day.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The parents were aware of the protocol but the treatment was
known only at the end of the study.” (letter from author)
COMMENT: The 2 interventions were silver nitrate and tetracycline. The oxyte-
tracycline hydrochloride used in the study was not ointment but aqueous,
quite possibly making it similar in appearance to silver nitrate. However, sil-
ver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. It is un-
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clear if oxytetracycline chloride leads to lid stains. The mothers of neonates
with noticeable medication may handle the eyes of the infant more, potential-
ly affecting the outcome.
Blinding of study partici-




Unclear risk QUOTE: “The parents were aware of the protocol but the treatment was
known only at the end of the study.” (letter from author)
COMMENT: The 2 interventions were silver nitrate and tetracycline. The oxyte-
tracycline hydrochloride used in the study was not ointment but aqueous,
quite possibly making it similar in appearance to silver nitrate. However, sil-
ver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. It is un-
clear if oxytetracycline chloride leads to lid stains. The mothers of neonates
with noticeable medication may handle the eyes of the infant more, potential-
ly affecting the outcome of bacterial conjunctivitis, and even chlamydial con-
junctivitis, depending on hygiene measures.
Lack of masking, with concomitant bias, could influence which neonates are
brought forward by parents for bacteriological analysis. This is important con-
sidering chlamydial conjunctivitis exists as an asymptomatic carrier.




Unclear risk QUOTE: (translated from French) “The nurses, who knew which drop was giv-
en, wrote down on a notebook what medication was given on that day, and
the name… of the child who received them…”
COMMENT: The study does not state whether the person administering the
medication was masked, or if the vials holding the different medications were
made to look the same or kept in their original labelled vials.
Knowledge of the medication being dispensed, along with any concomitant
bias, could affect adherence and differential application of prophylaxis, which,
in turn, could affect preventive effect of the development of conjunctivitis.





Unclear risk QUOTE: (translated from French) “The nurses, who knew which drop was giv-
en, wrote down on a notebook what medication was given on that day, and
the name… of the child who received them…”
COMMENT: The study does not state whether the person administering the
medication was masked, or if the vials holding the different medications were
made to look the same or kept in their original labelled vials.
Knowledge of the medication being dispensed, along with any concomitant
bias, could affect adherence and differential application of prophylaxis, which,
in turn, could affect preventive effect of the development of chlamydial con-
junctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The nurse providing care after the birth room did not know which
treatment had been given” (letter from author)
QUOTE: (translated from French) “The nurses, who knew which drop was giv-
en, wrote down on a notebook what medication was given on that day, and
the name… of the child who received them…”
COMMENT: Since silver nitrate causes lid stains that can last up to 30 to 48
hours, those involved in postnatal care were likely not masked to the medica-
tion used until this time period. It is unclear if the nurses who wrote down the
medication administered had a specific communication barrier with those in-
volved in postnatal care.
Blinding of persons in-




Unclear risk QUOTE: “The nurse providing care after the birth room did not know which
treatment had been given” (letter from author)
QUOTE: (translated from French) “The nurses, who knew which drop was giv-
en, wrote down on a notebook what medication was given on that day, and
the name… of the child who received them…”
COMMENT: Since silver nitrate causes lid stains that can last up to 30 to 48
hours, those involved in postnatal care were likely not masked to the medica-
tion used until this time period. It is unclear how many cases of conjunctivitis
were identified for referral for bacteriological analysis during this time period.
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Lack of masking could differentially lead to referral of clinical cases with “mini-
mal” ocular signs for bacteriological analysis, which could, in turn, falsely and
differentially identify chlamydial carriers as opposed to true cases of chlamy-
dial conjunctivitis. Considering the low event rate of chlamydial conjunctivitis,
this could be important.
COMMENT: It is unclear if the nurses who wrote down the medication admin-
istered had a specific communication barrier with those involved in postnatal
care.




Unclear risk QUOTE: “The investigators did not have access to the notebook until the end
of the study.”
QUOTE: ”Only the midwives knew the result and noted a number on the infant
case history.” (letter from author)
COMMENT: These statements appear to infer that the outcome assessors were
masked, but this is not entirely clear. As silver nitrate creates lid stains that last
30 to 48 hours, outcome assessments during this time were likely not masked.
It is uncertain what efforts were undertaken to overcome this. There is no for-
mal clinical conjunctivitis definition in the paper, only grading of clinical ocu-
lar signs, which creates more subjectivity. Any lack of masking could therefore
influence the outcome more so.





Unclear risk QUOTE: “The investigators did not have access to the notebook until the end
of the study.”
QUOTE: ”Only the midwives knew the result and noted a number on the infant
case history.” (letter from author)
COMMENT: These statements appear to infer that the outcome assessors were
masked, but this is not entirely clear. As silver nitrate creates lid stains that last
30 to 48 hours, outcome assessments during this time were likely not masked.
It is uncertain what efforts were undertaken to overcome this. There is no for-
mal clinical conjunctivitis definition in the paper, only grading of clinical ocu-
lar signs, which creates more subjectivity. Any lack of masking could therefore
influence the outcome more so.
Neonates’ ocular signs were graded as normal, minimal, and pathological.
It appears that all neonates, possibly including those with minimal ocular
signs, were sent for bacteriological analysis. This widens diagnostic ambigui-
ty, therefore any lack of masking by the outcome assessors could significantly
bias those chosen for bacteriological analysis.
“Minimal” eyes signs were defined in the paper as “simple palpebral edema,
more or less important, on one or both sides with no or minimal tearing”.
Chlamydia found on bacteriological analysis with minimal eye signs, as de-
fined in the paper, may not be chlamydial conjunctivitis, but could also be





High risk QUOTE: (translated from paper) “1128 children were born in the nursery dur-
ing the study period…All newborns that had disease were excluded from the
study, even if that disease did not motivate the transfer to a neonatal depart-
ment: 228 charts were excluded”
COMMENT: What type of disease motivated exclusion is not specified, and ex-
clusions by allocation group are not provided.
QUOTE: (translated from paper) “407 forms…among the 900 charts have been
sent by the practitioners who performed the first month visit.”
COMMENT: 2 examinations were performed for each neonate. The first was
performed during the stay at the maternity hospital, which was about 1 week.
The second exam was conducted outside the hospital by the neonate’s gener-
al practitioner or paediatrician at the end of the first month of age. At day 30,
there was 55% loss in the tetracycline group, and 54% loss in the silver nitrate
group. Although balanced, the losses to follow-up are high relative to event
rate.
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High risk QUOTE: (translated from paper) “1128 children were born in the nursery dur-
ing the study period…All newborns that had disease were excluded from the
study, even if that disease did not motivate the transfer to a neonatal depart-
ment: 228 charts were excluded”
COMMENT: What type of disease motivated exclusion is not specified, and ex-
clusions by allocation group are not provided.
QUOTE: (translated from paper) “407 forms…among the 900 charts have been
sent by the practitioners who performed the first month visit.”
COMMENT: 2 examinations were performed for each neonate. The first was
performed during the stay at the maternity hospital, which was about 1 week.
The second exam was conducted outside the hospital by the neonate’s gen-
eral practitioner or paediatrician at the end of the first month of age. At day
30, there was 55% loss in the tetracycline group, and 54% loss in the silver ni-
trate group. Although balanced, the losses to follow-up are very high relative
to event rate for chlamydial conjunctivitis.
Selective reporting (re-
porting bias)
High risk COMMENT: We cannot extract the outcome of bacterial conjunctivitis from
this study, as it appears that “minimal” and “pathological” ocular signs were
swabbed for bacteriological analysis. Neonates with “minimal” ocular signs is
inconsistent with a definition of conjunctivitis. Swabbing eyes with minimal
signs may over-represent neonates with growth of normal flora of the eye, and
may not necessarily indicate that the isolated organism caused the eye signs.
As a result, as an outcome of interest in the review it is reported incompletely
and so cannot be entered in the meta-analysis.
COMMENT: It is also unclear if the organisms recovered represent individual
neonates or the same neonate having multiple different organisms.
Other bias Unclear risk COMMENT: In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
more neonates in the silver nitrate allocation group could be referred for cul-
ture in the first 72 hours. Finding bacteria in the culture does not necessarily
prove that the bacteria caused the conjunctivitis. The conjunctivitis could be
chemical, but growing normal flora of the eye. Alternatively, the conjunctivitis
could be chemical with a chlamydial carrier. Finally, the conjunctivitis could
very well be caused by the bacteria or chlamydia. Consideration of incubation
periods, and assessing for carriers and normal flora with asymptomatic cases,





Methods Parallel-group, single-centre trial.
Method of allocation: rotated monthly.
Unit of randomisation: neonate.
Rates of follow-up in comparison groups: not reported.
Analysis by intention-to-treat: unclear.
Exclusions after allocation: none specified.
Losses to follow-up: none specified.
Unusual study design: none identified.
No comment on how missing data handled.
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No reported power calculation.
Participants Setting: Taichung, Taiwan, Republic of China.
Number allocated: 4544:
• silver nitrate: 1082;
• tetracycline: 1156;
• erythromycin:1163;
• no prophylaxis: 1143.
Age: neonates.
Sex: M:F unknown.
Inclusion criteria: neonates born at Chung Shan Medical and Dental College Hospital.
Exclusion criteria: none specified.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 4.
• Intervention 1: erythromycin 0.5% ointment, 1 dose applied to eyes (dose amount not specified) (n
= 1163).
• Intervention 2: tetracycline 1% ointment, 1 dose applied to eyes (dose amount not specified) (n =
1156).
• Intervention 3: silver nitrate 1% solution, 1 dose applied to eyes (dose amount not specified) (n = 1082).
• Intervention 4: no prophylaxis (no sham or placebo) (n = 1143).
Time to intervention: immediately after birth.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with any conjunctivitis.
2. Infants with bacterial conjunctivitis.
3. Infants with non-bacterial conjunctivitis.
4. Infants with chlamydial conjunctivitis.
5. Infants with non-chlamydial conjunctivitis.
Follow-up: up to 4 weeks of age.
Infants examined in nursery. Also, infants examined 1 week after discharge and at 4 weeks of age, or
when infants developed conjunctivitis.
Definition of conjunctivitis: purulent conjunctival discharge and conjunctival hyperaemia for infants
meeting clinical criteria: aerobic and anaerobic bacterial cultures, and monoclonal antibody stain to
detect Chlamydia trachomatis were obtained.
No adverse events reported in study.
Notes Date of recruitment: November 1989 to October 1991.
No source of funding specified.
No declaration of interest specified.
No reported subgroup analysis.
We contacted authors for clarifications on masking, but have received no reply to date.
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “The neonatal ocular prophylactic preparations… were rotated
monthly.”
COMMENT: Non-random component in the sequence generation process
Allocation concealment
(selection bias)
High risk QUOTE: “The neonatal ocular prophylactic preparations… were rotated
monthly.”
COMMENT: Participants or investigators enrolling participants could foresee
assignments.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study did address masking by the study participants. The 4 in-
terventions differ in colour and consistency. Silver nitrate is a clear solution.
Also, silver nitrate sometimes causes a chemical conjunctivitis that can last up
to 72 hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Ery-
thromycin is a translucent ointment that may leave residue that can be notice-
able for hours. Tetracycline is a light-yellow ointment that may be difficult to
distinguish from erythromycin, but that also leaves a residue in the eyes that
can last for hours. There was no placebo in the allocation group that received
no prophylaxis. The mothers of neonates with noticeable medication of the
eyes may handle the eyes of the infant more than mothers of neonates with no
prophylaxis, potentially affecting the outcome of clinical conjunctivitis.
Blinding of study partici-




Unclear risk COMMENT: The study did address masking by the study participants. The 4 in-
terventions differ in colour and consistency. Silver nitrate is a clear solution.
Also, silver nitrate sometimes causes a chemical conjunctivitis that can last
up to 72 hours, and silver nitrate causes lid stains that can last 30 to 48 hours.
Erythromycin is a translucent ointment that may leave residue that can be no-
ticeable for hours. Tetracycline is a light-yellow ointment that may be diffi-
cult to distinguish from erythromycin, but that also leaves a residue in the eyes
that can last for hours. There was no placebo in the allocation group that re-
ceived no prophylaxis. The mothers of neonates with noticeable medication
of the eyes may handle the eyes of the infant more than mothers of neonates
with no prophylaxis, potentially affecting the outcome of clinical conjunctivitis
through introduction of pathogenic material into the eyes.
Lack of masking may lead the mothers of neonates with noticeable medication
of the eyes to handle the eyes of the infant more than mothers of neonates
with no prophylaxis, potentially affecting the outcome of bacterial conjunctivi-
tis, and even chlamydial conjunctivitis, depending on hygiene measures.
Lack of masking, with concomitant bias, could influence which neonates are
brought forward by parents for bacteriological analysis. This is important con-
sidering that chlamydial conjunctivitis can exist as an asymptomatic carrier, or
be the cause of chlamydial conjunctivitis.




High risk COMMENT: The study did not address masking by the person who administers
the medication.
The 4 interventions differ in colour and consistency. Silver nitrate is clear solu-
tion. Erythromycin is a translucent ointment that may leave residue that can
be noticeable for hours. Tetracycline is a light-yellow ointment that may be
difficult to distinguish from erythromycin. There was no placebo in the alloca-
tion group that received no prophylaxis.
Lack of masking of the person who administers the medication could influ-
ence the outcome of clinical conjunctivitis, if preferences affected adherence
to application. Furthermore, there was no placebo. Therefore, in 3 arms of the
study, there was handling of the eyes by the person who administers medica-
tion, and no handling of the eyes in the remaining arm. Handling of eyes for
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application of prophylaxis could differentially introduce pathogenic organ-
isms, depending on hygiene practices.





High risk COMMENT: The study did not address masking by the person who administers
the medication.
The 4 interventions differ in colour and consistency. Silver nitrate is clear solu-
tion. Erythromycin is a translucent ointment that may leave residue that can
be noticeable for hours. Tetracycline is a light-yellow ointment that may be
difficult to distinguish from erythromycin. There was no placebo in the alloca-
tion group that received no prophylaxis.
Lack of masking of the person who administers the medication could influ-
ence the outcome of clinical conjunctivitis, if preferences affected adherence
to application. Furthermore, there was no placebo. Therefore, in 3 arms of the
study, there was handling of the eyes by the person who administers medica-
tion, and no handling of the eyes in the remaining arm. Handling of eyes for
application of prophylaxis could differentially introduce pathogenic organ-
isms, depending on hygiene practices. This could differentially affect the rates
of conjunctivitis, and consequent pick-up of more chlamydial carriers, which
are not true cases of chlamydial conjunctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The 4 interventions differ in colour and consistency. Silver nitrate
is clear solution. Also, silver nitrate sometimes causes a chemical conjunc-
tivitis that can last up to 72 hours, and silver nitrate causes lid stains that can
last 30 to 48 hours. Erythromycin is a translucent ointment that may leave
residue that can be noticeable for hours. Tetracycline is a light-yellow oint-
ment that may be difficult to distinguish from erythromycin, but that also
leaves a residue in the eyes that can last for hours. There was no placebo in the
allocation group that received no prophylaxis, therefore the eyes of neonates
in the no-prophylaxis arm would differ from the eyes of the neonates in the
other arms. There is certainly the possibility that in the first 72 hours people in-
volved in postnatal care could identify the medication dispensed.
Blinding of persons in-




Unclear risk COMMENT: The study did not address masking of people involved postnatal
care. The 4 interventions differ in colour and consistency. Silver nitrate is a
clear solution. Also, silver nitrate sometimes causes a chemical conjunctivi-
tis that can last up to 72 hours, and silver nitrate causes lid stains that can
last 30 to 48 hours. Erythromycin is a translucent ointment that may leave
residue that can be noticeable for hours. Tetracycline is a light-yellow oint-
ment that may be difficult to distinguish from erythromycin, but that also
leaves a residue in the eyes that can last for hours. There was no placebo in the
allocation group that received no prophylaxis, therefore the eyes of neonates
in the no-prophylaxis arm would differ from the eyes of neonates in the other
arms. There is certainly the possibility that in the first 72 hours people involved
in postnatal care could identify the medication dispensed.
Lack of masking of people involved in postnatal care could lead to selection or
reporting bias of cases referred for further clinical assessment, and this could
vary by treatment arm, depending on the bias of the person involved in post-
natal care. This would, in turn, bias rates of conjunctivitis by treatment arm. 




Unclear risk QUOTE: “The infants were examined in the nursery. The parents were advised
to bring their infants to the pediatric clinic of our hospital for follow-up 1 week
after discharge and at 4 weeks of age or when the infants developed conjunc-
tivitis within the first month of life.”
COMMENT: The study does not mention masking of outcome assessors. The
3 interventions differ in colour or consistency, or both. No placebo was used.
Silver nitrate sometimes causes a chemical conjunctivitis that can last up to
72 hours, and lid stains that can last 30 to 48 hours. Tetracycline is a yellowish
ointment that may leave an ocular residue for hours. Erythromycin is a translu-
cent ointment that may leave residue that can be noticeable for hours. It is un-
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known how many cases of conjunctivitis were identified during the time peri-
od when these stains remained.





Unclear risk COMMENT: The study does not mention masking of outcome assessors. Silver
nitrate creates lid stains that last 30 to 48 hours and chemical conjunctivitis
that can last 72 hours, therefore outcome assessments during this time peri-
od were likely not masked. Although the mean age of onset of chlamydial con-
junctivitis was 6.4 days with a range of 3 to 18 days, which is likely beyond the
period of residual lid stains, the study authors do not provide the range of on-





Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. Attritions and exclusions are not re-
ported. Although it is possible there were no attritions or exclusions, this is
unlikely. For example, the infant mortality rate for Taiwan for 2009 is estimat-
ed to be 5.35 (5.35 deaths/1000 live births). In this study, which was conduct-
ed from 1989 to 1991, 4544 infants were included in the study. Therefore, we
would expect at least a few infants excluded by death within the observation






Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. Attritions and exclusions are not re-
ported. Although it is possible there were no attritions or exclusions, this is
unlikely. For example, the infant mortality rate for Taiwan for 2009 is estimat-
ed to be 5.35 (5.35 deaths/1000 live births). In this study, which was conduct-
ed from 1989 to 1991, 4544 infants were included in the study. Therefore, we
would expect at least a few infants excluded by death within the observation
period of 4 weeks.
QUOTE: “Schulz observed that the apparent lack of exclusions was associated
with more ‘beneficial’ effect sizes as well as with less likelihood of adequate al-
location concealment (Schulz 1996). Hence, failure to report exclusions in tri-
als in Schulz’s study may have been a marker of poor trial conduct rather than
true absence of any exclusions.” (from the Cochrane Handbook)
Selective reporting (re-
porting bias)
High risk COMMENT: The study authors report the microbial agents recovered from con-
junctival cultures, but do not report the results by intervention group, except
for chlamydia. They also create a category of “nonchlamydial conjunctivitis",
which would have been better categorised as bacterial conjunctivitis and no
growth on culture conjunctivitis, for inclusion in the meta-analysis.
Therefore, 1 or more outcomes of interest in the review are reported incom-
pletely so that they cannot be entered in a meta-analysis.
Other bias Unclear risk COMMENT: In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
in the first 72 hours, more neonates in the silver nitrate allocation group could
be referred for culture in the first 72 hours. Finding bacteria in the culture does
not necessarily prove that the bacteria caused the conjunctivitis. The conjunc-
tivitis could be chemical, but growing normal flora of the eye. Alternatively,
the conjunctivitis could be chemical with a chlamydial carrier. Finally, the con-
junctivitis could very well be caused by the bacteria or chlamydia. Consider-
ation of incubation periods, and assessing for carriers and normal flora with
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Methods Parallel-group, single-centre trial.
Allocation was by alternate infants.
Unit of randomisation: neonate.
Rates of follow-up in comparison groups: unclear.
Exclusions after allocation: none specified or addressed in paper.
Losses to follow-up: : none specified or addressed in paper.
Unusual study design: Difference in allocation group sizes due to “difficulty in initiating the routine of
alternating patients during the first 2 months of the study”.
Participants Setting: Chicago, IL, USA.
Newborn Nurseries of Lewis Memorial Maternity Hospital, Chicago.
Ethnic group: 56% of neonates were African-American.
Number allocated: 4292 neonates:




Inclusion criteria: all infants born June 1958 to June 1959 at the Newborn Nurseries of Lewis Memorial
Maternity Hospital, Chicago.
Exclusion criteria: none specified.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: erythromycin ointment 1-centimetre strip 5 mg/g wax ampoule (n = 1933).
• Intervention 2: silver nitrate 1% solution wax ampoule, 1 to 2 drops (n = 2359).
Time to intervention: no later than 10 minutes after delivery.
Pre-intervention manoeuvres: eyes of the newborn were wiped thoroughly with absorbent cotton.
Postintervention manoeuvres: none specified.
Outcomes 1. Reaction grades:
• 0 - no reaction;
• I - redness and swelling;
• II - redness, swelling, and discharge;
• III - redness, swelling, and copious purulent discharge.
2. Infants with positive bacterial culture of those eyes having reaction grades I, II, or III.
3. Infants with gonococcal conjunctivitis.
Follow-up: 4 to 5 days postpartum in methods, but results reported up to day 8.
Eyes of each infant were examined daily by a paediatric resident; methods indicate cultures were on-
ly taken on those having reactions II or III, but in practice, it appears that cultures were taken in those
having reactions I, II, and III.
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Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
Definition of ophthalmia neonatorum or conjunctivitis: not defined in paper.
Notes Dates of study: June 1958 to June 1959.
Funding source not specified.
No declaration of interest.
No reported subgroup analysis.
Trial investigators not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “An attempt was made to alternate infants irrespective of type of de-
livery, prematurity, race, etc. A total of 4292 infants were observed during a pe-
riod of 1 year”
QUOTE: ”The discrepancy in the two groups resulted from difficulty in initiat-
ing the routine of alternating the routine of alternating patients during the first
two months of the study."
COMMENT: Non-random process in the sequence generation
Allocation concealment
(selection bias)
High risk QUOTE: “An attempt was made to alternate infants irrespective of type of de-
livery, prematurity, race, etc. A total of 4292 infants were observed during a pe-
riod of 1 year”
QUOTE: ”The discrepancy in the two groups resulted from difficulty in initiat-
ing the routine of alternating the routine of alternating patients during the first
two months of the study."
COMMENT: Participants or investigators enrolling participants could possibly
have foreseen assignments, thus introducing selection bias.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether mothers were masked to
the intervention. Silver nitrate sometimes causes a chemical conjunctivitis
that can last up to 72 hours, and silver nitrate causes lid stains that can last 30
to 48 hours. Erythromycin ointment leaves a ocular residue that can last for
hours. The mother may be able to identify the medication; the impact on per-
formance bias is unknown.
Blinding of study partici-




Unclear risk COMMENT: The study does not mention whether mothers were masked on
the intervention. Silver nitrate sometimes causes a chemical conjunctivitis
that can last up to 72 hours, and silver nitrate causes lid stains that can last 30
to 48 hours. Erythromycin ointment leaves a ocular residue that can last for
hours. The mother may be able to identify the medication; the impact on per-
formance bias is unknown.
Mothers may differentially refer neonates with chemical conjunctivitis or lid
stains for assessment for conjunctivitis, which could lead to systematic bias
on swabbing neonates for bacterial assessment. The presence of bacteria on
swab may indicate pathogenic cause of conjunctivitis, presence of chemical
conjunctivitis with normal bacterial flora, or carrier state with chemical con-
junctivitis.




High risk COMMENT: The study does not mention whether the person administering the
medication is masked, but the medications appear different.
The 2 interventions differ in colour and consistency. Silver nitrate is a clear so-
lution. Erythromycin is a translucent ointment that leaves an ocular residue
Christian 1960  (Continued)
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that can last for hours. Therefore, it would be apparent which medication was
being dispensed in a given infant’s eyes.





High risk COMMENT: The study does not mention whether the person administering the
medication is masked, but the medications appear different.
The 2 interventions differ in colour and consistency. Silver nitrate is a clear so-
lution. Erythromycin is a translucent ointment that leaves an ocular residue
that can last for hours. Therefore, it would be apparent which medication was
being dispensed in a given infant’s eyes.
Lack of masking, combined with bias on the part of the person administering
medication, could influence adherence to administration. This could selective-
ly predispose 1 allocation group to obtain bacterial conjunctivitis over the oth-
er, and therefore affect the bacterial conjunctivitis cases differentially by allo-
cation group.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether those involved in postnatal
case are masked to the intervention. Silver nitrate sometimes causes a chem-
ical conjunctivitis that can last up to 72 hours, and silver nitrate causes lid
stains that can last 30 to 48 hours. Erythromycin is a translucent ointment that
leaves an ocular residue that can last for hours. Therefore, people involved in
postnatal care may not be masked as to the medication used during this initial
time period.
Blinding of persons in-




Unclear risk COMMENT: The study does not mention whether those involved in postnatal
case are masked to the intervention. Silver nitrate sometimes causes a chem-
ical conjunctivitis that can last up to 72 hours, and silver nitrate causes lid
stains that can last 30 to 48 hours. Erythromycin is a translucent ointment that
leaves an ocular residue that can last for hours. Therefore, people involved in
postnatal care may not have been masked to the medication used during this
initial time period.
We are uncertain of the participation of people involved in postnatal care in
identifying conjunctivitis cases for bacterial swabbing. Bias and lack of mask-
ing could lead to systematic differential rates of conjunctivitis cases referred
for swabbing for bacterial assessment. Considering the follow-up of the study
is only 5 to 8 days, lack of masking could have a significant effect on the event
rates.
The presence of bacteria on swab may indicate pathogenic cause of conjunc-
tivitis, presence of chemical conjunctivitis with normal bacterial flora, or carri-
er state with chemical conjunctivitis.




Unclear risk COMMENT: The study does not mention masking of outcome assessors. As sil-
ver nitrate creates lid stains that last 30 to 48 hours, and tetracycline ointment
may leave residue for hours, outcome assessments during this time were likely
not masked. Considering that neonates were only followed up 4 to 5 days post-
partum, there is greater potential for bias on outcome assessments.
Furthermore, there is no formal clinical conjunctivitis case definition, only
grading the eyes by varying amounts of redness and discharge. This makes the
definition of conjunctivitis more subjective, adding further possible bias.





Unclear risk COMMENT: The study does not mention whether outcome assessors and those
assessing for bacterial culture were masked as the allocation group. As silver
nitrate creates lid stains that last 30 to 48 hours, and tetracycline ointment
may leave residue for hours, outcome assessments during this time were likely
not masked. Considering that neonates were only followed up 4 to 5 days post-
partum, there is greater potential for bias on outcome assessments.
The data further show that most of the ocular reactions and positive bacterial
cultures were obtained on day 1 and day 2, when there would be the greatest
potential to identify allocation group based on ocular staining.
In ambiguous cases of clinical conjunctivitis, there may be differential asses-
sor behaviour to include or exclude cases of clinical conjunctivitis, thereby in-
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creasing or decreasing likelihood of swabbing the neonate’s eye for bacteri-
al conjunctivitis. Presence of bacteria on a swab does not necessarily prove
that the bacteria caused the conjunctivitis, as the bacteria could be a carrier
but the conjunctivitis caused by chemical conjunctivitis. This possible bias is
further magnified by the fact that the swabs for culture were not reserved for
those conjunctivitis cases with purulent discharge, as specified in the meth-
ods, but were taken from red eyes with no discharge. This widened definition
of clinical conjunctivitis allows for more subjective ambiguous cases of con-





Unclear risk QUOTE: “The period of observation of all infants except premature or full term
infants with some disturbance requiring prolonged hospitalization, was 4-5
days postpartum.”
COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. It appears that all infants were fol-







Unclear risk COMMENT: As above, the study authors do not provide any information on the
number of infants with clinical conjunctivitis who were not assessed for bacte-
rial conjunctivitis due to loss of follow-up.
Selective reporting (re-
porting bias)
High risk COMMENT: The authors specified in the methods that cultures would be tak-
en from eyes graded II and III, but in the results cultures were taken from eyes
graded I, II, III, without explanation. Therefore, a primary outcome is reported
using measurements not prespecified.
Other bias High risk COMMENT: In any trial with silver nitrate, there could be differential diagnos-
tic activity. This could lead to increased diagnosis of true but harmless cases
of disease. For example, silver nitrate induces a chemical conjunctivitis. This
chemical conjunctivitis could lead to increased selective bacterial cultures of
infants’ eyes in the silver nitrate group. A positive bacterial culture found from
a swab of conjunctivitis due to chemical conjunctivitis does not necessarily
mean that the bacteria caused the conjunctivitis. The bacteria could be part of
the normal flora of the eye, with an associated chemical conjunctivitis, or the
bacteria could be the causal agent of the conjunctivitis.
In addition to a high risk of bias for method of allocation, there was a discrep-
ancy in the number of infants in the 2 groups due to failure of alternation in
the first 2 months of the 1-year study, leading to 2359 in the group receiving





Methods Parallel-group, single-centre trial.
Method of allocation: alternation.
Unit of randomisation: neonate.
Exclusions after allocation: none specified and issue not addressed in paper.
Losses to follow-up: none specified and issue not addressed in paper.
No comment on how missing data were handled.
Cousineau 1952 
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No reported power calculation.
Participants Setting: Toronto, Canada.
Number allocated: 640 neonates:
• silver nitrate: 320;
• sulfacetamide: 320.
Age: neonates.
Sex: M:F not specified.
Inclusion criteria: infants born from February 1952 onward at the Burnside Division of Toronto General
Hospital.
Exclusion criteria: none specified.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: sulfacetamide 10% ophthalmic ointment 1/2 inch ribbon (n = 320).
• Intervention 2: silver nitrate 1% solution applied to eyes, number of drops not specified (n = 320).
Time to intervention: not specified.
Pre-intervention manoeuvres: eyes cleansed with sterile saline.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with purulent discharge from eyes.
2. Infants with purulent discharge from eyes due to drug reaction, defined as any discharge from eyes
in the first 3 days following birth.
3. Infants with purulent discharge from eyes due to infection, defined as eye discharge from which or-
ganisms were recovered after the third postnatal day.
4. Infants with gonococcal conjunctivitis.
Follow-up: at least 3 days and likely 9 days; frequency of follow-up not specified, but likely daily.
Definition of conjunctivitis: purulent discharge from 1 or both eyes.
Cultures were obtained from infants with purulent discharge after the third postnatal day.
No adverse events reported.
Notes No sources of funding specified.
No declaration of interest specified.
Date of study: February 1952; no end date specified.
No reported subgroup analysis.
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “…alternate babies received, as prophylaxis, 1 per cent silver nitrate
solution and 10 percent sulphacetimide ointment,…”
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COMMENT: Non-random process in the sequence generation
Allocation concealment
(selection bias)
High risk COMMENT: Participants or investigators enrolling participants could possibly
have foreseen assignments, thus introducing selection bias.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention.
Silver nitrate sometimes causes a chemical conjunctivitis that can last up to
72 hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Sulfac-
etamide ointment leaves an ocular residue that can last for hours. The mother
may be able to identify the medication; the impact on performance bias is un-
known.
Blinding of study partici-




Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention.
Silver nitrate sometimes causes a chemical conjunctivitis that can last up to
72 hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Sulfac-
etamide ointment leaves an ocular residue that can last for hours. The mother
may be able to identify the medication; the impact on performance bias is un-
known.
The mothers of neonates with ocular signs of prophylaxis may handle the eyes
of the infant differently, which could, in turn, introduce pathogenic bacteria in-
to the eyes differently, and differentially affect bacterial conjunctivitis cases in
the allocation groups.
Mothers may be more or less likely to refer the neonate for assessment of clin-
ical conjunctivitis if they are aware of the prophylaxis administered. If the par-
ent is aware of the intervention, this may influence whether the neonate is
swabbed or not for conjunctivitis in ambiguous cases. Note that a positive
bacterial culture of a conjunctivitis case does not confirm the bacteria as the
cause of the conjunctivitis. Conjunctivitis could be chemical in nature with
normal flora bacteria on culture, or it could be true bacterial conjunctivitis.




High risk COMMENT: The study does not mention whether the person administering the
medication was masked, but the medications appear different.
The 2 interventions differ in colour and consistency. Silver nitrate is a clear so-
lution, and sulfacetamide is an ointment.
Lack of masking of the person who administers the medication could influence
the outcome of clinical conjunctivitis through differential handling of the eyes.





High risk COMMENT: The study does not mention whether the person administering the
medication was masked, but the medications appear different.
The 2 interventions differ in colour and consistency. Silver nitrate is a clear so-
lution, and sulfacetamide is an ointment.
Lack of masking of the person who administers the medication could influence
the outcome of clinical conjunctivitis through differential handling of the eyes.
Differential handling of the eyes may lead to differential introduction of bacte-
ria into the eyes of neonates by allocation group. Therefore, lack of masking of
the person who administers medication may influence the outcome of bacteri-
al conjunctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether the person involved in post-
natal care was masked.
The 2 interventions differ in colour and consistency. Silver nitrate sometimes
causes a chemical conjunctivitis that can last up to 72 hours, and silver nitrate
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causes lid stains that can last 30 to 48 hours. Sulfacetamide ointment leaves an
ocular residue that can last for hours.
The person involved in postnatal care may be able to identify the medication;
the impact on performance bias is unknown. This bias could be significant,
as follow-up time was 3 to 9 days in this study, and it appears that neonates
were kept in hospital in the nursery throughout this time. Therefore, people in-
volved in postnatal care may not be masked as to the medication used as pro-
phylaxis during this initial time period. Lack of masking of the people involved
in postnatal care could differentially affect the identification of clinical con-
junctivitis cases, and handling of the eyes, both of which could influence the
outcome of clinical conjunctivitis.
Blinding of persons in-




Unclear risk COMMENT: The study does not mention whether the person involved in post-
natal care was masked.
The 2 interventions differ in colour and consistency. Silver nitrate sometimes
causes a chemical conjunctivitis that can last up to 72 hours, and silver nitrate
causes lid stains that can last 30 to 48 hours. Sulfacetamide ointment leaves an
ocular residue that can last for hours.
The person involved in postnatal care may be able to identify the medication;
the impact on performance bias is unknown. This bias could be significant,
as follow-up time was 3 to 9 days in this study, and it appears that neonates
were kept in hospital in the nursery throughout this time. Therefore, people in-
volved in postnatal care may not be masked as to the medication used as pro-
phylaxis during this initial time period. Lack of masking of the people involved
in postnatal care could differentially affect the identification of clinical con-
junctivitis cases that may be referred for bacterial analysis, and the handling of
the eyes, both of which could influence the outcome of bacterial conjunctivi-
tis.




Unclear risk COMMENT: The study does not mention masking of outcome assessors. Sil-
ver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Sulfac-
etamide ointment leaves an ocular residue that can last for hours. Consider-
ing that neonates were only followed up 3 to 9 days postpartum, and the low
event rate, there is a greater potential for bias on outcome assessments.





Unclear risk COMMENT: The study does not mention masking of outcome assessors. Sil-
ver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Sulfac-
etamide ointment leaves an ocular residue that can last for hours. Consider-
ing that neonates were only followed up 3 to 9 days postpartum, and the low
event rate, there is a greater potential for bias on outcome assessments.
In ambiguous cases of clinical conjunctivitis, there may be differential asses-
sor behaviour to include or exclude cases of clinical conjunctivitis, thereby in-
creasing or decreasing likelihood of swabbing the neonate’s eye for bacterial
conjunctivitis. Presence of bacteria on a swab does not necessarily prove that
the bacteria caused the conjunctivitis, as the bacteria could be a carrier, but





Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete cases of clinical conjunctivitis. It appears that most
infants were followed in hospital for 3 to 9 days, and loss to follow-up was like-
ly low, but this is unclear from the study. Small losses to follow-up could signif-
icantly influence the results considering the low event rate and small sample
size.
Cousineau 1952  (Continued)
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Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete cases of bacterial conjunctivitis. It appears that most
infants were followed in hospital for 3 to 9 days, and loss to follow-up was like-
ly low, but this is unclear from the study. Small losses to follow-up could signif-




Unclear risk COMMENT: The study is not clear as to whether any neonate had gonococcal
conjunctivitis or inclusion conjunctivitis. Although other studies in the same
paper mention this outcome, and it is possible there were simply no cases of
gonococcal or inclusion conjunctivitis, this is not clear.
Other bias Unclear risk COMMENT: In any trial with silver nitrate, there could be differential diagnos-
tic activity, which could lead to increased diagnosis of true but harmless cases
of disease. For example, silver nitrate induces a chemical conjunctivitis. This
chemical conjunctivitis could lead to increased selective bacterial cultures of
infants’ eyes in the silver nitrate intervention group. A positive bacterial cul-
ture found from a swab of conjunctivitis due to chemical conjunctivitis does
not necessarily mean that the bacteria caused the conjunctivitis. The bacteria
could be part of the normal flora of the eye, with an associated chemical con-





Methods Parallel-group, single-centre RCT.
Method of allocation: “random”. No other details provided on method of allocation.
Unit of randomisation: neonate.
Losses to follow-up: in the povidone-iodine group, 7 (3.4%) were lost to follow-up, and in the tetracy-
cline group, 9 (4.4%) were lost to follow-up.
Exclusions after allocation: none specified in paper.
Handling of missing data not discussed in paper.
Reported power calculation: yes. 410 neonate sample size had 80% power to detect 20% difference.
Unusual study design: none.





1. full-term healthy neonates born after 37 weeks.
Exclusion criteria:
1. infants with ocular malformations.
2. mothers who were treated with systemic or local antibiotics 1 week before delivery.
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Equivalence of baseline characteristics: yes.
Interventions Number of interventions: 2.
• Intervention 1: 2.5% povidone-iodine solution in each eye 20 minutes after birth (n = 208).
• Intervention 2: 1% tetracycline ointment in each eye 20 minutes after birth (n = 202).
Time to intervention: 20 minutes after delivery.
Pre-intervention manoeuvres: washing of the baby’s face.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with clinical ophthalmia neonatorum, with extent of inflammation graded.
2. Infants with clinical ophthalmia neonatorum with sterile cultures.
3. Infants with clinical ophthalmia neonatorum with any positive culture results of eye specimen.
4. Infants with chlamydial conjunctivitis diagnosed with serological test.
5. Infants with gonococcal conjunctivitis.
Follow-up: 1 month of birth.
Intervals at which outcomes assessed: not specified.
Adverse events reported: none of the neonates had any adverse reaction to the interventions.
Definition of clinical ophthalmia neonatorum: “inflammation of the conjunctiva manifested as in-
creased secretions or conjunctival and eyelid congestion and chemosis with serous or purulent dis-
charge in the first month after delivery”.
Notes Recruited between November 2003 and May 2004.
Sources of funding: not identified.
Declaration of interest: “The author(s) have no proprietary or commercial interest in any materials dis-
cussed in this article.”
Trial investigators have not been contacted.
No reported subgroup analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk COMMENT: Paper states “random”. Method of allocation not specified.
Insufficient information about the sequence generation process to permit
judgement of low risk of high risk.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk Masking of the mother was not addressed in the paper.
COMMENT: The 2 interventions differ in colour and consistency. Povidone-io-
dine is an orange-red solution that leads to residual staining of the eye and
surrounding periocular skin can last minutes to hours, which the mother
would notice. Tetracycline is a light-yellow ointment that leaves a residue that
can last for hours in the eyes of the infant. The mothers may handle the eyes
of neonates differently by allocation group, based on eye staining and residue.
David 2011  (Continued)
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This could lead to differential introduction of pathogenic bacteria into these
neonates’ eyes, causing clinical conjunctivitis.
Blinding of study partici-




Unclear risk COMMENT: The study does not mention whether the mothers were masked as
to the intervention dispensed in the neonate’s eyes. As mentioned, the moth-
er may be able to identify what was dispensed in the infant’s eyes, as povi-
done-iodine can lead to periocular staining for minutes to hours, and tetra-
cycline is an ointment that leaves residue that can last hours. The mothers
may handle the eyes of neonates differently by allocation group, based on eye
staining and residue. This could lead to differential introduction of pathogen-
ic bacteria into the eyes of these neonates, causing bacterial conjunctivitis.
Although this is less likely to occur with Neisseria gonorrhoeae and Chlamy-
dia trachomatis, it is still possible in situations of poor hygiene. Furthermore,
chlamydia can cause asymptomatic infection, not necessarily conjunctivitis;
Furthermore, chlamydia can cause asymptomatic infection, not necessarily
conjunctivitis; therefore, selective bias of conjunctivitis cases sent for bacte-
riological analysis (cases caused by maternal contamination due to differen-
tial eye handling) may actually identify chlamydial carriers rather than true
chlamydial conjunctivitis.




High risk COMMENT: The study does not mention whether the person administering the
medication was masked.
The 2 interventions differ in colour and consistency. Povidone-iodine is an or-
ange-red solution. Tetracycline is a light-yellow ointment. There is no reported
attempt to mask the appearance of the medication.
Lack of masking could influence the outcome of clinical conjunctivitis if there
was bias on the part of the person who administered the medication.





High risk COMMENT: The study does not mention whether the person administering the
medication was masked.
The 2 interventions differ in colour and consistency. Povidone-iodine is an or-
ange-red solution. Tetracycline is a light-yellow ointment. There is no reported
attempt to mask the appearance of the medication.
Lack of masking could influence the outcome of bacterial conjunctivitis if
knowledge of the prophylaxis, say, systematically influenced adherence to dis-
pensing of the person who administered the medication.
It is uncertain if lack of masking could influence the outcomes of chlamydial
and gonococcal conjunctivitis cases. If the person who administered the med-
ication could also have been involved in the birth process, or if there were dif-
ferential hand-washing techniques by allocation group, this is a possibility.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of people involved in postnatal care was not addressed
in this paper. Since povidone-iodine causes staining of the eye that can last
minutes to hours, and tetracycline ointment can leave residual medication for
hours, those involved in postnatal care may not be masked to the medication
used as prophylaxis initially. Furthermore, there is no indication in the paper
that an attempt was made to mask those involved in postnatal care.
Blinding of persons in-




Unclear risk COMMENT: Masking of people involved in postnatal care was not addressed
in this paper. Since povidone-iodine causes staining of the eye that can last
minutes to hours, and tetracycline ointment can leave residual medication for
hours, those involved in postnatal care may not be masked to the medication
used as prophylaxis initially.
Lack of masking could influence case finding of conjunctivitis in ambigu-
ous cases, and subsequent referral for culture. This could affect identifica-
David 2011  (Continued)
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tion of bacterial conjunctivitis cases, and bring about spurious identification
of chlamydial carriers as opposed to true chlamydial conjunctivitis. Lack of
masking of people providing postnatal care is likely be at low risk of bias for
the outcome of gonococcal conjunctivitis.




Unclear risk COMMENT: The study does not mention masking of outcome assessors. In the
first hours of clinical assessment for conjunctivitis, there may be lack of mask-
ing as tetracycline is an ointment that leaves residue, and povidone-iodine is
orange-red and leads to eye staining. It is unclear how many cases of conjunc-
tivitis were diagnosed during this time period. In ambiguous cases of clinical
conjunctivitis, with lack of masking, there may be differential group behaviour
to include or exclude cases of clinical conjunctivitis. In this paper, conjunctivi-
tis was defined as inflammation of the conjunctiva with discharge, which pro-
vides less subjectivity in the diagnosis of conjunctivitis.





Unclear risk COMMENT: The study does not mention masking of outcome assessors. In the
first hours of clinical assessment for conjunctivitis, there may be lack of mask-
ing as tetracycline is an ointment that leaves residue, and povidone-iodine is
orange-red and leads to eye staining. It is unclear how many cases of conjunc-
tivitis were diagnosed during this time period. In ambiguous cases of clinical
conjunctivitis, with lack of masking, there may be differential group behaviour
to include or exclude cases of clinical conjunctivitis. In this paper, conjunctivi-
tis was defined as inflammation of the conjunctiva with discharge, which pro-
vides less subjectivity in the diagnosis of conjunctivitis.
With lack of masking, in ambiguous cases of clinical conjunctivitis, whether
identified by personnel, mother, or outcome assessor, there may be differen-
tial assessor behaviour to include or exclude cases of clinical conjunctivitis,
thereby increasing or decreasing the likelihood of swabbing the neonate’s eye
for bacterial or chlamydial conjunctivitis. Presence of bacteria or chlamydia on
a swab does not necessarily prove that the bacteria caused the conjunctivitis,
as the bacteria could be part of the normal flora of the eye, or the chlamydia
could be a carrier.
PCR was used for the diagnosis of chlamydia, which is objective, but is also
sensitive enough to detect a possible carrier.






High risk QUOTE: Sixteen newborns did not complete the 1 month follow-up and were
omitted from the study; 7 (3.4%) of them received povidone-iodine and 9
(4.4%) of them received tetracycline
COMMENT: Although there are small losses to follow-up and these are roughly






High risk QUOTE: Sixteen newborns did not complete the 1 month follow-up and were
omitted from the study; 7 (3.4%) of them received povidone-iodine and 9
(4.4%) of them received tetracycline
COMMENT: Although there are small losses to follow-up and these are roughly
symmetrical, they are high in relation to event rates of bacterial conjunctivitis.
Selective reporting (re-
porting bias)
Low risk It is highly likely that all prespecified outcomes were reported.
Other bias Low risk No other potential sources of bias were identified.
David 2011  (Continued)
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Study characteristics
Methods Parallel-group, single-centre trial.
Method of allocation: alternation by week.
Unit of randomisation: neonate.
Exclusions after allocation: none specified and issue not addressed in paper.
Losses to follow-up: none specified.
No comment on handling of missing data.
No reported power calculation.
Unusual study design: methods state that cultures were taken from neonates with ocular discharge.
The numbers that had discharge and the numbers that were cultured do not match. In some cases the
numbers cultured were less than those with discharge, but in 1 group, the number cultured was greater
than the number with discharge.
Participants Setting: Baltimore, USA.
Number randomised: 4163 neonates:
• penicillin ointment: 1436;
• penicillin IM: 1359;
• silver nitrate: 1368.
Age: neonates.
Sex: M:F not specified.
Inclusion criteria: infants born from 1 May 1948 to 20 March 1950.
Exclusion criteria: none specified.
Interventions Number of interventions: 3.
• Intervention 1: penicillin 100,000 units/gram ophthalmic ointment, per eye 1/2 inch length = 7000 units
or 0.07 g (n = 1436).
• Intervention 2: aqueous penicillin 10,000 units per IM injection (n = 1359).
• Intervention 3: silver nitrate 1% solution 2 drops per eye (n = 1368).
Time to intervention: immediately after birth.
Pre-intervention manoeuvres: none identified.
Postintervention manoeuvres: after administration of silver nitrate, eyes flushed out with normal
saline.
No comment on equivalence of baseline characteristics.
Outcomes 1. Infants with 1 or more signs of ocular irritation, such as redness, oedema, and/or discharge.
2. Infants with conjunctivitis where infection was "proved or probable" from ocular discharge.
3. Infants with clinical ophthalmia neonatorum.
4. Infants with gonococcal conjunctivitis.
5. Infants with ocular redness.
6. Infants with ocular oedema.
7. Infants with ocular discharge.
Davidson 1951 
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Follow-up: 10 days postpartum.
Adverse events reported 1 episode of penicillin sensitisation for neonate given IM injection of penicillin,
but unclear if in this particular study.
Definition of conjunctivitis: not defined.




• infection proved or probable.
Infection "proved or probable" included those eye discharge specimens that had organisms in both
smears and cultures and excluded diphtheroids and Micrococcus pyogenes.
Definition of clinical ophthalmia neonatorum: not defined.
Notes Dates of study: infants born from 1 May 1948 to 20 March 1950.
Source of funding: "All penicillin preparations used in this investigation were supplied by E.R. Squibb &
Sons."
Source of funding: "This project was supported by the United States Public Health Service, Division of
Venereal Diseases."
No declaration of interest report was made in this study.
Subgroup analysis of neonates born via caesarean section.
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “Three schemes of prophylaxis were used in rotation…. During one
week all newborns had penicillin ointment….The following week every infant
was given 10,000 units by intramuscular injection. During the third week silver
nitrate prophylaxis was carried out …”
COMMENT: Non-random process in the sequence generation
Allocation concealment
(selection bias)
High risk COMMENT: Participants or investigators enrolling participants could possibly
have foreseen assignments, thus introducing selection bias.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention.
Silver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Penicillin
ointment leaves an ocular residue that can last for hours. The penicillin given
IM could leave a needle mark on the neonate. The mother may be able to iden-
tify the medication; the impact on performance bias is unknown.
Blinding of study partici-




Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention.
Silver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Penicillin
ointment leaves an ocular residue that can last for hours. The penicillin given
Davidson 1951  (Continued)
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IM could leave an needle mark on the neonate. The mothers may handle the
eyes of neonates differently by allocation group, based on ocular signs of pro-
phylaxis, which could, in turn, introduce pathogenic bacteria into the eyes dif-
ferently, and differentially affect bacterial conjunctivitis cases in the allocation
groups.
Mothers may be more or less likely to refer the neonate for assessment of clin-
ical conjunctivitis if they are aware of the prophylaxis administered. If the
parent is aware of the intervention, it may influence whether the neonate
is swabbed or not for conjunctivitis in ambiguous cases. Note that positive
bacterial culture of a conjunctivitis case does not confirm the bacteria as the
cause of the conjunctivitis. Conjunctivitis could be chemical in nature with
normal flora bacteria on culture, or it could true bacterial conjunctivitis.




High risk COMMENT: The study does not mention whether the person administering the
medication was masked, but the medications appear different.
The 3 interventions differ in colour, consistency, and route of delivery. Silver
nitrate is a clear solution. Penicillin G ointment is a clear or white ointment.
Penicillin G IM is an aqueous solution administered intramuscularly as op-
posed to topically. Lack of masking could influence the outcome.





Unclear risk COMMENT: The study does not mention whether the person administering the
medication was masked, but the medications appear different.
The 3 interventions differ in colour, consistency, and route of delivery. Silver
nitrate is a clear solution. Penicillin G ointment is a clear or white ointment.
Penicillin G IM is an aqueous solution administered intramuscularly as op-
posed to topically. Lack of masking could influence the outcome. No ocular
or IM injection placebo was used, therefore in 2 allocation arms the neonate’s
eyes are handled by the person who administers the intervention, and in the
remaining arm, there is no ocular handling. This could influence the outcome
of bacterial conjunctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether those involved in postnatal
care were masked to the intervention. Silver nitrate sometimes causes a chem-
ical conjunctivitis that can last up to 72 hours, and silver nitrate causes lid
stains that can last 30 to 48 hours. Penicillin ointment leaves an ocular residue
that can last for hours. Post-injection of penicillin IM, there could be a resid-
ual needle mark. The person involved in postnatal care may be able to identify
the medication; the impact on performance bias is unknown. This bias could
be significant, as follow-up time was only 10 days, and it appears neonates
were kept in hospital in the nursery throughout this time. Therefore, people in-
volved in postnatal care may not be masked as to the medication used as pro-
phylaxis during this initial time period.
Blinding of persons in-




Unclear risk COMMENT: The study does not mention whether those involved in postnatal
care were masked to the intervention. Silver nitrate sometimes causes a chem-
ical conjunctivitis that can last up to 72 hours, and silver nitrate causes lid
stains that can last 30 to 48 hours. Penicillin ointment leaves an ocular residue
that can last for hours. Post-injection of penicillin IM, there could be a residual
needle mark. The person involved in postnatal care may be able to identify the
medication; the impact on performance bias is unknown. This bias could be
significant, as follow-up time was only 10 days, and it appears neonates were
kept in hospital in the nursery throughout this time, therefore people involved
in postnatal care may not be masked as to the medication used as prophylaxis
during this initial time period.
If people involved in postnatal care were also involved in identification of con-
junctivitis cases for swabbing, lack of masking could influence the outcome
of bacterial conjunctivitis. People involved in postnatal care not masked to
Davidson 1951  (Continued)
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intervention could also differentially handle the neonates’ eyes by allocation
group, also influencing the outcome.




Unclear risk COMMENT: The study does not mention masking of outcome assessors. Sil-
ver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Penicillin
ointment leaves an ocular residue that can last for hours. Post-injection of
penicillin IM, there could be a residual needle mark. Considering that neonates
were only followed up 10 days postpartum, there is greater potential for bias
on outcome assessments.
Furthermore, there is no formal clinical conjunctivitis case definition, only
grading the eyes by the presence of redness, oedema, or discharge.





Unclear risk COMMENT: The study does not mention masking of outcome assessors. Sil-
ver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and silver nitrate causes lid stains that can last 30 to 48 hours. Penicillin
ointment leaves an ocular residue that can last for hours. Post-injection of
penicillin IM, there could be a residual needle mark. Considering that neonates
were only followed up 10 days postpartum, there is greater potential for bias
on outcome assessments.
Furthermore, there is no formal clinical conjunctivitis case definition, only
grading the eyes by the presence of redness, oedema, or discharge.
In ambiguous cases of clinical conjunctivitis, there may be differential asses-
sor behaviour to include or exclude cases of clinical conjunctivitis, thereby in-
creasing or decreasing the likelihood of swabbing the neonate’s eye for bacte-
rial conjunctivitis. Presence of bacteria on a swab does not necessarily prove
that the bacteria caused the conjunctivitis, as the bacteria could be a carrier
but the conjunctivitis caused by chemical conjunctivitis. Although the study
indicated that cultures were only taken from neonates with discharge, reduc-






Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. It appears that most infants were fol-
lowed in hospital, and loss to follow-up was likely low, but this unclear from






High risk QUOTE: “A specimen for culture and smear was taken from every eye in which
a discharge developed…”
COMMENT: As above, the study authors do not provide any information on the
number of infants with clinical conjunctivitis who were not assessed for bacte-
rial conjunctivitis due to loss of follow-up. Furthermore, although the study in-
dicated that cultures were only taken from neonates with discharge, the num-
ber of neonates cultured does not match the number of neonates with ocular
discharge. This difference could be accounted for by the fact that the unit for
amount of discharge cases was the eye, whilst the unit for the amount of posi-
tive cultures was the neonate.
QUOTE: “Eleven unsatisfactory cultures from two infants treated with peni-
cillin ointment, two given intramuscularly, and seven treated with silver ni-
trate were omitted.”
COMMENT: Considering event rates of bacterial conjunctivitis, these losses to
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1. Although the study indicated that cultures were only taken from neonates
with discharge, the number of neonates cultured does not match the number
of neonates with ocular discharge.
2. There was no formal diagnosis of conjunctivitis provided in the study.
Other bias Unclear risk COMMENT: In any trial with silver nitrate, there could be differential diagnos-
tic activity. This could lead to increased diagnosis of true but harmless cases
of disease. For example, silver nitrate induces a chemical conjunctivitis. This
chemical conjunctivitis could lead to increased selective bacterial cultures of
infants’ eyes in the silver nitrate intervention group. A positive bacterial cul-
ture found from a swab of conjunctivitis due to chemical conjunctivitis does
not necessarily mean that the bacteria caused the conjunctivitis. The bacte-
ria could be part of the normal flora of the eye, with an associated chemical
conjunctivitis, or the bacteria could be the causal agent of the conjunctivitis.
This study, however, appeared to attempt to distinguish normal flora of the





Methods Parallel-group, single-centre trial.
Alternation by week.
Unit of randomisation: neonate.
Exclusions after randomisation: none specified.
Losses to follow-up: none specified.
No comment on handling of missing data.
No reported power calculation.
Unusual study design and issues: 91 neonates, the majority of whom were allocated to tetracycline, did
not receive any prophylaxis as delivery room staI "forgot". They were followed up.
The paper states that "a total of 16 more children were born during the weeks designated for silver ni-
trate than during the weeks designated for tetracycline". Considering there were 450 allocated, this
suggests that there were 233 in the silver nitrate group and 217 in the erythromycin group. The paper
also states that "several of the staI admitted that they tended to 'forget' the tetracycline most often
because it was 'messy'". Therefore, the 91 with no prophylaxis were likely in the tetracycline group. It
appears that 3 allocated to tetracycline crossed over into silver nitrate.
Participants Setting: Nyankunde, Zaire.
Number allocated: 450:
• silver nitrate: 233 (233 allocated but 236 received silver nitrate);
• tetracycline: 217 (217 allocated, but 214 received tetracycline - amongst 214, 123 received tetracy-
cline, and 91 "forgotten").
Age: neonates.
Sex: M:F unknown.
Inclusion criteria: babies born at Evangelical Medical Center between 10 November 1986 and 27 Janu-
ary 1987.
Fischer 1988 
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Exclusion criteria: none specified.
No comment of equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: tetracycline 1% ophthalmic ointment, dose not specified (n = 217 allocated) (233 allo-
cated but 236 received silver nitrate).
• Intervention 2: silver nitrate 1% ophthalmic solution, dose not specified (n = 233 allocated) (217 allo-
cated, but 214 received tetracycline - among 214, 123 received tetracycline, and 91 "forgotten").
Time to intervention: 1 dose "as soon as conveniently possible after birth".
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with conjunctivitis.
2. Infants with gonococcal conjunctivitis.
Follow-up: not specified, but cases found were diagnosed in first week of life.
Definition of conjunctivitis: conjunctival inflammation and discharge. Gram stain and culture of con-
junctival secretions.
Notes Date of recruitment was 10 November 1986 to 27 January 1987.
No source of funding was specified.
No declaration of interest was made.
No reported subgroup analysis.
Authors were contacted for clarifications on masking, but no response received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “Treatment was alternated during week-long periods between a solu-
tion of 1% silver nitrate and an ointment containing 1% tetracycline”
QUOTE: ”A total of 450 newborns were entered into the study. Of these 236 re-
ceived silver nitrate, 123 received tetracycline, and 91 were 'forgotten'"
Allocation concealment
(selection bias)
High risk QUOTE: “Treatment was alternated during week-long periods between a solu-
tion of 1% silver nitrate and an ointment containing 1% tetracycline”
QUOTE: “The name and treatment received were noted for each patient.”
COMMENT: Participants or investigators enrolling participants could possibly
foresee assignments, thus introducing selection bias.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of mothers of the intervention was not addressed in this
study. Furthermore, the 2 interventions differ in colour and consistency. Sil-
ver nitrate is a clear solution. Also, silver nitrate sometimes causes a chemical
conjunctivitis that can last up to 24 hours, and lid stains that can last 30 to 48
hours. Tetracycline is a light-yellow ointment that can leave a residue that can
last hours and be noticed by the mother. It is unknown how this could affect
performance bias.
Fischer 1988  (Continued)
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Blinding of study partici-




Unclear risk COMMENT: Masking of mothers to the intervention was not addressed in this
study. Furthermore, the 2 interventions differ in colour and consistency. Sil-
ver nitrate is a clear solution. Also, silver nitrate sometimes causes a chemical
conjunctivitis that can last up to 24 hours, and lid stains that can last 30 to 48
hours. Tetracycline is a light-yellow ointment that can leave a residue that can
last hours and be noticed by the mother. It is unknown how this could affect
performance bias.
The mothers may differentially handle the eyes of neonates based on the vis-
ible signs of prophylaxis. This could lead to differential introduction of patho-
genic bacteria into the eyes of these neonates. Therefore, the lack of masking
of medication appearance may lead to bias in the bacterial or gonococcal con-
junctivitis cases, depending on hygiene measures. Considering the low event
rates of gonococcal conjunctivitis, this could introduce important bias. It is un-
known how many neonates developed conjunctivitis in the time period when
the medication could be identified, but follow-up time was only 1 week.




High risk QUOTE: ”…several of the staI admitted that they tended to 'forget' the tetra-
cycline most often because it was 'messy'"
COMMENT: Masking of the person who administers the medication was not
specifically addressed in this study. As mentioned, the 2 interventions differ
in colour and consistency. Silver nitrate is a clear solution. Also, silver nitrate
sometimes causes a chemical conjunctivitis that can last up to 24 hours, and
lid stains that can last 30 to 48 hours. Tetracycline is a light-yellow ointment
that can leave a residue that can last hours. It appears that the nurses knew
which medication was tetracycline and that it affected adherence, and conse-
quently the outcome.





High risk QUOTE: ”…several of the staI admitted that they tended to 'forget' the tetra-
cycline most often because it was “messy'"
COMMENT: Masking of the person who administers the medication was not
specifically addressed in this study. As mentioned, the 2 interventions differ
in colour and consistency. Silver nitrate is a clear solution. Also, silver nitrate
sometimes causes a chemical conjunctivitis that can last up to 24 hours, and
lid stains that can last 30 to 48 hours. Tetracycline is a light-yellow ointment
that can leave a residue that can last hours.
With lack of masking, the person administering the medication could dispense
the medication differently, or there could be differential adherence problems,
thereby altering the bactericidal effect.
It appears that the nurses knew which medication was tetracycline and that it
affected adherence, and consequently the outcome.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of people involved in postnatal care was not addressed in
this study. Silver nitrate sometimes causes a chemical conjunctivitis that can
last up to 24 hours, and lid stains that can last 30 to 48 hours. Tetracycline is a
light-yellow ointment that can leave a residue that can last hours and be no-
ticed by those involved in postnatal care.
It is unclear how long the neonates were involved in postnatal care, and how
many cases of conjunctivitis were identified at this time. It is also unclear if
those involved in postnatal care were also involved in identifying cases of con-
junctivitis, and to what extent.
It is unknown how this could affect performance bias, however follow-up time
was only 1 week, and the event rates were very low. Therefore, minor bias
would significantly affect outcomes. For instance, people involved in postnatal
care may differentially handle the eyes of neonates based on the visible signs
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of prophylaxis. This could lead to differential introduction of pathogenic bac-
teria into the eyes of these neonates.
Blinding of persons in-




Unclear risk COMMENT: Masking of those involved in postnatal care was not addressed in
this study. Silver nitrate sometimes causes a chemical conjunctivitis that can
last up to 24 hours, and lid stains that can last 30 to 48 hours. Tetracycline is a
light-yellow ointment that can leave a residue that can last hours and be no-
ticed by those involved in postnatal care.
It is unclear how long the neonates were involved in postnatal care, and how
many cases of conjunctivitis were identified at this time. It is also unclear if
those involved in postnatal care were also involved in identifying cases of con-
junctivitis, and to what extent.
It is unknown how this could affect performance bias, however follow-up time
was only 1 week, and the event rates were very low. Therefore, minor bias
would significantly affect outcomes. For instance, those involved in postnatal
care may differentially handle the eyes of neonates based on the visible signs
of prophylaxis. This could lead to differential introduction of pathogenic bac-
teria into the eyes of these neonates, including Neisseria gonorrhoeae, in set-
tings where hygiene may not be ideal, such as the setting where this trial was
held, Zaire.
Any bias in identification of conjunctivitis cases could influence cases referred
for swabbing for N gonorrhoeae. For instance, if the people involved in postna-
tal care were aware that neonates were given silver nitrate, and were aware of
the concomitant chemical conjunctivitis, in ambiguous cases, the nurse may
erroneously ignore cases of 'true' gonococcal conjunctivitis.
The incubation period of gonococcal conjunctivitis is likely outside the peri-
od of time at which the people involved in postnatal care would be influencing
identification and care. Furthermore, these cases are likely more clinically se-
vere, eliminating ambiguity. Therefore, the lack of masking of those involved
in postnatal care will likely introduce less bias for the outcome of gonococcal
conjunctivitis. Still, the low event rate of gonococcal conjunctivitis could make
minor bias important and clinically significant.




Unclear risk QUOTE: “The name and treatment received were noted for each patient.”
COMMENT: From the statement above, it appears there was no attempt to
mask outcome assessors, however we cannot be certain of this. The 2 inter-
ventions differ in colour and consistency. Silver nitrate is a clear solution. Also,
silver nitrate sometimes causes a chemical conjunctivitis that can last up to 24
hours, and lid stains that can last 30 to 48 hours. Tetracycline is a light-yellow
ointment that can leave a residue that can last hours.
It is unknown how many cases of conjunctivitis were identified during the time
when these stains remained, but the follow-up was only 1 week in this study.





Unclear risk QUOTE: “The name and treatment received were noted for each patient.”
COMMENT: From the statement above, it appears there was no attempt to
mask outcome assessors, however we cannot be certain of this. The 2 inter-
ventions differ in colour and consistency. Silver nitrate is a clear solution. Also,
silver nitrate sometimes causes a chemical conjunctivitis that can last up to 24
hours, and lid stains that can last 30 to 48 hours. Tetracycline is a light-yellow
ointment that can leave a residue that can last hours.
It is unknown how many cases of conjunctivitis were identified during the time
when these stains remained, but the follow-up was only 1 week in this study.
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The incubation period of gonococcal conjunctivitis is likely outside the period
of time at which these stains would remain. Furthermore, gonococcal conjunc-
tivitis is likely more clinically severe, reducing ambiguity in diagnosis. In the
silver nitrate arm, if masking was compromised, any cases presenting within
the chemical conjunctivitis period could be ignored by the assessor aware of
chemical conjunctivitis, and possibly miss a 'true' gonococcal conjunctivitis






Unclear risk QUOTE: “Conjunctivitis was diagnosed during the first week of life in each
case.”
QUOTE: ”A total of 450 newborns were entered into the study. Of these 236 re-
ceived silver nitrate, 123 received tetracycline, and 91 were 'forgotten'"
COMMENT: The “forgotten” cases received no prophylaxis. The follow-up time
is not prespecified in the study. It was at least 1 week, as the study authors
state that the conjunctivitis cases were diagnosed in the first week. It is un-
known if any neonates allocated to prophylaxis were subsequently lost to
follow-up. It is unclear if neonates were in hospital throughout this time, or
when, and if they were discharged from hospital during this time. If they were
discharged from hospital, it is unclear how they were followed up. It appears
that some of the 91 infants who were “forgotten” were followed up, as all the
gonococcal conjunctivitis cases were in this group.
COMMENT: The paper states that "a total of 16 more children were born dur-
ing the weeks designated for silver nitrate than during the weeks designated
for tetracycline". Considering there were 450 allocated, this therefore suggests
that there were 233 in the silver nitrate group and 217 in the erythromycin
group. The paper also states that "several of the staI admitted that they tend-
ed to 'forget' the tetracycline most often because it was 'messy'". Therefore,
the 91 with no prophylaxis were likely in the tetracycline group. It appears that
3 allocated to tetracycline crossed over into silver nitrate. This is not explicit in






Unclear risk QUOTE: “Conjunctivitis was diagnosed during the first week of life in each
case.”
QUOTE: ”A total of 450 newborns were entered into the study. Of these 236 re-
ceived silver nitrate, 123 received tetracycline, and 91 were 'forgotten'”
COMMENT: The “forgotten” cases received no prophylaxis. The follow-up time
is not prespecified in the study. It was at least 1 week, as the study authors
state that the conjunctivitis cases were diagnosed in the first week. It is un-
known if any neonates allocated to prophylaxis were subsequently lost to
follow-up. It is unclear if neonates were in hospital throughout this time, or
when, and if they were discharged from hospital during this time. If they were
discharged from hospital, it is unclear how they were followed up. It appears
that some of the 91 infants who were “forgotten” were followed up, as all the
gonococcal conjunctivitis cases were in this group.
COMMENT: The paper states that "a total of 16 more children were born dur-
ing the weeks designated for silver nitrate than during the weeks designated
for tetracycline". Considering there were 450 allocated, this therefore suggests
that there were 233 in the silver nitrate group and 217 in the erythromycin
group. The paper also states that "several of the staI admitted that they tend-
ed to 'forget' the tetracycline most often because it was 'messy'". Therefore,
the 91 with no prophylaxis were likely in the tetracycline group. It appears that
3 allocated to tetracycline crossed over into silver nitrate. This is not explicit in
the paper, but had to be calculated.
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Selective reporting (re-
porting bias)
Unclear risk COMMENT: Insufficient information to permit judgement of low risk or high
risk.
Other bias Unclear risk In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
in the first 72 hours, more neonates in the silver nitrate allocation group could
be referred for culture in the first 72 hours. Finding bacteria in the culture does
not necessarily prove that the bacteria caused the conjunctivitis. The conjunc-
tivitis could be chemical, but growing normal flora of the eye. Alternatively,
the conjunctivitis could be chemical with a chlamydial carrier. Finally, the con-
junctivitis could very well be caused by the bacteria or chlamydia. Consider-
ation of incubation periods, and assessing for carriers and normal flora with





Methods Parallel-group, single-centre RCT.
Unit of allocation: neonate.
Losses to follow-up: 300 allocated, but follow-up data on 268 only. Uncertain if 32 for which no fol-
low-up data were available were losses to follow-up, exclusions before or after randomisation, or miss-
ing data.
Missing data handling: available-case analysis.
Power calculation: based on between-group difference of one SD or less, with 90% power and an error
of less than 0.05. A minimum of 80 participants was calculated for each group.
Unusual study design: excluded neonates with culture-negative eye swabs before prophylaxis.
Participants Setting: University of Medical Sciences, Isfahan, Iran.
Number allocated: 300; unknown allocation by intervention; only numbers followed up available; loss-
es by allocation group unavailable.
Age: neonates.
Sex: M:F not available.
Inclusion criteria:
1. preterm neonates;
2. preterm neonates with culture-negative eye swabs.
Exclusion criteria:
1. neonates with positive culture of eye swabs, apparently taken before application of prophylaxis.
There was no comment on equivalence of baseline characteristics.
Interventions Number of interventions: 3.
• Intervention 1: 2 drops of mother’s colostrum in each eye (n = 89 followed up).
• Intervention 2: 0.5% erythromycin ophthalmic ointment in each eye (n = 82 followed up).
• Intervention 3: no intervention (n = 97 followed up).
Ghaemi 2014 
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
Time to intervention: “Immediately after birth”.
Pre-intervention manoeuvres: eyes of neonates swabbed for bacterial culture.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with clinical conjunctivitis.
2. Infants with positive culture results of eye swabs. It is uncertain if the reported results of positive cul-
ture of eye swabs are pre-prophylaxis or postprophylaxis, therefore this outcome was not entered into
the review, pending author clarification.
Follow-up: 28 days.
Frequency of follow-up: weekly or at the time of occurrence of symptoms of neonatal conjunctivitis.
Notes on definition of conjunctivitis: the clinical definition of conjunctivitis was not specified. Only in-
fants with a diagnosis of clinical conjunctivitis were referred to eye swab and bacterial culture/PCR.
No adverse events reported.
Notes Study was conducted from November 2011 to July 2012, and published in 2014.
Source of funding: Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
Authors indicated no conflict of interest.
No reported subgroup analysis.
Trial investigators were contacted, but no response received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk QUOTE: “…and then by using the table of random numbers, they were ran-
domly assigned into three groups”
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The study was double-masked, the parents and the person who fol-
lowed up the patients were not aware about the treatment used”
COMMENT: The study does not note specifically what was done to mask par-
ents.
Erythromycin is a translucent ointment that the mother would initially notice
in the infant. Colostrum is yellowish or creamy in colour. There was no place-
bo in the allocation group that received no prophylaxis. The mothers of the
neonates with noticeable residual ointment or colostrum of the eyes may han-
dle the eyes of the infant more than mothers of neonates with no prophylaxis.
This could lead to differential introduction of pathogenic bacteria into the eyes
of these neonates. It is unclear what degree of bias these factors could intro-
duce to the study.
Blinding of study partici-




Unclear risk See support for judgement above for masking of study participants for clinical
conjunctivitis.
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High risk COMMENT: Masking of the person who administers the medication was not
addressed in this paper. Erythromycin is a translucent ointment. Colostrum
is yellowish or creamy in colour. There was no placebo in the allocation group
that received no prophylaxis. Those who administer the medication would
handle the eyes of neonates with erythromycin and colostrum, but not the
eyes of the neonates with no prophylaxis, as there was no placebo. This could
lead to differential introduction of pathogenic bacteria into the eyes of these
neonates.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, or this information could not be extracted from the study. Con-
sequently, there was no assessment of bias for this category with these out-
comes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The study was double-masked, the parents and the person who fol-
lowed up the patients were not aware about the treatment used”
COMMENT: Masking of the person who was involved in postnatal care was not
addressed in this paper.
Erythromycin is a translucent ointment.
Colostrum is yellowish or creamy in colour.
There was no placebo in the allocation group that received no prophylaxis.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, or this information could not be extracted from the study. Con-
sequently, there was no assessment of bias for this category with these out-
comes.




High risk QUOTE: “The study was double-masked, the parents and the person who fol-
lowed up the patients were not aware about the treatment used”
COMMENT: It is unclear if the person who followed up the participant was the
actual outcome assessor. In the initial stages of clinical assessment for con-
junctivitis, there may be a lack of masking, as erythromycin is an ointment that
leaves residue, and colostrum can leave stains. It is unclear how many cases of
conjunctivitis were diagnosed during this early period of time. There was no
placebo in the no-prophylaxis group. In
ambiguous cases of clinical conjunctivitis, whether identified by personnel,
mother, or outcome assessor, there may be differential group behaviour to in-
clude or exclude cases of clinical conjunctivitis with lack of masking. Conjunc-
tivitis was not defined in this paper to permit a determination of how subjec-
tive diagnosis could have been.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, or this information could not be extracted from the study. Con-






High risk COMMENT: 32 of 300 (10.6%) neonates had no data reported. Only 268 had
follow-up data. It is unclear why there was no follow-up data for the other 32
neonates. There is no further information. This number is high relative to event
rates.
Ghaemi 2014  (Continued)
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Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, or this information could not be extracted from the study. Con-




High risk QUOTE: “Overall, 300 preterm neonates, with culture negative eye swabs, were
enrolled…”
QUOTE: “Using swab, ocular culture from each participant was examined and
neonates with positive eye cultures were excluded from the study.”
COMMENT: It appears that neonates with positive eye cultures on delivery, be-
fore application of prophylaxis, were excluded from the study for unexplained
reasons. The primary initial purpose of the neonatal ophthalmia prophylax-
is was to prevent transmission of pathogens from the mother’s birth canal to
the neonate’s eyes. Therefore, this study appears to be evaluating the effect
of neonatal prophylaxis on infections acquired from sources other than the
mother.
Other bias Unclear risk QUOTE: “The results of eye swab culture of all patients reported Staphlyococ-
cus aureus”
COMMENT: It is unusual for all 66 neonates to have culture-positive conjunc-






Methods Parallel-group, single-centre RCT.
Neonates “randomly divided”. No further information on method of allocation provided.
Unit of randomisation: neonate.
Losses to follow-up: not discussed in paper.
Missing data handling: not discussed in paper.
Exclusions after allocation: none specified in paper.
Reported power calculation: no.
Unusual study design: none identified.
Participants Setting: Gonabad, Iran.
Number allocated: unknown, but 130 were included in the study. Unknown if there were exclusions af-
ter allocation.
Age: neonates.
Sex: M:F 54.6%:45.4% of all neonates. M:F ratio: tetracycline group: 1.9; no-prophylaxis group: 1.3.
Inclusion criteria: full-term neonates born through the birth canal.
Exclusion criteria: infants born through caesarean section. Unclear if this exclusion occurred before or
after allocation.
Ghahramani 2007 
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Interventions Number of interventions: 2.
• Intervention 1: 0.5% erythromycin ointment into both eyes; dose not specified (n = 65).
• Intervention 2: no prophylaxis (n = 65).
Time to intervention: not specified.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with clinical conjunctivitis.
Definition for clinical conjunctivitis: "...observing the signs [sic] of inflammation or conjunctival dis-
charge, an observation form was filled out and then sent to the laboratory for culture and smear."
Length of follow-up: 10 days postdelivery.
Intervals at which outcomes assessed: Day 3 and Day 10 after birth.
No adverse events reported.
Notes Date conducted: not specified; received for publication 5 May 2006.
Sources of funding: not identified.
No subgroup analysis.
Declaration of interest: stated as follows: “We have no competing interests.”
Trial investigators not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk COMMENT: Paper states “randomly divided”. No further information on
method of allocation.
Exact same number in each group: 65 and 65.




Unclear risk Insufficient information to permit judgement.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of the mother was not addressed in this paper.
Erythromycin is a translucent ointment that the mother would initially notice
in the infant. There was no placebo in the allocation group that received no
prophylaxis. The mothers of neonates with noticeable medication of the eyes
may handle the eyes of the infant more than mothers of neonates with no pro-
phylaxis. This could lead to differential introduction of pathogenic bacteria in-
to the eyes of these neonates.
Ghahramani 2007  (Continued)
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Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.





Masking of the person who administers medication was not addressed in this
paper.
Erythromycin is a translucent. There was no placebo in the allocation group
that received no prophylaxis. Those who administer the medication would
handle the eyes of neonates with erythromycin, but not neonates with no pro-
phylaxis. This could lead to differential introduction of pathogenic bacteria in-
to the eyes of these neonates.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-




Masking of the person who was involved in postnatal care was not addressed
in this paper.
Erythromycin ointment may leave a residual medication for a temporary pe-
riod, such that those involved in postnatal care were likely not masked to the
medication used as prophylaxis in the initial few hours.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk COMMENT: The study does not mention masking of outcome assessors. In the
first hours of clinical assessment for conjunctivitis, there may be lack of mask-
ing, as erythromycin is an ointment that leaves residue. It is unclear how many
cases of conjunctivitis were diagnosed during this time period. In
ambiguous cases of clinical conjunctivitis, whether identified by personnel,
mother, or outcome assessor, there may be differential group behaviour to in-
clude or exclude cases of clinical conjunctivitis with lack of masking. In this pa-
per, conjunctivitis was defined as signs of inflammation OR conjunctival dis-
charge, which permits further subjectivity in the diagnosis of conjunctivitis.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis






Low risk COMMENT: No reporting of incomplete outcome data. See Table 2 in paper
where data appear to be present on all neonates.
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Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




High risk QUOTE: “Thus, all the neonates were examined on the third and tenth days af-
ter birth, and in case of observing signs of inflammation or conjunctival dis-
charge, an observation form was filled out and then sent to the laboratory for
culture and smear.”
COMMENT: The paper did not report culture results despite sending neonates
for culture and smear.
COMMENT: The study did not follow neonates for 28 days.
Other bias Unclear risk COMMENT: We ranked this study as at unclear risk of bias as there is a signifi-
cant amount of information not reported in the study. Consequently, there is





Methods Parallel-group, single-centre RCT.
Unit of randomisation: neonate.
No losses to follow-up specified.
No exclusions after randomisation specified.
No comment on missing data.
No reported power calculation.
Participants Setting: Medical Science University Pediatric Ward, Kurdistan, Sanandaj, Iran.
Number allocated: 330.
Age: neonates.
Sex: M:F 143 (43%):187 (57%).
Inclusion criteria:
1. term neonates born by vaginal or C-section in the obstetrical ward of Sanandaj spring of 2011 to spring
of 2012.
Exclusion criteria:
1. neonates with congenital ophthalmic anomalies;
2. neonates whose mothers had antibiotic treatment during the 48 hours before delivery;
3. neonates whose mothers had ruptured membranes during the 18 hours prior to delivery;
4. neonates with meconium aspiration.
Baseline characteristics reported. Equivalence for birthweight, type of delivery, level of literacy, age of
the mother, parity of mother, vaginal infection.
Interventions Number of interventions: 3.
Ghotbi 2012 
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• Intervention 1: tetracycline ointment, 1 cm; administered into eyes (n = 110).
• Intervention 2: 0.5% erythromycin ointment, 1 cm; administered into eyes (n = 110).
• Intervention 3: no intervention (n = 110).
Time to intervention: 1 hour after birth.
Pre-intervention manoeuvres: cleaning, washing, and drying the infant, and after feeding breast milk.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with clinical conjunctivitis.
Follow-up: 4 weeks
Intervals at which outcomes assessed:
1. before discharge;
2. end of first week;
3. end of second week;
4. end of the fourth week.
No adverse events reported.
Notes on definition of conjunctivitis: defined erythema or discharge.
Notes Data abstracted for this study based upon translation from a native language speaker.
Study was translated.
Date recruited neonates: spring of 2011 to spring of 2012.
No sources of funding specified.
No declarations of interest specified among researchers.
Trial investigators were not contacted.
No reported subgroup analysis.
Trial registration ID: IRCT201101295714N1
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk QUOTE: (translated) “This study was a randomized controlled and single blind-
ed in one center with no placebo”.
COMMENT: No other information was provided on the random sequence
generation process. Insufficient information about the sequence generation
process to permit judgement.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of the mother was not addressed in this paper. Ery-
thromycin is a translucent ointment. Tetracycline is a light-yellow ointment.
Both medications leave a residue in the eyes that can be noticed for hours.
There was no placebo in the allocation group that received no prophylaxis.
The mothers of neonates with noticeable medication of the eyes may handle
the eyes of the infant more than mothers of neonates with no prophylaxis. This
Ghotbi 2012  (Continued)
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could lead to differential introduction of pathogenic bacteria into the eyes of
these neonates, depending on hygiene measures.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




High risk COMMENT: Masking of the person who administers medication was not ad-
dressed in this paper. Erythromycin is a translucent ointment. Tetracycline is
a light-yellow ointment. There was no placebo in the allocation group that re-
ceived no prophylaxis. Those who administer the medication would handle
the eyes of neonates with erythromycin and tetracycline, but not neonates
with no prophylaxis. This could lead to differential introduction of pathogen-
ic bacteria into the eyes of these neonates, depending on hygiene measures.
There may also be differences in adherence to medication administration of
the person administering the medication, if there was no masking and there
was bias.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of the person who was involved in postnatal care was not
addressed in this paper.
Erythromycin is a translucent ointment. Tetracycline is a light-yellow oint-
ment. There was no placebo in the allocation group that received no prophy-
laxis.
The ointments may leave a residual medication for a temporary period, such
that those involved in postnatal care were possibly not masked to at least no
prophylaxis and ointments in the initial few hours.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk COMMENT: The study does not mention masking of outcome assessors.
In the first hours of clinical assessment for conjunctivitis, there may be a
lack of masking, as erythromycin and tetracycline are ointments that leave
a residue. The control group received no medication or placebo. It is unclear
how many cases of conjunctivitis were diagnosed during this time period. In
ambiguous cases of clinical conjunctivitis, there may be differential group be-
haviour to include or exclude cases of clinical conjunctivitis with lack of mask-
ing. In this paper, conjunctivitis was defined as signs of inflammation, oedema
OR conjunctival discharge, which permits further subjectivity in the diagnosis
of conjunctivitis.
Blinding of outcome as-
sessment (detection bias)
Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
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Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




Unclear risk COMMENT: The study appeared to only report clinical conjunctivitis cases.
There was no mention in the methods or results section of the translated pa-
per of any plan to culture conjunctivitis cases. The methods are not explicit on
prespecified outcomes. There is no access to the study protocol. There is insuf-
ficient information to permit a judgement of low risk or high risk of bias.
COMMENT: The study did not follow neonates for 28 days.
Other bias Unclear risk COMMENT: We ranked this study as at unclear risk of bias as there is a signifi-
cant amount of information not reported in the study. Consequently, there is





Methods Parallel-group, single-centre RCT.
Paper states "randomly" allocated, no additional detail available.
Unit of randomisation: neonate.
Number randomised: 40.
Exclusions after allocation: none specified and not addressed in paper.
Losses to follow-up: none specified and not addressed in paper.
Missing data: no comment on missing data.
No reported power calculation.
Unusual study design: none identified.
Participants Setting: not described, according to translation; authors' address in Germany.
Number allocated: 40 neonates:
• silver nitrate: 20;
• no prophylaxis: 20.
Age: neonates.
Sex: M:F not described, according to translation.
Graf 1994 
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Inclusion criteria:
1. vaginally delivered neonates;
2. parental consent.
Exclusion criteria: none, according to translation.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: silver nitrate 1%, 1 drop in each eye (n = 20).
• Intervention 2: no prophylaxis (n = 20).
Time to intervention: not described.
Pre-intervention manoeuvres: none identified.
Postintervention manoeuvres: none identified.
Outcomes Daily evaluation and grading of the following anatomical parts of the eye:





2. conjunctiva tarsi or bulbi - graded according to the degree of hyperaemia:
a. mild: mild redness with hyperaemic vessels;
b. moderate: more pronounced redness, significantly hyperaemic conjunctiva;
c. severe: pronounced redness and thickening, significant conjunctival injection.
3. cornea - graded according to the presence or absence of the following:
a. epithelial irregularity;
b. staining with fluorescein on Day 2.
Follow-up: daily examination for 5 days postpartum; fluorescein staining of the cornea performed on
Day 2.
Definition of conjunctivitis or ophthalmia neonatorum: none identified.
Notes Date study conducted not specified.
No source of funding specified.
No declaration of interest specified in study.
No known subgroup analysis.
German language article translated to English.
Authors written to for clarifications on unclear items, no reply received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk QUOTE: “…randomly distributed into two groups”
COMMENT: No information is provided on the method chosen to determine
method of randomisation.
Graf 1994  (Continued)
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Allocation concealment
(selection bias)
Unclear risk COMMENT: No information is provided.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does address masking of mothers. The 2 interventions
differ. There was no placebo in the allocation group that received no prophy-
laxis. Silver nitrate is a clear solution. Also, silver nitrate sometimes causes a
chemical conjunctivitis that can last up to 72 hours, and silver nitrate causes
lid stains that can last 30 to 48 hours. Therefore, it would be apparent which
neonate was given silver nitrate and which neonate was given no prophylaxis.
The parents of neonates with lid stains may systematically handle the eyes of
the infant differently than parents of neonates without lid stains, potentially
affecting the outcome of conjunctivitis.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk COMMENT: The study does not mention whether the person administering
the medication was masked as to which medication was used. However, no
placebo was used, enabling the person administering the medication to be
readily aware of which neonate received silver nitrate prophylaxis. The eyes
of neonates with silver nitrate prophylaxis were handled by the person admin-
istering the medication, whereas the eyes of neonates in the no-prophylax-
is group were not touched by the person dispensing medication. It is unclear
how this could influence the outcome of conjunctivitis.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Since silver nitrate causes lid stains that can last up to 30 to 48
hours, those involved in postnatal care were possibly not masked to the med-
ication used as prophylaxis until this time period. Furthermore, there is no
indication in the paper that an attempt was made to mask those involved in
postnatal care. The role of those involved in postnatal care on the outcome of
conjunctivitis measured is unclear.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk COMMENT: The study states that the examiner was unaware of the treat-
ment status of the neonate. As silver nitrate creates lid stains that last 30 to 48
hours, outcome assessments during this time were likely not masked. Further-
more, silver nitrate may induce a chemical conjunctivitis that can last up to 72
hours, further leading to loss of masking. This is an issue in any trial that uses
silver nitrate, but in this trial follow-up was only 5 days. The study does not ad-
dress these factors, i.e. lid stains and chemical conjunctivitis, which could af-
fect masking, and subjective determination of clinical conjunctivitis.
Blinding of outcome as-
sessment (detection bias)
Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
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Low risk COMMENT: The study included only 40 neonates, which were followed up for 5
days in hospital. The neonates were discharged on Day 6. It is therefore unlike-







Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




Low risk COMMENT: The study protocol was not available, but it appears that all ex-
pected outcomes were reported.





Methods Parallel-group, multicentre RCT.
Method of allocation: “randomly”; no other details on method of allocation provided.
Unit of randomisation: neonate.
Exclusions after allocation: none directly specified; possibly up to 5 as there were 5 “perinatal” deaths.
Losses to follow-up: none directly specified; 12 women who did not deliver at the University Hospital
were likely lost pre-allocation. Also, for 7 chlamydia-positive women, there is no follow-up data, for rea-
sons unknown (67 chlamydia-positive women, but follow-up data only on 60 neonates born to chlamy-
dia-positive women).
Missing data handled by available-case analysis.
No reported power calculation.
Unusual study design: only a subgroup of infants born to 60 mothers who were chlamydia-positive
were followed up.
Participants Setting: University Hospital and satellite clinic, Seattle, WA, USA (satellite clinic serves a high-risk, in-
ner-city population).
Number allocated: 559 to 564; 5 "perinatal" deaths - unclear whether this was before or after randomi-
sation; only a subgroup of 60 neonates born to chlamydia-positive women were followed up.
• Silver nitrate: number allocated = 317; subgroup of 36 born to chlamydia-positive mothers followed
up.
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1. pregnant women first seen for prenatal care at the University Hospital, Seattle and those seen at a
satellite maternal and infant care clinic that serves a high-risk, inner-city population;
2. written informed consent.
Exclusion criteria: none specified a priori.
Interventions Number of interventions: 2.
• Intervention 1: erythromycin ointment 2.5-centimetre ribbon to each eye (concentration not speci-
fied) (n = 242).
• Intervention 2: silver nitrate 1% solution, 2 drops in each conjunctival sac (n = 317).
Time to intervention: "at the time of delivery & in the delivery room".
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with chlamydial conjunctivitis.
2. Infants with positive nasopharyngeal cultures for chlamydia.
3. Infants with chlamydial pneumonia.
4. Infants with gonococcal ophthalmia.
Follow-up: 3 months; infants examined at 2 weeks, 6 weeks, and 3 months, or more frequently if clini-
cally indicated; follow-up data only available for infants born to chlamydia-positive mothers.
Definition of chlamydial conjunctivitis: "the presence of symptoms of conjunctivitis (discharge, erythe-
ma, swelling) associated with positive conjunctival cultures".
Adverse events: study reported rates of chlamydial pneumonia and rates of nasopharyngeal infection.
These are not adverse events.
Notes Date study conducted not specified.
Study funded by Dista Pharmaceuticals, which supplied erythromycin ointment, and the National Insti-
tute of Allergy and Infectious Diseases.
No declaration of interest specified.
Authors have been contacted for clarifications on unclear items, no reply received to date.
Subgroup analysis: amongst the 559 to 564 allocated, only a subgroup of 60 neonates born to chlamy-
dia-positive women were followed up.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk QUOTE: “At the time of delivery, infants born to these women, randomly re-
ceived either 1% silver nitrate drops or erythromycin ointment…”.
COMMENT: No other information provided.
Allocation concealment
(selection bias)
Unclear risk QUOTE: “At the time of delivery, infants born to these women, randomly re-
ceived either 1% silver nitrate drops or erythromycin ointment…”.
COMMENT: No other information provided.
Blinding of study partici-
pants (mothers of infants)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.
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Clinical conjunctivitis
(subjective)
Blinding of study partici-




Unclear risk COMMENT: Masking of mothers of the intervention was not addressed in this
study. Furthermore, the 2 interventions differ in colour or consistency, or both.
Erythromycin is a translucent ointment that may leave a residue in the eyes
that can last for hours. Silver nitrate is a clear solution. Silver nitrate some-
times causes a chemical conjunctivitis that can last up to 72 hours, and lid
stains that can last 30 to 48 hours. The mothers of the neonates with notice-
able ocular residual ointment or silver nitrate stains may handle the eyes of
the infant differently. This could lead to differential introduction of Chlamy-
dia trachomatis bacteria into the eyes of these neonates in the case of poor hy-
giene. Alternatively, it could lead to contamination with other bacteria, subse-
quent conjunctivitis, and identification of chlamydia carriers instead.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.





High risk COMMENT: Masking of the person who administers the medication was not ad-
dressed in this study. As mentioned, the 2 interventions differ in colour or con-
sistency, or both, making them readily identifiable. Any bias on the part of the
person who administers the medication could affect adherence or compliance
with method of application of the medication, which, in turn, could affect the
medication’s prophylactic effect against chlamydial conjunctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.
Blinding of persons in-




Unclear risk COMMENT: Masking of those involved in postnatal care was not addressed in
this study. As mentioned, silver nitrate sometimes causes a chemical conjunc-
tivitis that can last up to 24 hours, and lid stains that can last 30 to 48 hours.
Erythromycin ointment may leave a residue in the eyes that can last for hours.
In this study, it is uncertain if there were cases of chlamydial conjunctivitis
identified in the time period when masking would be affected. It is uncertain
if those involved in postnatal care were also involved in identification of cas-
es of conjunctivitis. If they were, and they were unmasked, this could influence
decisions to identify and refer clinical conjunctivitis cases for culture. The def-
inition of conjunctivitis used in this study is discharge, erythema swelling. It is
uncertain if all signs had to be present or some or 1, which would affect rates
of diagnostic ambiguity. Although chlamydial conjunctivitis tends to be more
severe, evidence shows that there is a clinical spectrum of presentation, and
any bias, however minor, could have been significant considering the very low
event rates in this trial.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.





Unclear risk COMMENT: Masking of the person involved in outcome assessment was not
addressed in this paper. As mentioned, silver nitrate causes lid stains that can
last 30 to 48 hours, and erythromycin ointment leaves an ocular residue. Fur-
thermore, chlamydial conjunctivitis presents with a variable clinical spectrum.
Therefore, lack of masking, in cases of diagnostic ambiguity, may affect which
cases get referred for culture to identify chlamydial conjunctivitis. Under-refer-
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ral for culture may be caused by the erroneous perception that conjunctivitis
is chemical from silver nitrate, thereby missing chlamydial conjunctivitis cas-
es. Over-referral may be caused by knowledge of which infants received silver
nitrate, or bias, and lead to identifying cases of chemical conjunctivitis with





Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-






High risk QUOTE: “Chlamydia trachomatis was isolated from 67 (12%) of the 572 women
enrolled in the study..”
QUOTE: “Of the total 572 women enrolled in the study, 17 mother-infant pairs
were excluded: 12 did not deliver at the University Hospital, and there were
five perinatal deaths.”
QUOTE: ” …a total of 559 infants were born to the remaining 555 women, in-
cluding 60 infants born to Chlamydia-positive women.”
QUOTE: “The infants were randomly assigned to ocular prophylaxis regimens:
317 (57%) received silver nitrate, and 242 (43%) received erythromycin after
delivery”
QUOTE: “To assess the effect of silver nitrate or erythromycin on the subse-
quent development of chlamydial infection, we prospectively followed up 60
infants born to women with positive chlamydial culture”
COMMENT: The authors only followed up a subset of the 559 infants allocated
to prophylaxis, i.e. the subset born to chlamydia-positive women.
COMMENT: There were 67 chlamydia-positive women, but outcome data on
only 60 neonates. We are uncertain of the allocation group distribution of the
neonates born to the missing 7 chlamydia-positive women. We are also un-
certain of the proportion of the 7 missing neonates who eventually developed
chlamydial conjunctivitis. These 2 pieces of information could be quite sig-
nificant considering the low event rates: 12 of the neonates in the silver ni-
trate group developed chlamydial conjunctivitis, and zero in the erythromycin
group developed chlamydial conjunctivitis. For instance, if the majority of the
7 missing neonates were in the erythromycin group, and the majority devel-
oped chlamydial conjunctivitis, this could significantly alter the differences be-
tween the 2 groups.
COMMENT: The allocation group of 17 excluded mother-infant pairs is unclear.
As above, this is again significant considering the low event rates.
Selective reporting (re-
porting bias)
High risk QUOTE: “The infants were examined at two weeks, six weeks, and three
months, or more frequently if clinically indicated. At each visit, cultures for C.
trachomatis were obtained from the conjunctivae and nasopharynx"
COMMENT: The study authors do not report cases of non-chlamydial conjunc-
tivitis. They also do not report any cases of asymptomatic infants with positive
chlamydial conjunctival cultures, which could identify chlamydia carriers. This
may be important, as silver nitrate was used in this trial, and there could be
chemical conjunctivitis with chlamydia carrier in the first 72 hours, as opposed
to true chlamydial conjunctivitis. Finally, over 559 infants received prophylaxis
during this study, but only a subgroup of infants born to 60 chlamydia-positive
mothers were included in the study.
Other bias Unclear risk In any trial with silver nitrate, there could be diagnostic bias.
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Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
in the first 72 hours, more neonates in the silver nitrate allocation group could
be referred for culture in the first 72 hours. Finding bacteria in the culture does
not necessarily prove that the bacteria caused the conjunctivitis. The conjunc-
tivitis could be chemical, but growing normal flora of the eye. Alternatively,
the conjunctivitis could be chemical with a chlamydial carrier. Finally, the con-
junctivitis could very well be caused by the bacteria or chlamydia. Considera-
tion of incubation periods, assessing for carriers and normal flora with asymp-





Methods Parallel-group, single-centre trial.
Method of allocation: rotated monthly.
Unit of randomisation: neonate.
Exclusions after allocation: yes; not specified by allocation group: amongst 279 infants, 49 infants were
excluded postallocation for the following reasons:
• 14 born by caesarean section with no rupture of membranes;
• 15 women received antibiotic therapy effective against Chlamydia trachomatis before delivery;
• 2 infants delivered at home;
• 2 infants received unknown prophylaxis;
• 16 infants received therapy against C trachomatis before being seen by investigators.
Losses to follow-up: not specified by allocation group; 54 women lost to follow-up postenrolment, but
likely pre-allocation.
Missing data were handled by available-case analysis.
No reported power calculation.
Unusual study design: 12,431 infants received prophylaxis, but only infants born to chlamydia-positive
mothers were followed up.
Participants Setting: Kings County Hospital Medical Center, Brooklyn, NY, USA.
Ethnicity: "Clinic serves a high-risk inner-city population of patients that is 90 percent black."
Number allocated: 12,431 infants received prophylaxis, but only 279 infants born to chlamydia-positive
mothers were followed up.
Subroup followed up in each group:






1. pregnant women presenting to prenatal clinic at Kings County Hospital Medical Center;
2. women screened for chlamydia infection;
3. women providing informed consent;
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4. chlamydia-positive women.
Exclusion criteria: see exclusions after allocation above. No exclusion criteria were specified in the
methods a priori.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 3.
• Intervention 1: erythromycin 0.5% ointment 2.5-centimetre ribbon to lower eyelids (n = 4159).
• Intervention 2: tetracycline or oxytetracycline 1% ointment 2.5-centimetre ribbon to lower eyelids (n
= 4468).
• Intervention 3: silver nitrate 1% solution; number of drops not specified (n = 3804).
Supply problems required changing from tetracycline ointment to oxytetracycline ointment 6 months
into this 2.5-year study.
Time to intervention: 1 dose applied within 5 minutes of delivery.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with chlamydial conjunctivitis.
2. Infants with nasopharyngeal infection.
3. Infants with chlamydial pneumonia.
Follow-up: from 2 to 19 weeks of age.
Most infants were seen at least 2 times from 2 to 19 weeks of age; the rest were seen 1 time between 2
and 16 weeks of age.
Definition of chlamydial conjunctivitis: presence of the symptoms of discharge, erythema, and swelling
associated with positive chlamydial cultures.
No adverse events reported.
Notes Date conducted: January 1986 to June 1988.
Authors have been contacted for clarifications on masking, no reply received.
Source of funding: supported by a grant from the Division of Maternal and Child Health, Bureau of
Health Care Delivery Assistance.
No declaration of interest made in paper.
Subgroup analysis: 12,431 infants received prophylaxis, but only 279 infants born to chlamydia-positive
mothers were followed up.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “The prophylactic preparations … were rotated monthly”.
COMMENT: Sequence generated by odd or even date of birth.
Allocation concealment
(selection bias)
High risk QUOTE: “The prophylactic preparations … were rotated monthly”.
COMMENT: Participants or investigators enrolling participants could possibly
foresee assignments and thus introduce selection bias based on date of birth.
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Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.
Blinding of study partici-




Unclear risk COMMENT: Masking of mothers of the intervention was not addressed in this
study. Furthermore, the 3 interventions differ in colour or consistency, or both.
Erythromycin is a translucent ointment, and tetracycline is a light-yellow oint-
ment. Both ointments may leave a residue in the eyes that can last for hours.
Silver nitrate is a clear solution. Silver nitrate sometimes causes a chemical
conjunctivitis that can last up to 72 hours, and lid stains that can last 30 to 48
hours. Although it may be difficult to distinguish erythromycin from tetracy-
cline, silver nitrate could be readily distinguished from the two ointments. The
mothers of neonates with noticeable ocular residual ointment or silver nitrate
stains may handle the eyes of the infant differently. This could lead to differ-
ential introduction of C trachomatis bacteria into the eyes of these neonates
in the case of poor hygiene. Alternatively, it could lead to contamination with
other bacteria, subsequent conjunctivitis, and identification of chlamydia car-
riers instead. There is no evidence of Neisseria gonorrhoeae having a carrier
status, but the chemical conjunctivitis and lid stains may lead to systematic
differential handling of the eyes, which in cases of poor hygiene could bias the
outcome of gonococcal conjunctivitis.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.





High risk COMMENT: Masking of the person who administers the medication was not
addressed in this study. As mentioned, the 3 interventions differ in colour or
consistency, or both, making them readily identifiable. Any bias on the part of
the person who administers the medication could affect adherence or method
of application of the medication, which, in turn, could affect the medication’s
prophylactic effect against chlamydial or gonococcal conjunctivitis. Allocation
by month and the low event rates of chlamydial conjunctivitis magnify any po-
tential bias.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.
Blinding of persons in-




Unclear risk COMMENT: Masking of those involved in postnatal care was not addressed in
this study. As mentioned, silver nitrate sometimes causes a chemical conjunc-
tivitis that can last up to 24 hours, and lid stains that can last 30 to 48 hours.
Both of the ointments may leave a residue in the eyes that can last for hours.
In this study, the mean onset of chlamydial conjunctivitis was 15+/−14 days
with a range of 1 to 61 days, and median of 11.5 days. Consequently, there
were cases of chlamydial conjunctivitis identified in the period of time when
masking would be affected. The days of onset of gonococcal conjunctivitis
were not identified in the study. It is uncertain if those involved in postnatal
care were also involved in identification of cases of conjunctivitis. If they were,
and they were unmasked, this could influence decisions to identify and refer
clinical conjunctivitis cases for culture. The definition of conjunctivitis used is
more robust and includes erythema, swelling AND discharge; and chlamydial
and gonococcal conjunctivitis tends to be more severe, thereby reducing diag-
nostic ambiguity. However, evidence shows that there is a clinical spectrum of
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presentation of at least chlamydial conjunctivitis, and any bias, however mi-
nor, could have been significant considering low event rates.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.





Unclear risk COMMENT: Masking of the person involved in outcome assessment was not
addressed in this paper. As mentioned, silver nitrate causes lid stains that can
last 30 to 48 hours, and the mean onset of chlamydial conjunctivitis in this
study was 15+/−14 days with a range of 1 to 61 days, and median of 11.5 days.
In fact, chlamydial conjunctivitis developed in 74% of the infants before they
were 14 days of age. Furthermore, chlamydial conjunctivitis presents with a
variable clinical spectrum. Therefore, lack of masking, in cases of diagnostic
ambiguity, may affect which cases get referred for culture to identify chlamy-
dial conjunctivitis. Under-referral for culture may be caused by the erroneous
perception that conjunctivitis is chemical from silver nitrate, thereby missing
chlamydial conjunctivitis cases. Over-referral may be caused by knowledge
of which infants received silver nitrate, or bias, and lead to identifying cases
of chemical conjunctivitis with chlamydia carrier, rather than conjunctivitis
caused by C trachomatis.
This study does not report the mean age of onset of gonococcal conjunctivitis,






Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-






High risk QUOTE: “The prophylactic preparations…were rotated monthly, from January
1986 through June 1988, and all newborns received them.”
QUOTE: ”A total of 4357 women were screened, 341 (8 percent) were found to
have chlamydial infection."
QUOTE: “Of the 341 pregnant women with chlamydial infection…”
QUOTE: “The remaining 230 infants born to women with chlamydial infection
form the population studied for chlamydial conjunctivitis.”
COMMENT: The denominator used in this study is the subset of 230 infants
born to a subset of mothers with chlamydia, amongst the 4357 women en-
rolled in the study. The subset of women with chlamydia infection was actually
341, but was reduced to 230 after exclusions and loss to follow-up. The distri-
bution of women excluded or lost to follow-up by allocation group is unclear.
The number of women out of the 4357 that were allocated to each interven-
tion is also unclear.
COMMENT: Postenrolment, 54 out of 339 chlamydia-positive enrolled women
were lost to follow-up. It is unclear whether this was pre-allocation or postal-
location of prophylaxis. 8 women out of 339 enrolled had a miscarriage or still-
birth. It is unclear how these women were distributed across the allocation
groups.
COMMENT: Amongst 279 infants allocated and given prophylaxis, 49 were
excluded from the analysis. However, their distribution across intervention
groups was not reported. Conjunctivitis developed in 1 of the excluded infants
and was treated in the emergency room, but no chlamydial cultures were con-
ducted; the paper did not report the allocation group of this infant.
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COMMENT: Amongst the 49 excluded infants, 14 were born by caesarean sec-
tion with no rupture of membranes; 15 received antibiotic therapy effective
against C trachomatis before delivery; 2 infants were delivered at home with
some delay before application of prophylaxis; 2 infants received unknown pro-
phylaxis; and 16 infants received therapy effective against C trachomatis be-
fore being assessed. We were unable to impute outcomes for these data in
sensitivity analyses or intention-to-treat analysis, as the intervention groups
were not specified.
QUOTE: “None of the other excluded infants had an illness compatible with
chlamydial infection or had positive chlamydial cultures”
COMMENT: It is unclear if this statement in the study pertains to all the 49
mother-infant pairs excluded from analysis.
COMMENT: The ratio of participants with missing data to participants with
events was minimum 49/35 (1.4) or maximum 93/35 (2.7), if we include the 54
women lost to follow-up. Either ratio suggests a high risk of bias, in relation to




High risk QUOTE: “Infants born to mothers with chlamydial infection were seen at two
weeks, six weeks and three months of age, or more frequently if clinically in-
dicated. A cohort of infants born to mothers without chlamydial infection was
also followed at the same intervals…Specimens for chlamydial culture were
obtained from the conjunctivae and nasopharynx at each visit, whether or not
the infant was symptomatic.“
COMMENT: The study authors do not report cases of non-chlamydial conjunc-
tivitis. They also do not report any cases of asymptomatic infants with posi-
tive chlamydial conjunctival cultures, which could identify chlamydia carri-
ers. This may be important as silver nitrate was used in this trial, and there
could be chemical conjunctivitis with chlamydia carrier in the first 72 hours,
as opposed to true chlamydial conjunctivitis. Finally, over 12,431 infants re-
ceived prophylaxis during this study, but only a subgroup of infants born to
341 chlamydia-positive mothers were included in the study, and only 230 were
followed up.
QUOTE: “During the 30-month period from January 1986 through June 1988,
gonococcal ophthalmia developed in 8 of 12, 431 infants born at Kings County
Hospital. Seven of the mothers of these infants had received no prenatal care.”
COMMENT: These mothers and infants entered the trial through a different
route, as they had no prenatal screening.
Other bias Unclear risk In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
in the first 72 hours, more neonates in the silver nitrate allocation group could
be referred for culture in the first 72 hours. Finding bacteria in the culture does
not necessarily prove that the bacteria caused the conjunctivitis. The conjunc-
tivitis could be chemical, but growing normal flora of the eye. Alternatively,
the conjunctivitis could be chemical with a chlamydial carrier. Finally, the con-
junctivitis could very well be caused by the bacteria or chlamydia. Consider-
ation of incubation periods, and assessing for carriers and normal flora with
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Study characteristics
Methods Parallel-group, single-centre trial.
Method of allocation: alternate neonates.
Unit of randomisation: neonate.
Exclusions after allocation: none specified and not addressed in paper.
Losses to follow-up: none specified and not addressed in paper.
Missing data: no comment on how missing data were handled.
No reported power calculation.
Unusual study design: outcome definition was changed part way through the study.
Participants Setting: Beyer Memorial Hospital, Ypsilanti, MI, USA.
Number allocated: 2424 neonates;
• penicillin: 1219;
• silver nitrate: 1205.
Age: neonates.
Sex: M:F not specified.
Inclusion criteria: all infants born 1 March 1955 to 29 February 1956 at Beyer Memorial Hospital.
Exclusion criteria: none specified.
No comment in study on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: penicillin G 1% ophthalmic ointment (n = 1219).
• Intervention 2: silver nitrate 1% solution (n = 1205).
Time to intervention: not specified.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes Used 2 classification schemes. 1 was changed to the other during the study:
Initial classification scheme:
0 - no conjunctival reaction;
1 - mild erythema of conjunctiva without discharge;
2 - moderate erythema of conjunctiva without discharge;
3 - moderate erythema of conjunctiva with discharge;
4 - severe erythema of conjunctiva with discharge.
Subsequent classification scheme:
1 - no conjunctivitis;
2 - conjunctivitis without discharge;
3 - conjunctivitis with discharge.
All conjunctivitis with discharge had smears and cultures made of the discharge.
The results reported total "reactions" and subdivided each "reaction" as either:
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1. mild without discharge; or
2. severe with discharge.
Follow-up: newborn nursery nurses examined infants on the 2nd and 5th days postpartum.
Definition of conjunctivitis: not explicitly defined.
Notes on outcomes:
1. Apparently, about one-half of two-thirds of the conjunctivitis cases followed were identified as con-
genitally obstructed tear ducts, but these results were not reported by intervention group. It is un-
known if these were subtracted from the total. It is unknown what criteria were used to make the diag-
nosis of obstructed tear ducts.
2. There was 1 case of gram-negative diplococcus on smear only, but not on culture; allocation group is
unknown.
Notes Date study conducted: 1 March 1955 to 29 February 1956.
No source of funding specified.
No declaration of interest statement made.
No reported subgroup analysis.
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: "Alternate babies had one per cent penicillin G. ophthalmic ointment
supplied by Abbott Laboratories used in their eyes in the delivery room."
Allocation concealment
(selection bias)
High risk QUOTE: "Alternate babies had one per cent penicillin G. ophthalmic ointment
supplied by Abbott Laboratories used in their eyes in the delivery room."
COMMENT: Allocation was based on alternation, therefore participants or in-
vestigators enrolling participants could possibly have foreseen assignments,
thus introducing selection bias.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention. The 2 interventions differ in colour and consistency. Silver nitrate
is a clear solution, and penicillin is a clear or white ointment.
Furthermore, silver nitrate sometimes causes eyelid stain that can last for 30 to
48 hours and a chemical conjunctivitis that can last up to 72 hours. Penicillin
is an ointment that can leave residue for hours and be noticed in the infant by
the mother.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




High risk COMMENT: The study does not address masking of the person who adminis-
ters the medication. The 2 interventions differ in colour and consistency. Silver
nitrate is a clear solution, and penicillin is a clear or white ointment.
Lack of masking by the person who administers the medication could influ-
ence the outcome of clinical conjunctivitis. There could be differences in ad-
Harris 1957  (Continued)
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herence to method of dispensing based on any bias by the person applying the
ocular prophylaxis.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “Memoranda of which (silver nitrate or penicillin) was used were
sent directly to the record room so that the personnel of the newborn nursery
would not know which had been used.”
QUOTE: “Nurses in the newborn nursery examined all babies’ eyes on the sec-
ond and fiEh days postpartum.”
COMMENT: Silver nitrate is a clear solution, and penicillin is an ointment. Fur-
thermore, silver nitrate sometimes causes eyelid stain that can last for 30 to
48 hours and a chemical conjunctivitis that can last up to 72 hours. This could
affect masking of those involved in postnatal care. Apparently the nurses in-
volved in the newborn nursery were involved in outcome assessment also.
Even though there were efforts to mask the nurses to intervention, follow-up
time in this study was only 5 days.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk QUOTE: “Memoranda of which (silver nitrate or penicillin) was used were
sent directly to the record room so that the personnel of the newborn nursery
would not know which had been used.”
QUOTE: “Nurses in the newborn nursery examined all babies’ eyes on the sec-
ond and fiEh days postpartum.”
COMMENT: Silver nitrate is a clear solution, and penicillin is an ointment. Fur-
thermore, silver nitrate sometimes causes eyelid stain that can last for 30 to 48
hours and a chemical conjunctivitis that can last up to 72 hours. This could af-
fect masking of those involved in outcome assessments. Apparently the nurses
involved in the newborn nursery were involved in outcome assessment. Even
though there were efforts to mask the nurses to intervention, follow-up time in
this study was only 5 days.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis






Unclear risk COMMENT: The study did not comment on exclusions or loss to follow-up. This
was likely low, as the follow-up time was only 5 days.
Incomplete outcome data
(attrition bias)
Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
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High risk QUOTE: “Nurses in the newborn nursery examined all babies’ eyes on the sec-
ond and fiEh days postpartum and marked the chart as follows:…It was soon
found that such differentiation was not practical and three classifications has
to be used.”
COMMENT: The classification of categorising ocular signs was modified during
the study.
QUOTE: “Only one case showed bacteria on smear and in this case nothing
grew on culture.”
Other bias Unclear risk COMMENT: In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
in the first 72 hours, more neonates in the silver nitrate allocation group could
be referred for culture in the first 72 hours. Finding bacteria in the culture does
not necessarily prove that the bacteria caused the conjunctivitis. The conjunc-
tivitis could be chemical, but growing normal flora of the eye. Alternatively,
the conjunctivitis could be chemical with a chlamydial carrier. Finally, the con-
junctivitis could very well be caused by the bacteria or chlamydia. Consider-
ation of incubation periods, and assessing for carriers and normal flora with





Methods Parallel-group, single-centre RCT.
Method of allocation: randomisation by a pre-randomised ledger.
Unit of randomisation: neonate.
Exclusions after allocation:
1. infants with a history of treated eye infection at the 2-week check-up;
2. infants with evidence of conjunctival inflammation at the time of the 2-week check-up.
Losses to follow-up: yes; complete follow-up data available for 145 of 496 neonates.
Missing data handled by available-case analysis.
No reported power calculation.
Unusual study design: none
Participants Setting: Rochester Methodist Hospital, Rochester, MN, USA.
Number allocated: 496; unknown how many allocated to each group:
• tetracycline: only 69 followed up;
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Inclusion criteria: newborns of consenting parents at Rochester Methodist Hospital.
Exclusion criteria: none specified.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: tetracycline hydrochloride 1% ophthalmic solution; dose not specified. (n = unknown
allocated; 69 followed up).
• Intervention 2: silver nitrate 1% solution; dose not specified. (n = unknown allocated; 76 followed up).
Time to intervention: not specified.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: excess medication wiped from eyes of neonates; instructed not to irri-
gate eyes with water.
Outcomes 1. Nasolacrimal duct obstruction.
Follow-up: 2 months. Parents of children questioned at the time of 2-week and 2-month well-child ex-
aminations.
Definition of nasolacrimal duct obstruction: chronic eye discharge at 2-week visit that persisted to 2-
month visit in the absence of signs of conjunctival inflammation.
No other outcomes or adverse events reported. Nasolacrimal duct obstruction is considered to be an
adverse event of silver nitrate.
Notes Date study conducted: not specified.
No source of funding identified.
No declaration of interest made.
No reported subgroup analysis.
Trial investigators were contacted and reply received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk QUOTE: “All newborns of consenting parents at Rochester Methodist Hospital
were randomized to one of two ophthalmic prophylaxis treatment groups,…”
QUOTE: “Randomization was accomplished through the use of a pre-random-
ized ledger”.




Low risk COMMENT: Allocation concealment was not addressed in this study. However,
letter from author states that sequence of allocation of participants to groups
was concealed until after treatments had been allocated. Method was not de-
scribed.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk Total number of all cases of clinical conjunctivitis was not reported as an out-
come in this study. Consequently, there was no assessment of bias for this cat-
egory for the outcome of clinical conjunctivitis.
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Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk Total number of all cases of clinical conjunctivitis was not reported as an out-
come in this study. Consequently, there was no assessment of bias for this cat-
egory for the outcome of clinical conjunctivitis.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk Total number of all cases of clinical conjunctivitis was not reported as an out-
come in this study. Consequently, there was no assessment of bias for this cat-
egory for the outcome of clinical conjunctivitis.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk Total number of all cases of clinical conjunctivitis was not reported as an out-
come in this study. Consequently, there was no assessment of bias for this cat-
egory for the outcome of clinical conjunctivitis.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis






Unclear risk Total number of all cases of clinical conjunctivitis was not reported as an out-
come in this study. Consequently, there was no assessment of bias for this cat-






Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




Unclear risk QUOTE: “Infants with a history of treated eye infection and those with evi-
dence of conjunctival inflammation at the time of the two-week check-up were
excluded from the study.”
COMMENT: Number of infants with a history of conjunctivitis would have been
collected, but this was not reported in the study.
QUOTE: “Physical signs of inflammation were not found significantly more in
one group than the other at two weeks of age.”
Hick 1985  (Continued)
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COMMENT: This outcome was collected but data were not reported.
QUOTE: “The overall incidence of persistent eye discharge at two months of
age 13%.”
COMMENT: This number of 13% cannot be re-calculated from the data provid-
ed in the paper. The number calculated from the data was 11.7%.
COMMENT: Despite missing data above, the purpose of the study was to look
for the relationship between silver nitrate and nasolacrimal duct obstruction.
The study protocol was not available. Consequently, there is insufficient infor-
mation to permit judgement.
Other bias Unclear risk In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
in the first 72 hours, more neonates in the silver nitrate allocation group could
be referred for treatment of eye infection, thereby excluding them from the
study. This does not appear to have occurred in this study, based on the fact
that the groups seem evenly balanced. However, we do not have the numbers






Methods Parallel-group, single-centre trial.
Method of allocation: alternation by week of birth.
Unit of randomisation: neonate.
Exclusions after randomisation: not addressed in this paper.
Losses to follow-up: parents were advised to return to hospital only if their child had conjunctivitis. Un-
able to determine how many infants had conjunctivitis but did not return.
Number randomised: 3117.
Missing data: unknown how many losses to follow-up; available-case analysis.
No reported power calculation.
Unusual study design: none.




• silver nitrate: 929.
Age: neonates.
Sex: M:F 1452 (53%):1665 (47%).
Inclusion criteria: babies born from March 1991 to August 1993 at the Prebyterian Church Hospital.
Exclusion criteria:
Isenberg 1995 
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1. infants with ocular malformations;
2. mothers who had received antibiotics during the last month of pregnancy;
3. mothers who were unable to bring infant back to hospital if conjunctivitis developed.
Equivalence of baseline characteristics: yes.
Interventions Number of interventions: 3.
• Intervention 1: povidone-iodine, 1 drop 2.5% solution in each eye (n = 1076).
• Intervention 2: erythromycin, 1-centimetre strip of 0.5% ointment in each eye (n = 1112).
• Intervention 3: silver nitrate, 1 drop of 1% solution in each eye (n = 929).
Time to intervention: 1 dose within 20 minutes of birth.
Pre-intervention manoeuvres: eyes and face cleaned.
Postintervention manoeuvres: none specified.
Outcomes Infants with any conjunctivitis were only determined from mothers who self- reported their infants to
hospital.
1. Infants with conjunctivitis.
2. Infants with non-infectious conjunctivitis.
3. Infants with infectious conjunctivitis.
4. Infants with chlamydial conjunctivitis.
5. Infants with gonococcal conjunctivitis.
Follow-up: within a month of birth.
Definition of conjunctivitis: mother shown picture of inflamed eyes and advised to return if eye had dis-
charge or became red. Once infant returned, ophthalmologist assessed for infection clinically, and mi-
crobiological analysis was performed.
No adverse events reported.
Notes Date conducted: March 1991 to August 1993.
Source of funding: Karl Kirchgessner Foundation.
No declaration of interest statement made.
No reported subgroup analysis.
Trial investigators contacted and reply received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “The three medications were rotated after each was used for a week in
the maternity unit. Thus, each infant was assigned to receive a drug according
to the week of birth”
Allocation concealment
(selection bias)
High risk QUOTE: “The three medications were rotated after each was used…”
QUOTE: “…each infant was assigned to receive a drug according to the week of
birth.”
COMMENT: Allocation could have been foreseen in advance of or during enrol-
ment by using a particular medication for 1 week. Therefore, allocation was
not adequately concealed.
Isenberg 1995  (Continued)
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Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “…the parents, they were unaware of the medication given.” (letter
from author)
COMMENT: The 3 interventions differ in colour and consistency. Povidone-io-
dine is an orange-red solution that leads to transient residual staining of the
eye, skin, and lids that can last minutes to hours, which the mother may no-
tice. Erythromycin is a translucent ointment that can last hours and could have
been noticed by the mother. Silver nitrate is a clear solution that sometimes
causes a chemical conjunctivitis that can last up to 72 hours, and also causes
lid stains that can last 30 to 48 hours. It is unknown how this could affect per-
formance bias.
Blinding of study partici-




Unclear risk QUOTE: “…the parents, they were unaware of the medication given.” (letter
from author)
COMMENT: The 3 interventions differ in colour and consistency. Povidone-io-
dine is an orange-red solution that leads to transient residual staining of the
eye, skin, and lids that can last minutes to hours, and that the mother may no-
tice. Erythromycin is a translucent ointment that can last hours and could have
been noticed by the mother. Silver nitrate is a clear solution that sometimes
causes a chemical conjunctivitis that can last up to 72 hours, and also causes
lid stains that can last 30 to 48 hours. It is unknown how this could affect per-
formance bias.
The mothers may differentially handle the eyes of neonates based on the vis-
ible signs of prophylaxis. This could lead to differential introduction of path-
ogenic bacteria into the eyes of these neonates. Therefore, lack of masking
of medication appearance could lead to bias in bacterial conjunctivitis cases.
This bias would be less likely for chlamydial and gonococcal conjunctivitis cas-
es, depending on hygiene measures. However, considering the low event rates
of gonococcal conjunctivitis and possible carrier state of Chlamydia trachoma-
tis, this could introduce important bias. It is unknown how many neonates de-
veloped conjunctivitis in the time period when the medication could be identi-
fied.




High risk QUOTE “The only person who knew and recorded which medication was given
was the Ophthalmology Research Nurse. At times, she also administered the
eyedrops at birth.” (letter from author)
COMMENT: The 3 interventions differ in colour and consistency: povidone-io-
dine is an orange-red solution, erythromycin is a translucent ointment, and sil-
ver nitrate is a clear solution. All 3 medications are readily identifiable to any-
one administering the medication. The author states that at times the person
administering the prophylaxis was not masked and knew the medication giv-
en.





High risk QUOTE “The only person who knew and recorded which medication was given
was the Ophthalmology Research Nurse. At times, she also administered the
eyedrops at birth.” (letter from author)
COMMENT: The 3 interventions differ in colour and consistency: povidone-io-
dine is an orange-red solution, erythromycin is a translucent ointment, and sil-
ver nitrate is a clear solution. All 3 medications are readily identifiable to any-
one administering the medication. The author states that at times the person
administering the prophylaxis was not masked and knew the medication giv-
en. With lack of masking, the person administering the medication could have
dispensed the medications differently or there could be differential adherence
problems, thereby altering the bactericidal effect. We have seen this in 1 study
where 1 of the medications was ointment, and tended to be "skipped" more
than solution, owing to difficulty in handling the ointment.
Isenberg 1995  (Continued)
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Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
High risk QUOTE: “The only individual who knew precisely what prophylaxis was giv-
en to the child was the research nurse and nurses on duty in the nursery. No
physician or other healthcare worker was aware of the medication used.” (let-
ter from author)
COMMENT: The author states that nurses on duty in the nursery were not
masked as to the study. The 3 interventions differ in colour and consisten-
cy. Povidone-iodine is an orange-red solution that leads to transient residual
staining of the eye, skin, and lids that can last minutes to hours, depending on
whether the surrounding periorbital skin is cleaned or not. Erythromycin is a
translucent ointment that can last hours. Silver nitrate is a clear solution that
sometimes causes a chemical conjunctivitis that can last up to 72 hours, and
also causes lid stains that can last 30 to 48 hours.
It is unclear how long the neonates were in the nursery, and how many cas-
es of conjunctivitis were identified at this time. It is also unclear if the nurses
on duty in the nursery were also involved in identifying cases of conjunctivitis,
and to what extent.
The nurses in the nursery may have differentially handled the eyes of neonates
based on visible signs of prophylaxis. This could lead to differential introduc-
tion of pathogenic bacteria into the eyes of these neonates.
Blinding of persons in-




High risk QUOTE: “The only individual who knew precisely what prophylaxis was giv-
en to the child was the research nurse and nurses on duty in the nursery. No
physician or other healthcare worker was aware of the medication used.” (let-
ter from author)
COMMENT: The author states that nurses on duty in the nursery were not
masked as to the study. The 3 interventions differ in colour and consisten-
cy. Povidone-iodine is an orange-red solution that leads to transient residual
staining of the eye, skin, and lids that can last minutes to hours, depending on
whether the surrounding periorbital skin is cleaned or not. Erythromycin is a
translucent ointment that can last hours. Silver nitrate is a clear solution that
sometimes causes a chemical conjunctivitis that can last up to 72 hours, and
also causes lid stains that can last 30 to 48 hours.
It is unclear how long the neonates were in the nursery, and how many cas-
es of conjunctivitis were identified at this time. It is also unclear if the nurses
on duty in the nursery were also involved in identifying cases of conjunctivitis,
and to what extent.
Any bias in identification of cases of conjunctivitis cases could influence cases
referred for swabbing for bacteria, chlamydia, and gonorrhoea. For instance,
the nurse was aware that neonates were given silver nitrate, and were aware of
the concomitant chemical conjunctivitis; in ambiguous cases, the nurse may
erroneously have ignored cases of 'true' bacterial conjunctivitis that happen to
have presented outside the chemical conjunctivitis window.
The incubation period of gonococcal conjunctivitis and chlamydial conjunc-
tivitis is likely outside the time period at which the nurses in the nursery would
be influencing identification and care. Furthermore, these cases are likely
more clinically severe, eliminating ambiguity. Therefore, the lack of masking of
the nurses in the nursery will likely have introduced less bias for the outcomes
of gonococcal and chlamydial conjunctivitis. Still, the possible carrier state of
chlamydia and the low event rate of gonococcal conjunctivitis could make mi-
nor bias important and clinically significant.
Blinding of outcome as-
sessment (detection bias)
Unclear risk QUOTE: “Infants returning with conjunctivitis were taken to the clinical labo-
ratory of the Nairobi Hospital for microbiologic analysis of the inflamed eye-
s.” (from journal article)
Isenberg 1995  (Continued)
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Clinical conjunctivitis
(subjective)
QUOTE: “…the outcome assessors (were) totally masked as to the medication
used. The clinical outcome assessors (were) primarily the microbiologist who
determined the source of infection and the ophthalmologist who determined
if the infection or other form of conjunctivitis was present.” (letter from author)
QUOTE: “Outcome assessments were determined by the parents who detected
an infection and the microbiologist who determined the organism. Both were
unaware of the medications used.” (letter from author)
COMMENT: The 3 interventions differ in colour and consistency. Povidone-io-
dine is an orange-red solution that leads to transient residual staining of the
eye, skin, and lids that can last minutes to hours, depending on whether the
periorbital skin is cleaned. Erythromycin is a translucent ointment that can
last hours. Silver nitrate is a clear solution that sometimes causes a chemical
conjunctivitis that can last up to 72 hours, and also causes lid stains that can
last 30 to 48 hours.
It is unknown how many cases of conjunctivitis were identified during the time
when these stains remained.





Low risk QUOTE: “ Infants returning with conjunctivitis were taken to the clinical labo-
ratory of the Nairobi Hospital for microbiologic analysis of the inflamed eye-
s.” (from journal article)
QUOTE: “…the outcome assessors (were) totally masked as to the medication
used. The clinical outcome assessors (were) primarily the microbiologist who
determined the source of infection and the ophthalmologist who determined
if the infection or other form of conjunctivitis was present.” (letter from author)
QUOTE: “Outcome assessments were determined by the parents who detected
an infection and the microbiologist who determined the organism. Both were
unaware of the medications used.” (letter from author)
COMMENT: The 3 interventions differ in colour and consistency. Povidone-io-
dine is an orange-red solution that leads to transient residual staining of the
eye, skin, and lids that can last minutes to hours, depending on if the peri-
orbital skin is cleaned. Erythromycin is a translucent ointment that can last
hours. Silver nitrate is a clear solution that sometimes causes a chemical con-
junctivitis that can last up to 72 hours, and also causes lid stains that can last
30 to 48 hours.
It is unknown how many cases of conjunctivitis were identified during the time
when these stains remained. This could affect bias in the decision to swab by
the ophthalmologist, thereby altering bacterial conjunctivitis cases, and false-
ly identifying chemical conjunctivitis cases with normal flora bacteria.
The incubation period of gonococcal conjunctivitis and chlamydial conjunc-
tivitis is likely outside the time period at which these stains would remain. Fur-
thermore, these cases are likely more clinically severe, reducing ambiguity in
diagnosis. In the silver nitrate arm, any cases presenting within the chemical
conjunctivitis period, but before the incubation period of chlamydial conjunc-
tivitis, could simply be cases of chemical conjunctivitis with chlamydial carri-
ers. It is unclear how authors handled these cases. This bias is likely low in this
trial considering the higher event rate of chlamydial conjunctivitis. Although
gonococcal conjunctivitis has a lower event rate, there is no reported carrier





Unclear risk QUOTE: “Each mother was shown pictures of inflamed eyes and instructed
to return to the hospital with her infant if the child’s eye began to have a dis-
charge or became red within a month of birth. “ (from journal article)
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QUOTE: “Attrition is not an issue since we reported only babies returning with
conjunctivitis” (letter from author)
COMMENT: The mother first had to make decision as to whether the eyes re-
quired follow-up. The definition of conjunctivitis included discharge OR in-
flamed eyes, adding some ambiguity. It is unknown how many mothers did
not return for follow-up at all or for follow-up to the prescribed hospital. It is
unclear if loss to follow-up varied by intervention group, or the relationship
to event rates. Furthermore, considering allocation was by week of birth, we
do not know if allocation groups were equivalent, and if there was correlation
with 1 allocation group, and say, distance from hospital, thereby differentially






Unclear risk QUOTE: “Each mother was shown pictures of inflamed eyes and instructed
to return to the hospital with her infant if the child’s eye began to have a dis-
charge or became red within a month of birth. “ (from journal article)
QUOTE: “Attrition is not an issue since we reported only babies returning with
conjunctivitis” (letter from author)
COMMENT: It is unknown how many mothers did not return for follow-up at all
or for follow-up to the prescribed hospital. It is unclear if loss to follow-up var-
ied by intervention group, or the relationship to event rates. It is also unclear
how many infants identified with conjunctivitis, if any, failed to follow up at
the clinical laboratory for microbiologic analysis of the inflamed eyes.
Selective reporting (re-
porting bias)
Low risk COMMENT: There is no evidence of selective outcome reporting.
Other bias Unclear risk In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result,
in the first 72 hours, more neonates in the silver nitrate allocation group could
be referred for culture in the first 72 hours. Finding bacteria in the culture does
not necessarily prove that the bacteria caused the conjunctivitis. The conjunc-
tivitis could be chemical, but growing normal flora of the eye. Alternatively,
the conjunctivitis could be chemical with a chlamydial carrier. Finally, the con-
junctivitis could very well be caused by the bacteria or chlamydia. Consider-
ation of incubation periods, and assessing for carriers and normal flora with





Methods Parallel-group, single-centre trial.
Unit of randomisation: neonate.
Method of allocation: alternation by week of birth.
Exclusions after allocation: neonates who returned with conjunctivitis within 48 hours of birth were ex-
cluded; number not specified.
Losses to follow-up: parents were advised to return to hospital only if their children had conjunctivitis;
unable to determine how many infants had conjunctivitis but did not return.
Number randomised: 719.
Missing data: unknown how many were lost to follow-up; available-case analysis.
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Power calculation: yes; power of 80% by 1-sided test requires 286 neonates per arm.
Unusual study design: none.
Participants Setting: Presbyterian Church of East Africa Hospital, Kikuya, Kenya.
Number allocated: 719 neonates:
• single-dose povidone-iodine: 402;
• double-dose povidone-iodine: 317.
Age: neonates.
Sex: M:F:
• single-dose group: 49.8%:50.2%;
• double-dose group: 53%:47%.
Inclusion criteria: all babies born from January 2000 to October 2001 at the Presbyterian Church of East
Africa Hospital.
Exclusion criteria:
1. infants with ocular malformations;
2. mothers who had received antibiotics during the last month of pregnancy;
3. mothers who were unable to bring infant back to hospital if conjunctivitis developed;
4. infants born by caesarean section.
Equivalence of baseline characteristics: yes.
Interventions Number of interventions: 2.
• Intervention 1: 1 drop 2.5% povidone-iodine solution in each eye within 20 minutes of birth (n = 402).
• Intervention 2: 1 drop 2.5% povidone-iodine solution in each eye within 20 minutes of birth AND 1
drop 2.5% povidone-iodine solution at hospital discharge or 24 hours after delivery, whichever was
first. Time to intervention: 1 dose within 20 minutes of birth; second dose at hospital discharge or 24
hours after delivery, whichever was first (n = 317).
Pre-intervention manoeuvres: eyes and face cleaned.
Postintervention manoeuvres: none specified.
Outcomes Each mother was shown pictures of inflamed eyes and advised to return infant to hospital if infant's
eye had a discharge or became red.






2. Infants with positive culture results of eye specimens, described by type.
3. Infants with positive Gram stain results of eye specimens, described by type.
4. Cases of Chylamdia trachomatis diagnosed by Giemsa stain, Gram stain, and/or direct fluorescent an-
tibody assay.
5. No cases on gonococcal conjunctivitis found.
Follow-up: within a month of birth, self-report by parent.
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Definition of conjunctivitis or ophthalmia neonatorum: no explicit definition. Mother shown picture of
inflamed eyes and advised to return if eye had discharge or became red. Amongst neonates returning
for assessment, it was unclear how many neonates actually had red eyes or eye discharge.
No adverse events reported.
Notes Date study conducted: January 2000 to October 2001.
Source of funding: Ronald McDonald House Charities, The Karl Kirchgessner Foundation, Research to
Prevent Blindness Senior Scientific Investigator Award.
No declaration of interest statement made in paper.
No reported subgroup analysis.
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




High risk QUOTE: “Each infant was assigned a dosing schedule according to the week of
birth”
COMMENT: Allocation could have been foreseen in advance or during enrol-
ment by using a particular medication for 1 week. Therefore, allocation was
not adequately concealed.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study did not address this outcome. The 2 interventions were
the same, except that 1 allocation group received the intervention once at
birth, and the other allocation group received the intervention twice, once at
birth and the second time within 24 h. Povidone-iodine is an orange-red solu-
tion that leads to transient residual staining of the eye, skin, and lids that can
last minutes to hours, depending on whether the surrounding periorbital skin
is cleaned or not. It is likely that the mothers of neonates knew if their child
had received the intervention twice. It is uncertain how possible lack of mask-
ing could influence the outcome of clinical conjunctivitis.
Blinding of study partici-




Unclear risk COMMENT: The study did not address this outcome. The 2 interventions were
the same, except that 1 allocation group received the intervention once at
birth, and the other allocation group received the intervention twice, once at
birth and the second time within 24 h. Povidone-iodine is an orange-red solu-
tion that leads to transient residual staining of the eye, skin, and lids that can
last minutes to hours, depending on whether or not the surrounding perior-
bital skin is cleaned.
The mothers may differentially handle the eyes of neonates based on the visi-
ble signs of prophylaxis, at birth vs within 24 hours. This could lead to differen-
tial introduction of pathogenic bacteria into the eyes of these neonates with
more time in the hospital. Therefore, lack of masking in the single- vs dou-
ble-application allocation group may lead to bias in bacterial conjunctivitis
cases. This bias would be less likely for chlamydial and gonococcal conjunc-
tivitis cases, depending on hygiene measures. However, considering the ze-
ro event rates of gonococcal conjunctivitis and possible carrier state of C tra-
chomatis, this could introduce important bias.
Blinding of caregiver who
administered medication
Unclear risk COMMENT: The study did not address this outcome. The 2 interventions were
the same, except that 1 allocation group received the intervention once at
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Clinical conjunctivitis
(subjective)
birth, and the other allocation group received the intervention twice, once at
birth and the second time within 24 h. Povidone-iodine is an orange-red solu-
tion that leads to transient residual staining of the eye, skin, and lids that can
last minutes to hours, depending on whether the surrounding periorbital skin
is cleaned or not. Masking would be difficult, but once again it is uncertain how
lack of masking would influence outcome of clinical conjunctivitis.
It appears that no placebo was used.
If the person administering the medication knew that the infant was in the
double-application group, there could possibly be lack of compliance knowing
the neonate was obtaining another application later. This could affect rates
of conjunctivitis, as it has been shown that delay in prophylaxis can lead to in-
creased risk of conjunctivitis.
There could be a reporting bias of conjunctivitis in the double-application
group, as the eyes of the neonates would have been more closely examined
in the double-application group to dispense the second drop of prophylaxis.
There could also be more reinforcement of follow-up instructions in the dou-
ble-application group, which could also lead to reporting bias.
Any reporting bias differentially in 1 arm vs the other could introduce bias in
rates of conjunctivitis cases.





Unclear risk COMMENT: The study did not address this outcome. The 2 interventions were
the same, except that 1 allocation group received the intervention once at
birth, and the other allocation group received the intervention twice, once at
birth and the second time within 24 h. Povidone-iodine is an orange-red solu-
tion that leads to transient residual staining of the eye, skin, and lids that can
last minutes to hours, depending on whether the surrounding periorbital skin
is cleaned or not. It appears that no placebo was used. It is likely that those
involved in postnatal care were not masked as to which neonates were in the
double-application group, but it is uncertain how this would affect outcome.
If the person administering the medication knew that the infant was in the
double-application group, there could possibly be lack of compliance knowing
the neonate was obtaining another application later. This could affect rates
of conjunctivitis, as it has been shown that delay in prophylaxis can lead to in-
creased risk of conjunctivitis.
There could be a reporting bias in the double-application group, as the eyes
of the neonates would have been more closely examined in the double-appli-
cation group to dispense the second drop of prophylaxis. There could also be
more reinforcement of follow-up instructions in the double-application group,
which could also lead to reporting bias.
Any bias in identification of cases of conjunctivitis cases could influence cas-
es referred for swabbing for bacteria, chlamydia, and gonorrhoea, and subse-
quent rates.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study did not address this outcome. The 2 interventions were
the same, except that 1 allocation group received the intervention once at
birth, and the other allocation group received the intervention twice, once at
birth and the second time within 24 h. Povidone-iodine is an orange-red solu-
tion that leads to transient residual staining of the eye, skin, and lids that can
last minutes to hours, depending on whether the surrounding periorbital skin
is cleaned or not.
It is likely that those involved in postnatal care were not masked as to which
neonates were in the double-application group, but it is uncertain how this
would affect outcome.
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Blinding of persons in-




Unclear risk COMMENT: The study did not address this outcome. The 2 interventions were
the same, except that 1 allocation group received the intervention once at
birth, and the other allocation group received the intervention twice, once at
birth and the second time within 24 h. Povidone-iodine is an orange-red solu-
tion that leads to transient residual staining of the eye, skin, and lids that can
last minutes to hours, depending on whether the surrounding periorbital skin
is cleaned or not.
It is likely that those involved in postnatal care were not masked as to which
neonates were in the double-application group, but it is uncertain how this
would affect outcome.




Unclear risk QUOTE: “The laboratory assessors had no knowledge of which prophylactic
ocular medication dose was given to any infant”
COMMENT: Parents returned infants for clinical assessment before being sent
to the laboratory. It is unknown if the clinical assessors were aware of alloca-
tion group.





Unclear risk QUOTE: “The laboratory assessors had no knowledge of which prophylactic
ocular medication dose was given to any infant”
COMMENT: Parents returned infants for clinical assessment before being sent
to the laboratory. It is unknown if the clinical assessors were aware of allo-
cation group. If there was lack of masking, then it could bias referrals for fur-






Unclear risk QUOTE: “Each mother was shown pictures of inflamed eyes and instructed
to return to the hospital with her infant if the child’s eye began to have a dis-
charge or became red within a month of birth. “ (from journal article)
COMMENT: The mother first had to make a decision as to whether the eyes re-
quired follow-up. The definition of conjunctivitis included discharge OR in-
flamed eyes, adding some ambiguity. It is unknown how many mothers did
not return for follow-up at all or for follow-up to the prescribed hospital. It is
unclear if loss to follow-up varied by intervention group, or the relationship to
event rates. Furthermore, considering that allocation was by week of birth, it
is unclear if allocation groups were equivalent, and if there was a correlation
with 1 allocation group and, say, distance from hospital, thereby differentially






Unclear risk QUOTE: “Each mother was shown pictures of inflamed eyes and instructed
to return to the hospital with her infant if the child’s eye began to have a dis-
charge or became red within a month of birth. “ (from journal article)
COMMENT: The mother first had to make a decision as to whether the eyes re-
quired follow-up. The definition of conjunctivitis included discharge OR in-
flamed eyes, adding some ambiguity. It is unknown how many mothers did
not return for follow-up at all or for follow-up to the prescribed hospital. It is
unclear if loss to follow-up varied by intervention group, or the relationship to
event rates. Furthermore, considering that allocation was by week of birth, it
is unclear if allocation groups were equivalent, and if there was a correlation
with 1 allocation group and, say, distance from hospital, thereby differentially
affecting rates of follow-up in allocation groups.
Reporting bias by allocation group would affect clinical conjunctivitis cases,
and similarly rates of bacterial, chlamydial, and gonococcal conjunctivitis.
Isenberg 2003  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
Selective reporting (re-
porting bias)
Low risk COMMENT: There is no evidence of selective outcome reporting.





Methods Parallel-group, single-centre trial.
Method of allocation: daily alternation.
Unit of randomisation: neonate.
Exclusions after allocation: none specified.
Losses to follow-up: none specified.
Number allocated: 231.
Missing data handling: not specified.
No reported power calculation.
Unusual study design:
1. samples for bacteriologic studies were taken from the conjunctiva of both eyes, irrespective of inflam-
mation, usually a day before child went home;
2. for those infants found by questionnaire to have conjunctivitis after discharge from hospital, cultures
were actually taken from infants before discharge from hospital.
Participants Setting: University Women's Hospital, Helsinki, Finland.
Number allocated: 231 neonates:
• silver nitrate: 115;
• "Biosept" (cetyl-pyridinium chloride): 116.
Age: neonates.
Sex: M:F unknown.
Inclusion criteria: all children born 6 November to 20 December 1957 at the obstetric wards of Univer-
sity Women's Hospital and who were not moved from the hospital before the bacterial sample was tak-
en.
Exclusion criteria: none specified.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: "Biosept" (cetyl-pyridinium chloride) 0.1% solution, 1 drop into each eye (n = 116).
• Intervention 2: silver nitrate 1% solution, 1 drop into each eye (n = 115).
Time to intervention: 1 dose at the time of delivery.
Pre-intervention manoeuvres: ocular region cleaned with dry, sterile gauze.
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Postintervention manoeuvres: eyes cleaned with dry, sterile cotton every 3 to 4 hours.
Outcomes 1. Total number of infants with inflammation - see definition of inflammation below.                              
                                                               = [(Infants with purulent discharge on Day 1 and possibly Day
2 postpartum) + (infants with purulent discharge on Day 1 and continuing after Day 2 postpartum)
+ (infants with purulent discharge beginning after the first day postpartum) + (infants with purulent
discharge first seen at home).
2. Infants with culture-positive inflammation - see definition of inflammation below.                            
                                                                                              = [(Infants with culture-positive purulent discharge on Day
1 and possibly Day 2 postpartum) + (infants with culture-positive purulent discharge on Day 1 and
continuing after Day 2 postpartum) + (infants with culture-positive purulent discharge beginning after
the first day postpartum) + (infants with culture-positive purulent discharge first seen at home)].
3. Infants with ophthalmia neonatorum - see definition of ophthalmia neonatorum below.
4. Infants with culture-positive ophthalmia neonatorum - see definition of ophthalmia neonatorum be-
low.
Follow-up: 2 weeks: in hospital, usually 4 to 6 days postpartum, infants examined once/day, 3 to 4
hours after the child's eyes had been cleaned last. Children's eyes opened daily by the author to search
for secretion and hyperaemia of the conjunctiva. On discharge, mothers were given a questionnaire
that asked if there had been redness, oedema of the lids, watery or purulent discharge in the child's
eyes at home, and were asked to return form 2 weeks postpartum. In the questionnaire, only purulent
discharge was regarded as a sign of inflammation.
Definition of conjunctivitis/inflammation in paper: infants with purulent eye discharge, classified as
scanty, moderate, profuse.
Definition of ophthalmia neonatorum in paper:
1. eyes with profuse purulent discharge only; or
2. eyes with moderate discharge, but combined with other signs of inflammation, such as oedema of
lids or hyperaemia of the conjunctiva.
Bacterial culture: cultures were generally taken from the conjunctiva of the leE eye of all children a day
before the infant went home. This was done irrespective of presence or absence of inflammation. If the
child developed purulent discharge whilst in the hospital, the sample was taken from the eye with a
heavier discharge, usually 1 to 2 days after its appearance.
Notes Date study conducted: 6 November to 20 December 1957.
Source of funding: not specified.
No statement of declaration of interest.
Subgroup analysis conducted by day of conjunctival signs and symptoms (inflammation, conjunctivitis
or ophthalmia neonatorum).
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “…silver nitrate and Biosept were administered to roughly every other
child..”
QUOTE: “A blank form with a running number on which no entry was made
concerning the prophylaxis employed was attached to the case report of every
newborn. The type of the prophylaxis was recorded on another sheet and at-
tached to the blank form later. Thus preconceived ideas on the part of the in-
vestigator could not affect the appraisal of the clinical symptoms."
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COMMENT: Non-random process in the sequence generation by alternation.
Allocation concealment
(selection bias)
High risk QUOTE: “…silver nitrate and Biosept were administered to roughly every other
child..”
QUOTE: “A blank form with a running number on which no entry was made
concerning the prophylaxis employed was attached to the case report of every
newborn. The type of the prophylaxis was recorded on another sheet and at-
tached to the blank form later. Thus preconceived ideas on the part of the in-
vestigator could not affect the appraisal of the clinical symptoms."
COMMENT: Participants or investigators enrolling participants could possibly
have foreseen assignments, thus introducing selection bias
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention. Silver nitrate sometimes causes a chemical conjunctivitis that
can last up to 72 hours, and silver nitrate also causes lid stains that can last 30
to 48 hours. The mother may have been able to identify the medication; the
impact on performance bias is unknown.
Blinding of study partici-




Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention. Silver nitrate sometimes causes a chemical conjunctivitis that
can last up to 72 hours, and silver nitrate also causes lid stains that can last 30
to 48 hours. The mothers of neonates with noticeable medication of the eyes
may handle the eyes of the infant more, potentially affecting the outcome of
bacterial conjunctivitis, depending on hygiene measures.




Unclear risk COMMENT: The study does not comment on whether or not the person ad-
ministering the medication was masked. It is uncertain if silver nitrate and
“Biosept” (cetyl-pyridinium chloride) appeared different or if they were dis-
pensed from labelled vials. They are both solutions.
COMMENT: Knowledge of the medication being dispensed, along with any
concomitant bias, could affect adherence and differential application of pro-
phylaxis, which, in turn, could affect preventive effect of the development of
conjunctivitis.





Unclear risk COMMENT: The study does not comment on whether or not the person ad-
ministering the medication was masked. It is uncertain if silver nitrate and
“Biosept” (cetyl-pyridinium chloride) appeared different or if they were dis-
pensed from labelled vials. They are both solutions.
COMMENT: Knowledge of the medication being dispensed, along with any
concomitant bias, could affect adherence and differential application of pro-
phylaxis, which, in turn, could affect preventive effect of the development of
bacterial conjunctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The children’s nurses cleaned the eyes with dry sterile cotton at feed-
ing time at intervals of 3-4 hours.”
COMMENT: The study does not comment on whether those involved in post-
natal case were masked to intervention. Silver nitrate sometimes causes a
chemical conjunctivitis that can last up to 72 hours, and silver nitrate causes
lid stains that can last 30 to 48 hours. The children were in hospital usually 4
to 6 days postpartum. Furthermore, the study identifies the day of identifica-
tion of conjunctivitis, and a significant number of cases of conjunctivitis have
been identified in the first 3 days of birth. Therefore, those involved in postna-
tal care may not be masked to the medication used as prophylaxis during this
initial time period. Lack of masking could lead to differential treatment of the
neonates’ eyes, resulting in differential cases of conjunctivitis.
Kaivonen 1965a  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
Blinding of persons in-




Unclear risk QUOTE: “The children’s nurses cleaned the eyes with dry sterile cotton at feed-
ing time at intervals of 3-4 hours.”
COMMENT: The study does not comment on whether those involved in post-
natal case were masked to intervention. Silver nitrate sometimes causes a
chemical conjunctivitis that can last up to 72 hours, and silver nitrate caus-
es lid stains that can last 30 to 48 hours. Therefore, those involved in postna-
tal care may not be masked as to the medication used as prophylaxis during
this initial time period. Lack of masking could lead to differential treatment of
the neonates’ eyes, resulting in differential cases of conjunctivitis. Note that
the neonates were in hospital usually 4 to 6 days postpartum. Furthermore,
the study identifies the day of identification of conjunctivitis, and a significant
number of cases of bacterial conjunctivitis have been identified in the first 3
days of birth.




Unclear risk QUOTE: “The type of prophylaxis was recorded on another sheet and attached
to the blank for later. Thus, preconceived ideas on the part of the investigator
could not affect the appraisal of clinical symptoms.”
QUOTE: “In series I of the earlier investigation, the children’s eyes were
opened daily by the author with the fingers to search for secretion and hyper-
emia of the conjunctiva.”
COMMENT: As silver nitrate creates lid stains that last 30 to 48 hours, outcome
assessments during this time may not have been masked. Considering that
neonates were only followed up 2 weeks postpartum and were in hospital 4
to 6 days postpartum, there is greater potential for bias on outcome assess-
ments.





Unclear risk QUOTE: “The type of prophylaxis was recorded on another sheet and attached
to the blank for later. Thus, preconceived ideas on the part of the investigator
could not affect the appraisal of clinical symptoms.”
QUOTE: “In series I of the earlier investigation, the children’s eyes were
opened daily by the author with the fingers to search for secretion and hyper-
emia of the conjunctiva.”
COMMENT: As silver nitrate creates lid stains that last 30 to 48 hours, outcome
assessments during this time may not have been masked. Considering that
neonates were only followed up 2 weeks postpartum and were in hospital 4
to 6 days postpartum, there is greater potential for bias on outcome assess-
ments.
Furthermore, there were a significant number of bacterial conjunctivitis cases
identified in the first 3 postpartum days.
In ambiguous cases of clinical conjunctivitis, there may be differential asses-
sor behaviour to include or exclude cases of clinical conjunctivitis, thereby in-
creasing or decreasing likelihood of swabbing the neonate’s eye for bacterial
conjunctivitis. Presence of bacteria on a swab does not necessarily prove that
the bacteria caused the conjunctivitis, as the bacteria could be a carrier but
the conjunctivitis caused by chemical conjunctivitis. This possible bias was re-
duced by the fact that the swabs for culture were reserved those conjunctivitis





Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. Neonates were in hospital 4 to 6 days
postpartum, and follow-up time in this study was 2 weeks.
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Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. Neonates were in hospital 4 to 6 days
postpartum, and follow-up time in this study was 2 weeks.
Selective reporting (re-
porting bias)
High risk QUOTE: "The growth of gonococcus with the method employed is uncertain. A
special method for the systematic culture of gonococcus was not regarded as
necessary as the incidence of gonorrhea in the material would in all probabili-
ty have been low"
COMMENT: Gonococcal conjunctivitis is of interest to this review, and the mi-
crobiological methods to identify Neisseria gonorrhoeae were “uncertain”.
There were, predictably, no cases identified in the study.
Other bias High risk COMMENT: In any trial with silver nitrate, there could be differential diagnos-
tic activity. This could lead to increased diagnosis of true but harmless cases
of disease. For example, silver nitrate induces a chemical conjunctivitis. This
chemical conjunctivitis could lead to increased selective bacterial cultures of
infants’ eyes in the silver nitrate intervention group. A positive bacterial cul-
ture found from a swab of conjunctivitis due to chemical conjunctivitis does
not necessarily mean that the bacteria caused the conjunctivitis. The bacteria
could be part of the normal flora of the eye, with an associated chemical con-
junctivitis, or the bacteria could be the causal agent of the conjunctivitis.
QUOTE: “For series I, the lids of the children were opened daily with the fin-
gers…Careful washing of the hands after every examination was very diffi-
cult in practice since over 100 children were examined every day in a relative-
ly short time. The risk of cross infection via the investigator’s fingers from one
child to another was thus considerable during the study of series I in 1957.”
COMMENT: For those infants found by questionnaire to have conjunctivitis af-
ter discharge from hospital, cultures were actually taken from infants before






Methods Parallel-group, single-centre trial.
Method of allocation: daily alternation.
Unit of randomisation: neonate.
Exclusions after allocation: none specified.
Losses to follow-up: none specified.
No comment on missing data in paper and how handled.
No reported power calculation.
Unusual study design:
1. samples for bacteriologic studies were taken from the conjunctiva of from one eye of the neonate,
irrespective of inflammation, usually a day before child went home;
Kaivonen 1965b 
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2. for those infants found by questionnaire to have conjunctivitis after discharge from hospital, cultures
were actually taken from infants before discharge from hospital.
Participants Setting: University Women's Hospital, Helsinki, Finland.
Number allocated: 368 neonates:
• silver nitrate: 183;
• "Biosept" (cetyl-pyridinium chloride): 185.
Age: neonates.
Sex: M:F unknown.
Inclusion criteria: all children born 6 November to 20 December 1957 at the obstetric wards of Univer-
sity Women's Hospital and who were not moved from the hospital before the bacterial sample was tak-
en.
Exclusion criteria: none specified.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: "Biosept" (cetyl-pyridinium chloride) 0.05% solution, 1 drop into each eye (n = 185).
• Intervention 2: silver nitrate 1% solution, 1 drop into each eye (n = 183).
Time to intervention: 1 dose at the time of delivery.
Pre-intervention manoeuvres: ocular region cleaned with dry, sterile gauze.
Postintervention manoeuvres: eyes cleaned with dry, sterile cotton every 3 to 4 hours.
Outcomes 1. Total number of infants with inflammation - see definition of inflammation below                              
                                                              = [(Infants with purulent discharge on Day 1 and possibly Day
2 postpartum) + (infants with purulent discharge on Day 1 and continuing after Day 2 postpartum)
+ (infants with purulent discharge beginning after the first day postpartum) + (infants with purulent
discharge first seen at home)].
2. Infants with culture-positive inflammation - see definition of inflammation below                              
                                                                                                = [(Infants with culture-positive purulent discharge on Day
1 and possibly Day 2 postpartum) + (infants with culture-positive purulent discharge on Day 1 and
continuing after Day 2 postpartum) + (infants with culture-positive purulent discharge beginning after
the first day postpartum) + (infants with culture-positive purulent discharge first seen at home)].
3. Infants with ophthalmia neonatorum - see definition of ophthalmia neonatorum below.
4. Infants with culture-positive ophthalmia neonatorum - see definition of ophthalmia neonatorum be-
low.
Follow-up: 2 weeks:
In hospital, usually 4 to 6 days postpartum, infants examined once/day, 3 to 4 hours after the child's
eyes had been cleaned last. Eyes only opened on the first day postpartum. Otherwise eyes were not
opened by the investigator as was done in series. 
1. Discharge was noted at the roots of the lashes and in the corner of the eye. Hyperaemia was noted if
the eyes were opened spontaneously. On discharge, mothers were given a questionnaire that asked if
there had been redness, oedema of the lids, watery or purulent discharge in the child's eyes at home,
and were asked to return form 2 weeks postpartum. In the questionnaire, only purulent discharge was
regarded as a sign of inflammation.
Definition of conjunctivitis/inflammation in paper: infants with purulent eye discharge, classified as
scanty, moderate, profuse.
Definition of ophthalmia neonatorum in paper:
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• eyes with profuse purulent discharge only; or
• eyes with moderate discharge, but combined with other signs of inflammation, such as oedema of
lids or hyperaemia of the conjunctiva.
Bacterial culture: cultures were generally taken from the conjunctiva of the leE eye of all children a day
before going home. This was done irrespective of presence or absence of inflammation. If the child de-
veloped purulent discharge whilst in the hospital, the sample was taken from the eye with a heavier
discharge, usually 1 to 2 days after its appearance.
Notes Date study conducted: 6 November to 20 December 1957.
Source of funding: not specified.
No statement of declaration of interest.
Subgroup analysis conducted by day of conjunctival signs and symptoms (inflammation, conjunctivitis
or ophthalmia neonatorum).
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “…silver nitrate and Biosept were administered to roughly every other
child.”
QUOTE: “A blank form with a running number on which no entry was made
concerning the prophylaxis employed was attached to the case report of every
newborn. The type of the prophylaxis was recorded on another sheet and at-
tached to the blank form later. Thus preconceived ideas on the part of the in-
vestigator could not affect the appraisal of the clinical symptoms."
COMMENT: Non-random process in the sequence generation by alternation.
Allocation concealment
(selection bias)
High risk QUOTE: “…silver nitrate and Biosept were administered to roughly every other
child.”
QUOTE: “A blank form with a running number on which no entry was made
concerning the prophylaxis employed was attached to the case report of every
newborn. The type of the prophylaxis was recorded on another sheet and at-
tached to the blank form later. Thus preconceived ideas on the part of the in-
vestigator could not affect the appraisal of the clinical symptoms."
COMMENT: Participants or investigators enrolling participants could possibly
have foreseen assignments, thus introducing selection bias.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention. Silver nitrate sometimes causes a chemical conjunctivitis that
can last up to 72 hours, and silver nitrate also causes lid stains that can last 30
to 48 hours. The mother may be able to identify the medication; the impact on
performance bias is unknown.
Blinding of study partici-




Unclear risk COMMENT: The study does not mention whether mothers were masked to the
intervention. Silver nitrate sometimes causes a chemical conjunctivitis that
can last up to 72 hours, and silver nitrate also causes lid stains that can last 30
to 48 hours. The mothers of neonates with noticeable medication of the eyes
may handle the eyes of the infant more, potentially affecting the outcome of
bacterial conjunctivitis, depending on hygiene measures.
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Unclear risk COMMENT: The study does not comment on whether or not the person ad-
ministering the medication was masked. It is uncertain if silver nitrate and
“Biosept” (cetyl-pyridinium chloride) appeared different or if they were dis-
pensed from labelled vials. They are both solutions.
COMMENT: Knowledge of the medication being dispensed, along with any
concomitant bias, could affect adherence and differential application of pro-
phylaxis, which, in turn, could affect preventive effect of the development of
conjunctivitis.





Unclear risk COMMENT: The study does not comment on whether or not the person ad-
ministering the medication was masked. It is uncertain if silver nitrate and
“Biosept” (cetyl-pyridinium chloride) appeared different or if they were dis-
pensed from labelled vials. They are both solutions.
COMMENT: Knowledge of the medication being dispensed, along with any
concomitant bias, could affect adherence and differential application of pro-
phylaxis, which, in turn, could affect preventive effect of the development of
bacterial conjunctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The children’s nurses cleaned the eyes with dry sterile cotton at feed-
ing time at intervals of 3-4 hours.”
COMMENT: The study does not comment on whether those involved in post-
natal care were masked to intervention. Silver nitrate sometimes causes a
chemical conjunctivitis that can last up to 72 hours, and silver nitrate causes
lid stains that can last 30 to 48 hours. The children were in hospital usually 4 to
6 days postpartum. Furthermore, the study identifies the day of identification
of conjunctivitis, and a significant number of cases of conjunctivitis were iden-
tified in the first 3 days of birth. Therefore, those involved in postnatal care
may not be masked to the medication used as prophylaxis during this initial
time period. Lack of masking could lead to differential treatment of the eyes of
these neonates, resulting in differential cases of conjunctivitis.
Blinding of persons in-




Unclear risk QUOTE: “The children’s nurses cleaned the eyes with dry sterile cotton at feed-
ing time at intervals of 3-4 hours.”
COMMENT: The study does not comment on whether those involved in postna-
tal care were masked to intervention. Silver nitrate sometimes causes a chem-
ical conjunctivitis that can last up to 72 hours, and silver nitrate causes lid
stains that can last 30 to 48 hours. Therefore, those involved in postnatal care
may not be masked to the medication used as prophylaxis during this initial
time period. Lack of masking could lead to differential treatment of the eyes
of these neonates, resulting in differential cases of conjunctivitis. Note that
the neonates were in hospital usually 4 to 6 days postpartum. Furthermore,
the study mentions the day of identification of conjunctivitis, and a significant
number of cases of bacterial conjunctivitis were identified in the first 3 days of
birth.




Unclear risk QUOTE: “The type of prophylaxis was recorded on another sheet and attached
to the blank for later. Thus, preconceived ideas on the part of the investigator
could not affect the appraisal of clinical symptoms.”
QUOTE: “The method was therefore changed for series II. The eyes were no
longer opened with the fingers except on the first day after birth, and to take
the bacterial sample.”
COMMENT: As silver nitrate creates lid stains that last 30 to 48 hours, outcome
assessments during this time may not have been masked. Considering that
neonates were only followed up 2 weeks postpartum and were in hospital 4
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to 6 days postpartum, there is greater potential for bias on outcome assess-
ments.





Unclear risk QUOTE: “The type of prophylaxis was recorded on another sheet and attached
to the blank for later. Thus, preconceived ideas on the part of the investigator
could not affect the appraisal of clinical symptoms.”
QUOTE: “The method was therefore changed for series II. The eyes were no
longer opened with the fingers except on the first day after birth, and to take
the bacterial sample.”
COMMENT: As silver nitrate creates lid stains that last 30 to 48 hours, outcome
assessments during this time may not have been masked. Considering that
neonates were only followed up 2 weeks postpartum and were in hospital 4
to 6 days postpartum, there is greater potential for bias on outcome assess-
ments.
Furthermore, a significant number of bacterial conjunctivitis cases were iden-
tified in the first 3 postpartum days.
In ambiguous cases of clinical conjunctivitis, there may be differential asses-
sor behaviour to include or exclude cases of clinical conjunctivitis, thereby in-
creasing or decreasing the likelihood of swabbing the neonate’s eye for bacte-
rial conjunctivitis. Presence of bacteria on a swab does not necessarily prove
that the bacteria caused the conjunctivitis, as the bacteria could be a carrier
but the conjunctivitis caused by chemical conjunctivitis. This possible bias was
reduced by the fact that the swabs for culture were reserved for those conjunc-





Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. The neonates were in hospital 4 to 6






Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. The neonates were in hospital 4 to 6
days postpartum, and follow-up time in this study was 2 weeks.
Selective reporting (re-
porting bias)
High risk QUOTE: "The growth of gonococcus with the method employed is uncertain. A
special method for the systematic culture of gonococcus was not regarded as
necessary as the incidence of gonorrhea in the material would in all probabili-
ty have been low"
COMMENT: Gonococcal conjunctivitis is of interest to this review, and the mi-
crobiological methods to identify Neisseria gonorrhoeae were “uncertain”.
There were, predictably, no cases identified in the study.
Other bias Unclear risk COMMENT: In any trial with silver nitrate, there could be differential diagnos-
tic activity. This could lead to increased diagnosis of true but harmless cases
of disease. For example, silver nitrate induces a chemical conjunctivitis. This
chemical conjunctivitis could lead to increased selective bacterial cultures of
infants’ eyes in the silver nitrate intervention group. A positive bacterial cul-
ture found from a swab of conjunctivitis due to chemical conjunctivitis does
not necessarily mean that the bacteria caused the conjunctivitis. The bacteria
could part of the normal flora of the eye, with an associated chemical conjunc-
tivitis, or the bacteria could be the causal agent of the conjunctivitis.
QUOTE: “Touching of the eye region with the fingers was avoided as much as
possible with series II of the earlier material… The possibility of cross infec-
Kaivonen 1965b  (Continued)
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tion and of the transfer of bacteria from the lids to the conjunctiva was thus re-
duced considerably.”
COMMENT: For those infants found by questionnaire to have conjunctivitis af-
ter discharge from hospital, cultures were actually taken from infants before






Methods Parallel-group, single-centre trial.
Method of allocation: alternation by week.
Unit of randomisation: neonate.
Exclusions after allocation: none specified.
Losses to follow-up: yes:
• Day 7: silver nitrate 28% loss; tetracycline 32% loss;
• Day 28: silver nitrate 54% loss; tetracycline 59% loss.
Missing data handled by imputation (assumed losses to follow-up did not have outcome).
Number allocated: 2732.
Statistical power: "Statistical power was calculated with the method of Pocock".
Unusual study design: none identified.
Participants Setting: Nairobi City Council maternity hospital, Nairobi, Kenya.
Number allocated: 2732:





• 10 women/day in established labour at the Nairobi City Council maternity hospital from February 1985
to April 1986;
• resided in a certain area;
• verbal consent.
Exclusion criteria: none specified.
Equivalence of limited baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: tetracycline 1% ointment, dose not specified (n = 1499).
• Intervention 2: silver nitrate 1% solution, from single-dose ampoules, dose not specified (n = 1233).
Time to intervention: immediately after birth, no later than 30 minutes after birth.
Laga 1988 
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Pre-intervention manoeuvres: babies' eyes wiped dry with cotton.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with conjunctivitis.
2. Infants with gonococcal conjunctivitis.
3. Infants with chlamydial conjunctivitis.
4. Infants with gonococcal and chlamydial conjunctivitis.
5. Infants with non-gonococcal, non-chlamydial conjunctivitis.
6. Infants with gonococcal ophthalmia among newborns exposed to maternal Neisseria gonorrhoeae.
7. Infants with chlamydial ophthalmia among newborns exposed to Chlamydia trachomatis.
Follow-up: 28 days postpartum; infants eyes examined and history taken at 24 h, 7 days, and 28 days
postpartum.
Definition of ophthalmia neonatorum: abnormal discharge from 1 or both eyes and at least 1 PMN
leukocyte per 1000x field on a Gram stained smear of discharge. If signs of inflammation were present,
the infant's eyes and throat were swabbed for N gonorrhoeae and C trachomatis.
No adverse events reported.
Notes Date study conducted: February 1985 to April 1986.
Source of funding: grants from International Development Research Center, Ottawa, Canada; and
Subprogram Science and Technology for Development, Commission of European Communities (Brus-
sels, Belgium).
No declaration of interest statement made.
Subgroup analysis of neonates born to N gonorrhoeae-positive mothers and C trachomatis-positive
mothers.
Authors have been contacted for clarifications on masking, no reply received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “Silver nitrate and tetracycline were used during alternate weeks.”
QUOTE: “Over a 15 month period, 10 women in labor were enrolled in the
study every day but specially trained midwives at a Nairobi City Council mater-
nity hospital”.
QUOTE: “More infants were given tetracycline because of a two interruption in
randomization due to the unavailability of silver nitrate”
COMMENT: The paper does not state how these 10 women were selected.
Allocation concealment
(selection bias)
High risk QUOTE: “Silver nitrate and tetracycline were used during alternate weeks.”
COMMENT: Allocation concealment was not addressed in this study, howev-
er the allocation method itself, alternation, allowed for investigators enrolling
participants to foresee assignments, thus introducing selection bias.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of mothers to the intervention was not addressed in this
study. Furthermore, the 2 interventions differ in colour and consistency. Sil-
ver nitrate is a clear solution. Also, silver nitrate sometimes causes a chemical
conjunctivitis that can last up to 72 hours, and lid stains that can last 30 to 48
hours. Tetracycline is a light-yellow ointment that is readily distinguished from
Laga 1988  (Continued)
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silver nitrate, and may leave an ocular residue for hours. It is unknown how
this could affect performance bias.
Blinding of study partici-




Unclear risk COMMENT: Masking of mothers to the intervention was not addressed in this
study. Furthermore, the 2 interventions differ in colour and consistency. Sil-
ver nitrate is a clear solution. Also, silver nitrate sometimes causes a chemical
conjunctivitis that can last up to 72 hours, and lid stains that can last 30 to 48
hours. Tetracycline is a light-yellow ointment that is readily distinguished from
silver nitrate, and that may leave an ocular residue for hours that the mother
could notice. It is unknown how this could affect performance bias.
The mothers may differentially handle the eyes of neonates based on the vis-
ible signs of prophylaxis. This could lead to differential introduction of path-
ogenic bacteria into the eyes of these neonates. Therefore, lack of masking
of medication appearance may lead to bias in chlamydial and gonococcal
conjunctivitis cases, depending on hygiene measures. However, considering
the low event rates of gonococcal conjunctivitis and possible carrier state of
C trachomatis, this could introduce important bias. It is unknown how many
neonates developed conjunctivitis in the time period when the medication
could be identified.




High risk QUOTE: “Single-dose ampules were used to administer the silver nitrate…The
tetracycline ointment was administered from multidose tubes, which were
used for one day and then discarded.”
COMMENT: Masking of the person who administers the medication was not
addressed in this study. As mentioned, the 2 interventions differ in colour and
consistency. Tetracycline is a light-yellow ointment, and silver nitrate is a clear
solution. Both medications are readily identifiable to anyone administering
the medication.





High risk QUOTE: “Single-dose ampules were used to administer the silver nitrate…The
tetracycline ointment was administered from multidose tubes, which were
used for one day and then discarded.”
COMMENT: Masking of the person who administers the medication was not
addressed in this study. As mentioned, the 2 interventions differ in colour and
consistency.
Tetracycline is a light-yellow ointment, and silver nitrate is a clear solution.
Both medications are readily identifiable to anyone administering the medica-
tion.
With lack of masking, the person administering the medication could dispense
the medications differently, or there could be differential adherence, thereby
altering the bactericidal effect. We have seen this in 1 study in Africa where 1
of the medications was ointment, and tended to be “skipped” more than solu-
tion, owing to difficulty in handling the ointment.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The eyes of infants were examined 24 hours after delivery, and the
mother…”
COMMENT: Masking of those involved in postnatal care has not been ad-
dressed in this study. As mentioned, silver nitrate sometimes causes a chem-
ical conjunctivitis that can last up to 72 hours, and lid stains that can last 30
to 48 hours. Tetracycline is an ointment that leaves a residue that can last for
hours. The eyes of infants were examined 24 hours after delivery, therefore it is
possible that the prophylaxis could be determined at this time.
COMMENT:
Laga 1988  (Continued)
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It is unclear how long the neonates were in hospital, and how many cases of
conjunctivitis were identified at this time. It is also unclear if those involved in
postnatal care were also involved in identifying cases of conjunctivitis, and to
what extent.
Those involved in postnatal care may differentially handle the eyes of
neonates based on the visible signs of prophylaxis. This could lead to differen-
tial introduction of pathogenic bacteria into the eyes of these neonates.
Blinding of persons in-




Unclear risk QUOTE: “The eyes of infants were examined 24 hours after delivery, and the
mother…”
COMMENT: Masking of those involved in postnatal care has not been ad-
dressed in this study. As mentioned, silver nitrate sometimes causes a chem-
ical conjunctivitis that can last up to 72 hours, and lid stains that can last 30
to 48 hours. Tetracycline is an ointment that leaves a residue that can last for
hours. The eyes of infants were examined 24 hours after delivery, therefore it is
possible that prophylaxis could be determined at this time.
COMMENT: It is unclear how long the neonates were in hospital, and how
many cases of conjunctivitis were identified at this time. It is also unclear if
those involved in postnatal care were also involved in identifying cases of con-
junctivitis, and to what extent. Those involved in postnatal care may differen-
tially handle the eyes of neonates based on the visible signs of prophylaxis.
This could lead to differential introduction of pathogenic bacteria into the eyes
of these neonates.
Any bias in identification of cases of conjunctivitis cases could influence cas-
es referred for swabbing for chlamydia and gonorrhoea. For instance, if the
nurse was aware that neonates were given silver nitrate, and were aware of the
concomitant chemical conjunctivitis, in ambiguous cases the nurse may erro-
neously ignore cases of 'true' bacterial conjunctivitis that happen to present
outside the chemical conjunctivitis window.
The incubation period of gonococcal conjunctivitis and chlamydial conjunc-
tivitis is likely outside the time period at which the nurses in the nursery would
be influencing identification and care. Furthermore, these cases are likely to
be more clinically severe, eliminating ambiguity. Therefore, the lack of mask-
ing of the nurses in the nursery will likely introduce less bias for the outcomes
of gonococcal and chlamydial conjunctivitis. Still, the possible carrier state of
chlamydia and the low event rate of chlamydial and gonococcal conjunctivitis
in the study could make minor bias important and clinically significant.




Unclear risk QUOTE: “The eyes of the infants were examined 24 hours after delivery, and
the mother and baby were requested to return to one of three postnatal clin-
ics 7 and 30 days post partum. On day 7, the medical history of the infants was
taken, and their eyes were examined for evidence of conjunctival inflamma-
tion”
COMMENT: Masking of outcome assessors was not addressed in this study.
Silver nitrate sometimes causes a chemical conjunctivitis that can last up to 72
hours, and lid stains that can last 30 to 48 hours. Tetracycline may leave an oc-
ular residue for hours. It appears that the infants were examined 24 hours af-
ter delivery, when the prophylaxis could be identified. It is unknown how many
cases of conjunctivitis were identified during the time when these stains re-
mained.
The definition of conjunctivitis includes discharge and microscopic presenta-
tion of at least 1 polymorphonuclear leukocyte per oil-immersion field on a
Gram stained smear of the discharge, which adds more objectivity.
Laga 1988  (Continued)
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Unclear risk QUOTE: “The eyes of the infants were examined 24 hours after delivery, and
the mother and baby were requested to return to one of three postnatal clin-
ics 7 and 30 days post partum. On day 7, the medical history of the infants was
taken, and their eyes were examined for evidence of conjunctival inflamma-
tion”
QUOTE: “However, an evaluation of a subgroup of exposed newborns in the
present study population suggests that in at least 25% of these infants, asymp-
tomatic ocular infection with C. trachomatis did develop and was usually diag-
nosed after the first month of life" (Datta P et al; unpublished data)
COMMENT: Silver nitrate sometimes causes a chemical conjunctivitis that can
last up to 72 hours, and lid stains that can last 30 to 48 hours. Tetracycline is a
light-yellow ointment that may leave an ocular residue for hours.
It is unknown how many cases of conjunctivitis were identified during the time
when these stains remained. This could affect bias in the decision to swab the
eyes for microbiological analysis, thereby altering chlamydial and gonococcal
conjunctivitis cases. Any minor bias could be significant as event rates in this
study were low.
The incubation period of gonococcal conjunctivitis and chlamydial conjunc-
tivitis is likely outside the time period at which these stains would remain. Fur-
thermore, gonococcal and chlamydial conjunctivitis are usually more severe,
with less diagnostic ambiguity than other forms of conjunctivitis. In the case of
chlamydial conjunctivitis, however, it can present with a variable clinical spec-
trum. C trachomatis may also asymptomatically colonise the eye. Therefore,
lack of masking, in cases of diagnostic ambiguity, may affect which cases get
referred for culture to identify chlamydial conjunctivitis. Lack of masking may
lead to under-referral of neonates for culture due to the erroneous perception
that conjunctivitis is chemical from silver nitrate, thereby missing chlamydi-
al conjunctivitis cases. Over-referral may be caused by knowledge of which in-
fants received silver nitrate, or bias, and lead to identifying cases of chemical






High risk COMMENT: On Day 7, 351/1233 neonates were missing from the silver nitrate
group, and 474/1499 neonates were missing from the tetracycline group.
COMMENT: On Day 28, 665/1233 neonates were missing from the silver nitrate
group, and 888/1499 were missing from the tetracycline group.
COMMENT: Although there were no major asymmetries in loss to follow-up,






High risk COMMENT: Among the 82 newborns born to mothers with N gonorrhoeae, 11
did not return for follow-up in the silver nitrate group, and 27/99 did not return
for follow-up in the tetracycline group.
COMMENT: 16/115 infants born to mothers with C trachomatis infection in the
silver nitrate arm and 18/129 exposed infants in the tetracycline arm were not
followed up.
COMMENT: Although there were no major asymmetries in loss to follow-up,




Unclear risk QUOTE: “However, an evaluation of a subgroup of exposed newborns in the
present study population suggests that in at least 25% of these infants, asymp-
tomatic ocular infection with C. trachomatis did develop and was usually diag-
nosed after the first month of life" (Datta P et al; unpublished data)
Laga 1988  (Continued)
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COMMENT: It is unknown if asymptomatic ocular infection with C trachomatis
was prespecified in the protocol.
COMMENT: The study did not report cases of other bacterial conjunctivitis,
or conjunctivitis that led to no growth on culture. There is a category of non-
gonococcal and non-chlamydial conjunctivitis reported in the study, but this
category does not distinguish bacterial conjunctivitis from no-culture growth
conjunctivitis. It is unknown if these outcomes were prespecified in the study
protocol. However, these 2 outcomes of other bacterial conjunctivitis and no-
growth conjunctivitis are outcomes of interest to this review, and cannot be
entered in the meta-analysis.
Other bias Unclear risk In any trial with silver nitrate, there could be diagnostic bias.
Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a re-
sult, in the first 72 hours, more neonates in the silver nitrate allocation group
could be referred for culture. Finding bacteria in the culture does not necessar-
ily prove that the bacteria caused the conjunctivitis. The conjunctivitis could
be chemical, with a chlamydial carrier. This study did note the presence of
asymptomatic chlamydial infection. Finally, the conjunctivitis could very well
be caused by chlamydia. Consideration of incubation periods, and assessing






Method of allocation: randomisation into 2 groups by blocked randomisation with a fixed block size of
4.
Unit of randomisation: neonate.
Exclusions after randomisation: mothers were included in the study, but 72 neonates were excluded af-




4. transfer of the mother to a more specialised centre for dystocic delivery.
Losses to follow-up: 229 out of 245 were lost to follow-up, which is 93% loss to follow-up.
Number randomised: 245 neonates.
Missing data were handled by available-case analysis in the study.
Power calculation was done: sample size of 334 newborns with power of 80%.
Unusual study design: follow-up time only 7 to 10 days with 93% loss to follow-up.
Participants Country: Luanda, Angola.
Setting: General Augusto N'Gangula Specialized Hospital and the Health Center of Samba.
Ethnic group: not specified; maternal data were collected on race but not reported in study.
Total number of participants: 245.
Pastor 2015 
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Sex: M:F 118:123 (4 unknown as not registered).
Average age and age range: average age of neonates not available; gestational age range 36 to 40
weeks.
Inclusion criteria:
1. healthy children weighing at least 2.3 kg;
2. gestation period of at least 37 weeks.
Exclusion criteria:
1. respiratory distress at birth;
2. mother diagnosed with thyroid disease.
No comment was made in the study on equivalence of baseline characteristics.
Interventions Number of interventions: 2
• Intervention 1: povidone-iodine 2.5%; 1 drop of povidone-iodine in the lower sac of each eye from a
new bottle for each newborn (n = 115 neonates).
• Intervention 2: no intervention; no placebo was administered (n = 130 neonates).
Time to intervention: immediately after a basic eye examination and the collection of conjunctival
smears within 3 hours of birth.
Pre-intervention manoeuvres: basic eye exam and collection of conjunctival smears by vigorous swab-
bing across the interior tarsal conjunctiva.
Postintervention manoeuvres: none specified.
Outcomes 1. Presence or absence of Chylamdia trachomatis, Neisseria gonorrhoeae, or Mycoplasma genitalium in
mother endocervical samples or neonate conjunctival smears.
2. Conjunctivitis in neonates.
3. Ophthalmia neonatorum in neonates.
No comment was made on adverse events.
Follow-up:
1. up to 10 days;
2. planned follow-up: between the 5th day and 7th day postpartum phone calls were made to mothers
to bring their infants for observation, especially if they had signs of ophthalmia neonatorum;
3. actual follow-up: attempts were made to have every mother perform a follow-up visit within 7 to 10
days.
Notes Date conducted: 7 December 2011 to 22 November 2012.
Sources of funding: AECID: Spanish Agency for International Cooperation and Development.
Declaration of interest: the authors declared that there were no conflict of interests regarding the pub-
lication of the paper.
No reported subgroup analysis.
Trial investigators were contacted.
No data could be extracted from this study in spite of contacting the authors.
Risk of bias
Bias Authors' judgement Support for judgement
Pastor 2015  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk QUOTE: “Neonates were randomly distributed into two groups, A and B, by
blocked randomization with a fixed block size of 4.”
Allocation concealment
(selection bias)
Unclear risk COMMENT: No information is provided on allocation concealment.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “An interventional, randomized, and prospective study with a blinded,
randomized control group was designed.”
COMMENT: Povidone-iodine is an orange-red solution that leads to transient
residual staining of the eye, and possible periocular stains that can last min-
utes to hours. The mother could have noticed these stains.
The control group did not receive placebo, but received no prophylaxis.
The mothers may handle the eyes of neonates with periocular stains different-
ly than the neonates with no stains.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




High risk QUOTE: “The ophthalmologist responsible for the study (IA) administered the
P-I eyedrops.”
COMMENT: The ophthalmologist responsible for the study also administered
the prophylaxis, which is readily identifiable. Furthermore, povidone-iodine is
an orange-red solution that leads to transient residual staining of the eye, and
possible periocular stains that can last minutes to hours. The control group did
not receive placebo, but received no prophylaxis, therefore masking has been
compromised.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Povidone-iodine is an orange-red solution that leads to transient
residual staining of the eye, and possible periocular stains that can last min-
utes to hours. The control group did not receive placebo, but received no pro-
phylaxis. A significant number of cases of conjunctivitis were apparently di-
agnosed at delivery. It is unclear who diagnosed conjunctivitis, and whether
those involved in postnatal care were involved in identifying and referring pos-
sible conjunctivitis cases. Nonetheless, it remains possible that diagnosis of
conjunctivitis was made when the prophylaxis administered could be readily
identified.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk QUOTE: “The ophthalmologist responsible for the study (IA) administered the
P-I eyedrops.”
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COMMENT: The paper does not comment on who conducted the outcome as-
sessments of conjunctivitis. We do not know if the ophthalmologist responsi-
ble for administering the povidone-iodine drops was involved. If so, this would
affect masking. Separate from this issue, povidone-iodine is an orange-red so-
lution that leads to transient residual staining of the eye, and possible periocu-
lar stains that can last minutes to hours. The control group did not receive any
placebo, but received no prophylaxis. Considering that a significant number of
acute conjunctivitis cases were diagnosed at delivery, it remains possible that
outcome assessors were not masked for some outcome assessments.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis






High risk COMMENT: Only 5% of the total study participants were followed up. The pro-
portion of missing outcomes compared with the observed event risk is highly






Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




High risk COMMENT: The study protocol is not available. Furthermore, considerable
communication was required with the study author to clarify actual numbers
of conjunctivitis cases by allocation group in the small number of cases that
were followed up. Questions remain.





Methods Parallel-group, single-centre trial.
Method of allocation: alternation by date of birth (odd days allocated to 1 group and even days to an-
other).
Unit of randomisation: neonate.
Exclusions after allocation: none specified and not addressed in paper.
Losses to follow-up: none specified and not addressed in paper.
Number allocated: 3355 neonates.
No comment on how missing data handled.
No reported power calculation.
Unusual study design: none identified
Participants Setting: Harlem Hospital, New York, NY, USA.
Posner 1959 
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Number allocated: 3355 neonates:
• bacitracin: 1719;
• "mechanical cleansing": 1636.
Age: neonates.
Sex: M:F not specified.
Inclusion criteria: all infants born 1 July 1957 to 30 June 1958 at Harlem Hospital.
Exclusion criteria: none specified.
Equivalence of baseline characteristics not addressed.
Interventions Number of interventions: 2.
• Intervention 1: "mechanical cleansing" + bacitracin-phenacaine ophthalmic ointment, 500 units bac-
itracin/gram and 2% phenacaine hydrochloride (n = 1719).
• Intervention 2: "mechanical cleansing" only; eyes swabbed with distilled water and wiped dry (n =
1636).
Time to intervention: not specified.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified (unclear if mechanical cleansing was before or after baci-
tracin administration).
Outcomes 1. Infants with non-specific conjunctivitis.
2. Infants with gonorrhoeal ophthalmia.
Follow-up: not specified.
Definition of non-specific conjunctivitis: not defined.
Definition of gonorrhoeal ophthalmia: not defined.
Notes Date conducted: 1 July 1957 to 30 June 1958.
Source of funding: Upjohn Company, Kalamazoo, MI, which supplied the bacitracin-phenacaine oint-
ment.
No declaration of interest statement made.
No reported subgroup analysis.
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “The infants born on the numerically even days of the calendar re-
ceived no medication for ophthalmia neonatorum, the eyes being swabbed
with distilled water, and wiped dry. For those delivered on the odd days, in ad-
dition to mechanical cleansing of the eyes, we used the bacitracin-phenacine
ointment.”
COMMENT: Sequence generated by odd or even date of birth.
Posner 1959  (Continued)
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Allocation concealment
(selection bias)
High risk Participants or investigators enrolling participants could possibly have fore-
seen assignments, thus introducing selection bias based on date of birth.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.
Blinding of study partici-




Unclear risk COMMENT: Masking of the mother was not addressed in this paper.
Bacitracin is an ointment that would initially be noticed in the infant by the
mother. There was no placebo in the allocation group that received no pro-
phylaxis. The mothers of neonates with noticeable residual ointment or
colostrum of the eyes may handle the eyes of the infant more than mothers of
neonates with no prophylaxis. This could lead to differential introduction of
Neisseria gonorrhoeae bacteria into the eyes of these neonates in the case of
poor hygiene. This would be less likely for N gonorrhoeae than for other bacte-
ria.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.





Unclear risk COMMENT: Masking of the person who administers medication was not ad-
dressed in this paper. Bacitracin is an ointment. There was no placebo in
the allocation group that received no prophylaxis. The person who adminis-
ters the medication would handle the eyes of neonates with bacitracin, but
not neonates with no prophylaxis as there was no placebo. This could lead
to differential introduction of N gonorrhoeae bacteria into the eyes of these
neonates, if the person administering the medication was potentially involved
in the delivery.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.
Blinding of persons in-




Unclear risk COMMENT: Masking of the person who was involved in postnatal care was not
addressed in this paper.
Bacitracin is a translucent ointment that can be noticed in the eyes for hours.
There was no placebo in the allocation group that received no prophylaxis.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.





Unclear risk COMMENT: Masking of the person who was involved in outcome assessment
was not addressed in this paper.
Bacitracin is an ointment that can be noticed in the eyes for hours. It is unclear
how many cases of conjunctivitis were diagnosed during this early period of
time. There was no placebo in the no-prophylaxis group. In ambiguous cases
of clinical conjunctivitis, whether identified by personnel, mother, or outcome
assessor, there may be differential group behaviour to include or exclude cas-
es of clinical conjunctivitis referred for culture with lack of masking. Although
gonococcal conjunctivitis usually presents with high clinical severity, reducing
ambiguity, there is a clinical spectrum of its presentation, and event rates are
Posner 1959  (Continued)
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so low that minor bias could seriously alter results. Conjunctivitis was not de-
fined in this paper, therefore it is unclear how much subjectivity was involved





Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-






Unclear risk COMMENT: The study authors do not provide any information on the presence
or absence of incomplete outcome data. Attritions and exclusions are not re-
ported. No statement is provided on how long neonates were followed up.
Selective reporting (re-
porting bias)
High risk COMMENT: The only outcome that could be extracted was rates of gonococ-
cal conjunctivitis. At the very least, rates of clinical conjunctivitis would be of
interest, but they are reported unclearly so that they cannot be entered into a
meta-analysis. The paper reports rates of “nonspecific” conjunctivitis; it is un-
clear whether this is clinical, bacterial, or inclusion conjunctivitis.





Methods Parallel-group, multicentre RCT.
Method of allocation: neonates “randomly assigned”. “Randomisation assignments were allocat-
ed centrally in a weekly fashion by the coordinating centre in a 1: 1 ratio”. No further information on
method of allocation provided in paper.
Unit of randomisation: neonate.
Number allocated: 2004.
Handling of missing data: unclear; review authors used imputation, assuming neonates lost to fol-
low-up had no conjunctivitis.
Exclusions after allocation: 22 neonates were excluded after enrolment but before randomisation.
Losses to follow-up:
Chloramphenicol group
1. First eye examination in the first 24 to 48 hours: 0 out of 972 lost to follow-up.
2. Second eye examination between Days 10 and 15: 310 out of 972 lost to follow-up.
3. Third eye examination between Day 16 and Day 30: 502 out of 972 lost to follow-up.
Povidone-iodine group
1. First eye examination in the first 24 to 48 hours: 0 out of 1032 lost to follow-up.
2. Second eye examination between Days 10 and 15: 348 out of 1032 lost to follow-up.
3. Third eye examination between Day 16 and Day 30: 572 out of 1032 lost to follow-up.
Reported power calculation: yes; power 0.80; sample size of 660 per allocation group calculated. “Al-
lowing for an estimated loss of 35% of cases after the start of the study, 270 additional infants were re-
cruited.”
Ramirez-Ortiz 2007 
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Unusual study design: none.
Participants Setting: 3 hospitals in the highlands of Chiapas, Mexico:
1. rural - San Felipe Ecatepec;





Inclusion criteria: all neonates born by vaginal or caesarean section.
Exclusion criteria:
1. eyelid malformations that prevented appropriate conjunctival evaluation;
2. death in the first month of life.
Equivalence of baseline characteristics: yes.
No statistically significant difference in the following characteristics:
1. birthweight;
2. M:F ratio;
3. mode of delivery;
4. sociodemographic characteristics;
5. cases by reference hospital;
6. there were statistically more cases of premature rupture of membranes in the chloramphenicol group.
Interventions Number of interventions: 2.
• Intervention 1: chloramphenicol eye drops; dose not specified (n = 972).
• Intervention 2: 2.5% povidone-iodine eye drops; dose not specified (n = 1032).
Time to intervention: within 20 minutes of birth.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: eyelids wiped immediately after prophylaxis.
Outcomes 1. “Incidence density per 1000 neonate days of bacteria isolated from conjunctival specimens by treat-
ment group.”
2. Paper reports cases of chlamydial conjunctivitis by treatment group.
3. No cases of gonococcal conjunctivitis reported in study.
Based on the data as currently reported, we are unable to determine total number of cases of conjunc-
tivitis and total number of cases of bacterial conjunctivitis per treatment group.
Length of follow-up: 30 days postdelivery.
Intervals at which outcomes assessed:
1. first interval: 24 to 48 hours in postnatal ward;
2. second interval: between Day 10 and Day 15;
3. third interval: between Day 16 and Day 30.
Definition of conjunctivitis or ophthalmia neonatorum: “Neonatal conjunctivitis was defined clinically
by a yellow or greenish discharge in the conjunctival cul-de-sac or involving the eyelids and eyelashes,
or both.”
Ramirez-Ortiz 2007  (Continued)
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Non-infectious conjunctivitis, described as side effect of prophylactic treatment, was defined as “con-
junctival hyperaemia, chemosis, and eyelid swelling without greenish or yellowish discharge”. It is un-
clear if clinical “non-infectious conjunctivitis” had swabs taken for bacterial cultures.
Adverse events reported as "non-infectious conjunctivitis", bronchospasm, or death.
Notes Date study conducted not specified.
Sources of funding: Hospital Infantil de Mexico Board of Trustees Grant HIM/ 2002/024.
Declaration of interest: “Competing interests: None declared.”
Subgroup analysis reported by method of delivery (vaginal versus caesarean).
Trial investigators were contacted on unclear items; reply received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Paper states neonates “randomly assigned”.
“Randomisation assignments were allocated centrally in a weekly fashion by
the coordinating centre in a 1: 1 ratio”.
Allocation concealment
(selection bias)
Low risk Paper states neonates “randomly assigned”.
“Randomisation assignments were allocated centrally in a weekly fashion by
the coordinating centre in a 1: 1 ratio”.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.
Blinding of study partici-




Unclear risk COMMENT: Masking of mothers of the intervention was not addressed in this
study. Furthermore, the 2 interventions differ in colour. Povidone-iodine is
an orange-red solution that may lead to periocular stains that last minutes to
hours. Chloramphenicol is a clear, colourless to slightly yellow solution.
The mothers of neonates with periocular stains may handle the eyes of the
infant differently than mothers of neonates with no stains. The paper does
state that eyelids were wiped immediately after birth, but it is uncertain if this
eliminated all periocular stains. This could lead to differential introduction of
Chlamydia trachomatis bacteria into the eyes of these neonates in the case of
poor hygiene. Alternatively, it could lead to contamination with other bacteria,
subsequent conjunctivitis, and identification of chlamydia carriers instead.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.





High risk COMMENT: Masking of the person who administers the medication was not ad-
dressed in this study. The 2 interventions differ in colour. Povidone-iodine is
an orange-red solution that may lead to periocular stains that last minutes to
hours. Chloramphenicol is a clear, colourless to slightly yellow solution. The in-
terventions are therefore readily identifiable. Any bias on the part of the per-
son who administers the medication could affect adherence or compliance
with method of application of the medication, which, in turn, could affect the
prophylactic effect of the medication against chlamydial conjunctivitis.
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Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.
Blinding of persons in-




Unclear risk COMMENT: Masking of those involved in postnatal care was not addressed
in this study. The 2 interventions differ in colour. Povidone-iodine is an or-
ange-red solution that may lead to periocular stains that last minutes to hours.
Chloramphenicol is a clear, colourless to slightly yellow solution. The paper
does state that eyelids were wiped immediately after birth, but it is uncertain if
this eliminated all periocular stains.
In this study, it is uncertain if there were cases of chlamydial conjunctivitis
identified in the time period when masking would be affected. It is unclear if
those involved in postnatal care were also involved in identification of cases of
conjunctivitis. If they were, and they were unmasked, this may have influenced
decisions to identify and refer clinical conjunctivitis cases for culture. The de-
finition of conjunctivitis used in this study included discharge, which reduced
diagnostic ambiguity. Although chlamydial conjunctivitis tends to be more se-
vere, evidence shows there is a clinical spectrum of presentation, and any bias,
however minor, can be significant considering the very low event rates in this
trial.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-
come of clinical conjunctivitis.





Unclear risk COMMENT: Masking of the person involved in outcome assessment was not
addressed in this paper. The 2 interventions differ in colour. Povidone-iodine
is an orange-red solution that may lead to periocular stains that last minutes
to hours. Chloramphenicol is a clear, colourless to slightly yellow solution. The
paper does state that eyelids were wiped immediately after birth, but it is un-
certain if this eliminated all periocular stains.
Chlamydial conjunctivitis presents with a variable clinical spectrum. There-
fore, lack of masking, in cases of diagnostic ambiguity, may affect which cases
get referred for culture to identify chlamydial conjunctivitis. C trachomatis can





Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
or total clinical conjunctivitis cases could not be extracted from this study.
Consequently, there was no assessment of bias for this category for the out-






High risk COMMENT: Loss to follow-up was greater than 50% in each intervention group
by Day 30. Whilst it is possible that missing outcome data may be unrelated to
true outcome, and they are balanced across intervention groups, the propor-
tion of missing outcomes compared with observed event risk was high enough
to induce clinically relevant bias in the intervention effect estimate.
Selective reporting (re-
porting bias)
High risk COMMENT: Based on the data as currently reported, we are unable to deter-
mine the total number of cases of conjunctivitis and total number of cases of
bacterial conjunctivitis per treatment group.
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Study characteristics
Methods Parallel-group single-centre randomised trial.
Method of allocation: "randomized".
Unit of randomisation: neonate.
Exclusions after allocation: at least n = 4, delayed urination greater than 12 hours postpartum.
Losses to follow-up: not specified, likely minimal as follow-up time until Day 5, and whilst neonate was
in hospital.
Number randomised: at least 73.
Number analysed: 69.
There was no comment on how missing data were handled.
Reported power calculation: yes. Sample size of 32 newborns per group to detect statistical power of
90%.
Participants Country: Germany.
Total number of participants: 69.
Sex: M:F 37 (54%):32 (46%).
Average age and range: neonates; specific weeks of age not specified, but neonates greater than 37
weeks included.
Inclusion criteria: newborns at the obstetrics department of the University of Griefswald and the Dem-
mim Community Hospital. 
Exclusion criteria:
1. newborns of mothers with thyroid disease or additional intake of iodine during pregnancy;
2. newborns with gestational age of less than 37 weeks;
3. refusal to participate;
4. delayed urination greater than 12 hours postpartum.
Setting: obstetrics department of the University of Greifswald and the Demmim Community Hospital, a
teaching hospital of the University of Greifswald.
Ethnic group: not specified.
Equivalence of baseline characteristics: yes.
Interventions Number of interventions: 2.
• Intervention 1: 1.25% povidone-iodine into each conjunctival sac (n = 36).
• Intervention 2: 1% silver nitrate into each conjunctival sac (n = 33).
Time to intervention: within 60 minutes of delivery.
Pre-intervention manoeuvres: cleansing.
Postintervention manoeuvres: none specified.
Outcomes 1. Blood thyroid-stimulating hormone concentrations on Day 1 and Day 5 (day of discharge).
2. Urinary iodide concentrations on Days 1, 2, and 5 of life.
3. "Irritations" (not specified in methods).
4. "Infections" (not specified in methods).
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5. "Pain reactions" (not specified in methods).
6. Chemical conjunctivitis categorised as mild hyperaemia, purulent discharge, oedema (not specified
in methods).
The paper was a study to look for adverse events of povidone-iodine that specifically influence thyroid
function.
Length of follow-up: appears to be 5 days although not explicit.
Notes Date conducted: September 2001 to February 2002.
Sources of funding: not specified.
Declaration of interest: not specified.
No subgroup analysis.
Trial investigators were contacted and no response was received.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk COMMENT: Reported that study was "randomized". No other information was
provided on the sequence generation process.
Allocation concealment
(selection bias)
Unclear risk COMMENT: Reported that study was "randomized". No other information was
provided on allocation concealment.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The 2 interventions differ in colour. Povidone-iodine is an or-
ange-red solution that leads to transient residual staining of the eye, skin, and
lids that can last minutes to hours, and that the mother may notice. Silver ni-
trate is a clear solution that sometimes causes a chemical conjunctivitis that
can last up to 72 hours, and also causes lid stains that can last 30 to 48 hours. It
is unknown how this could affect performance bias.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk QUOTE “The 1% SN (silver nitrate)...and 1.25% PVP-I (povidone-iodine) eye
drops...were prepared by the university pharmacy in single ready-for-use vials.
The test vials were labeled by code and completely covered. Laboratory sam-
ples were decoded at the end of the investigation."
COMMENT: The 2 interventions differ in colour: povidone-iodine is an or-
ange-red solution, and silver nitrate is a clear solution. The 2 medications are
readily identifiable to the person administering the medication once it is dis-
pensed into the eyes. There was no comment on whether the person adminis-
tering the medication was specifically masked to the medication, even though
the vials were covered.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
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Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: The 2 interventions differ in colour. Povidone-iodine is an or-
ange-red solution that leads to transient residual staining of the eye, skin, and
lids that can last minutes to hours, depending on whether the surrounding pe-
riorbital skin is cleaned or not. Silver nitrate is a clear solution that sometimes
causes a chemical conjunctivitis that can last up to 72 hours, and also causes
lid stains that can last 30 to 48 hours.
It is clear that follow-up was at least 5 days, but it is unclear how many cases
of conjunctivitis were diagnosed in the first 72 hours. The nurses in the nurs-
ery may differentially handle the eyes of neonates based on the type of visible
signs of prophylaxis. This could lead to differential introduction of pathogenic
bacteria into the eyes of these neonates.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk COMMENT: The 2 interventions differ in colour. Povidone-iodine is an or-
ange-red solution that leads to transient residual staining of the eye, skin, and
lids that can last minutes to hours, depending on whether the periorbital skin
is cleaned. Silver nitrate is a clear solution that sometimes causes a chemical
conjunctivitis that can last up to 72 hours, and also causes lid stains that can
last 30 to 48 hours.
It is unknown how many cases of conjunctivitis were identified during the time
when these stains remained.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis






Unclear risk COMMENT: There is no specific comment on incomplete outcome data in the
paper, however it is unlikely that there were incomplete data as neonates were






Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




High risk Reported outcomes of conjunctivitis were not prespecified and were reported
incompletely.





Methods Parallel-group, single-centre trial.
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Method of allocation: alternate weeks.
Unit of randomisation: neonate.
Exclusions after allocation: none specified.
Losses to follow-up: none specified.
Number allocated: 32,058.
No comment on how missing data were handled.
No reported power calculation.
Unusual study design: none identified.
Participants Setting: Parkland Memorial Hospital, Dallas, TX, USA.
Number allocated: 32,058:




Inclusion criteria: infants born at Parkland Memorial Hospital from 4 December 1977 to 31 December
1979.
Exclusion criteria: none specified.
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: penicillin G IM injection (50,000 units, greater than 2000 g birthweight; 25,000 units,
less than 2000 g birthweight) (n = 16,082).
• Intervention 2: tetracycline 1% ointment; dose not specified (n = 15,976).
Time to intervention: penicillin G IM within 60 minutes of delivery; unknown when tetracycline was ad-
ministered.
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Infants with gonococcal ophthalmia.
2. Infants with chlamydial ophthalmia.
3. Infants with systemic group B streptococcal infections.
4. Mortality.
Follow-up: unclear; likely 31 days. Interval of follow-up not specified.
Definition of conjunctivitis: method of outcome assessment not specified; clinical criteria for conjunc-
tivitis not specified in paper; chlamydial conjunctivitis diagnosed by growth in tissue culture.
Adverse events reported: "No hypersensitivity reactions to penicillin were observed."
Notes Date study conducted: 4 December 1977 to 31 May 1981.
No source of funding specified.
No declaration of interest made.
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No reported subgroup analysis.
Authors have been contacted for clarifications on unclear information, no reply received to date.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk QUOTE: “Newborn infants were assigned to one of two prophylactic regimens,
according to week of birth.”
COMMENT: Non-random component in the sequence generation process.
Allocation concealment
(selection bias)
High risk QUOTE: “Newborn infants were assigned to one of two prophylactic regimens,
according to week of birth.”
COMMENT: Participants or investigators enrolling participants could possibly
have foreseen assignments.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.
Blinding of study partici-




Unclear risk COMMENT: Masking of mothers to the intervention was not addressed in this
study. Furthermore, the 2 interventions differ in method of application. Tetra-
cycline is a light-yellow ointment that may leave a residue in the eyes that can
last for hours. Penicillin G IM is an injection that may leave a needle mark on
the neonate. There could be differential handling of the eyes by the mother, by
allocation group. This could lead to differential introduction of Chlamydia tra-
chomatis bacteria into the eyes of these neonates in the case of poor hygiene.
Alternatively, it could lead to contamination with other bacteria, subsequent
conjunctivitis, and identification of chlamydia carriers instead.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.





High risk COMMENT: Masking of the person who administers the medication was not
addressed in this study. Furthermore, the 2 interventions differ in method of
application. Tetracycline is a light-yellow ointment applied to the eyes. Peni-
cillin G IM is an injection. No placebo was used. Any lack of masking and con-
comitant bias on the part of the person administering the medication could af-
fect adherence or compliance with method of application of the medication,
which, in turn, could affect the prophylactic effect of the medication against
chlamydial conjunctivitis.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.
Blinding of persons in-




Unclear risk COMMENT: Masking of those involved in postnatal care was not addressed in
this study. Tetracycline is a light-yellow ointment that may leave a residue in
the eyes that can last for hours. Penicillin G IM is an injection that may leave a
needle mark on the neonate.
In this study, it is uncertain if there were cases of chlamydial conjunctivitis
identified in the time period when masking would be affected. It is unclear if
Siegel 1982  (Continued)
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those involved in postnatal care were also involved in identification of cases of
conjunctivitis. If they were, and they were unmasked, this could influence de-
cisions to identify and refer clinical conjunctivitis cases for culture. The defini-
tion of conjunctivitis used in this study was not specified. Although chlamydial
conjunctivitis tends to be more severe, evidence shows there is a clinical spec-
trum of presentation, and any bias, however minor, can be significant consid-
ering the low event rates in this trial.




Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-
sessment of bias for this category for the outcome of clinical conjunctivitis.





Unclear risk QUOTE: “Systemic bacterial infections were identified by daily review of the
microbiology laboratory records and hospital charts of infants regarded as in-
fected on the basis of positive culture results or clinical course.”
COMMENT: Masking of those involved in postnatal care was not addressed in
this study. Tetracycline is a light-yellow ointment that may leave a residue in
the eyes that can last for hours. Penicillin G IM is an injection that may leave a
needle mark on the neonate.
We do not know the follow-up time in this study.
Chlamydial conjunctivitis presents with a variable clinical spectrum. There-
fore, lack of masking, in cases of diagnostic ambiguity, may affect which cases





Unclear risk All cases of clinical conjunctivitis were not reported as outcomes in this study,
only chlamydial and gonococcal conjunctivitis. Therefore, there was no as-






Unclear risk COMMENT: Follow-up time is not explicitly stated in the paper. Also, losses to
follow-up are not addressed in the paper. There is no mention of attrition. On-
ly 2 exclusions were mentioned in the study. These 2 infants suffered menin-
gitis. 1 case was in the penicillin group and the other was in the tetracycline
group. In a trial where 16,082 neonates were allocated to the penicillin group
and 15,976 to the tetracycline group, it is likely that there was attrition and ex-
clusions from the analysis.
Selective reporting (re-
porting bias)
Unclear risk QUOTE: “Systemic bacterial infections were identified by daily review of the
microbiology laboratory records and hospital charts of infants regarded as in-
fected on the basis of positive culture results or clinical course.”
COMMENT: The study authors report no cases of gonococcal ophthalmia and
79 cases of chlamydial conjunctivitis, 34 in the penicillin group and 45 in the
tetracycline group. It is likely that there were other cases of conjunctivitis that
were due to pathogens other than C trachomatis and Neisseria gonorrhoeae,
but these have not been reported.
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Methods Parallel-group RCT: there was not equal amounts of each prophylactic intervention: 40% of the total
prophylaxis bottles contained Hexarginum; 20% of the total prophylaxis bottles contained silver ni-
trate; and 40% of the total prophylaxis bottles contained physiological saline.
Method of allocation: “randomized”; no further details on method of randomisation.
Unit of randomisation: neonate.
Exclusions after randomisation: unclear. The study reports 1027 deliveries during the study period, of
which 86% were reported to be vaginal (calculated to be 883) and 14% were reported to be caesarean
sections (calculated to be 144). Only vaginal deliveries were allocated to prophylaxis. However, only
544 of the 883 vaginal deliveries were allocated to prophylaxis for reasons unexplained in the study.
Losses to follow-up: not reported in study, but it appears that only subgroups of those allocated pro-
phylaxis were followed up. It is unclear if these are losses to follow-up or selective follow-up.
Number randomised: unclear; possibly all vaginal deliveries, which is 883. However, the study later
states that only 544 were allocated to prophylaxis, with no explanation for the discrepancy.
Missing data appeared to be handled by available-case analysis.
Power calculation: no reported power calculation in study.
Unusual study design: the study reports 1027 deliveries during the study period, of which 86% were re-
ported to be vaginal (calculated to be 883) and 14% were reported to be caesarean sections (calculated
to be 144). Only vaginal deliveries were allocated to prophylaxis. However, only 544 of the 883 vaginal
deliveries were allocated to prophylaxis for reasons that were unexplained in the study.
Participants Country: Stockholm, Sweden.
Setting: Karolinska Hospital.
Ethnic group: not specified.
Total number of participants: 1027 mother-infant pairs.
Sex: M:F not specified.
Average age and age range: not specified.
Inclusion criteria:
1. mothers not suspected of having gonorrhoea;
2. informed consent.
Exclusion criteria:
1. mother suspected of having gonorrhoea.
Equivalence of baseline characteristics: there did not appear to be equivalence in some of the baseline
characteristics of the mothers. 40% of the total prophylaxis bottles contained Hexarginum; 20% of the
prophylaxis bottles contained silver nitrate; and 40% of the bottles contained physiological saline.
Interventions Number of interventions: 3.
• Intervention 1: silver nitrate 1% (n = 105).
• Intervention 2: Hexarginum 10% (1 g silver nitrate + 36 g methylamine dissolved in 63 g of sterile water)
(n = 225).
• Intervention 3: physiological saline (n = 214).
Time to intervention: approximately 2 hours postpartum.
Pre-intervention manoeuvres:
Wahlberg 1982  (Continued)
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1. neonate placed on the mother’s abdomen and leE there for 20 to 30 minutes;
2. neonate then taken away for weighing, measuring, and dressing;
3. neonate leE alone with mother and father for 2 hours.
Postintervention manoeuvres: not specified.
Outcomes 1. Daily inspection of eye irritation in a subset of 627 neonates, for the following:
a. swelling of the eyelids classified as none, slight, moderate, considerable;
b. redness of the conjunctiva classified as none, slight, moderate, considerable;
c. secretion classified as none, serous, mucous or purulent.
2. Neonates with bacterial conjunctivitis in a subset of 156 neonates with conjunctival secretion.
3. Neonates with gonococcal conjunctivitis among the 156 neonates with conjunctival secretion.
4. Neonates with chlamydial conjunctivitis among the 156 neonates with conjunctival secretion.
5. Neonates without conjunctivitis, cultured for chlamydia. Done in a subset of 250 neonates, Days 5 to
7 postpartum.
6. Pain reaction to prophylaxis in a subset of 810 neonates, looking at 2 variables:
a. cry;
b. averting movements of the head and extremities.
7. Visual alertness in a subset of 39 neonates via score from 0 to 5.
8. Mother-infant relationship in 65 mothers measured by the following:
a. two 6- to 10-minute observation sessions on Days 4 to 5 postpartum followed by an interview on
Day 5;
b. follow-up telephone interview 6 to 8 weeks later.
9. Long-term effects on conjunctival secretion, infant behaviour, breastfeeding, and maternal feelings
for the baby, and experiences of the care system in a subset of 136 mothers, via:
a. interview 3 to 3.5 months postpartum;
b. questionnaire 6 months postpartum.
Length of follow-up for conjunctivitis:
1. daily inspection of eye irritation in 544 neonates until Day 6;
2. a small subset of 15 neonates with conjunctivitis were followed until Day 15 and cultured for chlamy-
dia.
Adverse events: many of the outcomes listed above can be considered adverse events.
Notes Dates conducted:
1. May 1978 to May 1979 for conjunctivitis;
2. “Spring 1979” for outcome of mother-infant relationship.
Sources of funding: “Aided by the Swedish Delegation for Social Research; Medical Research Council
(grant no. 21x-5433) and Radda Barnen –the Swedish Save the Children Foundation; Stockholm, the
SSSH Foundation, Lund; The Swedish Midwives’ Association; Medical Faculty, Karolinska Institute,
Stockholm."
Declaration of interest: none made.
Multiple subgroup analyses.
Trial investigators were contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk QUOTE: “One thousand such bottles were prepared and numbered in a ran-
dom series. We elected to make the proportion of infants receiving silver ni-
trate less than the two other comparison groups, based on the investigators’
Wahlberg 1982  (Continued)
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previous experiences with the irritating quality of this agent. Out of the bottles
20% contained silver nitrate, 40% contained Hexarginum, and 40% contained
physiological saline.”
COMMENT: Sequence generation method unclear.
Allocation concealment
(selection bias)
Unclear risk QUOTE: “One thousand such bottles were prepared and numbered in a ran-
dom series. We elected to make the proportion of infants receiving silver ni-
trate less than the two other comparison groups, based on the investigators’
previous experiences with the irritating quality of this agent. Out of the bottles
20% contained silver nitrate, 40% contained Hexarginum, and 40% contained
physiological saline.”
QUOTE: “The study was performed as a double-blind randomized test with 1%
silver nitrate…10% Hexarginum… and physiological saline…administered
from dark brown, non-returnable bottles.”
COMMENT: Method of concealment not described in detail.
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “The study was performed as a double-blind, randomized test with 1%
silver nitrate (AgNO3), 10% Hexargiunum ( a less irritating compound consist-
ing of 1g AgNO3 + 36 g CH3NH2 dissolved in 63g sterile water) and physiolog-
ical saline (NaCl as placebo) administered from dark-brown, non-returnable
bottles.”
COMMENT: Silver nitrate is a clear solution that sometimes causes a chemical
conjunctivitis that can last up to 72 hours, and also causes lid stains that can
last 30 to 48 hours. Physiological saline is a clear solution that does not cause
lid stains. It is unknown if Hexarginum is a clear solution, but it is possible that
it is. Both Hexarginum and silver nitrate have the same concentration of silver
nitrate in solution. It is unknown if Hexarginum causes lid stains. According to
the study Hexarginum causes significantly less chemical conjunctivitis than sil-
ver nitrate. It is unknown if the mother is able to differentiate the prophylactic
agents on the basis of lid stains.
Blinding of study partici-




Unclear risk We were unable to extract bacterial, gonococcal, and chlamydial conjunctivi-
tis cases from the reported data, therefore there was no assessment of bias for
this category with these outcomes.




Unclear risk QUOTE: “The study was performed as a double-blind, randomized test with 1%
silver nitrate (AgNO3), 10% Hexargiunum ( a less irritating compound consist-
ing of 1g AgNO3 + 36 g CH3NH2 dissolved in 63g sterile water) and physiolog-
ical saline (NaCl as placebo) administered from dark-brown, non-returnable
bottles.”
COMMENT: The prophylactic agents were administered from dark-brown, non-
returnable bottles. This may have concealed any colour differences between
the solutions. However, it is unknown if all 3 solutions appeared the same
when dispensed from the bottle. Silver nitrate is a clear solution that some-
times causes a chemical conjunctivitis that can last up to 72 hours, and also
causes lid stains that can last 30 to 48 hours. Physiological saline is a clear so-
lution. It is unknown if Hexarginum is a clear solution, but it is possible that it
is. Both Hexarginum and silver nitrate have the same concentration of silver
nitrate in solution, but it is unknown if Hexarginum causes lid stains. Accord-
ing to the study Hexarginum causes significantly less chemical conjunctivitis
than silver nitrate. Depending on the time of onset of chemical conjunctivitis,
chemical conjunctivitis may affect the masking of the person administering
the medication. For example, if chemical conjunctivitis is almost immediate,
Wahlberg 1982  (Continued)
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the person administering the medication may know which prophylaxis has
been administered.





Unclear risk We were unable to extract bacterial, gonococcal, and chlamydial conjunctivi-
tis cases from the reported data, therefore there was no assessment of bias for
this category with these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk QUOTE: “Two observers made all daily inspections of the infants’ eyes. The ob-
servers did not know to which prophylaxis group the infants belonged.”
COMMENT: The role of those involved in postnatal care is unknown in this
study. Silver nitrate is a clear solution that sometimes causes a chemical con-
junctivitis that can last up to 72 hours, and also causes lid stains that can last
30 to 48 hours. Physiological saline is a clear solution that does not cause lid
stains. Both Hexarginum and silver nitrate solution have the same concentra-
tion of silver nitrate, but it is unknown if Hexarginum causes lid stains. Certain-
ly the presence of lid stains with silver nitrate, and the absence of lid stains
with physiological saline, would permit such neonates to be distinguished, at
least up to 72 hours. Conjunctivitis outcomes were assessed on Days 1 to 3, in
the first 72 hours.
Blinding of persons in-




Unclear risk We were unable to extract bacterial, gonococcal, and chlamydial conjunctivi-
tis cases from the reported data, therefore there was no assessment of bias for
this category with these outcomes.




Unclear risk QUOTE: “Two observers made all daily inspections of the infants’ eyes. The ob-
servers did not know to which prophylaxis group the infants belonged.”
COMMENT: Silver nitrate is a clear solution that sometimes causes a chemical
conjunctivitis that can last up to 72 hours, and also causes lid stains that can
last 30 to 48 hours. Physiological saline is a clear solution that does not cause
lid stains. Both Hexarginum and silver nitrate solution have the same concen-
tration of silver nitrate, but it is unknown if Hexarginum causes lid stains. Cer-
tainly the presence of lid stains with silver nitrate, and the absence of lid stains
with physiological saline, would permit such neonates to be distinguished,
at least up to 72 hours. The study reports that conjunctivitis outcomes were
assessed on Days 1 to 3, in the first 72 hours, thereby affecting masking. Cul-
tures were taken from a subset of neonates with purulent conjunctivitis. A sig-
nificant proportion of purulent conjunctivitis developed in the first 48 hours,
when lid stains would be present, and masking would be affected.





Unclear risk We were unable to extract bacterial, gonococcal, and chlamydial conjunctivi-
tis cases from the reported data, therefore there was no assessment of bias for





High risk QUOTE: “In the investigation, there was a main study group of 1027 mother-in-
fant pairs.... There were also six subsamples…The second subsample com-
prised the first 810 infants entered into the study…observed for pain reaction
to eye drop prophylaxis. The third subsample came from this group of 810 in-
fants, among whom the first 627 were observed for symptoms of eye irrita-
tion. The fourth subsample came from the group of 627 infants, namely 156 in-
fants with purulent conjunctivitis and from whom bacterial cultures were ob-
tained…Finally, a small group of 15 subjects from the 627 observed for eye irri-
Wahlberg 1982  (Continued)
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tation who displayed prolonged conjunctivitis were also cultured for Chlamy-
dia.”
QUOTE: “One thousand such bottles were prepared and numbered in a ran-
dom series. We elected to make the proportion of infants receiving silver ni-
trate less than the two other comparison groups, based on the investigators’
previous experiences with the irritating quality of this agent. Out of the bottles
20% contained silver nitrate, 40% contained Hexarginum, and 40% contained
physiological saline.”
COMMENT: As the above quotes validate, significant numbers of neonates
were not followed up. Furthermore, despite having 1000 bottles, only 544
neonates were allocated to prophylaxis. The remaining 83 of the 627 neonates






Unclear risk We were unable to extract bacterial, gonococcal, and chlamydial conjunctivi-
tis cases from the reported data, therefore there was no assessment of bias for
this category with these outcomes.
Selective reporting (re-
porting bias)
High risk COMMENT: The study protocol is not available. Conjunctivitis outcomes are re-
ported incompletely so that they cannot be entered into a meta-analysis. The
study reports percentages in a bar graph only and by time periods, making it
impossible to determine absolute numbers for extraction into a meta-analysis.





Methods Parallel-group, single-centre RCT.
Unit of randomisation: neonate (not eye).
No losses to follow-up specified.
Number randomised: 100.
No exclusions after randomisation specified.
No comment on missing data or how handled.
No reported power calculation.
Participants Setting: hospital in Slovenia.
Number allocated: 100.
Age: neonates.
Sex: M:F not specified.
Inclusion criteria:
1. neonates.
Exclusion criteria: not specified.
Zbojan 2004 
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There was no comment on equivalence of baseline characteristics.
Interventions Number of interventions: 2.
• Intervention 1: povidone-iodine solution 2.5% 1 drop administered into eyes (n = 50).
• Intervention 2: “O-Septonex” solution (carbethopendecinium bromide (C-bromide)) 1 drop adminis-
tered into eyes (n = 50).
Time to intervention: within 48 hours of birth.
Pre-intervention manoeuvres: not specified.
Postintervention manoeuvres: not specified.




2. Average concentration of thyroid stimulating hormone on Day 5 of birth.
Follow-up: 4 weeks.




Notes on definition of conjunctivitis: defined erythema or discharge.
No comments on adverse events.
Notes Study report was translated.
Date recruited neonates: study published in 2004; otherwise not specified.
No sources of funding specified.
No declarations of interest specified among researchers.
Trial investigators were not contacted.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk COMMENT: Translation of study states that the study was randomised. No oth-
er information was provided on the sequence generation process.
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of study partici-
pants (mothers of infants)
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of the mother was not addressed in this paper.
Povidone-iodine is an orange-red solution that may lead to periocular stains
that last minutes to hours. The colour of C-bromide is unknown. The mothers
of neonates
with noticeable medication of the eyes may handle the eyes of the infant dif-
ferently than mothers of neonates with no stains. This could lead to differen-
Zbojan 2004  (Continued)
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tial introduction of pathogenic bacteria into the eyes of these neonates, de-
pending on hygiene measures.
Blinding of study partici-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




High risk COMMENT: Masking of the person who administers the medication was not ad-
dressed in this study.
Povidone-iodine is an orange-red solution that may lead to periocular stains
that last minutes to hours. The colour of C-bromide is unknown.
These medications may be readily distinguishable. Lack of masking and any
bias on the part of the person administering the medication could affect ad-
herence or compliance with method of application of the medication, which,
in turn, could affect the prophylactic effect of the medication against conjunc-
tivitis.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Blinding of persons in-
volved in postnatal care
Clinical conjunctivitis
(subjective)
Unclear risk COMMENT: Masking of the person who was involved in postnatal care was not
addressed in this paper. Povidone-iodine is an orange-red solution that may
lead to periocular stains that last minutes to hours. The colour of C-bromide is
unknown.
In this study, it is uncertain if there were cases of conjunctivitis identified in the
time period when masking would be affected. It is unclear if those involved in
postnatal care were also involved in identification of cases of conjunctivitis. If
they were, and they were unmasked, this may influence decisions to identify
clinical conjunctivitis cases. Considering the low event rates in this small trial,
this may be significant.
Blinding of persons in-




Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.




Unclear risk COMMENT: The study does not mention masking of outcome assessors.
In the first hours after application, there may be residual periocular povi-
done-iodine skin stains that can last minutes to hours. The colour of C-bro-
mide is unknown. Therefore, there may be lack of masking of outcome asses-
sors during this time, and there may be recall of the prophylaxis applied after
this time. Where there is ambiguity in the diagnosis of conjunctivitis, and there
is concomitant lack of masking, bias could result in clinical diagnosis. This bias
could be significant considering the low event rates.





Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis
as outcomes, therefore there was no assessment of bias for this category with
these outcomes.
Zbojan 2004  (Continued)
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Unclear risk The study did not report bacterial, gonococcal, or chlamydial conjunctivitis




Unclear risk COMMENT: The study appeared to only report clinical conjunctivitis cases.
There was no mention in the methods or results section of the translated pa-
per of any plan to culture conjunctivitis cases. The methods are not explicit on
prespecified outcomes. There is no access to the study protocol. There is insuf-
ficient information to permit a judgement of low risk or high risk of bias.
Other bias Unclear risk COMMENT: We assessed this study as at unclear risk of bias, as a significant
amount of information is not reported in the study. Consequently, there is in-
sufficient information to assess whether an important risk of bias exists.
Zbojan 2004  (Continued)
IM: intramuscular ; PCR: polymerase chain reaction; PMN: polymorphonuclear; RCT: randomised controlled trial
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Assadian 2002 Not an RCT or a quasi-RCT
Bailey 1993 Intervention for treatment, not prophylaxis of conjunctivitis, and population not restricted to
neonates
Baptista 1968 Unable to determine method of allocation
Baveja 1997 Not an RCT or a quasi-RCT of ophthalmia neonatorum prophylaxis
Bobo 1997 Not an RCT or a quasi-RCT of ophthalmia neonatorum prophylaxis
Brady 1997 Not a randomised or quasi-randomised prophylaxis trial; case report
Burr 2017 Unit of randomisation is expecting mothers, not neonates.
Candano 1951 Not an RCT or a quasi-RCT
CDC 1998 Not a randomised or quasi-randomised prophylaxis trial; outbreak report
Clark 1951 Method of allocation to groups not directly addressed in paper; likely not an RCT or a quasi-RCT
based on description in methods section.
Cohen 1990 Intervention for treatment of conjunctivitis, not prophylaxis; population not neonates
Darling 2010 Not an RCT or a quasi-RCT; this is a meta-analysis
Darougar 1977 Intervention for treatment of conjunctivitis, not prophylaxis; population not neonates
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
Study Reason for exclusion
Dhir 1967 Population not neonates
Drago 1998 Intervention for treatment, not prophylaxis; population not neonates
Fok 1995 Intervention not topical, systemic or, combination medication, and not for prophylaxis of conjunc-
tivitis
Fransen 1984 Intervention for treatment of ophthalmia neonatorum, not prophylaxis
Gross 1997 Intervention for treatment of conjunctivitis, not prophylaxis
Hammerschlag 1997 Not a randomised or quasi-randomised prophylaxis trial
Hammerschlag 1998 Intervention for treatment, not prophylaxis
Heggie 1985 Intervention for treatment of ophthalmia neonatorum, not prophylaxis
Horven 1993 Intervention for treatment, not prophylaxis of conjunctivitis, and not restricted to neonates
Iroha 1998 Intervention for treatment, not prophylaxis
Isenberg 1994 Unit of randomisation is eyes as opposed to neonates; unable to transform results reported in pa-
per into clinically relevant outcomes. Dr Isenberg was contacted 25 March 2002, and a response
was received 8 May 2002.
Jacobson 1988 Intervention for treatment of conjunctivitis, not prophylaxis, and population not neonates
Keenan 2010 Cost-analysis letter
Khan 2016 Unit of randomisation is eye.
Klein 1997 Not a randomised or quasi-randomised prophylaxis trial
Kramer 1997 Not a randomised or quasi-randomised prophylaxis trial; review article
Laga 1986 Intervention for treatment of conjunctivitis, not prophylaxis
Lietman 1998 Review article, not a trial
Maharajan 1997 Not an RCT or a quasi-RCT of ophthalmia neonatorum prophylaxis
Mani 1997 Retrospective study
Mann 1954 Not an RCT or a quasi-RCT
Margileth 1957 Not an RCT or a quasi-RCT
Markham 1994 Not an RCT or a quasi-RCT of prophylaxis of ophthalmia neonatorum
McAuley 1994 Intervention not for prophylaxis of ophthalmia neonatorum
Mets 1997 Not an RCT or a quasi-RCT prophylaxis trial of neonates
Meyer 1997 Not a trial of ophthalmia neonatorum prophylaxis; letter
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Study Reason for exclusion
Nakagawa 1997 Not a randomised or quasi-randomised prophylaxis trial
Nichols 1966 Intervention is trachoma vaccine; population was not exclusively neonates and included children
up to 3 years of age.
Normann 2002 Intervention is for treatment of ophthalmia neonatorum, not prophylaxis.
Peters 1992 Not a trial of ophthalmia neonatorum prophylaxis; review article
Ratelle 1997 Retrospective cohort study
Reimer 1997 Review article; no trial identified
Rivlin 1997 Not a randomised or quasi-randomised prophylaxis trial
Rosenman 2003 Not an RCT or a quasi-RCT; decision analysis
Schaller 1997 Not a randomised or quasi-randomised prophylaxis trial
Seiga 1993 Unable to determine method of allocation from translated paper; communication from author
states alternation
Silva 2008 Study did not measure clinical conjunctivitis in the methods, only eye cultures of all neonates with-
in the first 2 hours of life and 1 week later; study did not report any clinical conjunctivitis cases in
the outcomes. Study author was contacted via email 1 August 2016, no response received.
Sorsby 1949 Intervention for treatment of conjunctivitis, not prophylaxis
Stenberg 1991 Intervention for treatment of conjunctivitis, not prophylaxis
Sud 1995 Intervention for treatment of conjunctivitis, not prophylaxis
Sung 1998 Not a randomised or quasi-randomised prophylaxis trial
van Bogaert 1997 Not a randomised or quasi-randomised prophylaxis trial; letter
Wallace 1998 Review article; no trial identified
West 1995 Intervention for treatment of conjunctivitis, not prophylaxis. Population not neonates
Winceslaus 1987 Not an RCT or a quasi-RCT
Woolridge 1967 Intervention is trachoma vaccine; population included preschool-aged children.
Wu 2003 Not an RCT or a quasi-RCT
Yasunaga 1977 Interventions in trial were different irrigation solutions with silver nitrate; outcome was chemical
conjunctivitis; follow-up time was 2 days.
Yetman 1997 Not a trial of ophthalmia neonatorum prophylaxis; clinical practice guideline
Zanoni 1992 Not an RCT or a quasi-RCT
RCT: randomised controlled trial
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Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Method of allocation uncertain:
• "In this random clinical case-control study..."
• "These infants were classified into three groups. Selection of newborn for each group was done
regardless of sex, kind of birth and exclusively done randomly."
• "Type of study was clinical trial, and sampling method was census form."
Number allocated: 1002.
No comment on exclusions after allocation.
No comment on losses to follow-up, however the study states that 1002 newborns were included,
but the numbers in the 3 allocation groups add up to 992, leaving 10 neonates unaccounted for
with no explanation.
No comment on missing data.
No reported power calculation.
Participants Country: Tehran, Iran.
Setting: Najmieh Hospital.
Ethnic group: not specified.
Sex: M:F 523 (52%):479 (48%).
Average age and age range: not specified.
Inclusion criteria:
1. healthy term infants;
2. weight greater than 2500 g;
3. gestation age more than 37 weeks.
Exclusion criteria: none specified
No comment on equivalence of baseline characteristics.
Interventions Number of interventions: 3.
Intervention 1: erythromycin ointment 0.5% used for both eyes (n = 320).
Intervention 2: sterile normal saline 1 drop into each eye (n = 337).
Intervention 3: no treatment used for both eyes (n = 335).
Time to intervention: "immediately".
Pre-intervention manoeuvres: none specified.
Postintervention manoeuvres: none specified.
Outcomes 1. Conjunctivitis.
2. Culture-positive conjunctivitis, but not by allocation group.
3. Severe sight-threatening disease.
4. Systemic disease.
5. Gonococcal conjunctivitis.
Follow-up length: unknown: self-report by mother, follow-up limit unknown.
Matinzadeh 2007 
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"Tenth day visit was mandatory to diagnose or rule out conjunctivitis.
"There was no case of severe sight-threatening or systemic disease in our cases on tenth-day visit
and afterwards."
Adverse events: no specific comment on adverse events.
Notes Date conducted: July to December 2001.
Sources of funding: not specified.
Declaration of interest: not specified.
No reported subgroup analysis.





D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Any prophylaxis versus no prophylaxis





Statistical method Effect size
1.1 Chlamydial conjunctivitis 2 4874 Risk Ratio (IV, Fixed, 95% CI) 0.96 [0.57, 1.61]
1.2 Bacterial conjunctivitis 2 3685 Risk Ratio (IV, Fixed, 95% CI) 0.84 [0.37, 1.93]
1.3 Any conjunctivitis of any aetiol-
ogy
8 9666 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.54, 0.78]
1.4 Conjunctivitis of unknown aeti-
ology
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
1.5 Nasolacrimal duct obstruction 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
1.6 Keratitis 1 40 Risk Ratio (IV, Fixed, 95% CI) Not estimable
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Heterogeneity: Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 0.16 (P = 0.87)
























IV, Fixed, 95% CI
0.93 [0.55 , 1.59]
1.50 [0.16 , 14.25]
0.96 [0.57 , 1.61]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours any prophylaxis Favours no prophylaxis
Footnotes
(1) Three intervention arms: erythromycin 0.5%, tetracycline 1%, silver nitrate 1%
(2)  Two intervention arms: povidine-iodine 2.5%, erythromycin 0.5%
 
 






Heterogeneity: Chi² = 0.04, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 0.41 (P = 0.68)
























IV, Fixed, 95% CI
0.76 [0.20 , 2.83]
0.90 [0.31 , 2.62]
0.84 [0.37 , 1.93]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours any prophylaxis Favours no prophylaxis
Footnotes
(1) Bacitracin-phenacaine ointment (both intervention and control received mechanical cleansing)
(2) Two intervention arms: povidine-iodine 2.5%, erythromycin 0.5%
 
 
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews












Heterogeneity: Tau² = 0.01; Chi² = 7.88, df = 7 (P = 0.34); I² = 11%
Test for overall effect: Z = 4.65 (P < 0.00001)






















































M-H, Random, 95% CI
0.40 [0.23 , 0.69]
0.63 [0.43 , 0.93]
0.76 [0.60 , 0.96]
0.60 [0.40 , 0.91]
0.14 [0.02 , 1.13]
0.76 [0.48 , 1.19]
0.20 [0.01 , 3.92]
0.76 [0.20 , 2.83]
0.65 [0.54 , 0.78]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours any prophylaxis Favours no prophylaxis
Footnotes
(1) Two intervention arms: povidine-iodine 2.5%, erythromycin 0.5%
(2) Two intervention arms: erythromycin 0.5%, silver nitrate 1%
(3) Three intervention arms: erythromycin 0.5%, tetracycline 1%, silver nitrate 1%
(4) Two intervention arms: colostrum, erythromycin 0.5%
(5) Erythromycin 0.5%
(6) Two intervention arms: tetracycline, erythromycin 0.5%  
(7) Silver nitrate 1%
(8) Bacitracin-phenacaine ointment (both intervention and control received mechanical cleansing)
 
 
Analysis 1.4.   Comparison 1: Any prophylaxis versus no














IV, Fixed, 95% CI
1.75 [0.37 , 8.28]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours any prophylaxis Favours no prophylaxisFootnotes
(1) Two intervention arms: povidine-iodine 2.5%, erythromycin 0.5%
 
 














IV, Fixed, 95% CI
0.93 [0.68 , 1.28]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours any prophylaxis Favours no prophylaxisFootnotes
(1) Two intervention arms: erythromycin 0.5%, silver nitrate 1%
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Test for overall effect: Not applicable





















IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours any prophylaxis Favours no prophylaxis
Footnotes
(1) Silverr nitrate 1%
 
 
Comparison 2.   Silver nitrate versus no prophylaxis





Statistical method Effect size
2.1 Gonococcal conjunctivitis 1 2225 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 Chlamydial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2.3 Any conjunctivitis of any aetiolo-
gy
3 2713 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.52, 0.87]
2.4 Corneal abrasion 1 40 Risk Ratio (IV, Fixed, 95% CI) Not estimable
2.5 Nasolacrimal duct obstruction 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours silver nitrate Favours no prophylaxis
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IV, Fixed, 95% CI
1.06 [0.55 , 2.02]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours silver nitrate Favours no prophylaxis
 
 







Heterogeneity: Tau² = 0.00; Chi² = 0.70, df = 2 (P = 0.70); I² = 0%
Test for overall effect: Z = 3.05 (P = 0.002)





























M-H, Random, 95% CI
0.65 [0.41 , 1.02]
0.69 [0.51 , 0.95]
0.20 [0.01 , 3.92]
0.67 [0.52 , 0.87]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours silver nitrate Favours no prophylaxis
 
 






Test for overall effect: Not applicable





















IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours silver nitrate Favours no prophylaxis
 
 














IV, Fixed, 95% CI
1.03 [0.72 , 1.46]
Risk Ratio
IV, Fixed, 95% CI
0.85 0.9 1 1.1 1.2
Favours silver nitrate Favours no prophylaxis
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Comparison 3.   Erythromycin versus no prophylaxis





Statistical method Effect size
3.1 Gonococcal conjunctivitis 2 2526 Risk Ratio (IV, Fixed, 95% CI) Not estimable
3.2 Chlamydial conjunctivitis 2 2526 Risk Ratio (IV, Fixed, 95% CI) 0.93 [0.49, 1.77]
3.3 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3.4 Any conjunctivitis of any aetiolo-
gy
6 3509 Risk Ratio (IV, Random, 95% CI) 0.68 [0.51, 0.89]
3.5 Conjunctivitis of unknown aeti-
ology
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3.6 Nasolacrimal duct obstruction 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 







Test for overall effect: Not applicable


























IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours no prophylaxis
 
 






Heterogeneity: Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.22 (P = 0.83)
























IV, Fixed, 95% CI
1.00 [0.06 , 15.79]
0.93 [0.48 , 1.79]
0.93 [0.49 , 1.77]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours no prophylaxis
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IV, Fixed, 95% CI
0.80 [0.22 , 2.90]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours no prophylaxis
 
 










Heterogeneity: Tau² = 0.04; Chi² = 8.08, df = 5 (P = 0.15); I² = 38%
Test for overall effect: Z = 2.81 (P = 0.005)












































IV, Random, 95% CI
0.79 [0.46 , 1.36]
0.62 [0.39 , 0.99]
0.90 [0.68 , 1.19]
0.44 [0.25 , 0.79]
0.14 [0.02 , 1.13]
0.64 [0.36 , 1.13]
0.68 [0.51 , 0.89]
Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours no prophylaxis
 
 














IV, Fixed, 95% CI
1.50 [0.26 , 8.80]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours no prophylaxis
 
 














IV, Fixed, 95% CI
0.83 [0.56 , 1.23]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours no prophylaxis
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Comparison 4.   Tetracycline versus no prophylaxis





Statistical method Effect size
4.1 Gonococcal conjunctivitis 1 2299 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 Chlamydial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4.3 Any conjunctivitis of any aetiology 2 2519 Risk Ratio (IV, Fixed, 95% CI) 0.72 [0.55, 0.94]
 
 






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours tetracycline Favours no prophylaxis
 
 














IV, Fixed, 95% CI
0.82 [0.42 , 1.63]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours tetracycline Favours no prophylaxis
 
 






Heterogeneity: Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 2.43 (P = 0.02)
























IV, Fixed, 95% CI
0.67 [0.49 , 0.91]
0.88 [0.53 , 1.46]
0.72 [0.55 , 0.94]
Risk Ratio
IV, Fixed, 95% CI
0.85 0.9 1 1.1 1.2
Favours tetracycline Favours no prophylaxis
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Comparison 5.   Povidone-iodine versus no prophylaxis





Statistical method Effect size
5.1 Gonococcal conjunctivitis 1 220 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Chlamydial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5.3 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5.4 Any conjunctivitis of any aetiolo-
gy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5.5 Conjunctivitis of unknown aeti-
ology
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours no prophylaxis
 
 














IV, Fixed, 95% CI
2.00 [0.18 , 21.74]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours no prophylaxis
 
 














IV, Fixed, 95% CI
1.00 [0.30 , 3.36]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours no prophylaxis
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IV, Fixed, 95% CI
0.38 [0.18 , 0.77]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours no prophylaxis
 
 
Analysis 5.5.   Comparison 5: Povidone-iodine versus no














IV, Fixed, 95% CI
2.00 [0.37 , 10.70]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours no prophylaxis
 
 
Comparison 6.   Bacitracin-phenacaine versus no prophylaxis




Statistical method Effect size
6.1 Gonococcal conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 














IV, Fixed, 95% CI
0.76 [0.20 , 2.83]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours bacitracin-phenacaine Favours no prophylaxis
 
 
Comparison 7.   Colostrum versus no prophylaxis




Statistical method Effect size
7.1 Any conjunctivitis of any aetiology 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews














IV, Fixed, 95% CI
0.72 [0.45 , 1.14]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours colostrum Favours no prophylaxis
 
 
Comparison 8.   Erythromycin versus silver nitrate





Statistical method Effect size
8.1 Chlamydial conjunctivitis 4 13472 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.51, 1.09]
8.2 Bacterial conjunctivitis 2 6333 Risk Ratio (IV, Fixed, 95% CI) 0.83 [0.69, 1.01]
8.3 Any conjunctivitis of any aetiology 3 4729 Risk Ratio (IV, Random, 95% CI) 1.02 [0.80, 1.30]
8.4 Conjunctivitis of unknown aetiolo-
gy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
8.5 Nasolacrimal duct obstruction 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 








Heterogeneity: Tau² = 0.05; Chi² = 4.30, df = 3 (P = 0.23); I² = 30%
Test for overall effect: Z = 1.51 (P = 0.13)


































M-H, Random, 95% CI
0.88 [0.46 , 1.70]
0.05 [0.00 , 0.88]
0.93 [0.44 , 1.95]
0.70 [0.53 , 0.93]
0.75 [0.51 , 1.09]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours silver nitrate
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Heterogeneity: Chi² = 2.21, df = 1 (P = 0.14); I² = 55%
Test for overall effect: Z = 1.88 (P = 0.06)
























IV, Fixed, 95% CI
0.49 [0.24 , 1.01]
0.87 [0.71 , 1.05]
0.83 [0.69 , 1.01]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours silver nitrate
 
 







Heterogeneity: Tau² = 0.02; Chi² = 4.12, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 0.16 (P = 0.88)





























IV, Random, 95% CI
0.96 [0.57 , 1.60]
1.30 [0.94 , 1.78]
0.91 [0.79 , 1.04]
1.02 [0.80 , 1.30]
Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.96 [0.77 , 1.19]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.81 [0.55 , 1.20]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours erythromycin Favours silver nitrate
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Comparison 9.   Tetracycline versus silver nitrate





Statistical method Effect size
9.1 Chlamydial conjunctivitis 4 14142 Risk Ratio (IV, Random, 95% CI) 0.64 [0.40, 1.02]
9.2 Nasolacrimal duct obstruction 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 








Heterogeneity: Tau² = 0.00; Chi² = 2.19, df = 3 (P = 0.53); I² = 0%
Test for overall effect: Z = 1.88 (P = 0.06)


































IV, Random, 95% CI
2.68 [0.11 , 65.73]
0.78 [0.40 , 1.54]
0.40 [0.16 , 0.97]
0.66 [0.26 , 1.66]
0.64 [0.40 , 1.02]
Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours tetracycline Favours silver nitrate
 
 














IV, Fixed, 95% CI
1.57 [0.63 , 3.91]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours tetracycline Favours silver nitrate
 
 
Comparison 10.   Sulfacetamide versus silver nitrate





Statistical method Effect size
10.1 Gonococcal conjunctivitis 1 640 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.2 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
10.3 Any conjunctivitis of any aetiology 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
10.4 Conjunctivitis of unknown aetiolo-
gy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours sulphacetimide Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.88 [0.45 , 1.74]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours sulphacetimide Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.54 [0.32 , 0.89]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours sulphacetimide Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.27 [0.11 , 0.66]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours sulphacetimide Favours silver nitrate
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Comparison 11.   Cetyl-pyridinium chloride versus silver nitrate





Statistical method Effect size
11.1 Bacterial conjunctivitis 2 599 Risk Ratio (IV, Fixed, 95% CI) 1.79 [0.59, 5.41]
11.2 Any conjunctivitis of any aetiology 2 599 Risk Ratio (IV, Fixed, 95% CI) 1.08 [0.40, 2.90]
11.3 Conjunctivitis of unknown aetiology 2 599 Risk Ratio (IV, Fixed, 95% CI) 0.14 [0.01, 2.71]
 
 






Heterogeneity: Chi² = 1.18, df = 1 (P = 0.28); I² = 15%
Test for overall effect: Z = 1.04 (P = 0.30)
























IV, Fixed, 95% CI
1.24 [0.34 , 4.50]
4.95 [0.58 , 41.92]
1.79 [0.59 , 5.41]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours cetyl-pyridinium chloride Favours silver nitrate
 
 
Analysis 11.2.   Comparison 11: Cetyl-pyridinium chloride versus






Heterogeneity: Chi² = 2.49, df = 1 (P = 0.11); I² = 60%
Test for overall effect: Z = 0.14 (P = 0.89)
























IV, Fixed, 95% CI
0.71 [0.23 , 2.17]
4.95 [0.58 , 41.92]
1.08 [0.40 , 2.90]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours cetyl-pyridinium chloride Favours silver nitrate
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Analysis 11.3.   Comparison 11: Cetyl-pyridinium chloride versus







Test for overall effect: Z = 1.30 (P = 0.19)























IV, Fixed, 95% CI
0.14 [0.01 , 2.71]
Not estimable
0.14 [0.01 , 2.71]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours cetyl-pyridinium chloride Favours silver nitrate
 
 
Comparison 12.   Penicillin versus silver nitrate





Statistical method Effect size
12.1 Gonococcal conjunctivitis 1 2804 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.2 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
12.3 Any conjunctivitis of any aetiology 2   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
12.4 Conjunctivitis of unknown aetiolo-
gy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.34 [0.18 , 0.65]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin Favours silver nitrate
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IV, Fixed, 95% CI
0.15 [0.12 , 0.20]
0.78 [0.35 , 1.70]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.13 [0.10 , 0.18]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin Favours silver nitrate
 
 
Comparison 13.   Penicillin IM versus silver nitrate





Statistical method Effect size
13.1 Gonococcal conjunctivitis 1 2727 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13.2 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
13.3 Any conjunctivitis of any aetiology 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
13.4 Conjunctivitis of unknown aetiolo-
gy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours silver nitrate
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IV, Fixed, 95% CI
0.75 [0.46 , 1.24]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.26 [0.21 , 0.32]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.21 [0.17 , 0.27]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours silver nitrate
 
 
Comparison 14.   Povidone-iodine versus silver nitrate





Statistical method Effect size
14.1 Gonococcal conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
14.2 Chlamydial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
14.3 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
14.4 Any conjunctivitis of any aetiol-
ogy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
14.5 Conjunctivitis of unknown aeti-
ology
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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IV, Fixed, 95% CI
1.94 [0.60 , 6.29]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.52 [0.38 , 0.71]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.75 [0.61 , 0.92]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours silver nitrate
 
 














IV, Fixed, 95% CI
0.72 [0.63 , 0.84]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours silver nitrate
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Analysis 14.5.   Comparison 14: Povidone-iodine versus silver














IV, Fixed, 95% CI
0.70 [0.55 , 0.89]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours silver nitrate
 
 
Comparison 15.   Tetracycline versus erythromycin





Statistical method Effect size
15.1 Chlamydial conjunctivitis 2 10946 Risk Ratio (IV, Fixed, 95% CI) 0.72 [0.42, 1.25]
15.2 Any conjunctivitis of any aetiology 2   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 






Heterogeneity: Chi² = 0.95, df = 1 (P = 0.33); I² = 0%
Test for overall effect: Z = 1.16 (P = 0.25)
























IV, Fixed, 95% CI
0.89 [0.45 , 1.77]
0.50 [0.20 , 1.26]
0.72 [0.42 , 1.25]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours tetracycline Favours erythromycin
 
 



















IV, Fixed, 95% CI
0.75 [0.54 , 1.02]
1.38 [0.76 , 2.47]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours tetracycline Favours erythromycin
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Comparison 16.   Colostrum versus erythromycin




Statistical method Effect size
16.1 Any conjunctivitis of any aetiology 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 














IV, Fixed, 95% CI
1.49 [0.80 , 2.78]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours colostrum Favours erythromycin
 
 
Comparison 17.   Povidone-iodine versus erythromycin





Statistical method Effect size
17.1 Chlamydial conjunctivitis 2 2408 Risk Ratio (IV, Fixed, 95% CI) 0.74 [0.54, 1.02]
17.2 Bacterial conjunctivitis 2 2408 Risk Ratio (IV, Fixed, 95% CI) 0.87 [0.71, 1.07]
17.3 Any conjunctivitis of any aetiology 2 2408 Risk Ratio (IV, Fixed, 95% CI) 0.78 [0.68, 0.90]
17.4 Conjunctivitis of unknown aetiolo-
gy
2 2408 Risk Ratio (IV, Fixed, 95% CI) 0.74 [0.58, 0.93]
 
 






Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)
























IV, Fixed, 95% CI
0.50 [0.05 , 5.43]
0.74 [0.54 , 1.03]
0.74 [0.54 , 1.02]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours erythromycin
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Heterogeneity: Chi² = 0.31, df = 1 (P = 0.58); I² = 0%
Test for overall effect: Z = 1.33 (P = 0.18)
























IV, Fixed, 95% CI
1.25 [0.34 , 4.53]
0.86 [0.70 , 1.06]
0.87 [0.71 , 1.07]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours erythromycin
 
 
Analysis 17.3.   Comparison 17: Povidone-iodine versus






Heterogeneity: Chi² = 1.81, df = 1 (P = 0.18); I² = 45%
Test for overall effect: Z = 3.37 (P = 0.0007)
























IV, Fixed, 95% CI
0.47 [0.22 , 1.00]
0.80 [0.69 , 0.92]
0.78 [0.68 , 0.90]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours erythromycin
 
 
Analysis 17.4.   Comparison 17: Povidone-iodine versus






Heterogeneity: Chi² = 0.64, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 2.56 (P = 0.01)
























IV, Fixed, 95% CI
1.33 [0.31 , 5.82]
0.73 [0.57 , 0.92]
0.74 [0.58 , 0.93]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours erythromycin
 
 
Comparison 18.   Pencillin IM versus tetracycline





Statistical method Effect size
18.1 Gonococcal conjunctivitis 1 32058 Risk Ratio (IV, Fixed, 95% CI) Not estimable
18.2 Chlamydial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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Test for overall effect: Not applicable





















IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours tetracycline
 
 














IV, Fixed, 95% CI
0.75 [0.48 , 1.17]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours tetracycline
 
 
Comparison 19.   Povidone-iodine versus tetracycline





Statistical method Effect size
19.1 Gonococcal conjunctivitis 1 410 Risk Ratio (IV, Fixed, 95% CI) Not estimable
19.2 Chlamydial conjunctivitis 1 410 Risk Ratio (IV, Fixed, 95% CI) Not estimable
19.3 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
19.4 Any conjunctivitis of any aetiolo-
gy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
19.5 Conjunctivitis of unknown aeti-
ology
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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Test for overall effect: Not applicable





















IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours tetracycline
 
 






Test for overall effect: Not applicable





















IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours tetracycline
 
 














IV, Fixed, 95% CI
2.04 [0.99 , 4.22]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours tetracycline
 
 














IV, Fixed, 95% CI
3.01 [1.52 , 5.98]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours tetracycline
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Analysis 19.5.   Comparison 19: Povidone-iodine versus














IV, Fixed, 95% CI
20.40 [1.20 , 345.80]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours tetracycline
 
 
Comparison 20.   Povidone-iodine versus chloramphenicol





Statistical method Effect size
20.1 Gonococcal conjunctivitis 1 2004 Risk Ratio (IV, Fixed, 95% CI) Not estimable
20.2 Chlamydial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 






Test for overall effect: Not applicable





















IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours chloramphenicol
 
 














IV, Fixed, 95% CI
1.77 [0.97 , 3.22]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours chloramphenicol
 
 
Comparison 21.   Povidone-iodine versus carbethopendecinium bromide




Statistical method Effect size
21.1 Any conjunctivitis of any aetiology 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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Analysis 21.1.   Comparison 21: Povidone-iodine versus carbethopendecinium














IV, Fixed, 95% CI
0.44 [0.15 , 1.35]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine Favours C-Bromide
 
 
Comparison 22.   Povidone-iodine twice versus povidone-iodine once





Statistical method Effect size
22.1 Gonococcal conjunctivitis 1 719 Risk Ratio (IV, Fixed, 95% CI) Not estimable
22.2 Chlamydial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
22.3 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
22.4 Any conjunctivitis of any aetiolo-
gy
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
22.5 Conjunctivitis of unknown aeti-
ology
1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
 
 
Analysis 22.1.   Comparison 22: Povidone-iodine twice versus






Test for overall effect: Not applicable





















IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine twice Favours povidone-iodine once
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Analysis 22.2.   Comparison 22: Povidone-iodine twice versus














IV, Fixed, 95% CI
1.27 [0.26 , 6.24]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine twice Favours povidone-iodine once
 
 
Analysis 22.3.   Comparison 22: Povidone-iodine twice versus














IV, Fixed, 95% CI
1.69 [0.59 , 4.82]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine twice Favours povidone-iodine once
 
 
Analysis 22.4.   Comparison 22: Povidone-iodine twice versus














IV, Fixed, 95% CI
1.32 [0.99 , 1.75]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine twice Favours povidone-iodine once
 
 
Analysis 22.5.   Comparison 22: Povidone-iodine twice versus povidone-














IV, Fixed, 95% CI
1.29 [0.95 , 1.74]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours povidone-iodine twice Favours povidone-iodine once
 
 
Comparison 23.   Penicillin IM versus topical penicillin





Statistical method Effect size
23.1 Gonococcal conjunctivitis 1 2795 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
23.2 Bacterial conjunctivitis 1   Risk Ratio (IV, Fixed, 95% CI) Subtotals only
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Statistical method Effect size
23.3 Any conjunctivitis of any aetiology 1   Risk Ratio (IV, Fixed, 95% CI) Subtotals only
23.4 Conjunctivitis of unknown aetiology 1   Risk Ratio (IV, Fixed, 95% CI) Subtotals only
 
 






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours penicillin
 
 
Analysis 23.2.   Comparison 23: Penicillin IM versus topical penicillin, Outcome 2: Bacterial conjunctivitis
Study or Subgroup
Davidson 1951












IV, Fixed, 95% CI
2.19 [1.14 , 4.24]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours penicillin
 
 
Analysis 23.3.   Comparison 23: Penicillin IM versus topical penicillin, Outcome 3: Any conjunctivitis of any aetiology
Study or Subgroup
Davidson 1951












IV, Fixed, 95% CI
1.71 [1.26 , 2.32]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours penicillin
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Analysis 23.4.   Comparison 23: Penicillin IM versus topical
penicillin, Outcome 4: Conjunctivitis of unknown aetiology
Study or Subgroup
Davidson 1951












IV, Fixed, 95% CI
1.58 [1.12 , 2.25]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours penicillin IM Favours penicillin
 
 
A D D I T I O N A L   T A B L E S
 
Interventions studied in included tri-
als
Physical characteristics/method of delivery
Silver nitrate solution Clear solution, topical instillation
Erythromycin ointment Translucent/white ointment, topical application
Tetracycline ointment Light-yellow ointment, topical application
Oxytetracycline hydrochlorate solution Unknown colour/consistency, aqueous solution, topical instillation
Povidone-iodine solution Orange-red, clear solution, topical instillation
Hexarginum solution Colour unknown, solution with 1 g silver nitrate + 36 g methylamine dissolved in 63 g ster-
ile water, topical application
Penicillin G ointment Clear/white ointment, topical application
Penicillin G intramuscular injection Clear, aqueous solution, intramuscular injection
Cetyl-pyridinium chloride solution Solution of unknown colour/consistency, topical instillation
Bacitracin-phenacaine ointment Ointment of unknown colour, topical application
Sulfacetamide ointment Ointment of unknown colour, topical application
Chloramphenicol solution Clear, colourless to slightly yellow solution, topical instillation
Chloramphenicol ointment Colourless ointment; topical instillation
Colostrum Yellowish, white or clear liquid, topical instillation
Carbethopendecinium bromide solution Yellowish to white powder in solution, solution colour unknown, topical instillation
Mechanical cleansing Eyes swabbed with clear, distilled water and wiped dry
Table 1.   Physical characteristics of interventions studied in included trials 
 
Interventions for preventing ophthalmia neonatorum (Review)















































































Gonococcal conjunctivitis Chlamydial conjunc-
tivitis

































is vs no prophy-
laxis
3 0.79 (0.24 to 2.65) 2 0.96 (0.57 to
1.61)
2 0.84 (0.37 to
1.93)




1 No events reported
in 1 or both arms.
1 1.06 (0.55 to
2.02)
No data were available. 3 0.67 (0.52 to 0.87) No data were available.
Erythromycin vs
no prophylaxis
2 No events reported
in 1 or both arms.
2 0.93 (0.49 to
1.77)
1 0.80 (0.22 to
2.90)




1 No events reported
in 1 or both arms.
1 0.82 (0.42 to
1.63)
No data were available. 2 0.72 (0.55 to 0.94) No data were available.
Povidone-io-
dine vs no pro-
phylaxis
1 No events reported
in 1 or both arms.
1 2.00 (0.18 to
21.74)
1 1.00 (0.30 to
3.36)






1 0.76 (0.20 to 2.83) No data were available. No data were available. No data were available. No data were available.
Colostrum vs no
prophylaxis
No data were available. No data were available. No data were available. 1 0.72 (0.45 to 1.14) No data were available.
Erythromycin vs
silver nitrate
4 2.28 (0.88 to 5.90) 4 0.75 (0.51 to
1.09)
2 0.83 (0.69 to
1.01)
    No data were available.
Tetracycline vs
silver nitrate
5 0.66 (0.21 to 2.05) 4 0.64 (0.40 to
1.02)
No data were available. 4 0.80 (0.66 to 0.98) No data were available.
Sulfacetamide
vs silver nitrate
1 No events reported
in 1 or both arms.
No data were available. 1 0.88 (0.45 to
1.74)
1 0.54 (0.32 to 0.89) 1 0.27 (0.11 to
0.66)












































































































































No data were available. No data were available. 2 1.79 (0.59 to
5.41)
2 1.08 (0.40 to 2.90) 2 No events re-




1 No events reported
in 1 or both arms.





































dine vs silver ni-
trate
1 1.94 (0.60 to 6.29) 1 0.52 (0.38 to
0.71)
1 0.75 (0.61 to
0.92)




2 0.73 (0.18 to 2.95) 2 0.72 (0.42 to
1.25)




No data were available.
Colostrum vs
erythromycin




2 0.85 (0.36 to 2.01) 2 0.74 (0.54 to
1.02)
2 0.87 (0.71 to
1.07)




1 No events reported
in 1 or both arms.
1 0.75 (0.48 to
1.17)




1 No events reported





1 2.04 (0.99 to
4.22)
1 3.01 (1.52 to 5.98) 1 No events re-





1 No events reported
in 1 or both arms.
1 1.77 (0.97 to
3.22)




No data were available. No data were available. No data were available. 1 0.44 (0.15 to 1.35) No data were available.















































































































































1 No events reported
in 1 or both arms.
1 1.27 (0.26 to
6.24)
1 1.69 (0.59 to
4.82)





1 No events reported





1 2.19 (1.14 to
4.24)
1 1.71 (1.26 to 2.32) 1 1.58 (1.12 to
2.25)
Table 2.   Summary results  (Continued)
IM: intramuscular
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Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children
Setting: any maternity setting
Intervention: silver nitrate
Comparison: no prophylaxis




















Blindness (visual acuity less than
20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months
































assessed with: Chlamydia trachoma-
tis culture, PCR, or direct fluores-
cent monoclonal antibody stain
follow-up: 1 month










assessed with: any bacteria-positive
culture, smear, or Gram stain
follow-up: 1 month
2 of the 3 studies did not measure or report bacterial conjunctivitis (Bell 1993; Graf
1994). 1 study measured bacterial conjunctivitis but did not report this outcome by
study arm (Chen 1992).
 
 
Any conjunctivitis of any aetiology
assessed with: clinical assessment





Table 3.   Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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Conjunctivitis of unknown aetiology
assessed with: culture negative
follow-up: 1 month
2 of the 3 studies did not measure did not measure or report conjunctivitis of unknown aetiol-
ogy (Bell 1993; Graf 1994). 1 study measured conjunctivitis of unknown aetiology but did not




Adverse effects In a single study (Bell 1993), silver nitrate prophylaxis appeared to be
associated with an increased risk of nasolacrimal duct obstruction com-
pared with no prophylaxis, but the variance in the estimate was impre-
cise with wide confidence intervals (RR 1.28, 95% CI 0.40 to 4.02).
A single study comparing silver nitrate with control reported that no






*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from
relevant prevalence studies (Appendix 8).
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 3.   Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn
chi dren  (Continued)
1Downgraded for risk of bias (-1): single study with high risk of selection bias, unclear and high risk of performance bias, unclear risk of
detection bias.
2Downgraded for imprecision (-2): no events in either arm of trial; study underpowered to assess relative eIects of treatment on this
outcome.
3Downgraded for imprecision (-1): 95% confidence interval includes no eIect.
4Downgraded for risk of bias (-1): largest trial has high or unclear risk of bias; second-largest trial has low risk of selection bias, but higher
risk of performance or detection bias.
5Downgraded (-2) for imprecision: sparse data.
 
 
Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children
Setting: any maternity setting
Intervention: erythromycin
Table 4.   Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)


































Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months


































assessed with: Chlamydia trachomatis culture,
PCR, or direct fluorescent monoclonal antibody
stain
follow-up: 1 month
















assessed with: any bacteria-positive culture,
smear, or Gram stain.
follow-up: 1 month










Table 4.   Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)
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Low risk
3 per 1000 2 per 1000
(2 to 3)
High risk
Any conjunctivitis of any aetiology assessed
with: clinical assessment
follow-up: 1 month













Study populationConjunctivitis of unknown aetiology assessed
with: culture negative











Adverse effects In a single study of 269 people, there was no clear relation-
ship between erythromycin and nasolacrimal duct obstruc-





*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from
relevant prevalence studies (Appendix 8).
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 4.   Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): studies were at high risk or unclear risk of bias. High loss to follow-up in one trial, and unclear if follow-
up time is two weeks or one month in same trial. No placebo used in either trial.
2Downgraded for imprecision (-2): no events in either arm of trial.
3Downgraded for imprecision (-1): 95% confidence interval includes no eIect; very few events; one study; small sample size.
4Downgraded for risk of bias (-1): study has high or unclear risk of bias with high loss to follow-up. No placebo used.
5Downgraded for imprecision (-2): very wide confidence intervals.
 
 
Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children
Setting: any maternity setting
Intervention: tetracycline
Comparison: no prophylaxis














Table 5.   Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)


















Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months



























assessed with: Chlamydia trachomatis culture,
















assessed with: any bacteria-positive culture,
smear, or Gram stain
follow-up: 1 month
1 study did not measure or report bacterial conjunctivitis (Ghotbi 2012), whilst
the other study measured bacterial conjunctivitis but did not report by alloca-





3 per 1000 2 per 1000
(2 to 3)
High risk















Table 5.   Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)
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Conjunctivitis of unknown aetiology assessed
with: culture negative
follow-up: 1 month
1 study did not measure or report conjunctivitis of unknown aetiology (CUE)
(Ghotbi 2012), whilst the other study measured CUE but did not report by alloca-








*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from
relevant prevalence studies (Appendix 8).
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 5.   Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for imprecision (-3): no events in this trial.
2Downgraded for risk of bias (-1): single trial with high risk of bias for sequence generation, allocation concealment, and masking, and
unclear risk of bias for detection and attrition bias, which could aIect outcomes considering the low event rates.
3Downgraded for imprecision (-1): optimal information size not met, and confidence interval overlaps no eIect in this single study.
4Downgraded for risk of bias (-1): studies at high or unclear risk of bias.
 
 
Povidone-iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children




























Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
 
 
Table 6.   Povidone-iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
 
Any adverse visual outcome
follow-up: 12 months

































assessed with: Chlamydia trachomatis culture, PCR,




















assessed with: any bacteria-positive culture, smear,
or Gram stain.
follow-up: 1 month












3 per 1000 1 per 1000
(1 to 2)
High risk


















Conjunctivitis of unknown aetiology assessed with:
culture negative
Study population RR 2.00 220 ⊕⊝⊝⊝  
Table 6.   Povidone-iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)
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follow-up: 1 month












*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from
relevant prevalence studies (Appendix 8).
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 6.   Povidone-iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for imprecision (-3): no events in either arm of this study.
2Downgraded for risk of bias (-1): the study is unclear regarding sequence generation and allocation concealment. Masking is a concern
as there was no placebo. Very high losses to follow-up.
3Downgraded for imprecision (-1): optimal information size criteria not met, and 95% confidence interval includes no eIect.
4Downgraded for imprecision (-2): very wide confidence intervals.
 
 
Bacitracin-phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children




















Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
 
 
Table 7.   Bacitracin-phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in
newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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Low risk




assessed with: Neisseria gonorrhoeae-positive
culture
follow-up: 1 month
100 per 1000 76 per 1000









assessed with: Chlamydia trachomatis cul-
ture, PCR, or direct fluorescent monoclonal
antibody stain
follow-up: 1 month
The 1 study does not seem to have measured or reported cases of chlamydial con-
junctivitis (Posner 1959). Diagnostic methods for chlamydia would not have been





assessed with: any bacteria-positive culture
follow-up: 1 month
It is unknown if bacterial conjunctivitis was measured in the 1 study (Posner 1959),





Any conjunctivitis of any aetiology assessed
with: clinical assessment
follow-up: 1 month
It is unknown if all conjunctivitis were measured in the 1 study (Posner 1959), as
it categorises conjunctivitis only as "nonspecific conjunctivitis" and "gonorrhoeal
ophthalmia".
 
Conjunctivitis of unknown aetiology assessed
with: culture negative
follow-up: 1 month
The category of "nonspecific conjunctivitis" reported in the 1 study is undefined and
may or may not also include bacterial conjunctivitis cases (Posner 1959).
 
Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from
relevant prevalence studies (Appendix 8).
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 7.   Bacitracin-phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in
newborn children  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)
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1Downgraded for risk of bias (-1): single trial with high risk of selection bias, unclear risk of performance and detection bias, high risk of
selective outcome reporting.
2Downgraded for imprecision (-2): very wide confidence intervals, which include no eIect.
 
 
Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children




















Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis
assessed with: Neisseria gonorrhoeae-positive
culture
follow-up: 1 month
No discussion of gonococcal conjunctivitis in this study (Ghaemi 2014). The trial
excluded culture-positive neonates before application of prophylaxis.
Chlamydial conjunctivitis
assessed with: Chlamydia trachomatis culture,
PCR, or direct fluorescent monoclonal antibody
stain
follow-up: 1 month
No discussion of chlamydial conjunctivitis in this 1 study (Ghaemi 2014). It is un-
known if it was measured. Chlamydial conjunctivitis cases were not reported.
Bacterial conjunctivitis
assessed with: any bacteria-positive culture
follow-up: 1 month
The 1 trial trial does not report bacterial conjunctivitis cases as distinguished
from all conjunctivitis cases (Ghaemi 2014). It is unknown if bacterial conjunctivi-
tis was measured.
Low risk
3 per 1000 2 per 1000
(1 to 3)
High risk
Any conjunctivitis of any aetiology assessed
with: clinical assessment
follow-up: 1 month








Conjunctivitis of unknown aetiology assessed
with: culture negative
follow-up: 1 month
The 1 trial only reports all conjunctivitis cases, and does not distinguish bacteri-
al conjunctivitis cases from cases of conjunctivitis of unknown aetiology (Ghaemi
2014).
Adverse effects No studies reported this outcome.
Table 8.   Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from
relevant prevalence studies (Appendix 8).
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 8.   Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): single study at high or unclear risk of performance, detection, and attrition bias.
2Downgraded for imprecision (-1): 95% confidence interval includes no eIect.
 
 
Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children




























Blindness (visual acuity less than
20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months






















In 2 of the 4 trials, there were
no cases of gonococcal con-
junctivitis in either study arm.
Follow-up: range 8 days to 19
weeks









Follow-up: range 4 weeks to 19
weeks
Table 9.   Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)
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assessed with: Chlamydia trachoma-
























Follow-up: range 9 days to 60
days
Any conjunctivitis of any aetiology as-
sessed with: clinical assessment
follow-up: 1 month







A meta-analysis was not con-
ducted considering the consid-
erable statistical heterogene-
ity (I2 = 90%). Therefore, there
was no pooled effect.
Follow-up: range 9 days to 60
days
Study populationAny conjunctivitis of any aetiology as-

















After excluding 1 study (Chris-
tian 1960), I2 declined to 51%,
but was still moderate. A
pooled effect was then pre-
sented for these 3 remaining
studies.
Follow-up: range 9 days to 60
days
Study populationConjunctivitis of unknown aetiology
assessed with: culture negative













Adverse effects In 1 study, erythromycin was associated with a
reduced risk of nasolacrimal duct obstruction
compared with silver nitrate. This association






*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 9.   Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): studies at high or unclear risk of bias.
2Downgraded for imprecision (-2): very wide 95% confidence intervals including no eIect.
Interventions for preventing ophthalmia neonatorum (Review)
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3Downgraded for imprecision (-1): 95% confidence intervals include no eIect.
4Downgraded for risk of bias (-1): one of the four studies, the smallest one (Hammerschlag 1980), was funded by the pharmaceutical
company that produces erythromycin (Dista Pharmaceuticals). That trial favoured erythromycin, and was the only trial amongst four trials
with no chlamydial conjunctivitis in the erythromycin arm (12 cases in the silver nitrate arm). There were 36 infants in the silver nitrate
arm and only 24 in the erythromycin arm. Furthermore, 7 of 67 chlamydia-positive mothers remained unaccounted for. Their distribution
in the allocation arms is unknown. With a transmission rate of about 30%, low event rates, and small sample size, these missing mothers
could have a significant eIect on the results.
5Downgraded for inconsistency (-1): confidence intervals do not overlap; point estimates vary widely and on either side of no eIect; I2 is
90%; and Chi2 P < 0.001. Heterogeneity could be explained by one older trial that did not define conjunctivitis, and review authors applied
definition to eye reaction classifications.
 
 
Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children























Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months





assessed with: Neisseria gonorrhoeae-posi-
tive culture
follow-up: 1 month





















assessed with: Chlamydia trachomatis cul-
ture, PCR, or direct fluorescent monoclonal
antibody stain
follow-up: 1 month












Table 10.   Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)
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Bacterial conjunctivitis
assessed with: any bacteria-positive cul-
ture
follow-up: 1 month
Amongst 5 studies, 4 measured bacterial conjunctivitis but did not report the results





Study populationAny conjunctivitis of any aetiology as-
sessed with: clinical assessment











Conjunctivitis of unknown aetiology as-
sessed with: culture negative
follow-up: 1 month
Amongst 5 trials, 4 measured conjunctivitis of unknown aetiology (CUE) but did not re-





Adverse effects In 1 trial, tetracycline appeared to be associated with a
higher risk of nasolacrimal duct obstruction, but the esti-





*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 10.   Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): studies at high or unclear risk of bias.
2Downgraded for inconsistency (-1): I2 is 60%, Chi2 P value is 0.11. Two trials had no events in either arm. Downgraded due to variable
methods and length of follow-up.
3Downgraded for imprecision (-1): optimal information size is not met, but large sample size (7721 neonates in tetracycline group and
6780 neonates in silver nitrate group) with low baseline risk; however, confidence intervals are quite wide around relative eIects, but
around absolute eIects relatively narrow. Outcome of gonococcal conjunctivitis is of critical significance and can aIect vision. Therefore,
downgraded one level for imprecision.
4Downgraded for imprecision (-1): optimal information size is not met, but large sample size (7598 neonates in tetracycline group and
6544 neonates in silver nitrate group) with low baseline risk; confidence intervals are wide around relative eIects, but around absolute
eIects relatively narrow. Confidence interval overlaps no eIect. RR of 60% with tetracycline versus RR increase of 2% with tetracycline.
Confidence interval fails to exclude important benefit. Chlamydial conjunctivitis outcome is important. Downgraded for imprecision.
5Downgraded for imprecision (-1): confidence intervals include benefit and harm
 
 
Interventions for preventing ophthalmia neonatorum (Review)
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Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children


























Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months






















assessed with: Chlamydia trachomatis culture,
PCR, or direct fluorescent monoclonal antibody
stain
follow-up: 1 month
It is likely that chlamydial conjunctivitis was measured in this 1952 study but not
reported in this trial. It is described in other observational studies in the same pa-





assessed with: any bacteria-positive culture













Study populationAny conjunctivitis of any aetiology assessed
with: clinical assessment














Conjunctivitis of unknown aetiology assessed
with: culture negative
follow-up: 1 month










Table 11.   Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)


















*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 11.   Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): single study with high risk of selection bias, high risk of performance bias, unclear risk of detection bias.
2Downgraded for imprecision (-2): no events in either arm of trial; study was underpowered to assess this outcome.
3Downgraded for imprecision (-1): optimal information size criteria not met, and 95% confidence interval overlaps no eIect.
 
 
Cetyl-pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children




























Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months




Table 12.   Cetyl-pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in
newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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Gonococcal conjunctivitis
assessed with: Neisseria gonorrhoeae-positive cul-
ture
follow-up: 1 month
Gonococcal conjunctivitis not measured and not reported. Study explicitly re-
ported that there was no culture method used to detect Neisseria gonorrhoeae.
 
Chlamydial conjunctivitis
assessed with: Chlamydia trachomatis culture,
PCR, or direct fluorescent monoclonal antibody
stain
follow-up: 1 month
None of the studies reported the diagnosis of chlamydial conjunctivitis. None of
the studies specified if chlamydia was measured, which was unlikely consider-
ing publication date of 1965.
 
Study populationBacterial conjunctivitis
assessed with: any bacteria-positive culture












Study populationAny conjunctivitis of any aetiology assessed with:
clinical assessment













Study populationConjunctivitis of unknown aetiology assessed
with: culture negative












Adverse effects No studies reported this outcome.
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 12.   Cetyl-pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in
newborn children  (Continued)
1Downgraded for risk of bias (-1): studies at high risk of bias.
2Downgraded for imprecision (-1): optimal information size criteria not met, and 95% confidence interval overlaps no eIect. Confidence
intervals very wide.
3Downgraded for inconsistency (-1): point estimates on opposite sides of no eIect. I2 is 60%, but confidence intervals overlap and and Chi2
P value is 0.11. Borderline. Downgraded.
 
 
Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children
Setting: any maternity setting
Table 13.   Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children 
Interventions for preventing ophthalmia neonatorum (Review)







































Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months














The 1 study with this com-
parison measured gonococ-
cal conjunctivitis but found
no cases of gonococcal con-
junctivitis in either study arm
(Davidson 1951). follow-up: 10
days
Chlamydial conjunctivitis
assessed with: Chlamydia trachomatis cul-
ture, PCR, or direct fluorescent monoclonal
antibody stain
follow-up: 1 month
Studies comparing penicillin to silver nitrate do not report the diagnosis of chlamydi-
al conjunctivitis. They do not specify if chlamydia was measured, which is understand-

























Study populationAny conjunctivitis of any aetiology as-
sessed with: clinical assessment













sis not conducted. Hetero-
geneity may be explained by
differing definitions of con-
junctivitis between trials.
follow-up: 10 days
Study populationConjunctivitis of unknown aetiology as-
sessed with: culture negative
















Table 13.   Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
child en  (C ntinued)
Interventions for preventing ophthalmia neonatorum (Review)
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 13.   Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): single trial with high risk of selection bias, unclear and high risk of performance bias, and high risk of
attrition bias.
2Downgraded for imprecision (-2): no events in either penicillin or silver nitrate arms of trial. Study was underpowered to assess this
outcome.
3Downgraded for inconsistency (-1): point estimates vary; confidence intervals do not overlap; I2 is 93%; Chi2 P < 0.001.
 
 
Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children



























Blindness (visual acuity less than 20/200)
follow-up: 12 months




Any adverse visual outcome
follow-up: 12 months




Table 14.   Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)
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Gonococcal conjunctivitis


















assessed with: Chlamydia trachomatis culture,
PCR, or direct fluorescent monoclonal anti-
body stain
follow-up: 1 month
1 study comparing penicillin IM to silver nitrate does not report chlamydial con-
junctivitis and does not specify if chlamydia was measured, which is understand-





assessed with: any bacteria-positive culture














Study populationAny conjunctivitis of any aetiology assessed
with: clinical assessment













Study populationConjunctivitis of unknown aetiology assessed
with: culture negative

















*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; IM: intramuscular; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 14.   Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias: single trial with high risk of selection bias, unclear to high risk of performance bias, and unclear to high risk
of attrition bias.
2Downgraded for imprecision (-2): no events in either arm, likely not meeting optimal information size criteria.
3Downgraded for imprecision (-1): optimal information size criteria not met; confidence interval wide and crosses null eIect.
Interventions for preventing ophthalmia neonatorum (Review)
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Povidone-iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children




























Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Study populationGonococcal conjunctivitis
assessed with: Neisseria gonorrhoeae-positive culture














assessed with: Chlamydia trachomatis culture, PCR, or



















assessed with: any bacteria-positive culture
















Study populationAny conjunctivitis of any aetiology assessed with: clin-
ical assessment
















Study populationConjunctivitis of unknown aetiology assessed with:
culture negative
















Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Table 15.   Povidone-iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)
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Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 15.   Povidone-iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): single trial has high or unclear risk of selection bias, performance bias, and attrition bias.
2Downgraded for imprecision (-1): optimal information size criteria not met, and 95% confidence interval includes no eIect.
 
 
Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children


























Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Study populationGonococcal conjunctivitis
assessed with: Neisseria gonorrhoeae-posi-
tive culture
follow-up: 1 month
















assessed with: Chlamydia trachomatis cul-
ture, PCR, or direct fluorescent monoclonal
antibody stain
follow-up: 1 month











assessed with: any bacteria-positive culture
follow-up: 1 month
Amongst the 3 studies comparing these interventions, Chen 1992 measured and re-
ported bacterial conjunctivitis, but data could not be extracted, and Hammerschlag
1989 and Ghotbi 2012 did not report and outcome was unlikely measured.
Study populationAny conjunctivitis of any aetiology assessed
with: clinical assessment









Data not pooled be-
cause of significant
heterogeneity. I2 is
69% and point esti-
mates on opposite
Table 16.   Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
side of line of no ef-
fect.
Conjunctivitis of unknown aetiology as-
sessed with: culture negative
follow-up: 1 month
Amongst the 3 studies comparing these interventions, Chen 1992 measured and re-
ported conjunctivitis of unknown aetiology, but data could not be extracted, and
Hammerschlag 1989 and Ghotbi 2012 did not report and outcome was unlikely mea-
sured.
Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 16.   Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): studies at unclear or high risk of bias.
2Downgraded for imprecision (-1): optimal information size criteria not met, but sample size is large at 5624 in tetracycline group and 5322
in erythromycin group. However, confidence interval includes no eIect, confidence intervals wide, and one trial has no events.
3Downgraded for inconsistency (-1): significant statistical heterogeneity. Point estimates on either side of line of no eIect. I2 is 69%.
 
 
Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children























Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis
assessed with: Neisseria gonorrhoeae-positive
culture
follow-up: 1 month
The 1 study excluded neonates with any positive cultures before administration of
prophylaxis. Gonococcal conjunctivitis was not reported, and there is no evidence
that it was measured.
Table 17.   Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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Chlamydial conjunctivitis
assessed with: Chlamydia trachomatis cul-
ture, PCR, or direct fluorescent monoclonal
antibody stain
follow-up: 1 month
The 1 study excluded neonates with any positive cultures before administration of
prophylaxis. Chlamydial conjunctivitis was not reported, and there is no evidence
that it was measured.
Bacterial conjunctivitis
assessed with: any bacteria-positive culture
follow-up: 1 month
The 1 study excluded neonates with any positive cultures before administration of
prophylaxis. Bacterial conjunctivitis was reported, but data could not be extracted.
Study populationAny conjunctivitis of any aetiology assessed
with: clinical assessment










Conjunctivitis of unknown aetiology assessed
with: culture negative
follow-up: 1 month
The 1 study excluded neonates with any positive cultures before administration of
prophylaxis. Conjunctivitis of unknown aetiology was not reported, and there was
no evidence that it was measured.
Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 17.   Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): single trial at unclear or high risk of performance bias and attrition bias.
2Downgraded for imprecision (-1): optimal information size criteria not met, and 95% confidence interval includes no eIect.
 
 
Povidone-iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children




























Blindness (visual acuity less than 20/200) No studies reported this outcome.
Table 18.   Povidone-iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)
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follow-up: 12 months
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Study populationGonococcal conjunctivitis
assessed with: Neisseria gonorrhoeae-positive culture
























assessed with: Chlamydia trachomatis culture, PCR, or
















assessed with: any bacteria-positive culture













Study populationAny conjunctivitis of any aetiology assessed with: clin-
ical assessment















Study populationConjunctivitis of unknown aetiology assessed with:
culture negative













Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 18.   Povidone-iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): studies at high or unclear risk of bias.
2Downgraded for imprecision (-1): confidence interval overlaps no eIect and optimal information size criteria not met.
Interventions for preventing ophthalmia neonatorum (Review)
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3Downgraded for imprecision (-1): optimal information size criterion not met.
 
 
Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children


























Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis



















assessed with: Chlamydia trachomatis cul-



















assessed with: any bacteria-positive culture
follow-up: 1 month
In the 1 study with these 2 interventions (Siegel 1982), it is uncertain whether all cas-
es of bacterial conjunctivitis were measured. Bacterial conjunctivitis was not report-
ed in this study.
Any conjunctivitis of any aetiology assessed
with: clinical assessment
follow-up: 1 month
Total conjunctivitis cases of any aetiology (ACAE) was not reported in the 1 study
with this comparison (Siegel 1982). It is uncertain whether ACAE was measured.
Conjunctivitis of unknown aetiology assessed
with: culture negative
follow-up: 1 month
In the 1 study comparing these interventions (Siegel 1982), conjunctivitis of un-
known aetiology was not reported, and it is uncertain if it was measured.
Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk taken from the study population in the included studies.
Table 19.   Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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CI: confidence interval; IM: intramuscular; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of
Table 19.   Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): single trial has high risk of selection bias, high to unclear risk of performance bias, unclear attrition bias.
2We did not downgrade for imprecision even though number of events were low, sample sizes are very large (close to 16,000 in each group).
Long follow-up time of 41 months.
 
 
Povidone-iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children



































Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis









The 1 study included in this com-
parison measured gonococcal con-
junctivitis but did not find any cas-
es in either study arm (David 2011).
Chlamydial conjunctivitis
assessed with: Chlamydia trachomatis cul-









The 1 study included in this com-
parison measured chlamydial con-
junctivitis but did not identify any
cases in either study arm (David
2011).
Study population  Bacterial conjunctivitis
assessed with: any bacteria-positive culture












Table 20.   Povidone-iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)















Study populationAny conjunctivitis of any aetiology assessed
with: clinical assessment


















Study populationConjunctivitis of unknown aetiology as-
sessed with: culture negative
















There were no cases of conjunc-
tivitis in the comparator group.
The value of 1 per 1000 is the risk
for tetracycline for illustrative pur-
poses only.
Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 20.   Povidone-iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): study has unclear or high risk of bias, which could influence outcome.
2Downgraded for imprecision (-1): small trial size and lack of detection of any gonorrhoea cases.
3Downgraded for imprecision (-1): small trial size and lack of detection of any chlamydia cases.
4Downgraded for imprecision (-1): optimal information size criteria not met; confidence interval overlaps no eIect; small trial size.
5Downgraded for imprecision (-1): optimal information size criteria met, but one trial, wide confidence interval, low event rates, small
sample size.




Povidone-iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children














Table 21.   Povidone-iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn
children 
Interventions for preventing ophthalmia neonatorum (Review)


























Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis
















assessed with: Chlamydia trachomatis culture, PCR, or

















assessed with: any bacteria-positive culture
follow-up: 1 month
The 1 study measured and reported cases of bacterial conjunctivitis, but da-
ta could not be extracted (Ramirez-Ortiz 2007).
Any conjunctivitis of any aetiology assessed with: clin-
ical assessment
follow-up: 1 month
The 1 study measured and reported cases of any conjunctivitis of any aetiol-
ogy, but data could not be extracted (Ramirez-Ortiz 2007).
Conjunctivitis of unknown aetiology assessed with:
culture negative
follow-up: 1 month
The 1 study likely measured conjunctivitis of unknown aetiology, but data
could not be extracted (Ramirez-Ortiz 2007).
Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 21.   Povidone-iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn
children  (Continued)
1Downgraded for risk of bias (-1): masking not addressed or unclear; high losses to follow-up, which can create plausible bias about results.
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
2Downgraded for imprecision (-1): zero event rates, sample size small, and unable to determine relative eIects; single trial.
3Downgraded for imprecision (-1): optimal information size not met, and confidence interval overlaps no eIect; single trial.
 
 
Povidone-iodine compared to carbethopendecinium bromide for the prevention of ophthalmia neonatorum in newborn chil-
dren
Patient or population: newborn children


























Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome. 
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis
assessed with: Neisseria gonorrhoeae-positive
culture
follow-up: 1 month
Translation of the 1 study does not make any reference to gonococcal conjunctivitis
(GC). There is no reference to culturing. It is unknown if GC was measured. GC cases
were not reported.
Chlamydial conjunctivitis
assessed with: Chlamydia trachomatis cul-
ture, PCR, or direct fluorescent monoclonal
antibody stain
follow-up: 1 month
Translation of the 1 study does not make any reference to chlamydial conjunctivitis
(CC). It unknown if CC was measured. No reference to culturing. No CC cases were
reported.
Bacterial conjunctivitis
assessed with: any bacteria-positive culture
follow-up: 1 month
Translation of the 1 study does not make reference to bacterial conjunctivitis (BC). It
unknown if BC was measured. No reference to culturing. No BC cases reported.
Study populationAny conjunctivitis of any aetiology assessed
with: clinical assessment












Conjunctivitis of unknown aetiology assessed
with: culture negative
follow-up: 1 month
Translation of the 1 study does not make reference to conjunctivitis of unknown ae-
tiology (CUE). It unknown if CUE was measured. No CUE cases were reported and
CUE could not be calculated.
Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
Table 22.   Povidone-iodine compared to carbethopendecinium bromide for the prevention of ophthalmia
neonatorum in newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 22.   Povidone-iodine compared to carbethopendecinium bromide for the prevention of ophthalmia
neonatorum in newborn children  (Continued)
1Downgraded for risk of bias (-1): single trial with unclear risk of selection bias, performance bias, detection bias, and attrition bias.
2Downgraded for imprecision (-1): optimal information size criteria not met, and 95% confidence interval includes no eIect; small trial.
 
 
Double application of povidone-iodine compared to single application of povidone-iodine for the prevention of ophthalmia
neonatorum in newborn children
Patient or population: newborn children
Setting: any maternity setting
Intervention: double application of povidone-iodine































Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis
























Table 23.   Double application of povidone-iodine compared to single application of povidone-iodine for the
prevention of ophthalmia neonatorum in newborn children 
Interventions for preventing ophthalmia neonatorum (Review)
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Study populationChlamydial conjunctivitis
assessed with: Chlamydia trachomatis culture, PCR,
or direct fluorescent monoclonal antibody stain
follow-up: 1 month














assessed with: any bacteria-positive culture












Study populationAny conjunctivitis of any aetiology assessed with:
clinical assessment













Study populationConjunctivitis of unknown aetiology assessed with:
culture negative













Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 23.   Double application of povidone-iodine compared to single application of povidone-iodine for the
prevention of ophthalmia neonatorum in newborn children  (Continued)
1Downgraded for risk of bias (-1): single trial has high risk of selection bias, unclear risk of performance bias, and unclear risk of attrition
bias.
2Downgraded for imprecision (-2): no events in either arm.
3Downgraded for imprecision (-2): limited number of events in each arm, very wide confidence intervals.
4Downgraded for imprecision (-1): optimal information size criteria not met, and 95% confidence interval includes no eIect.
 
 
Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in newborn children
Patient or population: newborn children
Setting: any maternity setting
Intervention: penicillin IM
Comparison: topical penicillin ointment











Table 24.   Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in
newborn children 
Interventions for preventing ophthalmia neonatorum (Review)





















Blindness (visual acuity less than 20/200)
follow-up: 12 months
No studies reported this outcome.
Any adverse visual outcome
follow-up: 12 months
No studies reported this outcome.
Gonococcal conjunctivitis




















assessed with: Chlamydia trachomatis culture, PCR,
or direct fluorescent monoclonal antibody stain
follow-up: 1 month
This 1 study from 1951 did not report the diagnosis of chlamydial conjunctivi-
tis, nor did the authors specify if chlamydia was measured. It is unlikely that
techniques to detect chlamydia were used in this time period.
Study populationBacterial conjunctivitis
assessed with: any bacteria-positive culture









Study populationAny conjunctivitis of any aetiology assessed with:
clinical assessment









Study populationConjunctivitis of unknown aetiology assessed with:
culture negative










Adverse effects No studies reported this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.
CI: confidence interval; IM: intramuscular; PCR: polymerase chain reaction; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High-certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate-certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low-certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Table 24.   Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in
newborn children  (Continued)
Interventions for preventing ophthalmia neonatorum (Review)
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Very low-certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 24.   Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in
newborn children  (Continued)
1Downgraded for risk of bias (-1): single study at high risk or unclear risk of bias.
2Downgraded for imprecision (-2): optimal information size criteria likely not met; no events.
3Downgraded for imprecision (-1): optimal information size criteria not met. However, confidence interval excludes no eIect.
 
 
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Gonorrhea] explode all trees
#2 MeSH descriptor: [Neisseria gonorrhoeae] explode all trees
#3 gonorr*
#4 MeSH descriptor: [Chlamydia] explode all trees
#5 MeSH descriptor: [Chlamydia Infections] explode all trees
#6 chlamyd*
#7 MeSH descriptor: [Streptococcus] this term only
#8 MeSH descriptor: [Staphylococcus aureus] this term only
#9 MeSH descriptor: [Staphylococcal Infections] this term only
#10 MeSH descriptor: [Haemophilus] this term only
#11 MeSH descriptor: [Vaginal Diseases] this term only
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 MeSH descriptor: [Conjunctivitis] explode all trees
#14 conjunctiv*
#15 MeSH descriptor: [Eye Infections] explode all trees
#16 (eye* or ocular) near/3 infection*
#17 #13 or #14 or #15 or #16
#18 MeSH descriptor: [Infant, Newborn] explode all trees
#19 infan* or newborn or new-born* or neonat* or neo-nat*
#20 #18 or #19
#21 #12 and #17 and #20
#22 MeSH descriptor: [Ophthalmia Neonatorum] explode all trees
#23 ophthalmia near/2 neonat*
#24 ophthalmia near/2 newborn*
#25(neonatal or ophthalmia or gonococcal or Chlamydia) near/4 conjunctivit*
#26 #22 or #23 or #24 or #25
#27 #21 or #26
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. exp gonorrhea/
14. exp neisseria gonorrhoeae/
15. gonorr$.tw.
16. exp chlamydia/
17. exp chlamydia infections/
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27. exp Eye Infections/
28. ((eye or ocular) adj3 infection$).tw.
29. or/25-28
30. exp infant newborn/
31. (infan$ or newborn or neonat$).tw.
32. (new adj1 born$).tw.
33. (neo adj1 nat$).tw.
34. or/30-33
35. exp ophthalmia neonatorum/
36. (ophthalmia adj2 neonat$).tw.
37. (ophthalmia adj2 newborn$).tw.
38. ((neonatal or ophthalmia or gonococcal or Chlamydia) adj4 conjunctivit$).tw.
39. or/35-38
40. 24 and 29 and 34
41. 39 or 40
42. 12 and 41
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
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33. exp gonorrhea/
34. exp neisseria gonorrhoeae/
35. gonorr$.tw.
36. exp chlamydia/











48. ((eye or ocular) adj3 infection$).tw.
49. or/45-48
50. exp infant newborn/
51. (infan$ or newborn or neonat$).tw.
52. (new adj1 born$).tw.
53. (neo adj1 nat$).tw.
54. or/50-53
55. exp newborn ophthalmia/
56. (ophthalmia adj2 neonat$).tw.
57. (ophthalmia adj2 newborn$).tw.
58. ((neonatal or ophthalmia or gonococcal or Chlamydia) adj4 conjunctivit$).tw.
59. or/55-58
60. 44 and 49 and 54
61. 59 or 60
62. 32 and 61
Appendix 4. LILACS search strategy
ophthalmia or conjunctivitis and neonatorum or newborn or neonatal or gonococcal or Chlamydia
Appendix 5. ISRCTN search strategy
(ophthalmia OR conjunctivitis) AND (neonatorum OR newborn OR neonatal OR gonococcal OR Chlamydia)
Appendix 6. ClinicalTrials.gov search strategy
(ophthalmia OR conjunctivitis) AND (neonatorum OR newborn OR neonatal OR gonococcal OR Chlamydia)
Appendix 7. ICTRP search strategy
(ophthalmia OR conjunctivitis) AND (neonatorum OR newborn OR neonatal OR gonococcal OR Chlamydia)
Appendix 8. Estimating assumed risks in the comparator group (for no-prophylaxis comparisons)
 
Outcome Low risk Source High risk Source
Gonococcal conjunctivitis
assessed with: Neisseria gonor-
rhoeae-positive culture
follow-up: 1 month
1 per 1000 Prevalence of gonorrhoea in preg-
nant women estimated at 0.275%
in 1 study in the USA (Blatt 2012).
Assumed gonococcal ophthalmia
neonatorum occurs in 30% to 50%




Mullick 2005: The incidence
of gonococcal ophthalmia
neonatorum was 3.6 per 100
live births in Nairobi and 2.1%
in The Gambia.
Chlamydial conjunctivitis 5 per 1000 Studies from China have estimated
that chlamydial conjunctivitis occurs




prevalence in different stud-
ies in sub-Saharan Africa and
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assessed with: Chlamydia tra-
chomatis polymerase chain re-
action (PCR) or culture
follow-up: 1 month
Asia, range from 0% to 44%.
Unclear exactly what the risk
of conjunctivitis is in babies of
infected women, but likely to
be in the region of 30% to 50%
(Adachi 2016).
Bacterial conjunctivitis
assessed with: any bacte-
ria-positive culture
follow-up: 1 month
3 per 1000 Estimate taken from risk in the con-




Estimate taken from risk in
the control group of included
study Ali 2007.
Any conjunctivitis of any aeti-





Estimate taken from risk in the con-




Estimate taken from risk in




H I S T O R Y
Protocol first published: Issue 9, 2016
Review first published: Issue 9, 2020
C O N T R I B U T I O N S   O F   A U T H O R S
Designing the review: VK, SSV
Screening search results: VK, SSV
Organising retrieval of papers: CEV Information Specialist, VK
Screening retrieved papers against inclusion criteria: VK, SSV
Appraising risk of bias: VK, SSV
Extracting data from included studies: VK, SSV
Writing to authors of included trials for additional information: VK
Managing data for the review: SSV, VK
Entering data into Review Manager 5: VK, SSV
Analysis of data: SSV, VK
Interpretation of data
• Providing a methodological perspective: SSV, JE
• Providing a clinical perspective: VK
Writing the review: VK, JE, SSV
Edits in response to peer review and copy edit comments: VK, JE, SSV
D E C L A R A T I O N S   O F   I N T E R E S T
VK was funded by a three-month Pharmaceutical Manufacturers' Association of Canada/IWK-Grace Scholarship for part of the time spent
on this systematic review. However, neither Dr Kapoor nor anyone else involved with this review has ever had any financial links with the
Pharmaceutical Manufacturers' Association of Canada.
JE has no known interests to declare.
SSV's earlier eIort on this review was supported by the Cochrane Eyes and Vision Group US Project with funding through Contract N-01-
EY-2-1003 with the National Eye Institute, National Institutes of Health, USA. The Cochrane Eyes and Vision Group US Project is now
supported by co-operative agreement 1 U01 EY020522, National Eye Institute, National Institutes of Health, USA.
Interventions for preventing ophthalmia neonatorum (Review)









Cochrane Database of Systematic Reviews
S O U R C E S   O F   S U P P O R T
Internal sources
• Pharmaceutical Manufacturers' Association of Canada / IWK-Grace Studentship, Canada
• George Mattar Research Scholarship, Dalhousie University, Canada
External sources
• National Institute for Health Research (NIHR), UK
* Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV research
sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye
Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.
* This review was supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK editorial base where JE works.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health.
• Cochrane Eyes and Vision Group US Project, USA
SV worked with the Cochrane Eyes and Vision Group US Project, which is supported by Contract N01-EY-002, National Eye Institute,
National Institutes of Health, USA and Grant 1 U01 EY020522-01, National Eye Institute, National Institutes of Health, USA.
• Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We used a treatment arm continuity correction approach to include trials with zero events in meta-analyses (Sweeting 2004).
Interventions for preventing ophthalmia neonatorum (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
233
